GENE_NAME	CELL_TYPE	PUBMED_PMID	HALLMARK	IMPACT	DESCRIPTION	CELL_LINE
ABI1	colorectal cancer	24913355	invasion and metastasis	promotes	promotes tumour cell adhesion, extracellular matrix degradation and invasion	
ABI1		10499589	function summary		participates in the transduction of signals from Ras to Rac	
ABI1		16025998	role in cancer	TSG	TSG	
ABI1		9694699	role in cancer	fusion	fusion	
ABI1		23552839	role in cancer	TSG	TSG	
ABI1		9010225	suppression of growth	promotes	fibroblasts overexpressing e3B1 have reduced growth compared to matched controls 	
ABI1		9694699	function summary		Abl-interacting adaptor protein	
ABI1	AML	9694699	fusion partner		KMT2A	
ABI1	breast cancer	17951403	invasion and metastasis	promotes	KD decreases invasiveness and migration ability and decreases adhesion on collagen IV	MDA-MB-231
ABI1	breast cancer	17951403	proliferative signalling	promotes	KD decreases cell proliferation	MDA-MB-231
ABI1	hepatocellular carcinoma	28339046	role in cancer	oncogene	oncogene	HepG2 and MHCC97H
ABI1	hepatocellular carcinoma	28339046	invasion and metastasis	promotes	overexpression of ABI1 increases and KD decreases cell migration and invasion 	HepG2 and MHCC97H
ABI1	hepatocellular carcinoma	28339046	proliferative signalling	promotes	overexpression of ABI1 increases and KD decreases cell proliferation	HepG2 and MHCC97H
ABI1	mouse pre-B 	18453543	invasion and metastasis	promotes	KD inhibits the Bcr-Abl-stimulated abnormal cytoskeleton remodeling and Bcr-Abl-stimulated cell adhesion and migration on fibronectin-coated surfaces	baf3
ABI1		23552839	mouse model		development of prostatic intraepithelial neoplasia was observed in 8-month-old Abi1 knockout mice, but no progression beyond PIN was observed in mice as old as 12 months	
ABI1	glioblastoma	26473374	invasion and metastasis	suppresses	loss of the Abi1 gene enhances the Crk Tyr251 Abl axis to promote aggressive behavior in tumor cells	
ABL1	CML	19260121	fusion partner		BCR	
ABL1		23316053	function summary		protein-tyrosine kinase, plays a prominent role in cellular responses to genotoxic stress as well as in the regulation of the actin cytoskeleton.	
ABL1		23840065	angiogenesis	promotes	loss of Abl kinases leads to increased endothelial cell apoptosis both in vitro and in vivo, contributing to vascular dysfunction, infarction, and tissue damage	
ABL1		25368164	differentiation and development		promotes adipocyte differentiation	
ABL1		25999467	function summary		phosphorylates RAS proteins to allosterically enhance their effector binding capabilities	
ABL1		25561363	global regulation of gene expression		induces stabilisation of histone deacetylase 1 (HDAC1) in a kinase activity-dependent manner	
ABL1	breast cancer	26838548	invasion and metastasis	promotes	promotes osteolytic metastasis by modulating tumour-bone interactions through TAZ and STAT5 signaling	
ABL1		18945674	change of cellular energetics	promotes	regulates autophagy by promoting the trafficking and function of lysosomal components	
ABL1		17623672	invasion and metastasis	promotes	Abl-dependent phosphorylation of WAVE3 is critical for the stimulation of lamellipodia formation and cell migration	
ABL1		16943190	proliferative signalling	promotes	impairs EGFR internalisation	
ABL1		9461559	genome instability and mutations	promotes	interacts constitutively with Rad51 and phosphorylates Rad51 on Tyr-54 upon treatment with ionising radiation to inhibit the binding of Rad51 to DNA and the function of Rad51 in ATP-dependent DNA strand exchange reactions	
ABL1		9037071	escaping programmed cell death	suppresses	positively regulates DNA damage-induced apoptosis	
ABL1		19260121	role in cancer	fusion	fusion	
ABL1		24421390	role in cancer	oncogene	oncogene	
ABL2		23842646	role in cancer	oncogene	oncogene	
ACKR3	oesophageal SCC	27035873	proliferative signalling	promotes	downregulation by miR-100 results in decreased cell proliferation	EC109
ACKR3	breast cancer	26119946	types of alteration in cancer		overexpressed	
ACKR3	hepatocellular carcinoma	28429395	invasion and metastasis	promotes	KD inhibits tumour invasion and metastasis	HCCLM3
ACKR3	mouse xenograft models of lung cancer	17898181	proliferative signalling	promotes	promotes tumour growth	
ACKR3	mouse xenograft models of lung cancer	17898181	invasion and metastasis	promotes	enhances metastasis	
ACKR3	hepatocellular carcinoma	27572688	angiogenesis	promotes	enhances the angiogenic capacity	
ACKR3	GBM	28759950	clinical impact		high expression predicts poor survival	
ACKR3	colorectal cancer	25051350	escaping programmed cell death	promotes	KD induces apoptosis	SW480 and HT-29
ACKR3	oesophageal SCC	27035873	invasion and metastasis	promotes	downregulation by miR-100 results in decreased invasive capacity	EC109
ACKR3	gallbladder cancer	21986127	clinical impact		high expression predicts poor survival	
ACKR3	papillary thyroid carcinoma	26383519	angiogenesis	promotes	stimulates the expression of IL-8 and VEGF resulting in enhanced angiogenesis	
ACKR3	renal cell carcinoma	20578990	clinical impact		high expression is associated with poor survival	
ACKR3	lipoma	12118328	fusion partner		HMGA2	
ACKR3	lipoma	12118328	role in cancer	fusion	fusion	
ACKR3	colorectal cancer	25051350	invasion and metastasis	promotes	KD decreases invasive capacity	SW480 and HT-29
ACKR3	vascular endothelium	26119946	function summary		scavenger receptor for chemokine CXCL12	
ACKR3	mouse models of breast cancer	26119946	proliferative signalling	promotes	promotes tumour growth	
ACKR3	breast cancer	26119946	invasion and metastasis	suppresses	limits metastasis 	
ACKR3	breast cancer	26119946	role in cancer	oncogene	oncogene	
ACKR3	colorectal cancer	25051350	proliferative signalling	promotes	KD negatively impacts cell proliferation and tumour growth in xenograft models	
ACSL3		18594527	role in cancer	fusion	fusion	
ACSL3	prostate cancer	21829708	types of alteration in cancer		downregulated	
ACSL3	ER- breast cancer	23512947	types of alteration in cancer		overexpressed 	
ACSL3		15556626	function summary		involved in lipid metabolism, downregulates FASN in prostate cancer after vitamin D3 stimulation	
ACSL3	prostate cancer	18594527	fusion partner		ETV1	
ACSL3		18594527	impact of mutation on function		provides androgen upregulated promoter in fusion with ETV1	
ACSL6		16572202	fusion partner		ETV6	
ACSL6		15655248	function summary		regulator of lipid metabolism	
ACSL6		16572202	role in cancer	fusion	fusion	
ACVR1		24705254	role in cancer	oncogene	oncogene	
ACVR1	paediatric pontine glioma	27727438	types of alteration in cancer		recurrent missense mutations G328V, G328E, R206H	
ACVR1		22977237	function summary		kinase, receptor of bone morphogenetic protein	
ACVR1		25413979	differentiation and development		required for chondrogenesis during development	
ACVR1	glioma-initiating cells	28459464	escaping programmed cell death	promotes	overexpression of the constitutively active form of ACVR1 results in a marked increase in apoptotic cells	
ACVR1	erythroleukaemia	28782519	proliferative signalling	promotes	overexpression of ALK2 results in the autophosphorylation of Smad1/5, leading to consequent increase in cell growth, the effect is reversed after inhibition of ACVR1	TF-1
ACVR1	prostate cancer	19736306	invasion and metastasis	promotes	in the presence of constitutively active ACVR1, cell migration is not inhibited by endoglin	PC3-M
ACVR1	diffuse intrinsic pontine glioma	24705252	types of alteration in cancer		recurrent GOF mutations	
ACVR1	immortalized normal human astrocytes	24705254	proliferative signalling	promotes	GOF mutant promotes cell proliferation	
ACVR2A	gastric cancer	32440149	invasion and metastasis	promotes	overexpression of wild-type gene, but neither exon 3 nor exon 10 (A)8 tract frameshift-effecting deletion mutant, promotes cell migration	MKN28
ACVR2A	colorectal cancer	26497569	function summary		Activin ACVR2A signaling stabilises p21 via SMAD4	SW480
ACVR2A		28659341	suppression of growth	promotes	mice with osteoblast lineage-specific homozygous gene deletion display increased femoral trabecular bone volume at 6 and 12 weeks of age	
ACVR2A	chondrosarcoma	25024164	role in cancer	fusion	fusion	
ACVR2A	colorectal cancer	14988818	role in cancer	TSG	TSG	
ACVR2A	colorectal cancer	30310521	clinical impact		loss of expression associated with poor outcome and metastatic disease	
ACVR2A	high-grade serous ovarian cancer	28115208	clinical impact		higher expression associated with shorter disease-free survival	
ACVR2A	chondrosarcoma	25024164	types of alteration in cancer		missense mutations in 9% of tumours	
ACVR2A	colorectal cancer	14988818	types of alteration in cancer		frameshift-effecting single nucleotide deletion in exon 10 (A8) tract in 83% of microsatellite instability-high tumours	
ACVR2A	colorectal cancer	20011542	types of alteration in cancer		LOH in 16% and promoter hypermethylation in 4% of microsatellite stable tumours	HCT116, SW48, DLD1, HCA7, HCT15, LoVo, LS174T, SNU175, SNU407, SW48, RKO, CaCo2, HT29, SNU81, SNU503, SW480, T84
ACVR2A	high-grade serous ovarian cancer	28115208	types of alteration in cancer		frequently increased expression	
ACVR2A	multiple myeloma	19926132	types of alteration in cancer		characteristically increased expression in total mononuclear cell bone marrow aspirates	
ACVR2A	rectal adenocarcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma	27694933	types of alteration in cancer		exon 10 (A)8 tract is a hotspot for expansion or contraction in 28-87% of microsatellite instability-high tumours	
ACVR2A	bladder cancer	31101108	global regulation of gene expression		exon 3,4 and 5-containing circACVR2A RNA acts a miR-626 sponge, reducing its suppression of EYA4	
ACVR2A	zebrafish embryo 	15977175	differentiation and development		protein depletion results in defective development of cranial cartilage and bone, and pharyngeal tooth structures	
ACVR2A	osteoblasts	28659341	differentiation and development		KD enhances differentiation and maturation	
ACVR2A	T helper 17 lymphoctyes	22056434	differentiation and development		expression is associated with the IL6 and TGFB1-driven differentiation of Th17 lymphocytes from naive CD4+ T cells	
ACVR2A	murine embryonic stem cells 	25458897	cell division control		overexpression-mediated activin signalling leads to increased expression of CCNB1 and CCNE1, and progression to the cell cycle S phase	E14
ACVR2A	chondrosarcoma	25024164	fusion partner		FN1	
ACVR2A	colorectal cancer	14988818	impact of mutation on function		loss of expression in 62% of microsatellite instability-high tumours carrying an exon 10 (A)8 tract single nucleotide deletion	
ACVR2A	colorectal cancer	20011542	impact of mutation on function		loss of expression in 16% of microsatellite stable tumours associated with LOH or promoter hypermethylation	
ACVR2A	prostate cancer	16337854	impact of mutation on function		truncating frameshift mutations attenuate activin signaling	PC3, H660, LNCaP, DU145, 22Rv-1, LAPC-4
ACVR2A	colorectal cancer	17258738	invasion and metastasis	promotes	KD decreases cell migration	HCT116, HEC59, FET, CAPAN1
ACVR2A	prostate cancer, neuroblastoma	19308291	proliferative signalling	promotes	KD inhibits cell adhesion and growth	PC-3, LNCaP, M17
ACVR2A	osteoblasts	28659341	proliferative signalling	promotes	KD decreases cell proliferation	
ACVR2A	murine embryonic stem cells	25458897	proliferative signalling	promotes	overexpression-mediated activin signalling leads to increased cell proliferation	E14
ACVR2A	zebrafish embryo	15977175	escaping programmed cell death	promotes	protein depletion results in increased cell apoptosis in neural tissue	
ACVR2A	murine embryonic stem cells 	25458897	genome instability and mutations	promotes	overexpression-mediated activin signalling is associated with reduced single-strand break and double-strand break DNA repair	E14
ACVR2A		11815670	function summary		transmembrane, constitutively active serine-threonine kinase TGFbeta type II receptor that mediates activin signalling	
ACVR2A	colorectal cancer	17258738	suppression of growth	promotes	KD increases cell growth by removing the growth inhibitory effects of activin signaling	HCT116, HEC59, FET, CAPAN1
AFF1		10887138	differentiation and development		critical for normal lymphocyte development	
AFF1		22337994	function summary		upregulates expression of CD133, which is required for the growth of ALL cells	
AFF1	ALL	8506309	role in cancer	fusion	fusion	
AFF1		9233580	function summary		serine-proline-rich protein with properties of nuclear transcription factor	
AFF1	ALL	8506309	fusion partner		KMT2A	
AFF3		8555498	function summary		lymphoid nuclear protein with transactivation potential	
AFF3	breast cancer	15704140	types of alteration in cancer		overexpressed	
AFF3	ALL	8555498	fusion partner		KMT2A	
AFF3	ALL	8555498	role in cancer	fusion	fusion	
AFF4	ALL	20159561	role in cancer	fusion	fusion	
AFF4		20159561	function summary		component of the super elongation complex required for its stability and proper transcription by poised RNA polymerase II 	
AFF4	HNSCC	29741610	invasion and metastasis	promotes	ectopic expression promotes cell migration and invasion	SCC1 and SCC23
AFF4		28955517	differentiation and development		depletion of AFF4 significantly inhibits the osteogenic potential of mesenchymal stem cells	
AFF4	ALL	20159561	fusion partner		KMT2A	
AFF4		20159561	role in cancer	oncogene	oncogene	
AFF4	HNSCC	29741610	proliferative signalling	promotes	overexpression promotes and KD inhibits cell proliferation	SCC1 and SCC23
AKAP9	papillary thyroid carcinoma	15630448	impact of mutation on function		fusion protein lacks the autoinhibitory N-terminal portion of BRAF	
AKAP9	papillary thyroid carcinoma	19766698	fusion partner		BRAF	
AKAP9	papillary thyroid carcinoma	19766698	role in cancer	fusion	fusion	
AKAP9		9915845	function summary		protein kinase A-anchoring protein associated with centrosomes	
AKT1		17611497	impact of mutation on function		Lys 17 alters the electrostatic interactions of the lipid-binding pocket and forms new hydrogen bonds with a phosphoinositide ligand, resulting in hyperactivation of AKT1 by means of pathological localization to the plasma membrane and stimulation of downstream signalling	
AKT1	lung cancer	21242979	function summary		fibroblasts lacking Akt1 are resistant to transformation by mutant K-ras and stimulation by epidermal growth factor	
AKT1	breast cancer	27004402	proliferative signalling	promotes	induces mammary hyperplasia	
AKT1	breast cancer	27004402	suppression of growth	promotes	prevents HER2-driven tumorigenesis, in part through negative feedback inhibition of RTK signalling	
AKT1	melanocytes	25551293	escaping programmed cell death	promotes	promotes growth factor independent survival in a kinase-independent way	
AKT1	haemangioma	25388284	escaping programmed cell death	promotes	KD results in increased tumour cell apoptosis in response to serum starvation	
AKT1	haemangioma	25388284	invasion and metastasis	promotes	KD decreases basal and VEGF-stimulated cell migration	
AKT1	prostate cancer	25322691	change of cellular energetics	promotes	AKT1 activation is associated with accumulation of aerobic glycolysis metabolites	
AKT1	colorectal cancer	28339062	escaping programmed cell death	promotes	suppresses the cell apoptosis induced by DNA damage	HCT116 and HT29
AKT1	breast cancer	27515171	types of alteration in cancer		E17K was the only known driver alteration found in a subset of samples	
AKT1		27727438	types of alteration in cancer		recurrent missense E17K	
AKT1		3037531	role in cancer	oncogene	oncogene	
AKT1	hepatocellular carcinoma	24297510	invasion and metastasis	promotes	enforced expression of Akt1 induces cell migration and invasion	HepG2
AKT1	gastric adenocarcinoma	3037531	types of alteration in cancer		amplified	
AKT1	colorectal cancer	24297510	invasion and metastasis	suppresses	enforced expression of Akt1 suppresses cell migration and invasion	HCT116
AKT1	lung cancer	21925532	invasion and metastasis	suppresses	silencing of Akt1 increases the release of TGF-beta1, which induces a change of morphology, cancer cell dissociation, migration and eventually leads to EMT	
AKT1		28557977	function summary		serine/threonine kinase, a component of PI3K/Akt pathway, activated by phosphatidylinositol 3,4,5-trisphosphate (PIP3), translocates to the cell membrane, where it's activated via phosphorylation	
AKT1	NSCLC	28765579	invasion and metastasis	suppresses	inhibition of AKT1 signalling promotes invasion and metastasis of cancer cells with K-RAS or EGFR mutations	
AKT1	murine prostate cancer	28209968	genome instability and mutations	suppresses	E17K GOF mutant accelerates DSB repair and improves survival of irradiated cells	Tramp-C1
AKT1	cancer	11571628	escaping programmed cell death	promotes	KD inhibits anchorage-independent cell growth and induces apoptosis	MiaPaCa-2, H460, HCT-15, and HT1080
AKT1		25136137	angiogenesis	promotes	promotes angiogenesis largely due to phosphorylation and regulation of important downstream effectors that promote aspects of angiogenic signalling	
AKT1		16552185	angiogenesis	promotes or suppresses	vital for the maintenance of vascular integrity, regulates the proliferation-apoptosis signalling during vascular remodelling, regulates various signalling pathways to affect the balance of pro- and anti-angiogenic factors	
AKT1	adipocytes and L6 myotubes	9478990	change of cellular energetics	promotes	activation of ATK1 mimics insulin-induced glucose transport and protein synthesis	
AKT1	bladder carcinoma	26148825	escaping programmed cell death	promotes	KD results in impaired cell survival	T24
AKT1	bladder carcinoma	26148825	proliferative signalling	promotes	KD results in impaired cell  proliferation and colony formation	T24
AKT1	bladder carcinoma	26148825	invasion and metastasis	promotes	KD results in impaired cell migration and microinvasion	T24
AKT1	glioblastoma	25501279	proliferative signalling	promotes	PCAF-mediated Akt1 acetylation enhances Akt1 phosphorylation at both sites of Thr(308) and Ser(473) and promotes cell proliferation	
AKT1	gastric adenocarcinoma	3037531	role in cancer	oncogene	oncogene	
AKT2	ovarian and breast carcinomas	7657393	role in cancer	oncogene	oncogene	
AKT2	ovarian and breast carcinomas	7657393	types of alteration in cancer		amplified	
ALDH2		17543846	function summary		enzyme catalysing the conversion of acetaldehyde into acetic acid in ethanol metabolism	
ALDH2	uterine leiomyoma	8521389	fusion partner		HMGA2	
ALDH2	uterine leiomyoma	8521389	role in cancer	fusion	fusion	
ALDH2		16054980	genome instability and mutations	suppresses	performs oxidation of acetaldehyde into acetic acid preventing the formation of acetaldehyde-induced DNA adducts	
ALK		27573755	impact of mutation on function		regulatory domain is absent in fusion protein resulting in constitutive activation	
ALK		27573755	role in cancer	fusion	fusion	
ALK		27573755	types of alteration in cancer		overexpressed	
ALK		27727438	types of alteration in cancer		recurrent F1174L, R1275Q	
ALK	anaplastic large-cell non-Hodgkin's lymphoma	8122112	fusion partner		NPM1	
ALK		27573755	fusion partner		KIF5B, TFG, KLC1, PTPN3, HIP1, STRN, TPR in NSCLC; ALO17, TFG, MSN, TPM3, TPM4, ATIC, MYH9, CLTC, TRAF1 in ALCL	
ALK	neuroblastoma	21059859	impact of mutation on function		F1174S causes ligand-independent activity	
ALK	neuroblastoma	21242967	impact of mutation on function		R1275Q causes ligand-independent activity	
ALK	melanoma	26444240	impact of mutation on function		de novo alternative transcription initiation site results in shorter, constitutively active isoform	
ALK		18097461	invasion and metastasis	promotes	stimulates the cell migration	
ALK		18097461	proliferative signalling	promotes	enhances cell proliferation	
ALK		17611412	escaping programmed cell death	promotes or suppresses	in the absence of a ligand ALK is kinase inactive and its overexpression results in enhanced apoptosis, kinase activation, due to a ligand or constitutive, as in ALK fusion proteins, decreases apoptosis	
ALK		27573755	function summary		transmembrane receptor-tyrosine kinase, 	
ALK		26444240	role in cancer	oncogene	oncogene	
AMER1	Wilms tumour	22409817	types of alteration in cancer		frequently deleted	
AMER1		27727438	types of alteration in cancer		recurrent nonsense mutations in colon cancer and Wilms tumour	
AMER1		22285752	function summary		enhances p53 acetylation by CBP/p300	
AMER1		22215675	function summary		inhibits the ubiquitination of NRF2; AMER1 and NRF2 compete for binding to KEAP1	
AMER1	Wilms' tumour	21248786	role in cancer	TSG	TSG	
AMER1		21498506	function summary		binds to the tumour suppressor APC and acts as an inhibitor of Wnt signalling by inducing beta-catenin degradation	
AMER1		17510365	suppression of growth	promotes	promotes beta-catenin ubiquitination and degradation, which antagonize WNT/beta-catenin signalling	
AMER1		20956941	suppression of growth	promotes	induction of AMER1 inhibits cell growth and causes G(1)/G(0) arrest	
AMER1		22215675	impact of mutation on function		loss of AMER1 leads to rapid ubiquitination and degradation of NRF2 and a reduced response to cytotoxic insult	
APC		24224156	function summary		repressor of the Wnt signalling pathway, part of beta-catenin destruction complex	
APC		12486240	genome instability and mutations	suppresses	inactivation increases chances of chromosomal instability	
APC		11751382	escaping programmed cell death	suppresses	promotes apoptosis by down-regulating expression of survivin	
APC		16185824	invasion and metastasis	promotes	promotes cell migration	
APC		16185824	cell division control		regulates mitotic spindle assembly and orientation and chromosome segregation	
APC		24200292	role in cancer	TSG	TSG	
APC		10470088	types of alteration in cancer		location of germline mutation determines location of second-hit somatic mutation	
APC		27727438	types of alteration in cancer		recurrent somatic mutations R1450*, T1556fs, R876*, R213*, E1309fs,	
APC		16185824	differentiation and development		involved in neuronal differentiation	
APC		24224156	suppression of growth	promotes	repressor of Wnt signalling that reduces beta catenin stability and represses beta-catenin/TCF-dependent transcription	
APOBEC3B		25730878	tumour promoting inflammation	promotes	deletion is associated with immune activation	
APOBEC3B		23985681	role in cancer	oncogene	oncogene	
APOBEC3B		27233495	role in cancer	TSG	TSG	
APOBEC3B		23715497	types of alteration in cancer		germline deletion is associated with increased risk of breast cancer in European patients	
APOBEC3B		26476745	types of alteration in cancer		high expression is associated with aggressive phenotype of breast cancer in Japanese patients	
APOBEC3B	oesophageal cancer	26880326	types of alteration in cancer		overexpressed	
APOBEC3B	lung cancer	27076842	types of alteration in cancer		high expression is associated with worse outcome	
APOBEC3B		27233495	types of alteration in cancer		germline deletion is associated with increased risk of breast cancer with immune cell presentation in multi-ethnic Asian patients	
APOBEC3B		25848704	function summary		cytosine deaminase, an effector protein in the innate immune response to viral infections, carries out the transition of C to T in ssDNA	
APOBEC3B		16728505	genome instability and mutations	suppresses	inhibits LINE-1 retro-transposition and mediated by LINE-1 ORF2 Alu mobility	
APOBEC3B		23985681	genome instability and mutations	promotes	source of DNA damage and mutagenesis in breast, head and neck, cervical, bladder and lung cancer	
APOBEC3B	ovarian cancer	24154874	genome instability and mutations	promotes	source of DNA damage and mutagenesis	
AR		26813233	impact of mutation on function		mutants demonstrate elevated sensitivity to stimulation by DHT and others steroids	
AR		27727438	types of alteration in cancer		recurrent T878A, L702H	
AR	breast cancer	25979597	types of alteration in cancer		LOH 	
AR	CR prostate cancer	22722839	types of alteration in cancer		statistically significant overrepresentation of protein-coding mutations	
AR		26813233	role in cancer	oncogene	oncogene	
AR		11431338	proliferative signalling	promotes	stimulates proliferation of prostatic epithelial cells	
AR	prostatic epithelial cells	2340521	escaping programmed cell death	promotes	inhibits apoptosis	
AR		26991422	function summary		androgen receptor	
ARHGAP26	ovarian cancer	31004081	role in cancer	TSG	TSG	
ARHGAP26	AML	25088035	clinical impact		higher expression associated with longer overall survival	
ARHGAP26	gastric cancer	29961079	clinical impact		patients with CLDN18 gene fusion do not respond to adjuvant chemotherapy and have reduced survival	
ARHGAP26	MDS	20374274	clinical impact		promoter methylation associated with shorter overall survival	
ARHGAP26	AML	16404424	types of alteration in cancer		promoter methylation in 40% of tumours borne by German patients	
ARHGAP26	AML	21074269	types of alteration in cancer		promoter methylation in 67% of tumours borne by Chinese patients	
ARHGAP26	AML, CML, MDS	20704716	types of alteration in cancer		frequently decreased expression	
ARHGAP26	gastric cancer	26146084	types of alteration in cancer		in-frame gene fusion in 3% of tumours borne by south east asian patients	
ARHGAP26	gastric signet-ring cell cancer	29961079	types of alteration in cancer		in-frame CLDN18 gene fusion in 16% of tumours borne by Chinese patients	
ARHGAP26	infant acute monocytic leukaemia	15382263	types of alteration in cancer		rare ins(5;11)(q31;q23q23) leading to an in-frame gene fusion	
ARHGAP26	JMML	10908648	types of alteration in cancer		rare t(5;11)(q31;q23) leading to an in-frame gene fusion	
ARHGAP26	MDS	16404424	types of alteration in cancer		promoter methylation in 36% of tumours borne by German patients	
ARHGAP26	ovarian cancer	31004081	types of alteration in cancer		decreased expression in a large subset of tumours	
ARHGAP26	drosophila	28993397	differentiation and development		restrains macrophage-like plasmatocyte proliferation during haematopoiesis in drosophila	
ARHGAP26	gastric cancer	26146084	fusion partner		CLDN18	
ARHGAP26	infant acute monocytic leukaemia	15382263	fusion partner		KMT2A	
ARHGAP26	JMML	10908648	fusion partner		KMT2A	
ARHGAP26	AML	21074269	impact of mutation on function		promoter methylation associated with reduced expression	
ARHGAP26	gastric cancer	26146084	impact of mutation on function		ectopic expression of CLDN18 fusion gene in vitro reduces cell proliferation and increases cell invasion	HGC27
ARHGAP26	a GTPase activating protein that binds to focal adhesion kinase and regulates the GTP-binding proteins RhoA and Cdc42	8649427	function summary			
ARHGAP26	JMML	10908648	role in cancer	fusion	fusion	
ARHGAP26	infant acute monocytic leukaemia	15382263	role in cancer	fusion	fusion	
ARHGAP26	gastric cancer	26146084	role in cancer	fusion	fusion	
ARHGAP26	ovarian cancer	31004081	suppression of growth	promotes	KD leads to increased proliferation	SKOV3
ARHGAP26	ovarian cancer	31004081	invasion and metastasis	suppresses	KD leads to increased invasion and migration via Wnt/beta-catenin pathway activation	SKOV3
ARHGAP26	ductus arteriosus smooth muscle cells	30592323	invasion and metastasis	promotes	KD decreases cell migration	
ARHGAP26		10908648	role in cancer	TSG	TSG	
ARHGAP26	ductus arteriosus smooth muscle cells	30592323	proliferative signalling	promotes	KD decreases cell proliferation	
ARHGAP26	colorectal cancer	28834752	invasion and metastasis	suppresses	KD promotes membrane blebbing-based invasion and migration	SW480
ARHGEF12		19734946	role in cancer	TSG	TSG	
ARID1A		16230384	differentiation and development		ARID1A-depleted cells fail to undergo normal differentiation-associated cell cycle arrest	
ARID1A	hepatocellular carcinoma	28716731	suppression of growth	promotes	represses hepatocellular carcinoma cell proliferation through lncRNA MVIH	
ARID1A		28737768	escaping programmed cell death	suppresses	ARID1A LOF inactivates the apoptosis-promoting function of p53 by upregulating HDAC6, which directly deacetylates Lys120 of p53, a pro-apoptotic post-translational modification	
ARID1A		22101766	role in cancer	fusion	fusion	
ARID1A		20942669	role in cancer	TSG	TSG	
ARID1A	triple-negative breast cancer 	22101766	fusion partner		MAST2	
ARID1A		18448678	cell replicative immortality	promotes	ARID1A deficiency compromises ES cell pluripotency, severely inhibits self-renewal, and promotes differentiation into primitive endoderm-like cells	
ARID1A	colon cancer	24833095	escaping programmed cell death	suppresses	KD promoted proliferation and inhibited 5-fluorouracil-induced apoptosis	SW480
ARID1A	colorectal cancer	28062476	global regulation of gene expression		ARID1A loss disrupts SWI/SNF targeting to enhancers to alter gene expression and drive tumorigenesis	
ARID1A		28716731	invasion and metastasis	suppresses	represses hepatocellular carcinoma cell migration through lncRNA MVIH	
ARID1A	gastric epithelium	22808142	suppression of growth	promotes	silencing ARID1A expression significantly enhances cell growth rate	GES1
ARID1A	breast cancer	21892209	suppression of growth	promotes	re-expression in cells lacking functional ARID1A results in significant inhibition of colony formation	T47D
ARID1A		21900401	suppression of growth	promotes	KD in immortalised ovary epithelial cells is sufficient to enhance cellular proliferation and tumorigenicity	
ARID1A		27727438	types of alteration in cancer		frequent inactivating mutations in ovarian cancer, digestive tract cancers, bladder cancer	
ARID1A	endometrioid carcinoma	27727438	types of alteration in cancer		recurrent R1989*	
ARID1A		23097632	impact of mutation on function		in-frame deletions affecting the consensus nuclear export signal reduce steady-state protein levels of ARID1A, as it is rapidly degraded by the ubiquitin-proteasome system in the nucleus	
ARID1A		26953344	cell replicative immortality	suppresses	negatively regulates TERT transcriptional regulation and activity via binding to the regulatory element of TERT, loss of ARID1A protein expression caused by inactivating mutations reactivates TERT transcriptional activity	
ARID1A		26069190	genome instability and mutations	suppresses	recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR, facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signalling	
ARID1A		21654818	function summary		member of human SWI-SNF complexes	
ARID1B		26637902	role in cancer	TSG	TSG	
ARID2		26637902	role in cancer	TSG	TSG	
ARID2		22184115	differentiation and development		ARID2-containing complexes play a critical role in promoting osteoblast commitment and differentiation	
ARID2		25299188	differentiation and development		required for heart morphogenesis and coronary artery development	
ARID2	MDS	29099495	types of alteration in cancer		inactivating mutations and deletions tend to be acquired as early events	
ARID2	hepatoma	27351279	suppression of growth	promotes	suppresses tumour cell growth through repression of cyclin D1 and cyclin E1 expression, thereby retarding cell cycle progression and cell proliferation	
ARID2		26716708	function summary		a subunit of the PBAF complexes involved in ligand-dependent transcriptional activation by nuclear receptors through chromatin remodelling	
ARID2	hepatocellular carcinoma	28238438	genome instability and mutations	suppresses	KO impairs NER through inhibiting the recruitment of XPG, resulting in susceptibility to carcinogens and potential hypermutation	JHH4
ARID2		28381560	genome instability and mutations	suppresses	recruits Rad51 to DNA DSBs to enable their repair by homologous recombination	
ARNT	AML	10829078	role in cancer	fusion	fusion	
ARNT		8662957	change of cellular energetics	promotes	necessary for HIF1B-dependent hypoxic induction of gene expression	
ARNT		25839165	invasion and metastasis	suppresses	downregulation of ARNT protein promotes cancer cell migration and invasion	
ARNT		9121557	angiogenesis	promotes	stimulates angiogenesis	
ARNT		12754377	function summary		coactivator of estrogen receptor-dependent transcription	
ARNT		12032587	function summary		transcriptional coactivator	
ARNT	AML	10829078	fusion partner		ETV6	
ASPSCR1	renal cell carcinoma	11438465	fusion partner		TFE3	
ASPSCR1		23349634	function summary		cofactor of methyltransferase VCPKMT, enhances methylation of VCP	
ASPSCR1		22207755	function summary		required for efficient reassembly of the Golgi complex and regulates cellular membrane trafficking	
ASPSCR1		23288701	role in cancer	fusion	fusion	
ASPSCR1		17283122	impact of mutation on function		fusion with TFE3 causes strong MET autophosphorylation and activation of downstream signaling in the presence of hepatocyte growth factor due to hyperactive TFE3 	
ASPSCR1	soft part sarcoma and RCC 	23288701	fusion partner		TFE3	
ASXL1		19833123	differentiation and development		required for axial patterning in mice and both silencing and activation of Hox genes	
ASXL1	mouse	24218140	mouse model		loss of Asxl1 promotes myeloid transformation	
ASXL1		26470845	role in cancer	TSG	TSG	
ASXL1		22898539	global regulation of gene expression		part of polycomb-repressive deubiquitylase complex, which to deubiquitylates H2AK119	
ASXL1		16606617	function summary		ligand-dependent coactivator for retinoic acid receptor	
ASXL1		22897849	impact of mutation on function		inactivating mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation	
ASXL1		22898539	function summary		epigenetic regulator	
ATF1		25122751	function summary		binding of Atf1 to promoters serves as a barrier to phase nucleosome arrays and avoid cryptic transcription	
ATF1		1655749	function summary		transcription factor, activates transcription in response to cAMP-dependent protein kinase A	
ATF1		9569031	role in cancer	fusion	fusion	
ATF1	malignant melanoma of soft parts	9569031	fusion partner		EWSR1	
ATF1	malignant melanoma of soft parts	9569031	impact of mutation on function		fusion protein binds to ATF sites present in cAMP-responsive promoters via the ATF1 bZIP domain and activates transcription constitutively in a manner that is dependent on an activation domain present in EWSR1	
ATIC		14966129	function summary		a component of the purine biosynthesis pathway 	
ATIC	fibroblasts	15208656	impact of mutation on function		fusion protein with ALK induces phosphorylation of STAT3 and SRC, and has exclusively cytoplasmatic localisation due to loss of ALK's NLS sequence 	NIH3T3
ATIC		15208656	role in cancer	fusion	fusion	
ATIC	anaplastic large cell lymphoma	15208656	fusion partner		ALK	
ATIC	anaplastic large cell lymphoma	10702393	role in cancer	fusion	fusion	
ATIC	anaplastic large cell lymphoma	10702393	fusion partner		ALK	
ATM		25483068	escaping programmed cell death	promotes	loss of ATM activity results in increased mitochondria and reactive oxygen species that drive apoptosis	
ATM		25775545	genome instability and mutations	suppresses	ATM is activated by DNA SSBs and coordinates their repair with DNA replication by inducing G1 cell cycle delay	
ATM		26220524	invasion and metastasis	suppresses	loss of ATM accelerates EMT in mouse models of pancreatic ductal adenocarcinoma	
ATM		26143490	senescence		inactivation of ATM overcomes replication stress-induced senescence	
ATM	breast cancer	25970706	tumour promoting inflammation	promotes	oxidised ATM promotes abnormal proliferation of cancer-associated fibroblasts	
ATM		24553124	cell division control		controls proper structure of the mitotic spindle	
ATM		26586433	cell replicative immortality	promotes	required for the localisation of telomerase to telomeres and telomere elongation in immortal human cells	
ATM		27413114	genome instability and mutations	suppresses	plays a central role in the repair of DNA double-strand breaks, recruits and cooperates with other sensor proteins, including 53BP1 and BRCA1	
ATM		27727438	types of alteration in cancer		recurrent N1983S, D1853N, R337C, R3008H, frameshift and truncating mutations throughout the gene	
ATM		20719876	role in cancer	TSG	TSG	
ATM		27413114	function summary		plays a central role in the repair of DNA double-strand breaks, recruits and cooperates with other sensor proteins	
ATM		11571274	function summary		phosphorylates histone H2AX in response to DNA double-strand breaks	
ATP1A1		25967398	function summary		alpha-1 subunit of the sodium potassium ATPase, inhibition enhances antiproliferative effect of hyperosmotic conditions through an increased G2/M cell cycle block	
ATP1A1	aldosterone-producing adenoma	27727438	types of alteration in cancer		recurrent L104R	
ATP1A1	melanoma	19243476	invasion and metastasis	promotes	overexpression promotes metastasis	
ATP1A1	melanoma	19243476	role in cancer	oncogene	oncogene	
ATP1A1	aldosterone-producing adenoma	23416519	role in cancer	TSG	TSG	
ATP1A1	adrenal cells	26418325	impact of mutation on function		L104R mutation leads to cell acidification, membrane depolarisation and Ca(2+)-dependent stimulation of aldosterone synthesis	
ATP1A1	melanoma	19243476	escaping programmed cell death	promotes	overexpression inhibits apoptosis	
ATP1A1	medulloblastoma	21498719	types of alteration in cancer		overexpressed	
ATP1A1	melanoma	19243476	types of alteration in cancer		overexpressed	
ATP2B3		23416519	function summary		Ca2+ ATPase, essential to clear calcium ions from the cytoplasm	
ATP2B3	aldosterone producing adrenal adenomas	24179102	role in cancer	TSG	TSG	
ATP2B3	aldosterone producing adrenal adenomas	24179102	types of alteration in cancer		inframe deletions leading to distortion of Ca-binding region are associated with increased production of aldosterone	
ATP2B3	aldosterone producing adrenal adenomas	24179102	suppression of growth	promotes	LOF mutations result in increased production of aldosterone which stimulates tumour growth	
ATR		26567218	function summary		DNA-activated PIK kinase, regulator of DDR, upregulates cell cycle checkpoint pathways, protects the integrity of replicating chromosomes	
ATR		12526805	genome instability and mutations	suppresses	regulates chromosome fragile sites stability	
ATR		26387736	escaping programmed cell death	promotes	has antiapoptotic activity at the mitochondria in response to UV damage	
ATR		26586433	genome instability and mutations	suppresses	regulates the recruitment of telomerase to telomeres	
ATR		19230642	genome instability and mutations	suppresses	coordinates replication fork stability and repair	
ATR		15282542	genome instability and mutations	suppresses	critical for MMR	
ATR		23085754	change of cellular energetics	promotes	controls cellular adaptation to hypoxia through positive regulation of HIF-1 expression	
ATR		11865061	suppression of growth	promotes	causes accumulation of p53 under hypoxia, leading to cell growth arrest	
ATR		18245444	senescence	promotes	ectopic activation of ATR is sufficient to promote cell cycle arrest and, if persistent, triggers p53-dependent senescence	
ATR		26567218	role in cancer	TSG	TSG	
ATR		27727438	types of alteration in cancer		recurrent I774fs*, M211T, R2425Q	
ATR		10691732	differentiation and development		disruption leads to chromosomal fragmentation and early embryonic lethality	
ATR		11721054	cell division control		deletion of ATR causes loss of DNA damage checkpoint responses and cell death	
ATR		26567218	cell division control		controls S-phase checkpoint	
ATR	Hodgkin's lymphoma	18357388	impact of mutation on function		deletion of exon 29-34 and insertion of 137 bp in exon 46/47 is associated with a delay/abrogation in repair for DNA DSBs and SSBs as well as a defect in p53 accumulation	
ATR		16103057	impact of mutation on function		truncation of ATR protein abrogates damage-induced Chk1 phosphorylation and cell cycle arrest	K562
ATRX	mouse brain	18227278	genome instability and mutations	suppresses	transition from prometaphase to metaphase is prolonged in ATRX-depleted cells and is accompanied by defective sister chromatid cohesion and congression at the metaphase plate	
ATRX		26936505	impact of mutation on function		in human glioma ATRX mutations are associated with increased mutation rate at the single-nucleotide variant level, in mouse model deficiency impairs nonhomologous end joining and increases sensitivity to DNA-damaging agents that induce double-stranded DNA breaks	
ATRX	mouse brain	18227278	cell division control		required for sister chromatid cohesion and congression during mitosis	
ATRX		15242786	cell division control		required for chromosome alignment and meiotic spindle organisation in metaphase II	
ATRX		10742099	global regulation of gene expression		regulator of DNA methylation, mutations result in changes to cellular methylation patterns	
ATRX		23916100	function summary		ATP-dependent chromatin-remodelling factor	
ATRX	glioma	26936505	role in cancer	TSG	TSG	
ATRX	sarcomas	26428317	genome instability and mutations	suppresses	loss is strongly associated with alternative lengthening of telomeres	
ATRX	pancreatic neuroendocrine tumours	24148618	genome instability and mutations	suppresses	loss is associated with chromosome instability	
ATRX	mouse	20110566	genome instability and mutations	suppresses	interacts with H3.3 in maintaining the structural integrity of telomere in pluripotent embryonic stem cells	
ATRX		27727438	types of alteration in cancer		recurrent R1426*	
AXIN1		9601641	function summary		repressor of the Wnt signalling pathway, part of the beta-catenin destruction complex	
AXIN1	haematopoietic stem cells	12717450	cell replicative immortality	suppresses	ectopic expression of axin leads to inhibition of HSC growth in vitro and reduced reconstitution in vivo	
AXIN1		19731416	escaping programmed cell death	suppresses	activates p53 through phosphorylation, directing cell to apoptosis after high-dose UV irradiation	
AXIN1		19131971	suppression of growth	promotes	promotes formation of a degradation complex for c-Myc	
AXIN1	glioblastoma	25735981	suppression of growth	promotes	repressor of Wnt signalling that reduces beta catenin stability and represses beta-catenin/TCF-dependent transcription	
AXIN1	colorectal cancer	26894286	suppression of growth	promotes	mutations affect tumour sizes and the mucinous component via Wnt/ beta-catenin pathway	
AXIN1		26974125	impact of mutation on function		missense mutations R103M, RGS K203M and RGS L101P destabilise RGM domain which leads to formation of nanometre-scale aggregates of Axin and allows for activation of beta catenin	
AXIN1		25735981	role in cancer	TSG	TSG	
AXIN2		15735151	suppression of growth	promotes	repressor of Wnt signalling that reduces beta catenin stability and represses beta-catenin/TCF-dependent transcription	
AXIN2		25236910	function summary		negatively regulates beta-catenin-dependent Wnt signalling, expression is positively regulated by upstream Wnt- and beta-catenin-dependent signals	
AXIN2		25236910	role in cancer	TSG	TSG	
B2M		3312414	function summary		Component of the MHC class I antigen complex	
B2M		27727438	types of alteration in cancer		recurrent missense mutations of the 1st amino acid, recurrent L15fs	
B2M	melanoma	23784959	role in cancer	TSG	TSG	
B2M	melanoma	1898655	escaping immune response to cancer	suppresses	inactivating mutations in 5' region of the gene lead to impaired expression of HLA class I antigen, thus helping tumour to avoid the immune destruction	FO-1
BAP1		25533676	role in cancer	TSG	TSG	
BAP1	malignant peritoneal mesothelioma	28034829	types of alteration in cancer		altered by Copy Number Loss, mutation, and/or loss of protein expression in over 70% of tumour samples	
BAP1	primary fibroblasts an mesothelial cells	28614305	escaping programmed cell death	suppresses	localised at ER, it regulates the release of calcium ions from the ER to cytoplasm that promotes apoptosis; reduced levels of BAP1 at ER result in resistance to apoptosis	
BAP1	breast adenocarcinoma	25228651	genome instability and mutations	suppresses	inactivation results in chromosome instability caused by lack of gamma-tubulin deubiquitination during mitosis	MDA-MB-468
BAP1	breast cancer	26419610	proliferative signalling	promotes	promotes cancer cell proliferation by deubiquitinating and stabilising KLF5	
BAP1	breast cancer	26419610	invasion and metastasis	promotes	promotes metastasis by deubiquitinating and stabilising KLF5, KD decreases cell migration and invasiveness in vitro and inhibits lung metastasis in mouse model	
BAP1		22883232	change of cellular energetics	promotes	overexpression decreases ubiquitination of PGC-1alpha, protecting it from degradation and promoting gluconeogenesis	
BAP1		25582751	cell division control		important in the G1/S transition, regulates the levels of cell cycle proteins by affecting E2F1-dependent  S-phase gene expression	
BAP1	uveal melanoma	25582751	invasion and metastasis	promotes	KD reduces the invasiveness of cells	OCM1 and OM431
BAP1		25582751	function summary		crucial for histone H2A deubiquitination	
BAP1	melanoma	25521456	escaping programmed cell death	suppresses	KD causes drop in the protein levels of survivin, a member of anti-apoptotic proteins and increases apoptosis 	
BAP1		23550303	function summary		a deubiquitylase associated with multi-protein complexes that regulate the cell cycle, cellular differentiation, cell death, gluconeogenesis and the DNA damage response	
BAP1	NSCLC	18757409	escaping programmed cell death	suppresses	suppression of deubiquitinating activity or nuclear localisation of BAP1 reduces its ability to promote apoptosis	NCI-H226
BCL10		26771713	genome instability and mutations	suppresses	functions as part of the DNA damage response	
BCL10	kidney	9989495	escaping programmed cell death	suppresses	weakly proapoptotic	HEK-293
BCL10		10319863	function summary		CARD domain-containing protein, activator of NF-kB	
BCL10	peripheral T cell lymphoma	22818167	types of alteration in cancer		commonly down-regulated	
BCL10	MALT B-cell lymphoma	9989495	fusion partner		IGH	
BCL10	mouse B-cell	15878976	escaping programmed cell death	promotes	prevents B-cell antigen receptor-induced growth arrest and apoptosis via NF-kappaB activation	WEHI-231
BCL10	MALT B-cell lymphoma	21954216	escaping programmed cell death	promotes	overexpression is associated with inhibition of caspase-8-related apoptosis	
BCL10	cervical cancer	22564715	proliferative signalling	promotes	downregulation of BCL10 inhibits the viability of cancer cells through G1 arrest due to disrupted activation of NF-kB-dependent cyclin D1 signalling	
BCL10	ABC-DLBCL	26668357	proliferative signalling	promotes	in complex with CARD11 and MALT1 activates NF-kB and JNK, enforced activation of this complex is sufficient to drive transformed B-cell expansion in vivo	
BCL10		24681956	cell division control		knockdown of endogenous BCL10 retards cell proliferation by G0/G1 phase accumulation	
BCL10	oral cancer	24681956	role in cancer	oncogene	oncogene	
BCL10		11397650	role in cancer	TSG	TSG	
BCL10	MALT B-cell lymphoma	9989495	role in cancer	fusion	fusion	
BCL10		24681956	invasion and metastasis	promotes	knockdown of endogenous BCL10 significantly reduces cell migration and invasion abilities	
BCL11A		26375765	function summary		transcription factor, repressor of fetal hemoglobin expression 	
BCL11A	CLL	19369625	fusion partner		IGH 	
BCL11A	triple negative breast cancer 	25574598	cell replicative immortality	promotes	high levels of BCL11A promote tumour development by increasing the clonogenic potential of the cells	
BCL11A	NSCLC	28404650	fusion partner		ALK	
BCL11A		19369625	role in cancer	oncogene	oncogene	
BCL11A		19369625	differentiation and development	oncogene	upregulation by fusion to the IGH locus results in aberrant differentiation of lymphocytes	
BCL11A		28404650	role in cancer	fusion	fusion	
BCL11B		25486566	role in cancer	TSG	TSG	
BCL11B		23040356	role in cancer	oncogene	oncogene	
BCL11B		22245141	function summary		inhibits HDM2 (ubiquitin ligase for p53) expression in a p53-dependent manner 	
BCL11B	Ewing sarcoma	23527175	function summary		acts as a transcriptional repressor and it's upregulation by EWS-FLI fusion oncogene is necessary for the maintenance of the transformed phenotype 	
BCL11B		25486566	types of alteration in cancer		translocations that delete the Bcl11b promote atm-deficient T cell acute lymphoblastic leukaemia 	
BCL11B	bilineal T/myeloid acute leukaemia	21225930	fusion partner		TLX3 	
BCL11B	T-cell leukaemia	22867996	fusion partner		IKZF2 	
BCL11B	AML	26186352	fusion partner		ZEB2 	
BCL11B		12717433	function summary		Zn-finger transcription factor reqiured for diferentiation of T lymphocytes 	
BCL11B		21225930	role in cancer	fusion	fusion	
BCL9		19738061	function summary		enhances beta-catenin-mediated transcriptional activity	
BCL9		19738061	role in cancer	oncogene	oncogene	
BCL9	B-cell lymphoma	9490669	role in cancer	fusion	fusion	
BCL9		19738061	mouse model		knockdown significantly increases the survival of xenograft mouse models of cancer by reducing tumour load, metastasis, and host angiogenesis through down-regulation of c-Myc, cyclin D1, CD44 and VEGF expression by tumour cells 	
BCL9	B-cell lymphoma	9490669	fusion partner		IGL	
BCL9		19738061	angiogenesis	promotes	knockdown significantly increases the survival of xenograft mouse models by reducing host angiogenesis through down-regulation of VEGF expression by tumour cells	
BCL9		19738061	proliferative signalling	promotes	knockdown significantly increases the survival of xenograft mouse models of cancer by reducing tumour load through down-regulation of c-Myc, cyclin D1, CD44 expression by tumour cells	
BCL9		19738061	invasion and metastasis	promotes	knockdown significantly increases the survival of xenograft mouse models by reducing metastasis and EMT 	
BCL9	B-cell ALL	9490669	types of alteration in cancer		fusion partner of IGL	
BCL9L	pancreatic cancer	27713160	role in cancer	Oncogene	Oncogene	
BCL9L	colorectal cancer	28073006	role in cancer	TSG	TSG	
BCL9L	colon cancer	15371335	invasion and metastasis	promotes	KD reduces migration and promotes an epithelial-like morphology	SW480
BCL9L	pancreatic cancer	27713160	invasion and metastasis	promotes	KD reduces migration and invasion in vitro and reduces metastasis in a xenograft model	Panc-1
BCL9L	pancreatic cancer	27713160	proliferative signalling	promotes	KD reduces proliferation	Panc-1
BCL9L		15574752	proliferative signalling	promotes	overexpression enhances beta-catenininduced transformation	RK3E
BCL9L	colorectal cancer	28073006	genome instability and mutations	suppresses	KD promotes tolerance of chromosome missegregation and propogation of aneuploidy	
BCL9L		15574752	function summary		transcriptional regulator that interacts with and promotes transcriptional activity of beta-catenin	
BCL9L	aneuploid colorectal cancer	28073006	types of alteration in cancer		frequent inactivating mutations	
BCL9L		21703997	mouse model		overexpression in Apc-min+/- mouse model leads to formation of more and larger adenomas	
BCL9L		27727438	types of alteration in cancer		recurrent P1127fs*21, P449fs*14, Q452fs*11, P1128fs*42	
BCOR	endometrial stromal sarcoma 	23580382	fusion partner		ZC3H7B	
BCOR		26773734	role in cancer	TSG	TSG	
BCOR		23580382	role in cancer	fusion	fusion	
BCOR	undifferentiated small blue round cell sarcoma	26752546	fusion partner		MAML3	
BCOR	undifferentiated sarcomas of male children	25360585	fusion partner		CCNB3	
BCOR	APL	20807888	fusion partner		RARA	
BCOR		17517692	differentiation and development		required for vertebrate laterality determination	
BCOR	high-grade uterine sarcoma	29200103	types of alteration in cancer		internal tandem duplications (ITDs) involving exon 15 	
BCOR		10898795	function summary		co-repressor that potentiates transcriptional repression by BCL-6 	
BCOR		16943429	global regulation of gene expression		the BCOR complex contains Polycomb group proteins, including a histone H2A ubiquitin E3 ligase, an SCF ubiquitin E3 ligase, and a JmjC domain histone H3 K36 demethylase, which through epigenetic modifications of chromatin, enable silencing of BCL6 targets	
BCOR	bone marrow cells	26847029	suppression of growth	promotes	LOF mutations result in increased proliferation, while overexpression impairs proliferation	
BCOR		26847029	differentiation and development		helps control myeloid cell differentiation	
BCOR	T-ALL	28827447	impact of mutation on function		deletion of exon 4 results in Myc hyperactivation and induces leukaemic transformation	
BCOR	T-ALL	28827447	function summary		counteracts the oncogenic active NOTCH to restrain transformation	
BCORL1		17379597	function summary		transcriptional corepressor that contributes to the repression of E-cadherin, in complex with CTBP1 and class II HDACs	
BCORL1	hepatocellular carcinoma	26879601	invasion and metastasis	promotes	promotes cell migration and invasion	
BCORL1	AML	21989985	role in cancer	TSG	TSG	
BCORL1	colon carcinoma	27727438	types of alteration in cancer		recurrent P1681fs and G1682fs at C-terminus 	
BCORL1	HNSCC	25275298	types of alteration in cancer		recurrent L1132P	
BCORL1	hepatocellular carcinoma	26879601	types of alteration in cancer		frequently overexpressed, represses transcription of E-cadherin 	
BCORL1	hepatocellular carcinoma	26879601	role in cancer	oncogene	oncogene	
BIRC3		8548810	function summary		modulator of TNFR2/NF-kB signalling	
BIRC3	glioblastoma	26888114	function summary		inhibitor of apoptosis, indirectly regulates caspase activation through E3 ligase activity, TNF-signalling and NF-kB signalling	
BIRC3	glioblastoma	26888114	escaping programmed cell death	promotes	inhibitor of apoptosis through E3 ligase activity, TNF-signalling and NF-kB signalling	
BIRC3	NSCLC	26094954	impact of mutation on function		mutants lacking an intact RING finger domain lose their ubiquitin ligase activity and gain transforming capability	
BIRC3	glioblastoma	15711920	role in cancer	fusion	fusion	
BIRC3	glioblastoma	26888114	clinical impact		lower expression levels of BIRC3 are associated with a markedly favourable outcome	
BIRC3	MALT B-cell lymphoma	15711920	fusion partner		MALT1	
BIRC3	lung squamous cell carcinoma	26094954	role in cancer	TSG	TSG	H1703
BLM		25897130	function summary		highly active in binding and unwinding G-quadruplexes	
BLM		26788541	function summary		DNA helicase that participates in DNA DSB repair	
BLM		10823897	genome instability and mutations	suppresses	disrupts potentially recombinogenic molecules that arise at sites of stalled replication forks by promoting branch migration of Holliday junctions	
BLM		12019152	genome instability and mutations	suppresses	plays an important role in DNA DSB repair	
BLM		14642567	differentiation and development		homozygous mutant mice exhibit embryonic lethality	
BLM		11399766	escaping programmed cell death	suppresses	takes part in induction of p53-mediated apoptosis	
BLM		11781842	suppression of growth	promotes	ectopic expression of BLM causes an anti-proliferative effect	
BLM		26788541	role in cancer	TSG	TSG	
BLM		14642567	genome instability and mutations	suppresses	in heterozygous mouse mutants, a negative correlation between the quantity of Blm protein and the level of chromosome instability and tumour predisposition is observed	
BMPR1A	juvenile mixed polyposis syndrome	19438883	types of alteration in cancer		LOF mutations	
BMPR1A		15102710	differentiation and development		regulates differentiation in postnatal hair follicles and is essential for tooth development	
BMPR1A	breast cancer	26274893	invasion and metastasis	promotes	deletion of BMPR1a impairs metastasis	
BMPR1A	breast cancer	26274893	function summary		bone morphogenetic protein receptor, mediates growth inhibitory signals via TGF beta pathway	
BMPR1A	breast cancer	26274893	mouse model		deletion in mice results in delayed mammary tumour onset, metastasis and significantly extended survival	
BMPR1A	breast cancer	26274893	role in cancer	oncogene	oncogene	
BMPR1A		23531103	clinical impact		decreased expression of BMPR1A is associated with malignant gallbladder lesions	
BMPR1A	breast cancer	26274893	clinical impact		expression correlates with decreased survival 	
BMPR1A	juvenile mixed polyposis syndrome	19438883	role in cancer	TSG	TSG	
BRAF	lung invasive mucinous adenocarcinoma	26200269	fusion partner		TRIM4	
BRAF	lung adenocarcinoma	25985019	fusion partner		SND1	
BRAF	APL	10610177	fusion partner		TIF1A	
BRAF		21917714	proliferative signalling	promotes	increased phosphorylation of MAP2K1/MAP2K2 by BRAF directs cells towards proliferation rather than differentiation	
BRAF		12068308	impact of mutation on function		V600E mutation causes kinase hyperactivity by destabilising the native - inactive form and rendering kinase activity independent of RAS activation and dimerisation	
BRAF		21917714	differentiation and development		increased phosphorylation of MAP2K1/MAP2K2 by BRAF suppresses differentiation of cells	
BRAF		16547495	escaping programmed cell death	promotes	B-raf signalling protects melanoma cells from anoikis, which is induced by knock-out of BRAF	
BRAF	melanoma	14500344	escaping programmed cell death	promotes	knock-down induces apoptosis	
BRAF		15488754	function summary		serine/threonine protein kinase, component of RAS-ERK signalling pathway downstream of RAS, requires dimerisation for activity and downstream signalling	
BRAF		12068308	role in cancer	oncogene	oncogene	
BRAF		26200269	role in cancer	fusion	fusion	
BRAF	mouse	10610177	impact of mutation on function		fusion with TIF1A disrupts retinoic acid-dependent cell differentiation	
BRCA1	triple-negative breast cancer	28052035	invasion and metastasis	promotes	overexpression of IRIS, a product of alternative splicing of BRCA1 promotes cancer through suppressing BRCA1 expression, enhancing basal-biomarkers, EMT-inducers, and stemness-enforcers expression	
BRCA1	mouse models	22034435	impact of mutation on function		inactivation of C-terminal phosphoprotein recognition domain, but not the E3 ligase domain, inhibits tumour suppressing capability	
BRCA1		15448696	cell division control		IRIS, a product of alternative splicing of BRCA1 promotes DNA replication	
BRCA1		17505536	differentiation and development		involved in mammary gland development	
BRCA1		17616687	cell division control		activates G2-M checkpoint	
BRCA1		24950059	differentiation and development		haploinsufficiency leads to altered expression of genes involved in cellular differentiation	
BRCA1		15967981	differentiation and development		depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells	
BRCA1		27727438	types of alteration in cancer		recurrent missense mutations: K1183R, P871L	
BRCA1	breast cancer	7545954	role in cancer	TSG	TSG	
BRCA1	breast cancer	25010005	change of cellular energetics	promotes	inhibits glycolysis while keeping TCA cycle and oxidative phosphorylation activated, overexpression increases activity of antioxidation pathways	
BRCA1	skeletal muscle	24565757	change of cellular energetics	promotes	knock-down results in decreased oxygen consumption by the mitochondria and increased reactive oxygen species production	
BRCA1	breast cancer	26057449	invasion and metastasis	promotes	cytosolic misslocalisation promotes metastasis	
BRCA1		12082091	escaping programmed cell death	suppresses	induces apoptosis	
BRCA1		16843262	angiogenesis	suppresses	suppresses expression of angiogenic factors	
BRCA1		25956865	genome instability and mutations	suppresses	involved in nucleotide-excision repair, base-excision repair and non-homologous end-joining	
BRCA1		10197592	genome instability and mutations	suppresses	participates in DNA damage response pathway associated with the activation of homologous recombination and double-strand break repair	
BRCA1		16998500	function summary		DNA damage repair and cell cycle control nuclear protein, component of transcriptional machinery	
BRCA2		27727438	types of alteration in cancer		recurrent missense mutations: N372H	
BRCA2		25348552	clinical impact		germline variant N372H is associated with higher risk of ovarian cancer, non-Hodgkin lymphoma	
BRCA2		24902638	escaping programmed cell death	suppresses	silencing promotes resistance to anoikis	
BRCA2		25833843	genome instability and mutations	suppresses	stimulates RAD51-dependent homologous recombination during mitosis	
BRCA2		14660434	differentiation and development	suppresses	deficiency leads to meiotic impairment and infertility in mice	
BRCA2		24598993	function summary		DNA damage repair protein	
BRCA2		20719876	role in cancer	TSG	TSG	
BRCA2		26976601	cell division control		critical for meiotic recombination	
BRCA2		14681210	genome instability and mutations	suppresses	critical for stabilization of stalled replication forks	
BRD4		26939702	function summary		positively regulates EZH2 transcription through upregulation of C-MYC	
BRD4		24796395	cell replicative immortality	promotes	inhibition of BRD4 attenuates tumour cell self-renewal and suppresses stem cell signalling in MYC driven medulloblastoma	
BRD4		17329240	cell division control		inactivation blocks G2/M passage, overexpression causes cell cycle arrest at G1/S	
BRD4		17329240	global regulation of gene expression		plays a role in maintaining the global acetylation state of chromatin	
BRD4	NUT midline carcinoma	22017582	role in cancer	fusion	fusion	
BRD4		27450555	function summary		bromodomain protein, regulator of cell cycle, coordinates chromatin structure and transcription	
BRD4	HCC	26575167	role in cancer	oncogene	oncogene	
BRD4	RCC	28391274	escaping programmed cell death	promotes	inhibition of BRD4 induces apoptosis	
BRD4	RCC	28391274	proliferative signalling	promotes	inhibition of BRD4 suppresses cell proliferation	
BRD4		26111795	proliferative signalling	promotes	positively regulates transcription of HOTAIR, a long noncoding RNA essential for glioblastoma proliferation	
BRD4	NUT midline carcinoma	17329240	fusion partner		NUT	
BRD4		17329240	interaction with pathogen		cellular corepressor that inhibits the expression of HPV-encoded E6 and E7 oncoproteins which antagonise p53 and pRB tumour suppressor activity	
BRIP1		26637282	genome instability and mutations	suppresses	suppresses microsatellite instability	
BRIP1		23530059	genome instability and mutations	suppresses	takes part in DNA DSB repair through homologous recombination	
BRIP1	bladder cancer	22137763	genome instability and mutations	suppresses	downregulation by oncogenic H-RAS G12V triggers BRCA1 chromatin dissociation	T24
BRIP1		26709662	function summary		DNA repair RecQ DEAH helicase family protein	
BRIP1		26709662	role in cancer	TSG	TSG	
BRIP1		26637282	mouse model		mouse knock-outs are predisposed to lymphoma	
BRIP1		24040146	differentiation and development		loss results in abnormal mammary acinar morphogenesis	
BRIP1		21127055	cell division control		recognition of BRIP1 by TopBP1 is critical for the activation of the DNA replication checkpoint at stalled replication forks	
BTK	colorectal cancer	19471023	function summary		negatively regulates beta-catenin-dependent Wnt signalling	
BTK		24954503	function summary		non-receptor tyrosine kinase of the Tec family, plays a role in BCR signalling, is essential for B-cell development	
BTK	murine fibroblasts	7538439	genome instability and mutations	promotes	E41K shows an increase in phosphorylation on tyrosine residues, an increase in membrane targeting and drives proliferation of cells in soft agar	NIH 3T3
BTK	myeloma	25589346	cell replicative immortality	promotes	enforced transgenic expression of BTK intensifies features of cancer stemness	
BTK	B lymphocytes	17367410	escaping programmed cell death	suppresses	promotes apoptosis upon oxidative stress by preventing activation of the antiapoptotic and pro-proliferatory transcription factor STAT3 	
BTK		25082755	impact of mutation on function		C481S is a relapse-specific mutation in mantle cell lymphoma which results in constant activation and ibrutinib resistance	
BTK	prostate cancer	26383180	escaping programmed cell death	promotes	BTK-C isoform is abundantly expressed from alternative, upstream TSS and its downregulation or inhibition decreases cell survival and induces apoptosis	
BTK	colorectal cancer	19471023	role in cancer	TSG	TSG	
BTK		24954503	role in cancer	oncogene	oncogene	
BTK		26804170	types of alteration in cancer		p65 isoform is abundantly expressed in colon carcinoma and has strong transforming capabilities while it's inhibition abolishes the transforming activity of RAS	
BTK	breast cancer	23913792	escaping programmed cell death	promotes	overexpression inhibits apoptosis induced by Dox	
BUB1B	lung adenocarcinoma	26000094	invasion and metastasis	promotes	KD significantly inhibits anchorage-independent growth and reduces metastasis in mouse model studies	
BUB1B	premature chromatid separation syndrome	16411201	role in cancer	TSG	TSG	
BUB1B		19411850	cell division control		reduction of Bub1 levels during the G2 phase causes accelerated mitotic entry	
BUB1B		15592459	function summary		regulates chromosome-spindle attachments	
BUB1B		16411201	function summary		spindle-assembly checkpoint gene	
BUB1B	multiple myeloma	25698537	proliferative signalling	promotes	increased BUB1B expression promotes cell proliferation	
BUB1B	colorectal cancer	18699967	genome instability and mutations	suppresses	reduced level is associated with aneuploidy	
BUB1B		25964054	genome instability and mutations	suppresses	protects against aneuploidy	
BUB1B	lung adenocarcinoma	26000094	escaping programmed cell death	promotes	knockdown sensitises cells to anoikis	
BUB1B	DLBCL	23400934	proliferative signalling	promotes	overexpression is associated with increased cell proliferation	
BUB1B		17389228	function summary		essential for the assembly of the functional inner centromere	
CACNA1D	adrenal aldosterone-producing adenoma	23913001	proliferative signalling	promotes	activating mutations lead to elevated production of aldosterone and in consequence increased proliferation	
CACNA1D	adrenal aldosterone-producing adenoma	23913001	role in cancer	oncogene	oncogene	
CACNA1D	adrenal aldosterone-producing adenoma	27727438	types of alteration in cancer		recurrent F767L, G403R, I770M	
CACNA1D	adrenal aldosterone-producing adenoma	23913001	impact of mutation on function		G403R and I770M alteration results in channel activation at less depolarised potentials, resulting in an increased calcium ion influx and stimulation of aldosterone production, G403 alterations also impair channel inactivation	
CACNA1D		23913001	function summary		voltage-gated calcium channel	
CALR	oesophageal SCC	19684620	invasion and metastasis	promotes	promotes cell motility	
CALR	oesophageal SCC	19684620	escaping programmed cell death	promotes	increases resistance to anoikis	
CALR	gastric cancer	19050968	invasion and metastasis	promotes	high expression is associated with increased invasiveness	
CALR	gastric cancer	19050968	angiogenesis	promotes	overexpression enhances angiogenesis	
CALR	oral SCC	23375593	proliferative signalling	promotes	KD results in significantly reduced growth rate	
CALR	oral SCC	23375593	invasion and metastasis	promotes	KD impairs cell motility and  anchorage-independent growth	
CALR		28470469	types of alteration in cancer		frameshift mutations in exon 9	
CALR		19940256	function summary		a chaperon protein that directs proper conformation of proteins and glycoproteins in the ER, and plays a role in homeostatic control of cytosolic and ER calcium levels; also involved in wound healing, the immune response, and fibrosis	
CALR	IPSC-derived hematopoietic  cells	26817954	proliferative signalling	promotes	activates the JAK2 downstream pathway via its association with c-MPL, promoting proliferation	
CALR		28470469	impact of mutation on function		loss of C-terminal domain, containing ER-retention signal results in changed subcellular localisation of mutant protein; mutant C-terminal domain binds to and inactivates CALR autoinhibitory domain increasing its ability to activate MPL (thrombopoietin receptor)	
CALR		26697989	role in cancer	oncogene	oncogene	
CALR	mouse	24325356	impact of mutation on function		overexpression of L367fs*46 CALR deletion caused cytokine-independent growth in vitro due to the activation of STAT5	Ba/F3
CAMTA1	glioblastoma	21857646	role in cancer	TSG	TSG	
CAMTA1	glioblastoma	21857646	suppression of growth	promotes	induces the expression of cardiac natriuretic peptide A, which gives rise to peptide hormones with anti-proliferative effects	
CAMTA1	epithelioid hemangioendothelioma	25961935	fusion partner		 WWTR1	
CAMTA1	epithelioid hemangioendothelioma	25961935	role in cancer	fusion	fusion	
CAMTA1		21857646	function summary		transcription factor, induces the expression of the anti-proliferative cardiac hormone natriuretic peptide A (NPPA)	
CAMTA1	epithelioid hemangioendothelioma	25961935	impact of mutation on function		WWTR1-CAMTA1 fusion results in nuclear localisation and constitutive activation of WWTR1-like transcriptional program	
CANT1		12234496	function summary		soluble calcium-activated nucleotidase	
CANT1	prostate cancer	18451133	impact of mutation on function		provides prostate specific promoter to ETV4 	
CANT1	prostate cancer	18451133	fusion partner		ETV4	
CANT1	prostate cancer	18451133	role in cancer	fusion	fusion	
CARD11		23149938	impact of mutation on function		activating mutations disrupt autoinhibitory function of CARD11, promote BCL10 association and subsequent ubiquitination leading to constant NF-kB activation, which promotes cell survival	Jurkat T
CARD11	cutaneous squamous cell carcinoma	26212909	types of alteration in cancer		increased expression and somatic mutation rate	
CARD11	lymphoma	23149938	role in cancer	oncogene	oncogene	Jurkat T
CARD11		23149938	escaping programmed cell death	promotes	activating mutations promote cell survival via permanent NF-kB activation	Jurkat T
CARD11		12356734	function summary		membrane-associated guanylate kinase family member containing CARD, PDZ, SH3 and GUK domains, activator of NF-kB	
CARD11	DLBCL	20799731	role in cancer	oncogene	oncogene	
CARS		26184909	role in cancer	TSG	TSG	
CARS		13679433	role in cancer	fusion	fusion	
CARS	inflammatory myofibroblastic tumour	13679433	fusion partner		ALK	
CARS		26184909	escaping programmed cell death	suppresses	loss of CARS inhibits cystine deprivation-induced ferroptosis 	
CARS		8468064	function summary		attaches cysteine to its cognate tRNA 	
CASP8	TN breast cancer	27082853	proliferative signalling	promotes	KD strongly decreases cell growth by delaying G0/G1- to S-phase transition and increasing p21, p27 and hypo-phosphorylated/active form of pRb levels	MDA-MB-231
CASP8	AML	29191655	impact of mutation on function		Q482H mutation of procaspase-8 abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization	
CASP8		28462525	tumour promoting inflammation	suppresses	negatively regulates expression of pro-inflammatory genes and inflammatory signalling, inhibits necroptosis	
CASP8		28462525	escaping programmed cell death	suppresses	activates caspase3 and caspase7 by proteolytic cleavage, thus initiating apoptosis	
CASP8		25451151	tumour promoting inflammation	promotes or suppresses	both positively and negatively regulates NLRP3 inflammasome	
CASP8	GBM	28594322	angiogenesis	promotes	through activation of NF-kB, enhances the expression and secretion of VEGF, IL-6, IL-8, IL-1beta and MCP-1, leading to neovascularization	
CASP8		19383910	invasion and metastasis	promotes	promotes cell migration and metastasis in non-apoptotic cells	
CASP8		22343728	role in cancer	TSG	TSG	
CASP8	TN breast cancer	27082853	invasion and metastasis	suppresses	KD increases migratory and metastatic capacity	MDA-MB-231
CASP8		28462525	function summary		aspartatespecific cysteine protease, essential part of a deathinducing signalling complex (DISC)	
CBFA2T3	AML	26968532	fusion partner		RUNX1	
CBFA2T3	AML	23153540	fusion partner		GLIS2	
CBFA2T3	B-cell lymphoma	22420028	fusion partner		IGH	
CBFA2T3		20123979	differentiation and development		modulates Notch-dependent lineage allocation in haematopoiesis	
CBFA2T3	breast cancer	15301688	types of alteration in cancer		promoter aberrantly methylated	
CBFA2T3		23840896	role in cancer	TSG	TSG	
CBFA2T3	B-lymphoblasts	23840896	suppression of growth	promotes	induced expression is associated with increased phosphorylation of mitogen-activated protein kinases and inhibition of proliferation with a decreased fraction of cells in S-phase	Raji
CBFA2T3	B-lymphoblasts	25974097	change of cellular energetics	promotes	promotes degradation of HIF1A	Raji
CBFA2T3	B-lymphoblasts	23840896	change of cellular energetics	promotes	inhibits glycolysis and stimulates mitochondrial respiration and production of ROS	Raji
CBFA2T3		20123979	function summary		contributes to repression of canonical Notch target genes	
CBFA2T3		18456661	function summary		transcriptional corepressor	
CBFA2T3		22420028	role in cancer	fusion	fusion	
CBFB	mouse embryos	8929537	impact of mutation on function		CBFB-MYH11 fusion gene product acts as a dominant repressor of PEBP2/CBF function	
CBFB		9819429	impact of mutation on function		CBFB-SMMHC fusion protein sequesters RUNX1 into cytoskeletal filaments and aggregates, thereby disrupting RUNX1-mediated regulation of gene expression	
CBFB	AML	24342433	fusion partner		MYH11	
CBFB		8351518	fusion partner		SMMHC	
CBFB	mouse	25371180	differentiation and development		deficiency results in a block of differentiation and stem/progenitor cell expansion in haematopoiesis	
CBFB		12434156	differentiation and development		critical for bone development	
CBFB	mouse embryos	8929537	mouse model		knocked-in leukaemia gene CBFB-MYH11 causes failure of embryonic haematopoiesis and lethal haemorrhages	
CBFB		25371180	role in cancer	TSG	TSG	
CBFB		24342433	role in cancer	fusion	fusion	
CBFB	breast cancer	20591170	invasion and metastasis	promotes	required for the transcription of a subset of Runx2-target genes that are sufficient to maintain the invasive phenotype of the cells	
CBFB		25079347	function summary		negatively regulates RUNX-dependent ribosomal gene expression during mitosis	
CBFB		11276260	function summary		forms heterodimers with RUNX transcription factors to enhance their affinity for DNA	
CBL		26697989	role in cancer	oncogene, fusion	oncogene, fusion	
CBL		25952305	role in cancer	TSG	TSG	
CBL		12696071	fusion partner		KMT2A	
CBL	melanoma	27472394	proliferative signalling	promotes	KD results in decreased proliferation and clonogenic survival	A375, G361, Hs-294T, SK-Mel-2, SK-Mel-28 and 451Lu
CBL	melanoma	27472394	invasion and metastasis	promotes	KD results in decreased migration and invasive capacity	A375, G361, Hs-294T, SK-Mel-2, SK-Mel-28 and 451Lu
CBL		25477533	function summary		A RING finger E3 ubiquitin ligase, negatively regulating receptor tyrosine kinase (RTK) signalling by ubiquitination of active RTKs, targeting them for the lysosomal degradation	
CBL	fibroblasts	11239464	impact of mutation on function		mutations within a highly conserved alpha-helical structure linking the SH2 and RING finger domains negatively affect internalisation of EGFR and induce the transformation	NIH 3T3
CBLB		24553136	escaping immune response to cancer	promotes	inactivation of CBLB's E3 ligase activity in natural killer cells enables them to reject metastatic tumours	
CBLB		19901108	role in cancer	TSG	TSG	
CBLB		19901108	function summary		E3 ubiquitin ligase involved in the degradation of activated receptor tyrosine kinases and other tyrosine kinases	
CBLB	gastric cancer	24885194	invasion and metastasis	suppresses	represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation	
CBLB		18316398	suppression of growth	promotes	regulates EGFR degradation through its ubiquitination	
CCDC6	thyroid papillary carcinoma	2406025	fusion partner		RET	
CCDC6	NSCLC	24504365	fusion partner		RET	
CCDC6		24059746	function summary		element of the DNA damage checkpoint, proapoptotic substrate of ATM	
CCDC6		22363533	genome instability and mutations	suppresses	in the absence of CCDC6, genotoxic stress results in significantly increased accumulation of DNA damage	
CCDC6	testicular germ cell tumours	24059746	escaping programmed cell death	suppresses	loss of CCDC6 inhibits apoptosis upon oxidant-induced DNA damage	
CCDC6	NSCLC	24504365	role in cancer	fusion	fusion	
CCDC6		24059746	role in cancer	TSG	TSG	
CCDC6	thyroid papillary carcinoma	20498639	suppression of growth	promotes	represses CREB1 activity, which inhibits cell growth	
CCDC6	colorectal cancer	22399611	change of cellular energetics	promotes	silencing reduces the expression of SFN which has suppressive impact on cancer glycolysis, glutaminolysis, mitochondrial biogenesis and other major metabolic processes of tumours	
CCDC6		22363533	cell division control		loss of CCDC6 impairs intra-S-phase checkpoint control	
CCNB1IP1	mouse	17784788	cell division control		required for meiotic crossing-over	
CCNB1IP1	osteosarcoma	17297447	invasion and metastasis	suppresses	may be involved in coordinating cell cycle with cell migration and invasion, depletion increases migration and invasiveness	U2OS
CCNB1IP1	breast cancer	19543318	role in cancer	TSG	TSG	
CCNB1IP1	breast cancer	19543318	clinical impact		low levels of expression are significantly correlated with higher risks of recurrence	
CCNB1IP1		12612082	function summary		RING-finger family ubiquitin ligase that regulates cell cycle by interacting with cyclin B and promoting its degradation	
CCND1	small-cell B-non-Hodgkin lymphoma	15306823	role in cancer	fusion	fusion	
CCND1	breast cancer	21955753	invasion and metastasis	suppresses	suppresses EMT	
CCND1		27713153	impact of mutation on function		three most frequent mutations, E36K, Y44D and C47S increase CCND1 protein levels through defective proteolysis, Y44D and C47S mutants are characterised by deregulated nuclear export	
CCND1	small-cell B-non-Hodgkin lymphoma	15306823	fusion partner		IGK	
CCND1	mantle cell lymphoma	14514791	fusion partner		IGH	
CCND1	B-cell CLL	9671416	fusion partner		FSTL3	
CCND1		7557388	differentiation and development		plays a role in retina and mammary gland development	
CCND1	breast cancer	24862872	types of alteration in cancer		frequently amplified	
CCND1		20719876	role in cancer	oncogene	oncogene	
CCND1		16809779	change of cellular energetics	promotes	inhibits mitochondrial activity and aerobic glycolysis in vivo while enhancing cytosolic glycolysis	
CCND1		16705174	invasion and metastasis	promotes	positively regulates cellular migration through the inhibition of THBS1 and ROCK signalling	
CCND1	luminal B breast cancer	22307325	genome instability and mutations	promotes	high expression correlates with CIN	
CCND1		23562856	function summary		connects cytokine signalling with cell cycle apparatus, pushes cells through the G1 restriction point and into the S phase, plays a role in development 	
CCND2		22964630	cell division control		silencing causes G1 arrest in vitro 	
CCND2		22964630	proliferative signalling	promotes	silencing causes G1 arrest in vitro and growth retardation in glioblastoma 	
CCND2	chronic B-cell malignancies 	7742549	types of alteration in cancer		overexpressed	
CCND2	mantle cell lymphoma 	16861358	fusion partner		IGK	
CCND2		23562856	role in cancer	oncogene	oncogene	
CCND2		16861358	role in cancer	fusion	fusion	
CCND2		15322145	function summary		essential mediator of BCR-induced proliferation of mature B lymphocytes	
CCND2		15322145	cell division control		promotes G1-to-S phase progression	
CCNE1	breast cancer	25732226	proliferative signalling	promotes	KD results in decreased proliferation	
CCNE1		15322145	function summary		promotes G1-to-S phase progression	
CCNE1		25959964	cell division control		promotes entry into S phase 	
CCNE1		26416983	cell replicative immortality	promotes	plays a key role in balancing between totipotency and differentiation in human embryonic cells 	
CCNE1		25959964	role in cancer	oncogene	oncogene	
CD79A		15219998	function summary		Ig alpha, activator of Syk kinase	
CD79A		24146823	invasion and metastasis	promotes	CD79+ myeloid cells show enhanced ability to promote primary tumour metastasis	
CD79A		24146823	proliferative signalling	promotes	CD79+ myeloid cells show enhanced ability to promote primary tumour growth and metastasis	
CD79A		15219998	role in cancer	oncogene	oncogene	
CD79B	B-CLL	12384401	escaping programmed cell death	promotes	alternative transcript of CD79b is overexpressed and inhibits signalling for apoptosis	
CD79B		17709424	function summary		truncating mutation in Ig beta prevents the assembly of the IgM BCR on the cell surface, resulting in the absence of peripheral B cells and low/absent immunoglobulin serum levels	
CD79B		15219998	function summary		Ig beta, activator of Syk kinase	
CD79B		15219998	role in cancer	oncogene	oncogene	
CDC73		24257751	role in cancer	TSG	TSG	
CDC73	ovarian cancer	26409451	suppression of growth	promotes	overexpression caused a lower growth	
CDC73	ovarian cancer	26409451	invasion and metastasis	suppresses	overexpression negatively affects cell migration and invasive properties of the cells	
CDC73	parathyroid carcinoma	25388829	escaping programmed cell death	promotes	K34Q mutant has enhanced ability to target and destabilize p53 mRNA and therefore to control p53-mediated apoptosis	
CDC73		16989776	cell division control		overexpression induces cell cycle arrest in the G1 phase	
CDC73		24257751	function summary		binds to RNA polymerase II as part of a PAF1 transcriptional regulatory complex and causes transcriptional repression of oncogenes MYC and CCND1, represses beta-catenin-mediated transcription, is repressed by WT1	
CDC73		18987311	suppression of growth	promotes	inhibits cell proliferation by repression of the c-myc proto-oncogene	
CDC73	oral SCC	24257751	suppression of growth	promotes	transcriptional repression by WT1 promotes cell proliferation	
CDH1		26704932	invasion and metastasis	promotes	soluble E-cadherin promotes invasion and metastasis	
CDH1		26704932	function summary		soluble E-cadherin is the extracellular fragment of the protein that is cleaved from the membrane after proteolysis of full-length E-cadherin, as a paracrine/autocrine signalling molecule, sE-cadherin activates or inhibits multiple signalling pathways	
CDH1		9837810	function summary		calcium-dependent cell adhesion receptor, its function is suppressed during carcinogenesis and invasion	
CDH1		9837810	role in cancer	TSG	TSG	
CDH1	ovarian cancer	24973953	types of alteration in cancer		frequently downregulated through promoter hypermethylation	
CDH1		27727438	types of alteration in cancer		frameshift and nonsense somatic mutations throughout the gene	
CDH1	ductal breast cancer	25260805	types of alteration in cancer		frequently downregulated through promoter hypermethylation	
CDH1	breast cancer	25449012	change of cellular energetics	promotes	knockdown dysregulates pathways responsible for the regulation of response to oxidative stress and cellular energetics	MCF-7
CDH1	plasmacytoid bladder cancer	26901067	types of alteration in cancer		very frequent LOF somatic mutations	
CDH1		19487818	invasion and metastasis	suppresses	loss of E-cadherin is an essential step of EMT	
CDH11		25771201	differentiation and development		important for brain and spinal cord, and mesodermal lineages development	
CDH11		25771201	function summary		mediates Ca2+ dependent homophilic interactions between cells through formation of intercellular connections	
CDH11		25106495	invasion and metastasis	suppresses	antimetastatic, inhibits ER alpha-positive breast cancer invasion by targeting integrin beta 3 via the repression of ER alpha signaling 	
CDH11		22139084	invasion and metastasis	suppresses	inhibits EMT and downregulates stem cell markers through modulation of WNT/beta cathenin and AKT/Rho A signaling	
CDH11		22139084	types of alteration in cancer		frequently hypermethylated in multiple primary tumours	
CDH11	aneurysmal bone cyst 	15509545	fusion partner		USP6	
CDH11		22139084	role in cancer	TSG	TSG	
CDH11		15509545	role in cancer	fusion	fusion	
CDH11		22139084	escaping programmed cell death	suppresses	proapoptotic	
CDK12		26911346	function summary		RNA Pol II kinase, required for Nrf2 target gene expression in Drosophila	
CDK12		25712099	role in cancer	TSG	TSG	
CDK12		25712099	genome instability and mutations	suppresses	inactivating mutations in ovarian cancers result in aberrant expression of homologous recombination genes 	
CDK12	ovarian cancer	26787835	types of alteration in cancer		inactivating CDK12 mutations arise as a result of large tandem duplications 	
CDK12		26911346	change of cellular energetics	promotes	antioxidant gene expression is compromised in flies with reduced Cdk12 function 	
CDK4		16236519	cell replicative immortality	promotes	mouse KOs are characterised by decreased susceptibility to immortalisation or transformation by oncogenes 	
CDK4		8528263	types of alteration in cancer		germline mutations in p16 binding domain have been associated to familial melanoma 	
CDK4		16236519	cell division control		regulates progression through G1 phase	
CDK4		16236519	function summary		cyclin-dependent kinase, regulates progression through G1 phase, essential for the proliferation of some endocrine and hematopoietic cells, phosphorylates Cdt1, Marcks, p107, p130, pRb and Smad3 	
CDK4		26500059	role in cancer	oncogene	oncogene	
CDK6		25704240	function summary		regulates quiescence exit in human hematopoietic stem cells	
CDK6		16236519	differentiation and development		mouse KOs are characterised by defective erythroid lineage development 	
CDK6		16236519	cell division control		regulates progression through G1 phase	
CDK6	B-cell lymphoproliferative malignancies 	24726269	fusion partner		IGK	
CDK6		26500059	role in cancer	oncogene	oncogene	
CDK6		24726269	role in cancer	fusion	fusion	
CDK6		7610482	function summary		cyclin-dependent kinase, facilitates exit from G1 by phosphorylating key substrates, including the retinoblastoma protein	
CDK6	infant ALL	24736461	proliferative signalling	promotes	CDK6 is a direct target of KMT2A fusion proteins, playing an important role in the proliferation advantage of KMT2A-rearranged cells	
CDK6	hypopharyngeal SCC	24647829	proliferative signalling	promotes	downregulation of CDK6 by miR-504 inhibits cancer cell proliferation	
CDKN2A		25728247	invasion and metastasis	suppresses	p16(INK4A) inhibits the pro-metastatic potential of osteosarcoma cells through targeting the ERK pathway and TGF-beta 1	
CDKN2A		25752701	escaping programmed cell death	suppresses	p14(ARF) prevents proliferation of aneuploid cells by activating p53-dependent apoptosis	
CDKN2A		12789286	role in cancer	TSG	TSG	
CDKN2A		12789286	function summary		CDKN2A locus encodes two distinct proteins, p16INK4a and p14ARF, both of which demonstrate tumour suppressor activity in genetically distinct anticancer pathways: the 'Rb pathway' for p16INK4a and the 'p53 pathway' for p14ARF	
CDKN2A	HNC	26171937	angiogenesis	suppresses	p16-negative tumours associate with increased circulating levels of pro-angiogenic VEGF and angiopoietin-1	
CDKN2A		26845683	senescence	promotes	induces cellular senescence	
CDKN2A		12660818	suppression of growth	promotes	p14(ARF) inhibits the growth of human tumour cells lacking functional p53 by inducing a transient G(2) arrest and subsequently apoptosis	
CDKN2A		12660818	escaping programmed cell death	suppresses	p14(ARF) inhibits the growth of human tumour cells lacking functional p53 by inducing a transient G(2) arrest and subsequently apoptosis	
CDKN2A		22025288	senescence		p16 induces senescence through the retinoblastoma pathway	
CDKN2A		27727438	types of alteration in cancer		frequently deleted in cancers, recurrent nonsense mutations R80* and R58*	
CDKN2A		8761411	suppression of growth	promotes	inhibits cell proliferation through induction of cell-cycle arrest	
CDKN2C	breast cancer	19411068	clinical impact		high expression is associated with a low probability of survival	
CDKN2C	splenocytes	15680327	escaping programmed cell death	suppresses	decrease in extent of adriamycin-induced apoptosis of cells from mice heterozygous for inactivating intronic insertion	
CDKN2C	colon carcinoma	15107819	suppression of growth	promotes	silencing promotes increased proliferation	HCT116
CDKN2C	colon carcinoma	15680327	suppression of growth	promotes	increased expression in response to DNA damage, ectopic expression leads to reduced cell proliferation in cells with functional p53 and CDKN1A	HCT116
CDKN2C	melanoma	32090490	suppression of growth	promotes	downregulation by miR-21-5p promotes cell proliferation	A375
CDKN2C	multiple myeloma	11840272	suppression of growth	promotes	ecotopic expression in a cell line homozygous for CDKN2C deletion reduces cell proliferation	KMS12
CDKN2C	bone marrow haematopoietic progenitor cells	21936707	suppression of growth	promotes	KD in mice results in a decrease in cell numbers	
CDKN2C	murine mammary tumour 	19411068	suppression of growth	promotes	KD promotes proliferation	
CDKN2C	T helper 2 cells	24167278	suppression of growth	promotes	GATA3 downregulates CDKN2C expression, resulting in increased proliferation	
CDKN2C	glioblastoma multiforme	18381405	senescence		ecotopic expression in CDKN2C-deficient cell lines induces senescence	LN229, T98G
CDKN2C	melanoma	32090490	role in cancer	TSG	TSG	
CDKN2C		9744866	role in cancer	TSG	TSG	
CDKN2C		11544316	role in cancer	TSG	TSG	
CDKN2C	breast cancer	19411068	role in cancer	TSG	TSG	
CDKN2C	multiple myeloma	11840272	escaping programmed cell death	suppresses	ecotopic expression in a cell line homozygous for CDKN2C deletion causes apoptosis-associated DNA fragmentation	KMS12
CDKN2C	Hodgkin lymphoma	14645011	clinical impact		loss of expression is associated with a lower overall survival	
CDKN2C	medullary thyroid carcinoma	27610696	clinical impact		hemizygous deletion associated with distant metastasis at presentation and lower overall survival	
CDKN2C	multiple myeloma	18829482	clinical impact		hemizygous and homozygous deletions are associated with a lower overall survival	
CDKN2C		9744866	mouse model		mice homozygous for exon 3 deletion display gigantism and organomegaly, and develop pituitary adenoma	
CDKN2C		11544316	mouse model		mice homozygous for exon 2 deletion develop T-cell lymphoma	
CDKN2C		15680327	mouse model		mice heterozygous for inactivating intronic mutation develop lymphoma, hepatocarcinoma and adenocarcinomas at several sites	
CDKN2C		19411068	mouse model		mice homozygous for exon 3 deletion develop luminal ERalpha+ mammary tumours	
CDKN2C	glioblastoma multiforme	18381405	types of alteration in cancer		homozygous deletions in 5% of tumours	
CDKN2C	Hodgkin lymphoma	14645011	types of alteration in cancer		no expression in Reed-Sternberg cells in 45% of tumours, promoter hypermethylation in 19% of tumours	
CDKN2C	leiomyosarcoma	33015533	types of alteration in cancer		homozygous deletion in 3% of tumours, often concurrent with homozygous deletions in CIC, CDKN2A and/or RAD51B	
CDKN2C	melanoma	32090490	types of alteration in cancer		typically decreased expression	
CDKN2C	multiple myeloma	30371878	types of alteration in cancer		homozygous deletion in 9% of tumours	
CDKN2C	acute promyelocytic leukaemia	27888400	differentiation and development		overexpression causes partial differentiation into neutrophils	NB4
CDKN2C	erythroleukaemia	18642058	differentiation and development		ecotopic expression causes partial erythroid differentiation	K562
CDKN2C	haematopoietic stem cells	20671115	differentiation and development		KD in mice inhibits B lymphocyte development	
CDKN2C	acute promyelocytic leukaemia	27888400	cell division control		overexpression causes cell cycle arrest at G0/G1	NB4
CDKN2C	erythroleukaemia	18642058	cell division control		ecotopic expression causes cell cycle arrest at G0/G1	K562
CDKN2C	glioblastoma multiforme	18381405	cell division control		ecotopic expression in CDKN2C-deficient cell lines causes cell cycle arrest at G0/G1	
CDKN2C	melanoma	32090490	cell division control		downregulation by miR-21-5p promotes G1/S transition	A375
CDKN2C	breast cancer	8840966	impact of mutation on function		missense mutation in exon 3 reduces extent of inhibition of cell proliferation effected by overexpression	MCF-7
CDKN2C	glioblastoma multiforme	18381405	impact of mutation on function		loss of expression due to homozygous deletion	
CDKN2C	medullary thyroid carcinoma	18942719	impact of mutation on function		p.A61T, p.A72T and p.R79G missense mutations reduce the extent of G1 arrest achieved by ectopic expression	U2OS
CDKN2C	testicular cancer	10652429	impact of mutation on function		decrease in expression is associated with progression from a carcinoma in situ to an invasive germ cell tumour	
CDKN2C		10385618	function summary		inhibits the kinase activity of CDK4 and CDK6 by preventing binding to cyclin D thereby stopping cell cycle G1/S transition	
CDX2		26551082	function summary		homeobox transcription factor, critical for intestinal development, implicated in differentiation, proliferation, cell adhesion and migration and DNA miss-match repair	
CEBPA	AML	25227715	clinical impact		biallelic mutations convey a favourable prognosis	
CEBPA	pediatric AML	19304957	clinical impact		mutations more common in older children with normal karyotypes and convey a favorable prognosis	
CEBPA	prostate cancer	3043067	clinical impact		reduced expression in PTEN deleted and TMPRSS2:ERG fusion type tumours is associated with a poor prognosis	
CEBPA	AML	18394553	mouse model		homozygous for N-terminal nonsense mutation-containing allele and express only p30 isoform	
CEBPA	acute erythroid leukaemia	27389056	types of alteration in cancer		predominantly N-terminal and C-terminal frameshift mutations	
CEBPA	AML	20038735	types of alteration in cancer		biallelic mutations in cytogenetically normal AML, an N-terminal frameshift or nonsense mutation in one allele and C-terminal in-frame mutation affecting bZIP domain in second allele	
CEBPA	B-cell acute lymphoblastic leukaemia	16873674	types of alteration in cancer		increased expression due to positioning adjacent to IGH enhancer as a result of t(14;19)	
CEBPA	breast cancer	15867211	types of alteration in cancer		frequently downregulated	
CEBPA	chronic myeloid leukaemia	28560057	types of alteration in cancer		frequently increased expression	
CEBPA	glioblastoma	29464001	types of alteration in cancer		typically increased expression	
CEBPA	hepatocellular carcinoma	21038412	types of alteration in cancer		typically downregulated	
CEBPA	leukaemia	28720765	types of alteration in cancer		downregulated via fusion proteins derived from rearrangements (8;21), t(9;22), inv(16)	
CEBPA	non-small cell lung cancer	1180975	types of alteration in cancer		decreased expression in a subset of tumours	
CEBPA	oral squamous cell carcinoma	29281558	types of alteration in cancer		frequently increased expression	
CEBPA	pediatric acute leukaemia	29947237	types of alteration in cancer		frameshift mutations including c.487 del G identified	
CEBPA		19075268	global regulation of gene expression		regulates the expression of many genes involved in haematopoetic cell differentiation	
CEBPA	colorectal cancer	28341486	differentiation and development		differentiation induced upregulation of CEBPA downregulates PLK1 resulting in enhanced differentiation	HT29, Caco-2, SW480
CEBPA	fibroblast	1935900	differentiation and development		suppression diminishes terminal adipocyte differentiation	3T3-F442
CEBPA	murine myeloid 	30073773	differentiation and development		overexpression inhibits cell differentiation	
CEBPA	murine myloblast 	14704358	differentiation and development		ectopic expression induces dose-dependent adipocytic or osteoblastic differentiation	C2C12
CEBPA		15589173	differentiation and development		KD disrupts myeloid differentiation in mice	
CEBPA		25258381	differentiation and development		transcriptional downregulation inhibits monocyte/macrophage differentiation	HL-60, THP-1
CEBPA	breast cancer	15867211	cell division control		increased expression arrests cells in G0-G1	BT474, MCF-7, MDA-MB-231
CEBPA	hepatocellular carcinoma	23816696	cell division control		overexpression induced G0/G1 arrest	Huh7
CEBPA	keratinocytes	15572670	cell division control		expression induced by DNA damage and results in G1 checkpoint activation	NRK, NHEK, NIH3T3
CEBPA	murine pituitary 	11914124	cell division control		proliferation blocked in G1 and S phases by ectopic expression of transcriptionally-inactive CEBPA mutants	GHFTI-5
CEBPA	B-cell acute lymphoblastic leukaemia	16873674	fusion partner		IGH	
CEBPA	AML	31867767	impact of mutation on function		N-terminal frameshift mutations ablate translation of the full-length p42 isoform, leaving sole expression of shorter 2 transactivation element-lacking p30 isoform	
CEBPA	AML	31867767	impact of mutation on function		C-terminal bZIP domain in-frame mutations impair DNA-binding and homodimerisation	
CEBPA		12006103	function summary		transcription factor, expressed at high levels in hepatocytes, adipocytes and haematopoietic cells, involved in the control of cell proliferation and differentiation, glucose metabolism and the inflammatory response.	
CEBPA	chronic myeloid leukaemia	28560057	escaping programmed cell death	promotes	overexpression inhibits apoptosis through upregulated lncRNA PLIN2-mediated activation of the GSK3 and Wnt/beta-catenin pathways	KT-1/A3
CEBPA	colorectal cancer	28341486	escaping programmed cell death	suppresses	differentiation induced upregulation of CEBPA downregulates PLK1 resulting in increased apoptosis	HT29, Caco-2, SW480
CEBPA	glioblastoma	29464001	escaping programmed cell death	promotes	KD increases apoptosis	U87, U251
CEBPA	murine myeloid 	30073773	escaping programmed cell death	suppresses	overexpression promotes apoptosis	
CEBPA	oral squamous cell carcinoma	29281558	escaping programmed cell death	promotes	overexpression reduces apoptosis	Cal27, Tca8113
CEBPA	chronic myeloid leukaemia	28560057	proliferative signalling	promotes	overexpression increases cell proliferation through upregulated lncRNA PLIN2-mediated activation of the GSK3 and Wnt/_-catenin pathways	KT-1/A3
CEBPA	glioblastoma	29464001	proliferative signalling	promotes	KD decreases proliferation via transcriptional downregulation of TRAF4	U87, U251
CEBPA	glioblastoma	29464001	invasion and metastasis	promotes	KD decreases migration and invasion	U87, U251
CEBPA	lung adenocarcinoma	28746919	invasion and metastasis	suppresses	overexpression inhibits migration and invasion by transcriptionally downregulating CTNNB1	A549, H1299
CEBPA	oral squamous cell carcinoma	29281558	invasion and metastasis	promotes	overexpression increases cell invasion	Cal27, Tca8113
CEBPA	hepatocellular carcinoma	25363290	change of cellular energetics	promotes	promotes lipid catabolism during starvation and activates autophagy	Hep3B, PLC/5, Huh7
CEBPA	hepatocellular carcinoma	29566023	change of cellular energetics	promotes	KD results in transcriptional downregulation of FBP1 and related gluconeogenic enzymes	HepG2
CEBPA		7652557	change of cellular energetics	promotes	mice homozygous for gene deletion fail to synthesise liver glycogen, show delayed expression of gluconeogenic enzymes PCK1 and G6PC, and die from hypoglycaemia	
CEBPA	breast cancer	15867211	suppression of growth	promotes	increased expression reduces cell proliferation	BT474, MCF-7, MDA-MB-231
CEBPA	breast cancer	26823765	suppression of growth	promotes	inhibits cell growth via upregulation of miR-134 and subsequent downregulation of CREB and BCL2	MCF7
CEBPA	hepatocellular carcinoma	21038412	suppression of growth	promotes	downregulation mediates cell proliferation by precluding miR-122 suppression of IGF-1R/Akt signalling	HepG2, Huh7, L02-T
CEBPA	murine myeloid 	30073773	suppression of growth	promotes	overexpression reduces cell proliferation	
CEBPA	non-small cell lung cancer	1180975	suppression of growth	promotes	increased expression reduces cell proliferation	Calu-1, H358
CEBPA	hepatocellular carcinoma	23816696	suppression of growth	promotes	overexpression suppressed proliferation	Huh7
CEBPA	breast cancer	15867211	role in cancer	TSG	TSG	
CEBPA	chronic myeloid leukaemia	28560057	role in cancer	oncogene	oncogene	
CEBPA	glioblastoma	29464001	role in cancer	oncogene	oncogene	
CEBPA	hepatocellular carcinoma	21038412	role in cancer	TSG	TSG	
CEBPA	liver cancer	29159818	role in cancer	oncogene	oncogene	
CEBPA	non-small cell lung cancer	1180975	role in cancer	TSG	TSG	Calu-1, H358
CEBPA	oral squamous cell carcinoma	29281558	role in cancer	oncogene	oncogene	
CHD4		23624931	differentiation and development		takes part in preventing premature onset of gliogenesis	
CHD4	colon carcinoma	23708667	global regulation of gene expression		takes part in silencing via methylation of TSGs, depletion of CHD4 is synergistic with DNMT inhibition in reducing the viability of cancer cells in correlation with reactivation of TSGs	
CHD4		27727438	types of alteration in cancer		recurrent K73fs, R1162W, R975H, R877Q/W	
CHD4	colon carcinoma	23708667	role in cancer	oncogene	oncogene	
CHD4		23697937	cell division control		regulates cell cycle progression via DDR and p53 deacetylation	
CHD4		26546801	genome instability and mutations	suppresses	CHD4 and p300 ablation leads to impaired DSBs repair and sensitises cells to laser irradiation and etoposide due to HR dysfunction	
CHD4		26546801	function summary		recruited to DSB sites	
CHD4		9804427	function summary		component of the histone deacetylase NuRD complex	
CHD4		23697937	role in cancer	TSG	TSG	
CHEK2		16317088	senescence	promotes	promotes senescence	
CHEK2	intestinal epithelial cells	21834075	escaping programmed cell death	suppresses	promotes anoikis	
CHEK2		15950944	escaping programmed cell death	suppresses	regulates transcription-independent p53-mediated apoptosis in response to DNA damage	
CHEK2		10710310	cell division control		stabilises p53 upon gamma-irradiation-induced DNA damage inducing cell-cycle arrest in the G2 phase	
CHEK2		17101782	genome instability and mutations	suppresses	stimulates the expression of DNA repair genes	
CHEK2		10724175	genome instability and mutations	suppresses	activates BRCA1 after DNA damage	
CHEK2		18317453	genome instability and mutations	suppresses	initiates DNA DSB repair through activation of BRCA2	
CHEK2		25404613	function summary		a serine/threonine kinase, key component of the DNA damage response, upon DNA damage, CHK2 is phosphorylated by ATM or DNA-PKcs, and activates through phosphorylation proteins involved in DNA repair, cell cycle regulation, p53 signalling, and apoptosis	
CHEK2		20719876	role in cancer	TSG	TSG	
CHEK2		27716909	impact of mutation on function		K373E mutation disrupts CHK2 autophosphorylation as well as kinase activity, thus leading to impairment of CHK2 functions in suppressing cell proliferation and promoting cell survival after ionizing radiation	
CIC	prostate cancer 	26124181	invasion and metastasis	suppresses	CIC overexpression suppresses cell invasion and migration, whereas CIC RNAi exerts the opposite effects	
CIC		17398096	differentiation and development		growth repressor inhibited by RTK/Ras signalling in Drosophila imaginal discs, growth of cic mutant cells is undiminished in the complete absence of a Ras signal	
CIC	oligodendroglioma	25277207	global regulation of gene expression		R1515H mutation increases level of the oncometabolite - 2-hydroxyglutarate, which is a competitive inhibitor of histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases	
CIC		27727438	types of alteration in cancer		missense mutations, recurrent G939A, R215W, fusions	
CIC	medulloblastoma	21817013	types of alteration in cancer		overexpressed	
CIC	oligodendroglioma	15981098	types of alteration in cancer		homozygous LOF mutations	
CIC		15981098	function summary		component of the EGFR signalling pathway	
CIC	Drosophila	17398096	function summary		 growth repressor inhibited by RTK/Ras signalling in imaginal discs	
CIC		25277207	function summary		transcriptional corepressor with long - nuclear and short - cytoplasmatic (mitochondrial) isoforms	
CIC	Ewing-like sarcoma	16717057	impact of mutation on function		with a C-terminal fragment of DUX4, CIC acquires an enhanced transcriptional activity, upregulating ETV5 and ETV1	
CIC	oligodendroglioma	25277207	change of cellular energetics	promotes	interacts with metabolism related mitochondrial proteins, LOF mutations reduce phosphorylation of ACLY, leading to increased levels of 2-hydroxyglutarate	
CIC	prostate cancer	26124181	suppression of growth	promotes	CIC overexpression suppresses cell proliferation, whereas KD exerts opposite effect	
CIC	Ewing-like sarcoma	16717057	role in cancer	fusion	fusion	
CIC	oligodendroglioma	21817013	role in cancer	TSG	TSG	
CIITA		21368758	escaping immune response to cancer	suppresses	loss of function leads to downregulation of surface HLA class II expression and overexpression of ligands of the receptor molecule programmed cell death (PD-L1 and PD-L2) and thus negatively affects the tumour cell immunogenicity and the anti-tumour immune response	
CIITA		21368758	role in cancer	fusion	fusion	
CIITA		16879803	role in cancer	TSG	TSG	
CIITA	B-cell lymphoma 	21368758	fusion partner		C15orf65, CD274, PDCD1LG2, RALGDS, RMI2	
CIITA		16879803	types of alteration in cancer		promoter is frequently hypermethylated in cancers 	
CIITA		24391648	function summary		transcriptional coactivator that regulates transcription of MHC I and MHC II genes 	
CLIP1		11940666	function summary		participates in attachment of microtubules to the kinetochore 	
CLIP1		16230537	differentiation and development		essential for spermatogenesis	
CLIP1		21430156	differentiation and development		takes part in neurogenesis where it's induced by mTOR	
CLIP1		25602801	role in cancer	fusion	fusion	
CLIP1	Spitz tumour	24445538	fusion partner		ROS1	
CLIP1	Spitz tumour	25602801	fusion partner		ALK	
CLTC		24142740	role in cancer	fusion	fusion	
CLTC	congenital blastic plasmacytoid dendritic cell neoplasm 	24142740	fusion partner		ALK	
CLTC		15208656	impact of mutation on function		presents more granular cytoplasmatic distribution of fusion protein when compared to other ALK fusions, cells overexpressing CLTC-ALK have lost the cell contact growth inhibition and show foci consisting of cell multilayers 	
CLTC		15858577	role in cancer	TSG	TSG	
CLTC		15858577	genome instability and mutations	suppresses	depletion results in prolonged mitosis and destabilisation of kinetochore fibres and misalignment of chromosomes 	
CLTC		15858577	function summary		protein required for function of the mitotic spindle	
CLTCL1		22496928	role in cancer	TSG	TSG	
CLTCL1	anaplastic large cell lymphoma 	10807789	fusion partner		ALK	
CLTCL1		9147638	differentiation and development		fusion with a repeated region telomeric to the rDNA cluster on chromosome 21p has been associated with DIGeorge syndrome/velocardiofacial syndrome (DGS/VCFS) (non-cancer-related), translocation disrupts the 3' coding region of the CLTCL1 gene and leads to a truncation of the transcript 	
CLTCL1		22496928	invasion and metastasis	suppresses	suppressor of metastasis, downregulated prior to transformation of breast cancer from in situ to invasive form 	
CLTCL1		10807789	role in cancer	fusion	fusion	
CLTCL1		19478182	function summary		has a role in the formation of insulin-responsive GLUT4 compartments in human muscle and adipocytes	
CLTCL1		11687498	function summary		clathrin heavy chain isoform highly expressed in skeletal muscles	
CNBP		24594223	function summary		transcriptionally down-regulates the expression of heterogeneous ribonucleoprotein K (hnRNP K) through conversion of a G-rich sequence into G-quadruplex in the promoter of hnRNP K	
CNBP	fibrosarcoma	24594223	escaping programmed cell death	suppresses	overexpression of CNBP increases apoptosis 	
CNBP	fibrosarcoma	24594223	invasion and metastasis	suppresses	overexpression of CNBP reduces cell invasivenes	
CNBP	aneurysmal bone cyst 	15735689	fusion partner		USP6	
CNBP		24594223	role in cancer	TSG	TSG	
CNBP		15735689	role in cancer	fusion	fusion	
CNOT3	T-cell ALL	23263491	role in cancer	TSG	TSG	
CNOT3		22416820	function summary		component of Ccr4-Not complex which regulates transcription, decay of mRNA, translation, and protein degradation	
CNOT3	breast cancer	16778766	suppression of growth	promotes	depletion of CNOT3 increases estrogen-dependent expression of c-Myc	
CNOT3		26238124	escaping programmed cell death	promotes	essential for early B cell development, regulates their survival by destabilising p53 mRNA and is required for efficient IGH rearrangement	
CNOT3		22367759	differentiation and development		highly expressed in ESC and downregulated during differentiation, necessary for the maintenance of human ESCs, and silencing them initiates differentiation	
CNOT3		22342980	cell division control		involved in the regulation of the spindle assembly checkpoint through its ability to regulate the stability of MAD1 mRNA	
COL2A1		31824186	function summary		major collagen component of cartilage ECM, intervertebral discs, vitreous humour of the eye and the inner ear	
COL2A1	chondrosarcoma	23770606	role in cancer	fusion	fusion	
COL2A1	breast cancer	28396358	clinical impact		increased expression associated with lower clinical response of HER2+ tumours to neoadjuvant anti-HER2 therapy	
COL2A1	high grade serous ovarian cancer	26311224	clinical impact		high expression correlated with increased time to recurrence	
COL2A1	chondrosarcoma	23770606	types of alteration in cancer		intragenic rearrangements and truncating indels most frequent	
COL2A1	chondrosarcoma	23770606	fusion partner		GMEB1, LINC00513, LOC101927502, PPP1R42, TANC2, TMEM106C	
COL2A1	chondrosarcoma	31604924	types of alteration in cancer		indels found most often in tumours characterised by IDH1 mutation, a hypermethylated genome and loss of expression of 14q32 miRNA cluster	
COL2A1	dedifferentiated chondrosarcoma	33147331	types of alteration in cancer		truncating and splice site mutations common to chondrosarcoma and non-chondrogenic tumour components	
COL2A1	chondrocytes	12917109	differentiation and development		loss of function mutation results in inhibition of chondrocyte differentiation	
COL2A1		7655082	differentiation and development		transient, tissue-specific expression of type IIA and type IIB splice forms during human embryo development	
COL2A1	chondrosarcoma	25024164	types of alteration in cancer		missense mutations often in collagen triplex helix repeat domain-encoding regions	
CREB3L1		21536545	role in cancer	fusion	fusion	
CREB3L1		24126059	function summary		element of unfolded protein response	
CREB3L1		24126059	invasion and metastasis	suppresses	suppressor of metastasis	
CREB3L1		24126059	angiogenesis	suppresses	suppressor of  angiogenesis 	
CREB3L1	sarcoma	21536545	fusion partner		FUS	
CREB3L1		24126059	role in cancer	TSG	TSG	
CREB3L2	fibrosarcoma	24441665	fusion partner		EWSR1	
CREB3L2		17117415	function summary		transcription factor	
CREB3L2	fibromyxoid sarcoma	12915480	fusion partner		FUS	
CREB3L2		24332809	differentiation and development		plays crucial role in chondrocyte differentiation 	
CREB3L2	glioblastoma	25955804	proliferative signalling	promotes	secreted luminal C-terminus, cleaved out upon an ER stress is involved in Hedgehog ligand-dependent cancer cell proliferation through activation of Hedgehog signaling 	U251MG
CREB3L2		25955804	role in cancer	oncogene	oncogene	
CREB3L2	 thyroid carcinoma 	18757431	fusion partner		PPARG	
CREB3L2		24441665	role in cancer	fusion	fusion	
CREBBP	pancreatic ductal adenocarcinoma	25082960	proliferative signalling	promotes	disruption of interaction of CREBBP with _-catenin results in inhibition of anchorage-dependent and -independent growth primarily through robust induction of G_ cell-cycle arrest	
CREBBP		26628108	function summary		histone acetyltransferase involved in the transcriptional coactivation of many different transcriptional factors by interacting with them and increase the expression of their target genes	
CREBBP	juvenile myelomonocytic leukaemia	27158276	types of alteration in cancer		frequently hypermethylated	
CREBBP		9238046	role in cancer	fusion	fusion	
CREBBP		10887150	role in cancer	oncogene, TSG	oncogene, TSG	
CREBBP	therapy-related AML 	9238046	fusion partner		KMT2A	
CREBBP	AML	17296583	fusion partner		KAT6A	
CREBBP	lung cancer	26628108	invasion and metastasis	promotes	silencing of CBP expression or its activity inhibition resulted in the significant suppression of tumor cell migration	
CREBBP	airway epithelial cells	26315281	invasion and metastasis	promotes	disruption of beta-catenin/CBP signaling inhibits EMT	
CREBBP	pancreatic cancer	24419059	escaping programmed cell death	suppresses	CBP-mediated FOXO-1 acetylation initiates apoptosis	
CREBBP	lung cancer	26628108	escaping programmed cell death	promotes	silencing of CBP expression or its activity inhibition resulted in the significant suppression of tumor cell viability by regulation of the Bcl-2 and cytochrome C/caspase pathway	
CREBBP		17272271	cell division control		interacts with ATR and is required for the DNA replication checkpoint	
CREBBP	liver	23285190	genome instability and mutations	suppresses	contributes to homologous recombination by transcriptionally activating the BRCA1 and RAD51	
CRLF2	B-cell precursor ALL 	19641190	types of alteration in cancer		overexpression is associated with activation of the JAK-STAT pathway in cell lines and transduces primary B-cell progenitors, sustaining their proliferation	
CRLF2	Down syndrome-associated ALL	19965641	fusion partner		IGH	
CRLF2		22484421	role in cancer	fusion	fusion	
CRLF2		20807819	role in cancer	oncogene	oncogene	
CRLF2		20807819	function summary		cytokine receptor, with IL7R forms heterodimeric TSLP receptor involved in B-cell precursor proliferation and survival via JAK/STAT pathway	
CRLF2	B-cell precursor ALL 	22484421	fusion partner		P2RY8	
CRTC1	salivary gland carcinoma 	19827123	fusion partner		MAML2	
CRTC1		19164581	proliferative signalling	promotes	promotes cell proliferation and transformation via AP-1 	
CRTC1		19164581	function summary		transcriptional coactivator, modulator of AP-1 function, synergizes with c-Jun to promote cellular growth	
CRTC1	mucoepidermoid carcinoma	19164581	fusion partner		MAML2	
CRTC1		19164581	impact of mutation on function		CRTC1-MAML2 fusion protein activates both c-Jun and c-Fos increasing AP-1 activation 	
CRTC1		26300003	types of alteration in cancer		CRTC1 activity is enhanced in colorectal carcinoma due to increased protein stability	
CRTC1		19827123	role in cancer	fusion	fusion	
CRTC1		26300003	role in cancer	oncogene	oncogene	
CSF3R		27789332	function summary		transmembrane receptor for a hematopoietic cytokine, G-CSF,  that stimulates neutrophil production and hematopoietic stem cell mobilization	
CSF3R	SCF-dependent mouse hematopoietic cells	18923646	impact of mutation on function		loss of C-terminal lysine at position 762 impairs receptor ubiquitination	Ba/F3
CSF3R	bladder carcinoma	17572226	escaping programmed cell death	promotes	inhibition of ligand results in increased apoptosis	TCCSUP, 5637
CSF3R	murine myeloid	7542747	proliferative signalling	promotes	C terminal truncating mutations promote growth	32D.C10
CSF3R	SCF-dependent mouse hematopoietic cells	18923646	proliferative signalling	promotes	nonsense mutations that delete the C-terminal lysine at position 762 impair receptor ubiquitination and increase cell growth	Ba/F3
CSF3R	bladder carcinoma	17572226	proliferative signalling	promotes	overexpression increases tumour growth	TCCSUP, 5637
CSF3R	haematopoietic cells	20471446	invasion and metastasis	promotes	increased ligand-induced signaling upregulates expression of MMPs and promotes migration of haematopoietic cells	
CSF3R		26475333	role in cancer	oncogene	oncogene	
CSF3R		28031554	role in cancer	oncogene	oncogene	
CSF3R	AML	27034432	clinical impact		most frequently co-mutated gene in patients with biallelic CEBPA mutation and hypersensitivity to JAK kinase inhibitors	
CSF3R	rectal cancer	24574781	clinical impact		expression associated with poor radiotherapy response	
CSF3R	neuroblastoma	23687340	clinical impact		expression identifies side population of highly tumorigenic cells with stem cell characteristics	
CSF3R	chronic neutrophilic leukemia	29440636	clinical impact		presence of mutations is a key diagnostic component	
CSF3R	chronic neutrophilic leukemia primary patient cells	23656643	clinical impact		the presence of S783fs mutation is linked to improved response to dasatinib in mouse bone marrow cells, while the presence ot T618I mutation with higher sensitivity to ruxolitinib in chronic neutrophilic leukemia primary patient cells	
CSF3R	chronic neutrophilic leukemia	28031554	mouse model		membrane proximal mutations induce leukaemogenesis, dependent on enhanced MAPK signaling	
CSF3R		30371878	types of alteration in cancer		recurrent T618I missense mutations and truncating mutations at the 3' end	
CSF3R	murine myeloid	7542747	differentiation and development		C-terminal truncating mutations inhibit myeloid differentiation	32D.C10
CSF3R		8695841	differentiation and development		receptor activation promotes myeloid differentiation 	NB4-55 ,HL-60
CSF3R		26475333	impact of mutation on function		T618I and T640N mutations induce ligand independence and lead to G-CSF independent JAK-STAT and ERK activation	Ba/F3
CSF3R		24403076	impact of mutation on function		T6181I mutation confers ligand independent signaling through loss of O-linked glycosylation and increased receptor dimerisation	Ba/F3, HEK 293T17
CSF3R	SCF-dependent mouse hematopoietic cells	10706885	escaping programmed cell death	promotes	truncating GOF mutations confer resistance to apoptosis	Ba/F3
CTCF		26439501	global regulation of gene expression		responsible for the maintenance of chromatin loops	
CTCF		26053496	types of alteration in cancer		CTCF/cohesin binding sites are a major mutational hotspot in cancer genome	
CTCF		24794443	global regulation of gene expression		inactivating mutations change methylation patterns in mouse cells	
CTCF		24390350	types of alteration in cancer		one of the most frequently mutated genes in endometrial, breast and head and neck cancers	
CTCF		21663659	impact of mutation on function		removing CTCF binding site proximal to the RB promoter causes its increased methylation with loss of expression	K562
CTCF		19008940	genome instability and mutations	suppresses	regulates trinucleotide repeat instability in an epigenetic manner	
CTCF	mouse	24794443	mouse model		mice KO [+/-] are predisposed to spontaneous, ionizing radiation, and chemically induced tumours of epithelial, mesenchymal, and hematopoietic origin	
CTCF	endometrial cancer	26330387	role in cancer	TSG	TSG	
CTCF	mouse	24794443	role in cancer	TSG	TSG	
CTCF		26439501	function summary		involved in transcriptional regulation by binding to chromatin insulators and preventing interaction between promoter and nearby enhancers and silencers	
CTCF		19568426	function summary		acts as transcriptional repressor binding to promoters of MYC	
CTCF	endometrial cancer	26330387	types of alteration in cancer		recurrent T204fs mutations	
CTNNB1	melanoma	22172720	invasion and metastasis	promotes	promotes metastasis	
CTNNB1	hepatocellular carcinoma	20460486	invasion and metastasis	promotes	activated by hypoxia contributes to enhanced metastatic potential	
CTNNB1	breast cancer	17072303	invasion and metastasis	promotes	promotes EMT	
CTNNB1	melanoma	19144919	suppression of growth	promotes	elevated levels of nuclear beta-catenin in both primary tumors and metastases correlate with reduced expression of a marker of proliferation and with improved survival	
CTNNB1	melanoma	25970248	escaping immune response to cancer	promotes	tumour-intrinsic active beta-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy	
CTNNB1	multiple myeloma	28105169	change of cellular energetics	promotes	KD induces autophagy	RPMI-8826
CTNNB1	multiple myeloma	28105169	escaping programmed cell death	promotes	KD increases the rate of apoptosis	RPMI-8826
CTNNB1	mouse fibroblasts	11983872	proliferative signalling	promotes	induced expression of stabilized beta-catenin results in exhibited increased proliferation	
CTNNB1		11983872	mouse model		transgenic mice in which stabilized beta-catenin is expressed in mesenchymal cells under control of a tetracycline-regulated promoter develop aggressive fibromatoses and hyperplastic gastrointestinal polyps after 3 months of transgene induction	
CTNNB1		8582267	mouse model		loss of beta-catenin induces embryonic lethality in mice due to defect in the embryonic ectoderm cell layer at day 6.5-7.5 p.c.	
CTNNB1	mantle cell lymphoma	26227550	proliferative signalling	promotes	KD significantly inhibits cell proliferation	Jeko-1
CTNNB1	mantle cell lymphoma	26227550	escaping programmed cell death	promotes	KD induces apoptosis	Jeko-1
CTNNB1	sensory dorsal root ganglia	25885041	differentiation and development		required for proper formation and growth	
CTNNB1	mouse pituitary adenoma	25646597	proliferative signalling	promotes	KD decreases cell proliferation	
CTNNB1	mouse pituitary adenoma	25646597	invasion and metastasis	promotes	KD decreases cell decreases cell invasiveness	
CTNNB1	multiple myeloma	15067127	proliferative signalling	promotes	promotes cell proliferation	
CTNNB1	prostate cancer	28209613	cell replicative immortality	promotes	crucial for high-TERT-expression-mediated Cancer Stem Cell traits	
CTNNB1	nasopharyngeal carcinoma	24073846	cell replicative immortality	promotes	regulates self-renewal networks and plays a central role in the control of pluripotency genes	HONE1
CTNNB1		30683662	differentiation and development		essential for differentiation of primary myoblasts	
CTNNB1		30150300	differentiation and development		drives the differentiation of bone marrow stromal cells into osteoblasts	
CTNNB1		30085028	differentiation and development		regulates the formation of the POU1F1 lineage of pituitary cell types	
CTNNB1		30837277	escaping immune response to cancer	promotes	GOF alterations restrain T-cell rectruitment and generate non-inflamed tumors	
CTNNB1	colorectal cancer	30004146	escaping immune response to cancer	promotes	inhibits RIG-I-like receptor (RLR)-mediated IFN-beta signalling	
CTNNB1	breast cancer	28798698	change of cellular energetics	promotes	KD results in loss of mitochondrial mass and membrane potential, downregulates the expression of proteins involved in carbohydrate metabolism and tricarboxylic acid cycle and upregulates proteins associated to lipid metabolism	MCF7
CTNNB1	colon cancer	25805023	genome instability and mutations	suppresses	KD significantly enhances formation of covalent DNA adducts by benzo[a]pyrene due to deregulation of cytochrome CYP1A1	HCT116
CTNNB1	hepatocellular carcinoma	24944688	angiogenesis	promotes	stimulates the expression of the angiogenic factors, MMP-2, MMP-9, VEGF-A, VEGF-C and bFGF	HepG2
CTNNB1	hepatocellular carcinoma	19101982	angiogenesis	promotes	activating mutations are associated with increased macro- and microvascular invasion	
CTNNB1		28430641	function summary		binds to LEF-1/TCF4 and other co-regulators to promote the transcription of multiple target genes such as Jun, c-Myc and CyclinD-1 in a tissue specific manner	
CTNNB1		18957423	escaping programmed cell death	promotes	blocks anoikis and promotes anchorage-independent growth by down-regulating death-associated protein kinase-2 (DAPk-2)	
CTNNB1		14744872	cell division control		KD leads to the failure of centrosomes to fully separate	
CTNNB1		18086858	cell division control		a key regulator of mitotic centrosome separation	
CTNNB1	aldosterone producing adenomas	26815163	role in cancer	oncogene	oncogene	
CTNNB1	pleomorphic adenoma of the salivary gland	21394649	role in cancer	fusion	fusion	
CTNNB1	pleomorphic adenoma of the salivary gland	21394649	fusion partner		PLAG1	
CTNNB1	hepatoblastoma	10398436	role in cancer	oncogene	oncogene	
CTNNB1		26713771	genome instability and mutations	suppresses	required for activation of the Ku70/Ku80 DNA repair machinery upon irradiation	
CTNNB1		28430641	function summary		transcriptional co-regulator and an adaptor protein for intracellular adhesion, playing a central role in physiological homeostasis, a key mediator of the Wnt signal	
CTNNB1		12569130	differentiation and development		conditional KO in mouse limb ectoderm results in severe limb defects	
CUX1		25190083	function summary		homeobox gene which is implicated in both tumour suppression and progression. One of the isoforms participates in base excision repair, other isoforms act as transcriptional coactivators or corepressors 	
CUX1	breast cancer	21245318	genome instability and mutations	promotes	causes chromosomal instability by activating a transcriptional program that prevents multipolar divisions and enables the survival of tetraploid cells that evolve to become genetically unstable and tumourigenic	
CUX1		25190083	genome instability and mutations	suppresses	participates in base excision repair	
CUX1	pancreatic neuroendocrine tumours	25248790	angiogenesis	promotes	proangiogenic	
CUX1		25190083	escaping programmed cell death	promotes	induces resistance to apoptosis	
CUX1	pancreatic neuroendocrine tumours	25248790	proliferative signalling	promotes	overexpression increases cell proliferation	
CUX1		24316979	impact of mutation on function		CUX1 inactivating mutations activate phosphoinositide 3-kinase (PI3K) signalling through direct transcriptional downregulation of the PI3K inhibitor PIK3IP1 (phosphoinositide-3-kinase interacting protein 1), leading to increased tumour growth and susceptibility to PI3K-AKT inhibition	
CUX1	pancreatic neuroendocrine tumours	25248790	invasion and metastasis	promotes	high expression is associated with increased metastasis	
CUX1		25190083	suppression of growth	promotes	responsible for the repression of the PI3K-AKT pathway	
CUX1	pancreatic ductal adenocarcinoma	24336331	escaping immune response to cancer	promotes	modulates polarisation of tumour-associated macrophages by antagonising NF-kB signalling which antagonises T-cell attraction	
CUX1		25190083	role in cancer	TSG,oncogene	TSG, oncogene	
CUX1		27727438	types of alteration in cancer		missense, nonsense and frameshift mutations, deletion, overexpression	
CUX1		25190083	cell division control		accelerates S-phase entry, promotes bipolar mitosis after cytokinesis failure	
CUX1		25190083	invasion and metastasis	promotes	stimulates cell migration and invasion	
CXCR4		25961926	function summary		G protein-coupled chemokine receptor, it takes part in the shaping of the tumour microenvironment	
CXCR4		25961926	proliferative signalling	promotes	overexpression strongly promotes proliferation	
CXCR4	breast cancer	26083776	proliferative signalling	promotes	decreased expression of CXCR4 in metastatic tumour cells is associated with their dormancy	
CXCR4	pancreatic cancer	25145299	invasion and metastasis	promotes	promotes GSK3 beta expression, resulting in increased invasiveness	PANC-1
CXCR4	Waldenstrom macroglobulinaemia	24366360	impact of mutation on function		mutations result in GOF due to impairment of receptor internalisation and thereby prolonging G-protein and beta-arrestin signalling	
CXCR4		25961926	invasion and metastasis	promotes	overexpression strongly promotes cell migration and invasion	
CXCR4	T-ALL	26058076	invasion and metastasis	promotes	essential to the migratory properties of the Leukaemia Initiating Cells	
CXCR4	Waldenstrom macroglobulinaemia	24366360	role in cancer	oncogene	oncogene	
CXCR4		9689100	differentiation and development		involved in embryonic haematopoiesis and brain development	
CXCR4	glioblastoma	25326893	invasion and metastasis	promotes	promotes EMT	
CYLD		19109899	escaping programmed cell death	suppresses	KD inhibits necrotopsis in FADD-deficient cells	Jurkat
CYLD		23861985	function summary		a constitutive inhibitor of NF-kB	
CYLD		24469800	cell division control		promotes spindle orientation by stabilizing astral microtubules and deubiquitinating the cortical polarity protein dishevelled	
CYLD		12917690	escaping programmed cell death	suppresses	KD protects cells from TNF-alpha induced apoptosis through activation of NFKB	Hela, U2OS
CYLD	bladder cancer	27448305	invasion and metastasis	suppresses	decreases migratory and invasive potential	
CYLD	GBM	25071012	tumour promoting inflammation	suppresses	down-regulation is crucial for hypoxia-mediated inflammation	
CYLD	mammary epithelial cells	20797623	suppression of growth	promotes	KD promotes colony formation	MCF10A
CYLD		21478324	mouse model		catalytically deficient CYLD truncated mutant sensitizes mice to chemically-induced skin tumour development	
CYLD		18636086	interaction with pathogen		negatively regulates the DDX58-mediated antiviral response	
CYLD		20347313	function summary		deubiquitylating enzyme that removes lysine 63-linked polyubiquitin chains from several specific substrates	
CYLD	SCC	21900959	escaping programmed cell death	suppresses	ectopic expression induces a differentiated phenotype of the cells and promotes apoptosis	A431
CYLD	cylindroma	10835629	role in cancer	TSG	TSG	
CYLD		17072331	role in cancer	TSG	TSG	
CYLD	multiple myeloma	26282654	types of alteration in cancer		frequently deleted	
CYLD	hepatocellular carcinoma	16774947	types of alteration in cancer		Decreased expression	
CYLD		27727438	types of alteration in cancer		truncating mutations affecting mostly the C-terminal ubiquitin hydrolase domain	
CYLD	mouse SCC	20838385	angiogenesis	suppresses	expression of catalytically deficient truncated CYLD induces the expression of angiogenic factors and enhances the angiogenesis	PDVC57
CYLD	mouse model of colitis-associated cancer	17053834	tumour promoting inflammation	suppresses	KO increases colonic inflammation and tumour formation at the site of inflammation	
CYLD	breast cancer	20797623	tumour promoting inflammation	suppresses	downregulation by miR-181b-1 leads to increased NF-kB activity and maintenance of the inflammatory feedback loop necessary for the transformed states	MCF10A
CYLD	lung adenocarcinoma	29286108	suppression of growth	promotes	ectopic overexpression inhibits proliferation, and downregulation by miR-197-3p promotes cell proliferation	HCC827 and Calu-3
CYLD	colon cancer	16774947	types of alteration in cancer		Decreased expression	
CYLD		25342597	function summary		regulator of multiple pathways	
CYLD		20194890	angiogenesis	promotes	positively regulates angiogenesis by mediating vascular endothelial cell migration	
CYLD	mouse B-cells	17923499	escaping programmed cell death	suppresses	overexpression of splice variant lacking the TRAF2 and NEMO binding sites promotes B cell accummulation in all peripheral lymphoid organs, increases survival and expression of anti-apoptotic BCL2	
CYLD	lung cancer	22017589	escaping programmed cell death	suppresses	blocks TRAIL-induced NF-kB activation, and consequently increases TNFSF10-induced apoptosis	A549
CYLD	mice	22698400	tumour promoting inflammation		liver-specific expression of deubiquitinase deficient CYLD promotes inflammatory cell expansion and TNF-alpha production	
CYLD	chemically-induced mouse skin tumours 	16713561	suppression of growth	promotes	KO leads to increased proliferation, with increased cyclin D1 expression and increased nuclear activity of Bcl-3-associated NF-kB p50 and p52	
CYLD	mouse B-cells	17392286	suppression of growth	promotes	KO of both alleles results in extensive proliferation upon LPS or anti-IgM stimulation	
CYLD	hepatocellular carcinoma	24104553	suppression of growth	promotes	overexpression of CYLD prevents cell proliferation, without affecting apoptosis, adhesion and migration.	HepG2, PLC and Huh7
CYLD	cylindroma	10835629	types of alteration in cancer		germline truncating mutations, common LOH or somatic mutation of other allele	
CYLD	multiple myeloma	27775078	suppression of growth	promotes	Ectopic expression reduces BrdU incorporation and inhibits growth	UM-3
CYLD		17495026	cell division control		KD delays entry into mitosis, ectopically expressed protein leads to accumulation of multinucleated cells and fragmented nuclei and ocalises to the midbody in telophase	Hela and U2OS
CYLD		20593489	cell division control		negatively regulates the mitotic Aurora-B kinase in deubiquitinase-independent manner	
CYLD		28572092	function summary		regulates the magnitude of ubiquitination of several major effectors of the EGFR pathway by assisting the recruitment of the ubiquitin ligase Cbl-b to the activated EGFR complex	
CYLD	mice	27561390	escaping programmed cell death	suppresses	epithelial-specific inhibtion of CYLD catalytic activity reduces DNA damage-induced cell death and decreases p53 protein stability	
CYLD	SCC mouse models	21478324	invasion and metastasis	suppresses	ectopic expression of catalytically deficient CYLD truncated mutant enhances cell invasive properties 	A431
CYLD	glioblastoma	28901464	suppression of growth	promotes	inhibits cell proliferation	
CYLD	multiple myeloma	27775078	clinical impact		lower CYLD expression is associated with worse overall and progression free survival	
CYLD	melanoma	19124656	types of alteration in cancer		Decreased expression	
CYLD		16501569	differentiation and development		regulates T cell development through interaction and deubiquitination of Lck, null mice have fewer CD4+ and CD8+ T cells and slightly larger B-cell compartment	
CYLD		17925880	interaction with pathogen		negatively regulates the NF-kB-dependent inflammation in response to bacterial infection	
CYLD	lung adenocarcinoma	29286108	escaping programmed cell death	suppresses	CYLD overexpression increases, and downregulation by miR-197-3p inhibits apoptosis	HCC827 and Calu-3
CYLD	mouse SCC	20838385	invasion and metastasis	suppresses	expression of catalytically deficient truncated CYLD promotes mesenchymal phenotype and enhances the migration	PDVC57
CYLD	mouse model of lung cancer	22057290	tumour promoting inflammation	suppresses	KO increases expression of pro-inflammatory cytokines by tumour-associated macrophages	
CYLD	mice	22698400	suppression of growth	promotes	liver-specific expression of deubiquitinase deficient CYLD promotes cell proliferation leading to late-onset development of hepatocellular carcinoma	
CYLD	T-ALL	20832754	types of alteration in cancer		Decreased expression	
CYLD		21900959	differentiation and development		promotes epidermal differentiation through the inhibitory effect on the JNK signaling pathway	
CYLD		19893491	cell division control		negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin	
CYLD	melanoma	22832488	suppression of growth	promotes	ectopic expression of CYLD but not its catalytically deficient mutant inhibits cell proliferation and migration in vitro and subcutaneous tumor growth in vivo	
DAXX		9215629	function summary		proapoptotic protein, binds specifically to the Fas death domain, activates the Jun N-terminal kinase (JNK) pathway	
DAXX		25190083	cell division control		accelerates S-phase entry, promotes bipolar mitosis	
DAXX	 prostate cancer	23239745	genome instability and mutations	promotes	represses APC, promoting chromosome instability	
DAXX		23542781	genome instability and mutations	suppresses	DAXX silencing suppresses mouse ovarian surface epithelial cell growth by inducing DNA damage	
DAXX		26340527	genome instability and mutations	suppresses	safeguards the genome by silencing repetitive elements via H3K9 trimethylation when DNA methylation levels are low	
DAXX		9215629	escaping programmed cell death	suppresses	proapoptotic	
DAXX		25903140	escaping programmed cell death	promotes	suppresses autophagy by repressing DAPK1 and DAPK3	
DAXX	ovarian cancer	23539629	proliferative signalling	promotes	overexpression induces proliferation, whereas Daxx depletion by RNAi has the opposite effect 	
DAXX	ovarian cancer	23539629	invasion and metastasis	promotes	overexpression induces colony formation, and migration, whereas Daxx depletion by RNAi has the opposite effects	
DAXX		23542781	senescence	suppresses	DAXX silencing suppresses mouse ovarian surface epithelial cell growth by inducing senescence	
DAXX	pancreatic neuroendocrine tumours	21719641	role in cancer	TSG	TSG	
DAXX	prostate cancer	25903140	role in cancer	oncogene	oncogene	
DAXX	pancreatic neuroendocrine tumours	21719641	types of alteration in cancer		frequently inactivated	
DAXX	mouse ovarian surface epithelial tumours	23542781	types of alteration in cancer		highly expressed	
DAXX		21719641	genome instability and mutations	suppresses	crucial for telomere maintenance	
DCTN1		24698967	role in cancer	fusion	fusion	
DCTN1		20101786	clinical impact		mutations associated with multiple neurodegenerative diseases	
DCTN1		25185702	function summary		essential cofactor for most cellular functions of the microtubule motor, cytoplasmic dynein	
DCTN1	lung cancer	25813404	fusion partner		ALK	
DCTN1	Spitz tumours	24698967	fusion partner		ALK	
DDB2		19541625	escaping programmed cell death	suppresses	plays a central role in defining the response (apoptosis or arrest) to DNA damage, DDB2-deficient cells are resistant to apoptosis	
DDB2		14560002	escaping programmed cell death	suppresses	upregulates TP53 upon UV radiation and promotes UV-induced apoptosis	
DDB2		19109893	genome instability and mutations	suppresses	takes part in detection of UV-DNA lesions	
DDB2		26879405	function summary		DNA binding protein, involved in DNA repair, induces the transcription of IkB alpha, modulates the properties of the cytoskeleton	
DDB2	breast cancer	18431487	role in cancer	oncogene	oncogene	MCF-7
DDB2		14560002	role in cancer	TSG	TSG	
DDB2	breast cancer	26879405	invasion and metastasis	suppresses	impedes initiation of metastasis, overexpression is associated with a decrease of adhesion abilities and cell stiffness due to the loss of cortical actin	MDA-MB231, MCF7
DDB2	breast cancer	18431487	proliferative signalling	promotes	promotes proliferation by acceleration of G1/S transition and S-phase progression	MCF-7
DDIT3	hepatocellular carcinoma	24367269	role in cancer	oncogene	oncogene	
DDIT3	myxoid liposarcoma	26865464	fusion partner		FUS	
DDIT3	hepatocellular carcinoma	24367269	types of alteration in cancer		overexpressed	
DDIT3	myxoid liposarcoma	26865464	role in cancer	fusion	fusion	
DDIT3	hepatocellular carcinoma	24367269	tumour promoting inflammation	promotes	promotes hepatic inflammatory gene expression and fibrosis	
DDIT3		15601821	escaping programmed cell death	suppresses	induces cell death in reaction to ER stress 	
DDIT3		24367269	function summary		stress-regulated transcription factor	
DDR2		20734453	function summary		receptor tyrosine kinase, cell surface receptor for fibrillar collagen, regulates cell adhesion	
DDR2	HNSCC	24556606	invasion and metastasis	promotes	overexpression promotes cell invasion and migration	
DDR2	NSCLC	26826182	impact of mutation on function		E655K mutant causes low cellular level of ddr2 due to increased proteosomal degradation, which results in decreased inhibitory effect of collagen on proliferation, suggesting TSG role, however BRAF was mutated in the same sample	
DDR2		20734453	differentiation and development		regulates osteoblast differentiation and chondrocyte maturation via RUNX2	
DDR2		26826182	role in cancer	oncogene	oncogene	
DDR2	hepatocellular carcinoma	26362312	invasion and metastasis	promotes	facilitates invasion and metastasis via activating ERK signalling and stabilising SNAIL1	
DDX10	AML	23522748	fusion partner		NUP98	
DDX10	ovarian cancer	26713367	role in cancer	TSG	TSG	
DDX10	ovarian cancer	26713367	types of alteration in cancer		silenced by miR-155-5p	
DDX10	AML	23522748	role in cancer	fusion	fusion	
DDX10	ovarian cancer	26713367	suppression of growth	promotes	downregulated expression of DDX10 promotes proliferation through Akt/NF-kappaB pathway	
DDX10		8660968	function summary		DEAD-box RNA-helicase	
DDX3X	breast cancer	23696831	change of cellular energetics	promotes	expression of DDX3 is positively correlated with overexpression of HIF-1 alpha and many other hypoxia related proteins	
DDX3X	mouse fibroblasts	16301996	suppression of growth	promotes	knockdown of DDX3 results in enhancement of cell growth	NIH-3T3
DDX3X	breast cancer	18264132	invasion and metastasis	promotes	overexpression of DDX3 induces an epithelial-mesenchymal-like transformation, cells exhibit increased motility and invasive properties and have repressed E-cadherin expression	MCF-10A
DDX3X		25043297	invasion and metastasis	promotes	KD reduces the levels of both Rac1 and beta-catenin and causes increased cell-cell adhesion but decreased cell-extracellular matrix adhesion, suppresses cell motility and impairs directional migration	
DDX3X		27058758	impact of mutation on function		medulloblastoma-related DDX3 catalytically-impaired R534H mutant is defective for silencing chromatin associated genes upon stress 	
DDX3X	breast cancer	23470959	escaping programmed cell death	suppresses	positively regulates DNA damage-induced apoptosis and p53 stabilization	MCF-7
DDX3X	mouse fibroblasts	16301996	cell division control		knockdown of DDX3 results in a premature entry to S phase	NIH-3T3
DDX3X	mouse fibroblasts	16301996	invasion and metastasis	suppresses	knockdown of DDX3 enhances ras-induced anchorage-independent growth	
DDX3X		27058758	function summary		RNA helicase gene, interacts with RNA and ribosomal machinery through direct binding to 5'UTRs of nearly all coding RNAs, specific sites on the 18S rRNA, and multiple components of the translation initiation complex to help remodel the translation landscape in response to stress.	
DDX3X	mouse fibroblasts	16301996	escaping programmed cell death	suppresses	knockdown of DDX3 results in increased resistance to serum depletion-induced apoptosis	NIH-3T3
DDX3X		16301996	role in cancer	TSG	TSG	
DDX5	T-ALL	23108395	escaping programmed cell death	promotes	knock-down of DDX5 results in increased apoptosis	
DDX5	colon carcinoma	25745998	function summary		transcriptional coactivator of AKT and beta-catenin, induces nuclear exclusion and degradation of tumour suppressor FOXO3a	
DDX5		22476084	function summary		coactivator of steroid hormone receptors	
DDX5		18698352	function summary		DEAD-box RNA-helicase, regulates alternative splicing of H-Ras	
DDX5		22750847	cell division control		important for G1-S progression, directly regulates DNA replication factor expression by promoting the recruitment of RNA polymerase II to E2F-regulated gene promoters	
DDX5	basal breast cancer	22086602	global regulation of gene expression		regulates expression of miRNA responsible for organisation of the cytoskeleton	
DDX5	NSCLC	26212035	role in cancer	oncogene	oncogene	
DDX5	T-ALL	23108395	role in cancer	oncogene	oncogene	
DDX5		23322042	invasion and metastasis	promotes	in the presence of Ca-calmodulin can function as a microtubule motor enhancing cell migration	
DDX5	glioma	22810421	proliferative signalling	promotes	promotes cell proliferation via direct regulation of the NF-kB transcription factor p50	
DDX5	T-ALL	23108395	proliferative signalling	promotes	knock-down of DDX5 results in decreased expression of Notch target genes, reduced cell proliferation	
DDX5	NSCLC	26212035	proliferative signalling	promotes	activates beta catenin pathway promoting proliferation	
DDX6		8816452	function summary		involved in alternative splicing	
DDX6		23293030	function summary		DEAD-box RNA-helicase	
DDX6	breast cancer	23293030	angiogenesis	promotes	expression is elevated under hypoxia and VEGF translation is inhibited by interaction of DDX6 with its mRNA	MCF-7
DDX6	colorectal cancer	18769115	escaping programmed cell death	promotes	knockdown by RNAi increases apoptosis	
DDX6	colorectal cancer	18769115	proliferative signalling	promotes	knockdown by RNAi inhibits proliferation	
DDX6	nodal marginal zone lymphoma	22965301	role in cancer	fusion	fusion	
DDX6		10360675	types of alteration in cancer		overexpressed in colorectal tumours	
DDX6		25035296	global regulation of gene expression		mutations in DDX6 that disrupt the DDX6-CNOT1 interaction impair miRISC-mediated gene silencing in human cells	
DDX6		26412305	differentiation and development		DDX6 loss results in premature differentiation and decreased proliferation of epidermal progenitor cells	
DDX6	nodal marginal zone lymphoma	22965301	fusion partner		IGH	
DDX6	nodal marginal zone lymphoma	22965301	impact of mutation on function		fusion protein interferes with the expression of BCL6 and BCL2 in an NF-kB independent manner	
DICER1	endometrial carcinoma 	28381177	cell replicative immortality	suppresses	dysfunction promotes cell stemness	
DICER1	prostate cancer	23851498	escaping programmed cell death	promotes	KD increases the apoptosis	PC3, DU145, C4-2 and CWR22Rv1
DICER1		19903759	role in cancer	TSG	TSG	
DICER1	clear cell renal cell carcinoma	27732931	angiogenesis	suppresses	inhibits angiogenesis through suppressing VEGFA expression	
DICER1	clear cell renal cell carcinoma	27732931	invasion and metastasis	suppresses	decreases the cell capabilities of migration and invasion through suppressing MMP-2 expression	
DICER1	MDS and AML	29102598	global regulation of gene expression		downregulation of DICER1 gene results in abnormal miRNA and gene expression profile which dysregulates proliferative and differentiation potential of cells	
DICER1	ovarian cancer	28650464	invasion and metastasis	suppresses	downregulation by beta-catenin promotes metastasis	
DICER1		28642363	genome instability and mutations	suppresses	Dicer depletion causes endogenous DNA damage and delays the DDR by impaired recruitment of repair factors MDC1 and 53BP1	
DICER1		28402505	genome instability and mutations	suppresses	contributes to chromatin decondensation during nucleotide excision repair	
DICER1		28473628	function summary		a riboendonuclease in the small RNA pathway, a critical regulator of the biogenesis of microRNA and small interfering RNA, and other small RNAs, plays a role in antiviral response	
DICER1		20223951	escaping programmed cell death	suppresses	functions in fragmenting chromosomal DNA during apoptosis	
DICER1	NSCLC	26156018	types of alteration in cancer		frequently amplified	
DICER1	ovarian cancer	26408257	global regulation of gene expression		somatic hotspot mutations in RNase IIIb domain of DICER1 cause loss of IIIb cleavage activity of DICER1 in vitro and fail to produce 5p-derived miRNAs, resulting in deregulation of genes controlling cell proliferation and the cell fate	
DICER1	prostate cancer	25135428	role in cancer	oncogene	oncogene	
DICER1	prostate cancer	25135428	proliferative signalling	promotes	silencing Dicer inhibits cell proliferation and arrested the cell cycle	LNCaP, PC-3, DU145
DICER1	prostate cancer	25135428	escaping programmed cell death	promotes	silencing Dicer induces apoptosis	LNCaP, PC-3, DU145
DICER1	laryngeal squamous cell carcinoma	25123850	clinical impact		overexpression is associated with worse prognosis	
DICER1		15247924	function summary		essential for formation of the heterochromatin structure in vertebrate cells	
DICER1	colon cancer	24096488	cell replicative immortality	suppresses	impaired Dicer function causes upregulation of stem cell markers	
DICER1	colon cancer	24096488	invasion and metastasis	suppresses	impaired Dicer function promotes metastasis	
DICER1	prostate cancer	23851498	proliferative signalling	promotes	KD suppresses the growth and tumourigenic capacity 	PC3, DU145, C4-2 and CWR22Rv1
DICER1	prostate cancer	23851498	invasion and metastasis	promotes or suppresses	KD reduces capacity of cells to form colonies in vitro but also enhances the migratory potential of androgen receptor-positive cells	 CWR22Rv1
DICER1	endometrial carcinoma 	28381177	invasion and metastasis	suppresses	dysfunction promotes invasion	
DNM2		27118408	function summary		takes part in control of surface receptors exposition 	
DNM2		21599493	function summary		GTPase involved in clathrin-mediated endocytosis 	
DNM2	pancreatic ductal adenocarcinoma	21841817	types of alteration in cancer		frequently overexpressed	
DNM2		27118408	role in cancer	TSG	TSG	
DNM2	T-ALL	27118408	impact of mutation on function		LOF mutations at GTPase domain impair clathrin-mediated endocytosis of the interleukin (IL)-7 receptor, resulting in increased receptor density on the surface of leukemic stem cells 	
DNM2	glioblastoma	21996738	invasion and metastasis	promotes	stimulates cell migration and survival in vitro and tumour growth and invasion in the brains of mice as an effector downstream of the PDGFR alpha-PI3K/SHP-2 signaling  	
DNM2	pancreatic cancer	23537630	invasion and metastasis	promotes	overexpression potentiates invasive migration of cells through stabilisation of Vav1 	
DNM2		24598168	angiogenesis	promotes	crucial for developmental agiogenesis - the constitutive or inducible loss of Dnm2 in endothelium impairs branching morphogenesis and promotes the accumulation of beta 1 integrin at sites of failed angiogenic sprouting 	
DNM2		25088422	function summary		shares genomic locus with miR-638, which downregulates TP53, PTEN and BRCA1 	
DNM2	glioblastoma	21996738	proliferative signalling	promotes	stimulates tumour growth 	
DNMT3A	MDS	29619119	clinical impact		patients with mutations have a higher incidence of leukaemia transformation and shorter overall survival	
DNMT3A	AML	27149454	clinical impact		R882 mutations associated with poor prognosis	
DNMT3A	lung adenocarcinoma	27237029	clinical impact		expression is associated with the histologically non-invasive type and lepidic subtype, and a favorable prognosis	
DNMT3A		22138693	mouse model		in conditional mouse KOs, many genes associated with HSC self-renewal increase in expression, and some fail to be appropriately repressed during differentiatiation	
DNMT3A	haematological malignancies	28003281	types of alteration in cancer		most mutations in haematopoietic disorders occur within the methyltransferase domain, with significant enrichment for mutations at codon R882	
DNMT3A		24656771	impact of mutation on function		R882H mutation inhibits formation of DNMT3A tetramers in a dominant-negative fashion, leading to a change of cellular methylation patterns	
DNMT3A	pheochromocytoma	29740169	global regulation of gene expression		germline GOF mutations, K299I and R318W,  cause significant hypermethylation of homeobox-containing genes	
DNMT3A	AML	30245403	differentiation and development		missense mutations at R882 inhibit myelomonocytic differentiation	U-937
DNMT3A	hematopoietic stem cells	27010239	differentiation and development		R882H mutation inhibits hematopoietic stem cell differentiation via a methylation independent mechanismim involving interaction with PRC1	
DNMT3A	mice	9662389	differentiation and development		expressed abundantly in ES cells, but at very low levels in differentiated embryoid bodies or adult tissues	
DNMT3A	mouse HSC	22138693	differentiation and development		deletion shiftsh the self-renewal over differentiation balance, resulting in increased clonal expansion of KO mutant cells	
DNMT3A		28286768	function summary		DNA methyltransferase responsible for methylation of de novo (new) genomic sequence, it has two known splice isoforms DNMT3A1, expressed ubiquitously in all tissues at low levels , and DNMT3A2, predominantly expressed in embryonic stem cell found in the ovaries and testes	
DNMT3A	mesenchymal stem cells	26850336	angiogenesis	suppresses	KD promotes angiogenesis via demethylation of arterial specific transcription factors and marker genes	
DNMT3A		24292811	role in cancer	TSG	TSG	
DNMT3A		28872462	role in cancer	TSG	TSG	
DNMT3A	myeloid-derived suppressor cells	28978469	escaping immune response to cancer	promotes	downregulation erases Myeloid-derived suppressor cells (MDSC)-specific DNA hypermethylation, abolishing their immunosuppressive capacity	
DNMT3A	ovarian cancer	29993160	change of cellular energetics	promotes	promotes Warburg effect via methylation and downregulation of miR-145, thereby upregulating miR-145 targeted HK2	SK-OV-3, 3AO
DNMT3A	liver cancer	29724530	invasion and metastasis	promotes	downregulation by miR-876-5p inhibits migration and invasion	Hep-G2
DNMT3A	gastric cancer	29717263	invasion and metastasis	promotes	expression of DNMT3A2 isoform is positively associated with lymph node metastasis and promotes lung metastasis via downregulation of CDH1 in xenografts	MKN45, MKN28
DNMT3A	liver cancer	29724530	proliferative signalling	promotes	downregulation by miR-876-5p inhibits proliferation	Hep-G2
DNMT3A	AML	30245403	escaping programmed cell death	suppresses	inactivation by a missense mutation at R882 impairs apoptosis via impairment of DNA damage signalling	U-937
DNMT3A	ovarian cancer	27748882	escaping programmed cell death	promotes	overexpression decreases caspase-3 and caspase-9 activity	Caov-3
DNMT3A	cervical cancer	26191165	escaping programmed cell death	promotes	KD promotes and over-expression inhibits miR-182-induced apoptosis	C4-II
DNMT3A	AML	30245403	proliferative signalling	promotes	missense mutation of R882 stimulates cell growth via upregulation of hypomethylated PRDX2	U-937
DROSHA		15531879	function summary		catalytic subunit of the microprocessor complex responsible for miRNA maturation	
DROSHA		24786770	function summary		promotes splicing of a pre-microRNA-like alternative exon	
DROSHA	Wilms tumour	25190313	role in cancer	TSG	TSG	
DROSHA	bladder carcinoma	25656609	types of alteration in cancer		frequent amplification correlated with decreased survival rate	
DROSHA		26147304	types of alteration in cancer		3'-UTR polymorphisms is associated with higher risk of colorectal cancer in Korean population	
DROSHA		25670083	global regulation of gene expression		regulates cellular miRNAs	
DROSHA	gastric carcinoma	26694172	types of alteration in cancer		gradual loss of cytoplasmic Drosha is accompanied by tumour progression in both cancer tissues and cell lines	
DROSHA	Wilms tumour	24909261	impact of mutation on function		recurrent mutation (E1147K) affects the metal-binding residue of the RNase IIIb domain in 81% of the DROSHA -mutated tumours, this variant leads to a predominant downregulation of a subset of miRNAs and downregulation occurs exclusively in mature miRNAs and not in primary miRNA transcripts	
DROSHA	Wilms tumour	25190313	impact of mutation on function		DROSHA RNase IIIB mutations globally inhibit miRNA biogenesis through a dominant-negative mechanism	
DROSHA		25670083	impact of mutation on function		DROSHA mutatants strongly altered miRNA expression patterns in tumours	
DROSHA	NSCLC	26156018	types of alteration in cancer		frequent amplification correlated with decreased survival rate	
EBF1		26982363	function summary		transcription factor, takes part in B-cell programing by regulating chromatin landscape and DNA methylation 	
EBF1	BCP-ALL 	26872634	fusion partner		PDGFRB	
EBF1	lipoma	16276091	fusion partner		HMGA2	
EBF1		28555080	role in cancer	TSG	TSG	
EBF1		28555080	suppression of growth	promotes	oss of EBF1 function results in activation of STAT5 signaling and gain of interleukin-7 (IL-7)-independent cell proliferation 	
EBF1		26872634	role in cancer	fusion	fusion	
EBF1		28555080	impact of mutation on function		EBF1-PDGFRB fusion results in loss of EBF1 function, multimerisation and autophosphorylation of the fusion protein, activation of signal transducer and activator of transcription 5 (STAT5) signaling and gain of interleukin-7 (IL-7)-independent cell proliferation 	
EGFR		27727438	types of alteration in cancer		recurrent L858R, E746delELREA, T790M, G719A, G719S, S768I	
EGFR	NSCLC	26216352	change of cellular energetics	promotes	EGFR inhibitors reverse Warburg effect and reactivate oxidative phosphorylation of cancer cells	
EGFR		16152621	angiogenesis	promotes	activation of the EGFR pathway is involved in tumour associated angiogenesis	
EGFR		17314037	differentiation and development		takes part in morphogenesis of epithelial organs including mammary glands	
EGFR		12517767	escaping programmed cell death	promotes	activation of EGFR protects against anoikis	
EGFR	NSCLC	15142631	types of alteration in cancer		frequently overexpressed	
EGFR		15142631	proliferative signalling	promotes	promotes cell proliferation	
EGFR		27461822	function summary		receptor tyrosine kinase	
EGFR		26996308	function summary		requires dimerisation for activity and downstream signalling	
EGFR		25979928	role in cancer	oncogene	oncogene	
EGFR		26338423	invasion and metastasis	promotes	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway	
EGFR		26759242	change of cellular energetics	promotes	EGFR signalling enhances aerobic glycolysis in Triple-Negative Breast Cancer cells to promote tumour growth and immune escape	
EGFR		26134491	proliferative signalling	promotes	miR-133a inhibits cervical cancer growth by targeting EGFR	
EGFR		25658629	escaping immune response to cancer	promotes	EGFR activation by exon-19 deletions and L858R mutation in NSCLC induces PD-L1 expression through p-ERK1/2/p-c-Jun, which may induce the apoptosis of T cells through the PD-L1/PD-1 axis and thus enable immune escape	
EGFR	lung adenocarcinoma	26000960	invasion and metastasis	promotes	upregulation of EGFR and c-Met is associated with epithelial mesenchymal transition in response to increased matrix rigidity	
EGFR	NSCLC	15118073	impact of mutation on function		mutations clustered within tyrosine kinase domain increase activity and delay inactivation of EGFR	
EGFR	glioblastoma	9790506	types of alteration in cancer		frequently amplified, missense mutations and in frame deletions clustered within the extracellular domain result in constantly activated protein	
EGFR		15284455	escaping programmed cell death	promotes	activating mutations within the tyrosine kinase domain activate anti-apoptotic pathways	
EGFR		26996308	impact of mutation on function		deletions in exon 19 cause truncation of the beta3-alphaC loop and restrain alphaC in an active "in" conformation, imparting resistance to inhibitors like vemurafenib that bind the alphaC "out" conformation	
EGFR	NSCLC	26497368	change of cellular energetics	promotes	stimulates mitochondrial fission and redistribution in the lamellipodia, upregulates cellular ATP production, and enhances motility in vitro and in vivo	
EGFR	NSCLC	26497368	invasion and metastasis	promotes	promotes metastasis by altering mitochondria dynamics	
EGFR		22579287	impact of mutation on function		L858R causes abnormally high activity, primarily by promoting EGFR dimerisation through suppressing the disorder in the alphaC-helix region	
EIF3E		22532700	function summary		translation initiation factor necessary for eficient histone mRNA translation 	
EIF3E		8688078	function summary		 target of human T cell leukaemia virus type I Tax oncoprotein, which upon binding relocates EIF3E from the nucleus 	
EIF3E	glioblastoma	24481065	proliferative signalling	promotes	silencing of EIF3E decrease expression of HIF factors and cell proliferation	
EIF3E	glioblastoma	24481065	escaping programmed cell death	promotes	silencing of EIF3E induces cell cycle arrest and apoptosis	
EIF3E	neuronal cells	22960363	angiogenesis	suppresses	KD increases stability of HIF2A and induces agiogenesis	
EIF3E		22907435	invasion and metastasis	suppresses	decreased expression initiates ETM in breast epithelial cells 	
EIF3E	colon cancer	22895193	fusion partner		RSPO2	
EIF3E		22895193	role in cancer	fusion	fusion	
EIF3E		22457825	role in cancer	TSG, fusion	TSG, fusion	
EIF4A2		23559250	function summary		takes part in repression of translation of mRNA prior to its miRNA-mediated degradation 	
EIF4A2	DLBCL	10637510	fusion partner		BCL6	
EIF4A2	NSCLC	23867391	clinical impact		low expression is associated with poor prognosis	
EIF4A2		10637510	impact of mutation on function		fusion transcript contains of BCL6 gene expressed under the control of EIF4A2 promoter 	
EIF4A2		10637510	role in cancer	fusion	fusion	
ELF4		22307523	function summary		transcription factor	
ELF4		16303180	role in cancer	fusion	fusion	
ELF4		22307523	differentiation and development		stimulates adipogenic differentiation 	
ELF4	glioma	23217424	cell replicative immortality	promotes	promotes stemness	
ELF4	AML	16303180	fusion partner		ERG	
ELF4		21616937	escaping programmed cell death	suppresses	contributes to the persistence of gamma H2AX foci and promoter DDR leading to apoptosis, ATM phosphorylates ELF4, leading to its degradation and promoting DNA DSB repair 	
ELF4		19380490	function summary		activates MDM2 and blocks oncogene-induced activation of p16 in mouse embryonic fibroblasts 	
ELF4	ovarian cancer	17213815	proliferative signalling	promotes	overexpression significantly increases cell proliferation, enhances colony formation in soft agar and promotes tumour formation in nude mice 	SKOV3
ELF4	endothelial cells	21350194	cell division control		promotes cell-cycle entry by activating CDK4	
ELF4		12387738	mouse model		KO mice have a profound reduction in the number of NK-T and NK cells 	
ELF4		26921333	suppression of growth	promotes	supresses cell proliferation via the induction of DLX3, an inhibitor of cell growth	
ELF4		26921333	escaping programmed cell death	suppresses	induces HRK, an activator of apoptosis	
ELF4		17213815	role in cancer	oncogene	oncogene	
ELF4		26921333	role in cancer	TSG	TSG	
ELF4		26921333	impact of mutation on function		L211M reduces growth inhibitory properties of the protein 	
ELK4	prostate cancer	19136943	fusion partner		SLC45A3	
ELK4	prostate cancer	28716526	impact of mutation on function		the SLC45A3-ELK4 fusion RNA level is less than 1% of wild type ELK4; when the fusion RNA is silenced, cell proliferation is inhibited in both androgen-dependent and castration-resistant cells; this growth arrest can be rescued by exogenous expression of either the fusion and a mutant designed to prevent translation of the ELK4 protein, indicating that SLC45A3-ELK4 regulates cancer cell proliferation by its transcript, not translated protein	
ELK4		22719019	types of alteration in cancer		SLC45A3-ELK4 fusion transcript occurs without genomic rearrangement but is formed by cis-splicing of adjacent genes/read-through 	
ELK4		26028036	role in cancer	oncogene	oncogene	
ELK4		19136943	role in cancer	fusion	fusion	
ELK4	hepatocellular carcinoma	21499249	fusion partner		BCORL1	
ELK4	AML	16303180	fusion partner		ERG	
ELK4	glioblastoma	21846680	escaping programmed cell death	promotes	ELK4 downregulation reduced tumour formation in xenograft models via downregulation of antiapoptotic protein Mcl-1 	
ELK4	melanoma	26028036	proliferative signalling	promotes	KD significantly attenuated the proliferation and inhibited the anchorage-independent cell growth	
ELK4	melanoma	26028036	types of alteration in cancer		overexpressed in melanoma	
ELK4		18469865	function summary		androgen-dependent transcription factor	LNCaP
ELK4	prostate cancer	18469865	proliferative signalling	promotes	silencing of ELK4 retards the cell growth	LNCaP
ELL		19447890	angiogenesis	suppresses	inhibits zebrafish vasculogenesis, at least in part, through up-regulating TSP-1	
ELL		20166137	suppression of growth	promotes	inhibits cell growth and colony formation under normoxia via downregulation of HIF1A, the growth inhibition is alleviated under hypoxia	
ELL		11090074	cell replicative immortality	promotes	KMT2A-ELL chimeric protein is capable of immortalizing clonogenic myeloid progenitors, C-terminal domain of ELL is required and sufficient for this process	
ELL	AML	11090074	fusion partner		KMT2A	
ELL		8596958	function summary		elongation factor that can increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by polymerase at multiple sites along the DNA	
ELL		11090074	role in cancer	fusion	fusion	
ELL		24127601	function summary		involved in transcription restart after DNA repair	
ELL		11238904	role in cancer	TSG	TSG	
EML4		25789526	cell division control		required for the organisation of the mitotic spindle and for the proper attachment of kinetochores to microtubules through loading of NUDC onto the mitotic spindle 	
EML4	lung cancer	26755435	fusion partner		ALK	
EML4		17196341	function summary		microtubule stabilizing protein 	
EML4		26755435	role in cancer	fusion	fusion	
EP300		15313412	function summary		transcriptional coactivator, histone acetyltransferase	
EP300		15156177	function summary		acetylates p53, p73, Rb, E2F, myb, myoD, HMG(I)Y, GATA1 and alpha-importin	
EP300	AML	10824998	fusion partner		KAT6A	
EP300	AML	20980053	fusion partner		KMT2A	
EP300	SCLC	22941188	types of alteration in cancer		recurrent somatic mutations	
EP300		9613201	role in cancer	fusion	fusion	
EP300		21041953	types of alteration in cancer		inactivating mutations occur naturally in human DLBCL patients and may confer resistance to BCL6 inhibitors	
EP300		12237408	suppression of growth	promotes	truncating mutations increase cell proliferation through disruption of TGF-beta response	
EP300		10523850	escaping programmed cell death	suppresses	KD inhibits apoptosis	
EP300		12237408	role in cancer	TSG	TSG	
EP300		26354606	differentiation and development		involved in development of skeletal musceles	
EPAS1		16510872	differentiation and development		upregulates Oct-4, a transcription factor essential for maintaining stem cell pluripotency	
EPAS1	hemangioblastoma	26514359	impact of mutation on function		stop mutations affect prolyl hydroxylation resulting in reduced ubiquitination but intact transcriptional activity, which has activating effect 	
EPAS1		26837714	types of alteration in cancer		most human soft-tissue sarcomas have lower levels of EPAS1, epigenetic re-expression suppresses soft tissue sarcoma growth 	
EPAS1	NSCLC	25831463	types of alteration in cancer		binds to T790M EGFR but not WT EGFR and increases MET levels	
EPAS1	gastric cancer	25730079	types of alteration in cancer		transcript level and protein expression are significantly higher	
EPAS1		23090011	types of alteration in cancer		F374Y (germline) decreases VHL protein binding and ubiquitination, increasing the stability of EPAS1	
EPAS1	mice	23860500	tumour promoting inflammation	promotes	activates mediators of inflammation and promotes the development of colitis	
EPAS1		15192019	angiogenesis	promotes	promotes angiogenesis through the transactivation of VEGF and FLT1	
EPAS1		22169972	function summary		transcription factor involved in the induction of oxygen regulated genes	
EPAS1	RCC	19706526	escaping programmed cell death	promotes	inhibition promotes p53 pathway activity and tumour cell death	A-498
EPAS1	mouse model of RCC	26439684	proliferative signalling	promotes	knockdown abrogates CXCR4 expression and abolishes tumour growth	
EPAS1	cervical cancer	25966094	invasion and metastasis	promotes	knockdown reduces colony formation and invasion capacity under both normoxic and hypoxic conditions	HeLa
EPAS1	sarcomas	26837714	suppression of growth	promotes	loss of EPAS1 promotes proliferation	
EPAS1	pheochromocytoma	24741025	role in cancer	oncogene	oncogene	
EPAS1	sarcomas	26837714	role in cancer	TSG	TSG	
EPS15		28215104	role in cancer	TSG	TSG	
EPS15		8134107	role in cancer	fusion	fusion	
EPS15	mouse embryo fibroblasts	7689153	proliferative signalling	promotes	overexpression of eps15 stimulates proliferation and anchorage-independent growth	NIH 3T3
EPS15	AML	8134107	fusion partner		KMT2A	
EPS15		21832070	function summary		distinct forms of Eps15 direct EGFR either for degradation (Eps15) or to the recycling endosome for transit back to the cell surface (Eps15S) 	
EPS15		8910509	function summary		component of clathrin-coated pits 	
ERBB2		21555369	function summary		positive regulator of rRNA synthesis and cellular translation 	
ERBB2		20719876	role in cancer	oncogene, fusion	oncogene, fusion	
ERBB2		15254961	function summary		membrane tyrosine kinase	
ERBB2	breast cancer	21204711	escaping programmed cell death	promotes	controller of antiapoptotic signalling	
ERBB2	breast cancer	21204711	proliferative signalling	promotes	major driver of tumour cell proliferation	
ERBB2		15542430	invasion and metastasis	promotes	promotes metastasis via upregulation of CXCR4 	
ERBB2		15609325	escaping programmed cell death	promotes	overexpression suppresses the transcription of antiangiogenic factors and induces expression of angiogenic factors 	
ERBB2		15173068	function summary		promotes the nucleus-to-cytoplasm relocalisation of estrogen receptor	
ERBB2		25189649	escaping programmed cell death	promotes	inhibits apoptosis through downregulation of CASP-3 and CASP-8 	
ERBB2		23232401	change of cellular energetics	promotes	ErbB2 translocates into mitochondria, where it negatively regulates mitochondrial respiratory functions 	
ERBB2	gastric cancer	25889497	fusion partner		ZNF207, MDK,  NOS2 	
ERBB2	micropapillary urothelial carcinoma	24192927	fusion partner		GRB7 	
ERBB2	breast cancer	23260012	fusion partner		BCAS3 	ZR-75-30
ERBB2	breast cancer	21622959	fusion partner		WIPF2 	UACC812
ERBB2		15254961	differentiation and development		crucial for embryonic, cardiac and periperial nervous system development 	
ERBB3		22261253	proliferative signalling	promotes	promotes cell proliferation 	
ERBB3		15254961	differentiation and development		crucial for embryonic, cardiac and periperial nervous system development 	
ERBB3		15254961	function summary		member of the receptor tyrosine kinase family with impaired tyrosine kinase activity, binds to the p85 adaptator subunit of PI-3K	
ERBB3	prostate cancer	17638862	invasion and metastasis	promotes	secreted isoform enhances invasiveness of tumour cells 	
ERBB3		20719876	role in cancer	oncogene	oncogene	
ERBB3	lung adenocarcinoma	15688028	invasion and metastasis	promotes	KD attenuates invasiveness 	A549
ERBB3	lung adenocarcinoma	15688028	escaping programmed cell death	promotes	KD promotes apoptosis 	A549
ERBB4		16912174	function summary		receptor Y-protein kinase, Member of EGFR family, surface receptor for neuregulins, regulator of differentiation, coactivator of ER in breast cancer	
ERBB4	NSCLC	26050618	impact of mutation on function		Y285C, D595V, D931Y and K935I activating mutations enhance ErbB4 dimerisation and increase the transactivation in ErbB4 homodimers and ErbB4-ErbB2 heterodimers	
ERBB4		18454307	escaping programmed cell death	suppresses	activation is associated with apoptosis in vitro	
ERBB4	NSCLC	26050618	escaping programmed cell death	promotes	increases cell survival in serum depleted conditions 	
ERBB4	breast cancer	16251361	proliferative signalling	promotes	tumour-associated ErbB4 isoform promotes ligand-independent cancer cell growth	
ERBB4	melanoma	22661227	proliferative signalling	promotes	silencing ERBB4 has minimal effect on the proliferation of cells expressing WT receptor but substantially reduces the growth of lines carrying mutant ERBB4	
ERBB4	breast cancer	11390655	suppression of growth	promotes	mediates ligand-dependent antiproliferative and differentiation responses	
ERBB4	breast cancer	11390655	role in cancer	TSG	TSG	
ERBB4	breast cancer	16251361	role in cancer	oncogene	oncogene	
ERBB4	NSCLC	26050618	role in cancer	oncogene	oncogene	
ERBB4	mouse	24670412	mouse model		deletion of ErbB4 accelerates polycystic kidney disease progression	
ERBB4	oral cancer	24353162	types of alteration in cancer		frequent copy number loss	
ERBB4	breast cancer	18454307	cell division control		activation is associated with cell cycle arrest in vitro	
ERBB4		18454307	differentiation and development		activation is associated with differentiation in vitro	
ERBB4		27727438	types of alteration in cancer		recurrent T19A, R711C	
ERBB4	breast cancer	16251361	escaping programmed cell death	promotes	tumour-associated ErbB4 isoform promotes ligand-independent survival	
ERC1		15218148	function summary		essential regulatory subunit of the IKK complex, induces the expression of NF-kappaB target genes 	
ERC1	thyroid papillary carcinoma 	10337992	fusion partner		RET	
ERC1	AML	17690697	fusion partner		PDGFRB	
ERC1		12203787	impact of mutation on function		oligomerisation of ERC1-RET chimeric proteins through the coiled-coil domain of ERC1 dimerizes the RET kinase domains leading to constitutive autophosphorylation of RET 	
ERC1		12203787	role in cancer	fusion	fusion	
ERCC2		25969448	genome instability and mutations	suppresses	protects the mitochondrial genome from oxidative DNA damage 	
ERCC2		10673506	function summary		a subunit of basal transcription factor TFIIH 	
ERCC2		8413672	function summary		single-stranded DNA-dependent ATPase and DNA helicase, involved in NER 	
ERCC2		8675009	escaping programmed cell death	suppresses	component of p53-mediated apoptosis pathway 	
ERCC2	hepatocellular carcinoma	21264535	escaping programmed cell death	suppresses	may play role in apoptosis by enhancing expression of p53 and suppressing c-myc and cdk2	
ERCC2		26031757	role in cancer	TSG	TSG	
ERCC3		2167179	function summary		DNA helicase, involved in NER 	
ERCC3		10673506	function summary		subunit of basal transcription factor TFIIH 	
ERCC3		15549133	genome instability and mutations	suppresses	promotes the incision of the damaged DNA fragment	
ERCC3		8675009	escaping programmed cell death	suppresses	component of p53-mediated apoptosis pathway 	
ERCC3		2167179	role in cancer	TSG	TSG	
ERCC4		26074087	function summary		acatalytic subunit of the ERCC1-XPF nuclease involved in NER	
ERCC4		8887684	genome instability and mutations	suppresses	NER protein involved in removing DNA interstrand cross-linking damage 	
ERCC4		26411687	genome instability and mutations	promotes	required for generation of Helicobacter pylori induced DNA DSB 	
ERCC4	HNSCC	20372803	clinical impact		high expression is associated with resistance to cis-platin 	
ERCC4		23623386	role in cancer	TSG	TSG	
ERCC5		11266544	role in cancer	TSG	TSG	
ERCC5		26833090	genome instability and mutations	suppresses	partners with BRCA1 and BRCA2 to maintain genomic stability through homologous recombination, and its loss causes DNA breaks, chromosome aberrations, and replication fork stalling	
ERCC5		16167068	escaping programmed cell death	promotes	suppresses UV-induced apoptosis	
ERCC5		12644470	function summary		has cleavage preference for dsDNA with 3' overhang	
ERCC5		17466625	function summary		forms a stable complex with TFIIH	
ERCC5		26411687	genome instability and mutations	promotes	required for generation of Helicobacter pylori induced DNA DSB	
ERCC5		11266544	function summary		endonuclease involved in NER	
ERG	prostate cancer	20118910	fusion partner		SLC45A3	
ERG	CML and Ewing sarcoma	15988032	fusion partner		FUS	
ERG	prostate cancer	20878952	fusion partner		TMPRSS2	
ERG	AML	16303180	fusion partner		ELF4	
ERG		26385962	cell replicative immortality	promotes	loss of Erg accelerates HSC differentiation by >20-fold	
ERG		21673349	cell replicative immortality	promotes	required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice	
ERG		25915839	role in cancer	oncogene, fusion	oncogene, fusion	
ERG		7605748	differentiation and development		plays an important role in the differentiation of cartilage and bone tissue	
ERG		18500345	differentiation and development		critical for hematopoiesis	
ERG		18195090	differentiation and development		transcription factor, critical in development of vascular system and endothelial apoptosis	
ERG		18195090	function summary		transcription factor	
ERG	prostate cancer	19649210	fusion partner		NDRG1	
ERG		22932696	differentiation and development		regulator of endocardial-mesenchymal transformation during cardiac valve morphogenesis	
ESR1		26122181	function summary	1	estrogen receptor, transcription factor	
ESR1		27727438	types of alteration in cancer		recurrent missense mutations K303R, Y537S, D538G	
ESR1		25576212	invasion and metastasis	promotes	enhances metastatic capacity	
ESR1		25728938	invasion and metastasis	promotes	silencing of ESR1 in MCF-7 cell-line induces EMT and expression of specific matrix effectors associated with metastasis	
ESR1		25375021	function summary		stimulates transcription of mitochondrial genes	
ESR1		10945602	impact of mutation on function		K303R shows increased sensitivity to estrogen and increased proliferation at subphysiological levels of estrogen	
ESR1	papillary thyroid cancer	25594859	function summary		induces prosurvival autophagy	
ESR1	aggressive subset of ER+ breast cancer	25099679	fusion partner		CCDC170 	
ESR1		25534852	function summary		regulates chromosome alignment and spindle dynamics by stabilising microtubules during mitosis	
ESR1		22240483	interaction with pathogen		protects against HBV-associated hepatocellular carcinoma by repressing transcription of HBV genes	
ESR1	hepatoma	19027010	suppression of growth	promotes	overexpression of miR-18a decreases ERalpha levels and stimulates cell proliferation	
ESR1		24475282	escaping immune response to cancer	promotes	immune escape mechanisms in ERalpha breast cancer may be facilitated through an ERalpha suppressive mechanism on IFN-gamma signalling	
ESR1		24374826	invasion and metastasis	suppresses	ER alpha in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3	
ESR1		26122181	impact of mutation on function		missense mutations clustered in the ligand binding domain (D538G, Y537S) leads to constant, ligand-independent activity of ESR1	
ESR1		26122181	role in cancer	oncogene	oncogene	
ESR1		19027010	role in cancer	TSG	TSG	
ESR1		25099679	role in cancer	fusion	fusion	
ESR1		26122181	proliferative signalling	promotes	activation promotes cell proliferation and resistance to endocrine signals	
ETNK1		24201752	role in cancer	TSG	TSG	
ETNK1		24201752	escaping programmed cell death	suppresses	synthetic phosphoethanolamine has anti-leukaemic effects in an APL model by inducing apoptosis through the mitochondrial pathway	
ETNK1		13366993	function summary		catalyzes the first step of the de novo phosphatidylethanolamine (PE) biosynthesis pathway, responsible for the phosphorylation of ethanolamine to phosphoethanolamine	
ETV6	T-ALL	9360930	fusion partner		JAK2	
ETV6	breast cancer	20033038	fusion partner		ITPR2	
ETV6	AML, myeloproliferative neoplasms and ALL	27229714	fusion partner		ABL1	
ETV6		25213837	role in cancer	TSG	TSG	
ETV6	B-cell precursor ALL 	23090680	fusion partner		PAX5	
ETV6		22578774	function summary		transcription factor, member of the E-Twenty-Six (ETS) family, a strong transcriptional repressor	
ETV6		9694803	differentiation and development		required for hematopoiesis in the bone marrow	
ETV6		7805037	impact of mutation on function		in fusion with ABL1, it provides the helix-loop-helix motif, which mediates dimerisation and results in constitutive activation of ABL1	
ETV6		10913166	invasion and metastasis	suppresses	inhibits the invasiveness of Ras-transformed cells in vitro and in vivo	
ETV6		12960174	escaping programmed cell death	suppresses	induces apoptosis and represses transcription of antiapoptotic Bcl-XL	
ETV6		16828711	escaping programmed cell death	suppresses	induces apoptosis through activation of p53-dependent pathways	
ETV6		22578774	role in cancer	fusion	fusion	
ETV6	B-ALL	8751464	fusion partner		RUNX1	
ETV6	radiation-associated thyroid cancer	24327398	fusion partner		NTRK3 	
ETV6	triple negative breast cancer 	22129193	fusion partner		NTRK3 	
ETV6	AML	24469860	fusion partner		ARNT	
EWSR1		11289149	function summary		transcriptional activator of c-fos, ErbB2, Xvent-2 	
EWSR1		17415412	role in cancer	oncogene, fusion	fusion, oncogene	
EWSR1	Ewing sarcoma	25712098	fusion partner		FLI1	
EWSR1	Ewing sarcoma	25712098	impact of mutation on function		fusion partner of FLI1, aberrant cell cycle activation in Ewing sarcoma is due to the de-repression of E2F targets as a consequence of transcriptional induction and physical recruitment of E2F3 by EWSR1-FLI1 replacing E2F4 on their target promoters 	
EWSR1		17912356	genome instability and mutations	suppresses	KD in Hela cells resulted in mitotic defects accompanied by apoptotic cell death 	
EWSR1		27341063	cell division control		regulates mitosis by dynamically influencing microtubule acetylation	
EWSR1		27341063	genome instability and mutations	suppresses	depletion of EWSR1 results in cell cycle arrest in the mitotic phase, unaligned chromosomes and multipolar spindles	
EWSR1		25483190	genome instability and mutations	suppresses	EWSR1-knockdown cells display a high incidence of defects in the midzone, a midline structure located between segregating chromatids during anaphase, which can lead to the failure of cytokinesis and can result in the induction of aneuploidy	
EWSR1		25737553	impact of mutation on function		EWSR1-FLI1 fusion protein alters the patterns of alternative splicing of multiple proteins that potentially regulate oncogenesis by direct binding to exon-intron boundaries or to splicing factors including DDX5, hnRNP K, and PRPF6	
EWSR1	clear cell sarcoma 	10849331	fusion partner		ATF1	
EWSR1	Ewing sarcoma	8040301	fusion partner		ERG	
EWSR1	small round cell sarcoma	8604806	fusion partner		WT1	
EWSR1	myxoid chondrosarcoma	11679947	fusion partner		NR4A3	
EWSR1	aneurysmal fibrous histiocytoma	18094413	fusion partner		CREB1	
EWSR1	myxoid liposarcoma	12169678	fusion partner		DDIT3	
EWSR1	hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands	18338330	fusion partner		POU5F1	
EWSR1		21816343	function summary		depletion results in alternative splicing changes of genes involved in DNA repair and genotoxic stress signaling, including ABL1, CHEK2, and MAP4K2, which reduces cell viability and proliferation upon UV irradiation 	
EZH2		29035360	genome instability and mutations	suppresses	promotes degradation of stalled replication forks in HR-deficient cells via recruitment of MUS81	
EZH2		27830540	function summary		catalytic component of the polycomb repressive complex PRC2 that methylates histone H3K9 and H3K27 to induce transcriptional repression	
EZH2	breast cancer	21406404	genome instability and mutations	promotes	regulates the nuclear-cytoplasmic shuttling of BRCA1, upregulation results in nuclear export of BRCA1 protein, aberrant mitoses with extra centrosomes and genomic instability, dependent on AKT activation	CAL51, MCF10A
EZH2	ovarian cancer	20708159	angiogenesis	promotes	promotes angiogenesis by methylating and silencing vasohibin1	
EZH2	cutaneous anaplastic large cell lymphoma	29248547	escaping programmed cell death	promotes	KD increases apoptosis, mediated by de-repression of thioredoxin-interacting protein and consequent formation of reactive oxygen species	
EZH2	cholangiocarcinoma	29530475	escaping programmed cell death	promotes	KD leads to increase in apoptosis	HuCC-T1, KMBC, Mz-Ch-A1
EZH2	cutaneous anaplastic T-cell lymphoma	29248547	escaping programmed cell death	promotes	KD induces apoptosis	
EZH2	head and neck squamous cell carcinoma	26378043	escaping programmed cell death	promotes	KD induces mitochondrial dependent apoptosis in xenografts	
EZH2	osteosarcoma	30420287	proliferative signalling	promotes	promotes proliferation via transcriptional repression of APC	U2OS, Saos-2
EZH2	neuroblastoma	29202477	proliferative signalling	promotes	KD inhibits growth in xenografts and in vitro	
EZH2	cholangiocarcinoma	29530475	proliferative signalling	promotes	KD results in growth inhibition in xenografts and in vitro	
EZH2	ovarian cancer	28620234	invasion and metastasis	promotes	expression promotes migration, invasion, and metastasis via downregulation of TIMP2	SK-OV-3
EZH2	renal cell carcinoma	29286132	invasion and metastasis	promotes	increases migration and invasion through STAT3 mediated upregulation of MMP2	769-P, 786-O
EZH2	lung adenocarcinoma	28539837	tumour promoting inflammation	suppresses	KD in KRAS mutant mouse model results in increased infiltration of tumour associated macrophages and neutrophils and production of tumour associated cytokines IL-6 and TNF alpha	
EZH2	cholangiocarcinoma	29530475	change of cellular energetics	promotes	KD leads to increase in autophagy, involving STAT3 signaling	HuCC-T1, KMBC, MZChA1
EZH2	glioblastoma	27385092	change of cellular energetics	promotes	promotes aerobic glycolysis via epigenetic silencing of several mi-RNAs that target CTNNB1 	U251, U87
EZH2	lung adenocarcinoma	28539837	suppression of growth	promotes	KD results in accelerated and increased tumour growth in a KRAS mutant mouse model, mediated by increased AKT and ERK activation	
EZH2	cutaneous anaplastic T-cell lymphoma	29248547	escaping immune response to cancer	promotes	inhibits recruitment of infiltrating CD4+ and CD8+T cells through epigenetic silencing of CXCL10	
EZH2	liver cancer	29581297	escaping immune response to cancer	promotes	KD results in increase NK mediated tumour killing, mediated by re-expression of NK ligands ULBP1 and MICA	HepG2/C3A, SNU-423,  SK-HEP-1, PLC/PRF/5, SNU-387, SNU-475, SNU-449
EZH2	gastric cancer	26004298	senescence	suppresses	KD induces senecence via upregulation of CDKN2A and CDKN2B 	MKN28, AGS
EZH2		27830540	role in cancer	oncogene, TSG	oncogene, TSG	
EZH2		26845405	role in cancer		oncogene, TSG	
EZH2	breast cancer	26271144	clinical impact	promotes	high expression associated with poor prognosis	
EZH2		30371878	types of alteration in cancer		recurrent Y646F and Y646N missense mutations	
EZH2	neuroblastoma	29507419	differentiation and development		KD promotes differentiation	NB-39-nu, NGP, SK-N-DZ, and TGW
EZH2		27086351	differentiation and development		a critical regulator of normal hematopoiesis	
EZH2	cutaneous anaplastic large cell lymphoma	29248547	cell division control		KD induces G1 arrest	
EZH2	multiple myeloma	28362441	cell division control		KD results in cell cycle arrest, mediated by upregulation of CDKN1A	KMS11, KMM1
EZH2	head and neck squamous cell carcinoma	26378043	cell division control		KD induces cell cycle arrest	Cal27, SCC25
EZH2		29530751	clinical impact		D185H mutation is associated with downregulation of RARA and RARG and with APL phenotype in patients without PML-RARA fusion	
EZH2	DLBCL	30692681	global regulation of gene expression		Y641X mutations lead to genome-wide increase in H3K37me3, resulting in silencing of multiple tumour suppressors	OCI-Ly-19, WSU-DLCL2, Karpas422
EZH2	melanoma	25671303	invasion and metastasis	promotes	gain of function mutations Y641F, Y641N drive and EMT like process in 3D culture	A375
EZH2	melanoma	25671303	proliferative signalling	promotes	gain of function mutations Y641F, Y641N result in larger tumour growth in xenografts	
EZH2		21190999	impact of mutation on function		nontyrosine residues at position 641 decrease affinity for unmethylated and monomethylated H3K27 substrates and favor trimethylation	
EZH2	cutaneous anaplastic T-cell lymphoma	29248547	global regulation of gene expression		upregulates expression of genes involvd in regulation of cell survival and cell-cell communcation	
EZH2	breast cancer	32009798	clinical impact		high expression is linked to cisplatin resistance	
EZH2	triple-negatve breast cancer PDXs	31968251	invasion and metastasis	promotes	pharmacological or genetic inhibition of EZH2 catalytic activity decreases invasiveness and  impairs distant metastasis	
EZH2	myeloproliferative diseases	27830540	types of alteration in cancer		deletions, missense, and frameshift mutations that abrogate methyltransferase activity, leading to reduction in H3K27me3 levels, are frequently observed	
EZH2		26219303	mouse model		hematopoietic-specific deletion of Ezh2 in mice induced heterogeneous hematopoietic malignancies	
EZH2		29035360	clinical impact		loss of EZH2 activity results in stabilisation of stalled replication forks, causing resistance to PARP inhibitors in BRCA1/2 deficient cells	
EZR	lung adenocarcinoma	22327623	fusion partner		ROS1	
EZR		19935704	escaping programmed cell death	promotes	negative regulator of death receptor-induced apoptosis in T-cells 	
EZR	glioblastoma	20156804	proliferative signalling	promotes	overexpression inactivates NF2 tumour suppressor, enhancing cell proliferation and anchorage-independent growth	
EZR		24727320	role in cancer	fusion	fusion	
EZR	cervical cancer	26933912	invasion and metastasis	promotes	induces EMT, downregulation suppresses tumour progression	
EZR	oesophageal SCC	28504189	invasion and metastasis	promotes	enhances filopodia formation, contributing to the regulation of invasion and metastasis	
EZR		26983550	function summary		ERM (ezrin-radixin-moesin) family protein taking part in linking the plasma membrane to the cortical actin cytoskeleton	
EZR	lung adenocarcinoma	24727320	fusion partner		ERBB4	
FANCD2		26765540	genome instability and mutations	suppresses	protects UV-dependent, replication-coupled DSBs from aberrant processing by non-homologous end joining 	
FANCD2		26083937	genome instability and mutations	suppresses	required for correct recruitment of RPA2 and Rad51 to the sites of clustered DSBs and that is critical for proper processing of clustered DSBs 	
FANCD2		23965832	role in cancer	TSG	TSG	
FANCD2		27427384	genome instability and mutations	suppresses	limits BLM-dependent telomere instability in the alternative lengthening of telomeres pathway	
FANCD2		26640811	function summary		nuclear protein involved in the repair of DNA double-strand breaks	
FANCD2		21995812	senescence		KD preceding DNA damage in fibroblasts, partly prevented the initiation of the senescence-like phenotype, whereas KD in senesced fibroblasts released cells from growth arrest	
FANCD2		27773819	escaping programmed cell death	promotes	plays a role in the negative regulation of ferroptosis	
FANCD2		27322732	genome instability and mutations	suppresses	limits replication stress and genome instability in cells lacking BRCA2	
FANCD2		21912593	tumour promoting inflammation	suppresses	deficiency induces overproduction of TNF-which then sustains prolonged inflammatory responses 	
FANCD2		23965832	invasion and metastasis	suppresses	inactivation of FANCD2 upregulates delta Np63, which promotes metastasis	
FANCD2		23965832	proliferative signalling	suppresses	inactivation of FANCD2 upregulates delta Np63, which promotes cell proliferation	
FAS	gastric cancer	25992623	invasion and metastasis	promotes	promotes metastasis through the STAT3/Fascin pathway,	
FAS	fibroblasts	7538467	proliferative signalling	promotes	promotes proliferation in a TNF receptor-independent way.	
FAS		10690403	escaping programmed cell death	suppresses	binding of FasL to Fas, or cross-linking of Fas with agonistic antibodies, induces apoptosis in Fas-bearing cells	
FAS		25366259	cell replicative immortality	promotes	stimulation of FAS on cancer cells increases the number of cancer stem cells	
FAS		22669972	role in cancer	TSG	TSG	
FAS		10690403	function summary		apoptosis-signaling cell surface Ag belonging to the TNFR family	
FAS		20505730	proliferative signalling	promotes	cancer cells, regardless of their CD95 apoptosis sensitivity, depend on constitutive activity of CD95, stimulated by cancer-produced CD95L, for optimal growth	
FAS		24656822	escaping programmed cell death	promotes	complete elimination of FAS results in a form of cell death that is independent of caspase-8, RIPK1/MLKL, and p53, is not inhibited by Bcl-xL expression, and preferentially affects cancer cells	
FAS		7533181	escaping programmed cell death	promotes	soluble isoforms are expressed as a result of alternative splicing and have antiapoptocic activity	
FAT1		16682528	function summary		cadherin (calcium-dependent cell adhesion protein)	
FAT1		23354438	impact of mutation on function		inactivated FAT1 is unable to sequester beta-catenin at the cell membrane, and thereby promotes Wnt signalling and tumour growth	
FAT1		26104008	differentiation and development		regulates neuronal differentiation	
FAT1	oral cancer	23076869	types of alteration in cancer		frequently lost due to homozygous deletion or hypermethylation	
FAT1	hepatocellular carcinoma	24590895	role in cancer	oncogene	oncogene	
FAT1		23076869	role in cancer	TSG	TSG	
FAT1	ALL	22116550	role in cancer	oncogene	oncogene	
FAT1		23354438	suppression of growth	promotes	knockdown in GBM cell lines and immortalized astrocytes leads to an increase in cell growth	
FAT1	breast cancer	26721716	invasion and metastasis	suppresses	suppressor of metastasis	
FAT1		24590895	function summary		mediator of hypoxia and growth receptor signalling	
FAT1	glioblastoma	24442637	escaping programmed cell death	promotes	interacts with caspase-8 preventing the association of caspase-8 with the DISC	
FAT1		16682528	invasion and metastasis	promotes	involved in promotion of actin-mediated cell migration	
FAT4	gastric cancer	26633557	suppression of growth	promotes	knockdown promotes proliferation	
FAT4		23076869	suppression of growth	promotes	involved in the maintenance of planar cell polarity and inhibition of cell proliferation	
FAT4	gastric cancer	22484628	suppression of growth	promotes	silencing enhances proliferation	
FAT4	gastric cancer	26633557	invasion and metastasis	suppresses	knockdown promotes invasion through the activation of Wnt/beta-catenin signalling and induces EMT	
FAT4	gastric cancer	26575609	function summary		suppresses phosphorylation and nuclear accumulation of Yap, a protein associated to the promoted proliferation, migration and cell cycle progression	
FAT4		24056717	differentiation and development		necessary for cerebral cortical development	
FAT4		23076869	types of alteration in cancer		recurrently mutated in melanoma, pancreatic cancer, gastric cancer and hepatocellular carcinoma, repressed in breast cancer and lung cancer due to promoter hypermethylation	
FAT4	gastric cancer	26633557	role in cancer	TSG	TSG	
FAT4		23076869	function summary		protein belonging to cadherin (calcium-dependent cell adhesion protein) family	
FBXO11		22113614	function summary		E3 ubiquitin ligase that targets BCL6 for proteasomal degradation	
FBXO11		17098746	function summary		increases p53 neddylation, suppressing its transcriptional activity	
FBXO11	breast cancer	30526604	invasion and metastasis	promotes	specifically increasess invasive potential of differentiated non-EMT-like cells by restraining the p53/p21 pathway, while in the related EMT-like clone, FBXO11 operates through the BCL2 pathway with little or no impact on tumorigenesis	
FBXO11		25827072	impact of mutation on function		E281K, V301F lead to impaired in Snai1 interaction and degradation in vitro	
FBXO11	DLBCL	22113614	impact of mutation on function		mutations alter subcellular localisation and impair BCL6 degradation	
FBXO11	prostate cancer	25589783	escaping programmed cell death	suppresses	overexpression promotes apoptosis	DU145
FBXO11	colon cancer	25827072	invasion and metastasis	suppresses	KD promotes EMT, migration and invasion	HCT116
FBXO11	breast cancer	25203322	invasion and metastasis	suppresses	suppresses EMT by promoting ubiquitination and degradation of SNAIL	HMLEN
FBXO11	gastric cancer	29278851	invasion and metastasis	promotes	overexpression promotes migration and invasion	SGC-7901
FBXO11	hepatocellular carcinoma	29518611	invasion and metastasis	promotes	KD suppresses migration and invasion	HCCLM3
FBXO11	hepatocellular carcinoma	29518611	proliferative signalling	promotes	KD inhibits cell proliferation	HCCLM3
FBXO11	melanoma	25589783	role in cancer	TSG	TSG	B16
FBXO11	DLBCL	22113614	role in cancer	TSG	TSG	
FBXO11	melanoma	25589783	clinical impact		higher expression is associated with lower tumour grade	
FBXO11	breast cancer	25203322	clinical impact		high expression is associated with longer metastasis-free survival	
FBXO11	gastric cancer	29278851	clinical impact		high expression associated with shorter overall survival	
FBXO11	hepatocellular carcinoma	29518611	clinical impact		high expression associated with shorter overall survival	
FBXO11	lung cancer	25827072	clinical impact		higher expression is associated with increased recurrence free survival	
FBXO11		25827072	mouse model		KO mice die shortly after birth and display a thickened epidermis, fewer hair follicles and reduced E-cadherin expression	
FBXO11		27166359	mouse model		KO is associated with lymphoproliferative disease	
FBXO11	DLBCL	22113614	types of alteration in cancer		frequently deleted or mutated	
FBXO11	mice	27166359	differentiation and development		KO increases germinal centre B-cell formation	
FBXO11	mice	25827072	differentiation and development		KO leads to defective epidermal development	
FBXW7		17909001	impact of mutation on function		most frequently mutated R465 and R479 are are critical for substrate recognition, moreover, the R465 mutant can abrogate wild-type Fbxw7 function through a dominant negative mechanism 	
FBXW7		14999283	genome instability and mutations	suppresses	inactivation causes chromosomal instability 	
FBXW7		16131838	function summary		mediates the ubiquitin-dependent proteolysis of several key regulatory proteins involved in cell division and cell fate determination, including cyclin E1, c-Myc, c-Jun, Notch, and Aurora-A 	
FBXW7		17909001	role in cancer	TSG	TSG	
FCGR2B		16051361	function summary		inhibitory receptor in phagocytosis 	
FCGR2B		8107887	function summary		negatively regulates B cell activation 	
FCGR2B		14607277	suppression of growth	promotes	negatively regulates B cell antigen receptor (BCR)-mediated proliferative signalling and activates PTEN  	
FCGR2B		11753646	role in cancer	oncogene, fusion	fusion, oncogene	
FCGR2B		22647731	escaping programmed cell death	suppresses	immune complexes co-ligate the BCR and Fc gamma RIIB resulting in apoptosis 	
FCGR2B	follicular lymphoma 	11753646	types of alteration in cancer		overexpressed as a result of fusion with IGHG2	
FCGR2B	follicular lymphoma 	11753646	fusion partner		IGHG2	
FCGR2B		22647731	suppression of growth	promotes	immune complexes co-ligate the BCR and Fc gamma RIIB resulting in growth arrest 	
FGFR1		25501022	fusion partner		SQSTM1	
FGFR1		26391436	fusion partner		TPR	
FGFR1		21330321	fusion partner		CUX1 	
FGFR1		23558953	fusion partner		BAG4, ERLIN2	
FGFR1		26936993	cell replicative immortality	promotes	promotes stem cell-like phenotype 	
FGFR1		21666686	fusion partner		FOXO1	
FGFR1		15034873	fusion partner		FGFR1OP2	
FGFR1		9949182	fusion partner		FGFR1OP	
FGFR1		27443518	fusion partner		FN1	
FGFR1		15800673	fusion partner		MYO18A	
FGFR1		9716603	fusion partner		ZMYM2 (ZNF198)	
FGFR1		18205209	fusion partner		CPSF6 	
FGFR1		10688839	fusion partner		CNTRL	
FGFR1		11739186	fusion partner		BCR	
FGFR1		27727438	types of alteration in cancer		recurrent N546K, K656E, K656M, frequently amplified in breast and lung cancer	
FGFR1		23880303	role in cancer	oncogene, fusion	oncogene, fusion	
FGFR1		26936993	function summary		trans-membrane receptor, promotes stem cell-like phenotype 	
FGFR1		12141425	differentiation and development		expression is crucial for mesoderm induction, brain development, somite formation, controls cell migration during embryogenesis 	
FGFR1		12141425	proliferative signalling	promotes	promotes the proliferation of fibroblasts	
FGFR1		19224897	impact of mutation on function		N546K alters FGFR1 auto-phosphorylation, resulting in increased kinase activity and transforming potential 	
FGFR1		15509736	impact of mutation on function		K656E is a GOF kinase domain mutation resulting in increased transforming potential	
FGFR1	prostate cancer	18068632	invasion and metastasis	promotes	promotes EMT	
FGFR2		23558953	fusion partner		BICC1, AFF3, SLC45A3, CASP7, CCDC6, CCAR2, OFD1	
FGFR2	gastric cancer	18381441	escaping programmed cell death	promotes	stimulates survival	
FGFR2	gastric cancer	18381441	proliferative signalling	promotes	stimulates cell proliferation	
FGFR2		18636142	invasion and metastasis		splice isoforms b and c, with preference for different ligands, are expressed in epithelial or mesenchymal tissues respectively and a switch between these isoforms is observed during EMT in prostate and bladder cancer 	
FGFR2		18636142	role in cancer	oncogene	oncogene	
FGFR2		18636142	function summary		trans-membrane receptor implicated in embryonic development, wound healing and mucosal repair	
FGFR2		27727438	types of alteration in cancer		recurrent S252W, N549K	
FGFR2		23558953	role in cancer	fusion	fusion	
FGFR2		17525745	impact of mutation on function		S252W increases the binding affinity of the receptor for multiple FGFs from 2- to 8-fold, in addition to violating the ligand-binding specificities attributed to the alternatively spliced isoforms, N549K activates the kinase by loosening the autoinhibitory molecular brake at the kinase hinge region	
FGFR3		11429702	role in cancer	oncogene	oncogene	
FGFR3		23558953	role in cancer	fusion	fusion	
FGFR3		27727438	types of alteration in cancer		recurrent S249C, Y373C, R248C, G370C, S371C, K650E	
FGFR3		23558953	fusion partner		fusion partner of TACC3, BAIAP2L1	
FGFR3		9207791	fusion partner		IGH	
FGFR3		19749790	impact of mutation on function		S249C and Y373C cause reduced cell-cell adhesion, multilayered appearance, increase proliferation and viability in TERT-NHUC urothelial cells	
FGFR3		17384684	impact of mutation on function		S249C is constitutively phosphorylated	
FGFR3		11429702	impact of mutation on function		K650E is an activating mutation in kinase domain	
FGFR3		24295726	differentiation and development		inhibits chondrocyte proliferation and differentiation in developing bones	
FGFR3	myeloma	10648414	proliferative signalling	promotes	ectopic expression of FGFR3 promotes cell proliferation	
FGFR3	myeloma	10648414	escaping programmed cell death	promotes	ectopic expression of FGFR3 prevents apoptosis	
FGFR3	keratinocytes	20420824	escaping programmed cell death	promotes	FGFR3 mutant cells show significantly lower levels of apoptosis	
FGFR3	keratinocytes	20420824	proliferative signalling	promotes	at confluence, FGFR3 mutant keratinocytes have a significantly higher cell count than wildtype	
FGFR3		24295726	function summary		trans-membrane receptor implicated in skeletal development	
FGFR4		19946327	role in cancer	oncogene	oncogene	
FGFR4		25031272	invasion and metastasis	promotes	FGFR4 overexpression in non-tumourigenic hepatocarcinoma cells significantly reduces cell-matrix adhesion, enables cells to grow anchorage-independently in soft agar, to disintegrate the lymph-/blood-endothelial barrier for intra-/extravasation of tumour cells and to form tumours in SCID mice	
FGFR4	prostate cancer	18670643	impact of mutation on function		FGFR-4 G388R polymorphism results in increased receptor stability and sustained receptor activation	
FGFR4	prostate cancer	18670643	proliferative signalling	promotes	G388R is associated with enhanced proliferation	
FGFR4	prostate cancer	18670643	invasion and metastasis	promotes	G388R is associated with anchorage-independent growth in vitro	
FGFR4		23696246	function summary		transmembrane growth factor receptor with extracellular ligand-binding domain, and a cytoplasmic tyrosine kinase domain	
FGFR4		22174695	proliferative signalling	promotes	FGFR4 G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumourigenesis	
FGFR4	breast cancer	19946327	proliferative signalling	promotes	FGFR4 Y367C mutant stimulates proliferation	MDA-MB453
FGFR4	hepatocytes	20018895	proliferative signalling	promotes	activation of FGFR4 stimulates proliferation	
FGFR4		20876804	invasion and metastasis	promotes	FGFR4 R388 variant increases MT1-MMP-dependent collagen invasion, knockdown of FGFR4-R388 or MT1-MMP blocked tumour cell invasion and growth in collagen	
FGFR4	colorectal cancer	23943801	invasion and metastasis	promotes	promotes stroma-induced EMT	
FHIT		25283145	function summary		spans the Common Fragile Site - FRA3B 	
FHIT		25401976	genome instability and mutations	suppresses	loss of Fhit protein activity causes replication stress through reduced Thymidine Kinase 1 expression, increased DNA breaks, and global genome instability in normal and cancer cells, In vitro, silencing Fhit expression elevates APOBEC3B-directed C > T mutations in the TP53 gene 	
FHIT		25340791	invasion and metastasis	suppresses	FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs 	
FHIT		8988031	role in cancer	fusion	fusion	
FHIT		23209436	genome instability and mutations	suppresses	in normal, transformed, and cancer-derived cell lines Fhit-depletion causes replication stress-induced DNA double-strand breaks 	
FHIT	partoid adenoma 	8988031	fusion partner		HMGA2	
FHIT		25283145	role in cancer	TSG	TSG	
FHIT		23929738	genome instability and mutations	suppresses	Fhit loss also increases the fragility of other CFS 	
FIP1L1	idiopathic hypereosinophilic syndrome	23489324	fusion partner		PDGFRA 	
FIP1L1	juvenile myelomonocytic leukaemia	17301809	fusion partner		RARA 	
FIP1L1		24763514	role in cancer	fusion	fusion	
FIP1L1		14749727	function summary		a subunit of cleavage and polyadenylation specificity factor (CPSF) that binds to U-rich RNA elements and stimulates poly(A) polymerase	
FIP1L1		24763514	impact of mutation on function		FIP1 motif in FIP1L1-RARA plays a pivotal role in its homodimerisation and transcriptional repressor activity, in FIP1L1-PDGFRA, the C-terminal PDGFRA portion possesses the ability of forming a homodimer by itself, making FIP1L1 dispensable for constitutive activation of this kinase 	
FLT3		27727438	types of alteration in cancer		internal tandem duplication (ITD) mutations within the juxtamembrane domain	
FLT3		26697989	function summary		class III receptor tyrosine kinase that is involved in the regulation of apoptosis, proliferation, and differentiation of hematopoietic cells	
FLT3	AML	26697989	role in cancer	oncogene	oncogene	
FLT3		22422053	suppression of growth	promotes	has growth-suppressive properties in several human cancer cell lines	
FLT3	AML	11090077	proliferative signalling	promotes	GOF Flt3-ITD mutations induce factor-independent growth and leukemogenesis, mediated by the Ras and STAT5 pathways	
FLT3	AML	11090077	impact of mutation on function		Flt3-ITD mutations exhibited constitutive autophosphorylation of the immature form of the Flt3 receptor resulting in strong factor-independent activation of STAT5	
FLT3	AML	21067588	escaping programmed cell death	promotes	inhibition of FLT3 kinase results in downregulation of mTOR signalling associated with decreased survival of FLT3-mutated AML cells	
FLT3		18490735	escaping programmed cell death	promotes	Flt3 signalling prevents stem and progenitors from spontaneous apoptotic cell death	
FLT4		19556880	escaping programmed cell death	promotes	overexpression promotes cell survival and anchorage-independent growth	
FLT4		19556880	invasion and metastasis	promotes	overexpression promotes cell motility	
FLT4	breast cancer	19556880	proliferative signalling	promotes	overexpression promotes cell proliferation in the absence of ligand expression	
FLT4	gastric cancer	21805024	invasion and metastasis	promotes	KD significantly inhibits cell invasion	MKN45
FLT4	gastric cancer	21805024	escaping programmed cell death	promotes	KD promotes apoptosis	MKN45
FLT4	gastric cancer	21805024	proliferative signalling	promotes	KD significantly slows cell proliferation	MKN45
FLT4	laryngeal SCC	22502683	invasion and metastasis	promotes	 high expression is associated with lymphatic metastasis	
FLT4		23591595	invasion and metastasis	promotes	participates in stimulation of lymphangiogenesis during the early events of metastasis 	
FLT4	angiosarcoma	26735859	types of alteration in cancer		 amplified	
FLT4		26735859	role in cancer	oncogene	oncogene	
FOXA1		22115363	function summary		transcription factor involved in organ morphogenesis, ER and AR signalling	
FOXA1	endometrial cancer 	27349269	senescence	promotes	induces cell senescence by positive regulation of p16INK4a expression	
FOXA1	prostate cancer	23539448	invasion and metastasis	suppresses	inhibits cell motility and EMT through an AR-independent mechanism directly opposing the action of AR signalling 	
FOXA1	prostate cancer	23539448	proliferative signalling	promotes	induces cell growth requiring the AR pathway	
FOXA1	pancreatic ductal adenocarcinoma	20160041	invasion and metastasis	suppresses	inhibits EMT	
FOXA1	breast cancer	22391567	invasion and metastasis	suppresses	silencing increases migration and invasion of luminal cancer cells	
FOXA1	CR prostate cancer	22722839	proliferative signalling	promotes	mutated FOXA1 represses androgen signalling and increases tumour growth	
FOXA1	CR prostate cancer	22722839	role in cancer	oncogene	oncogene	
FOXA1		18039470	proliferative signalling	promotes	down-regulation suppresses proliferation of ErbB2-negative and FoxA1-positive breast cancer cell lines	
FOXL2	adult ovarian granulosa cell tumour	33215742	role in cancer	TSG	TSG	
FOXL2	adult ovarian granulosa cell tumour	30371878	types of alteration in cancer		87% of tumours carry at least one copy of c.402C>G (p.C134W) missense mutation	
FOXL2	adult ovarian granulosa cell tumour	33215742	types of alteration in cancer		number of transcripts containing c.402C>G mutation up to 2.6-fold less than wild-type transcripts in c.402C>G heterozygotes	
FOXL2	ovarian granulosa tumour cells	17360647	global regulation of gene expression		overexpression modulates the expression of genes involved in processes including cholesterol metabolism, proteolysis, signal transduction and transcriptional regulation	
FOXL2	myoblast cells	25317675	differentiation and development		downregulation via miR-133a promotes differentiation	C2C12
FOXL2		26134413	differentiation and development		mice homozygous for gene deletion display prenatal skeletal development delay and defective cartilage maturation	
FOXL2		27441599	differentiation and development		evolutionarily conserved role in sex determination, ovarian development and oogenesis	
FOXL2	adult ovarian granulosa cell tumour	30365048	cell division control		KD restricted cell cycle progression at the G0/G1 phase	KGN
FOXL2	adult ovarian granulosa cell tumour	24390485	impact of mutation on function		p.C134W mutant is aberrantly phosphorylated by GSK3B, inducing proteasomal degradation	KGN, 293T, COV434
FOXL2	adult ovarian granulosa cell tumour	33215742	impact of mutation on function		c.402C>G missense mutation creates a coding sequence target site for miR-1236, which directs degradation of the mutant transcripts	KGN
FOXL2	embryonic kidney cells	32332759	impact of mutation on function		p.C134W mutation decreases the inhibitory and stimulatory effects of wild-type gene overexpression on double-strand break repair by non-homologous end joining and homologous recombination, respectively	293TdA3-IRES-TK-EGFP, 293T-DR-GFP
FOXL2	ovarian granulosa cells	26791928	impact of mutation on function		p.C134W mutation results in increased activin-induced cell proliferation, decreased caspase 8 and BAK-dependent apoptosis, and excess oestrogen production	
FOXL2	ovarian granulosa cells	32641414	impact of mutation on function		p.C134W mutation alters transcription factor DNA-binding specificity and effects new transcriptional targets	SVOG3e
FOXL2		24049064	function summary		a forkhead type transcription factor involved in gonadal sex determination, and ovarian development and function	
FOXL2	embryonic kidney cells	32332759	genome instability and mutations	suppresses	overexpression decreases DNA double-strand break repair by non-homologous end joining and increases repair by homologous recombination	293TdA3-IRES-TK-EGFP, 293T-DR-GFP
FOXL2	adult ovarian granulosa cell tumour	21119601	escaping programmed cell death	suppresses	wild-type protein induces caspase 8 and BAK-dependent apoptosis, the p.C134W mutation attenuates FOXL2-induced apoptosis	KGN, TM4
FOXL2	cervical cancer	24817949	escaping programmed cell death	suppresses	KD inhibits apoptosis	HeLa, Siha
FOXL2	chicken ovarian granulosa cells 	32645018	escaping programmed cell death	suppresses	KD decreases the extent of pre-ovulatory follicle cell apoptosis	
FOXL2	cervical cancer	24817949	suppression of growth	promotes	KD enhances proliferation	HeLa, Siha
FOXL2	chicken ovarian granulosa cells 	32645018	suppression of growth	promotes	KD increases the proliferation of pre-ovulatory follicle cells	
FOXL2	adult ovarian granulosa cell tumour	24390485	suppression of growth	promotes	p.C134W mutant is aberrantly phosphorylated by GSK3B, inducing proteasomal degradation and promoting cell growth in vitro and in vivo	KGN, 293T, COV434
FOXL2	adult ovarian granulosa cell tumour	24332943	suppression of growth	promotes	overexpression of the wild-type gene (but not the p.C134W mutant) upregulates follistatin and attenuates activin A-induced cell proliferation	KGN
FOXL2	adult ovarian granulosa cell tumour	17360647	tumour promoting inflammation	promotes	overexpression upregulates the expression of pro-inflammatory cytokine ligands and PTGS2	KGN
FOXL2	gastric cancer	29060929	invasion and metastasis	promotes	overexpression promotes migration and invasion	
FOXL2	gastric cancer	28119367	invasion and metastasis	promotes	KD decreases cell migration and invasion in vitro and metastasis in vivo	SGC7901/ADR, SGC7901
FOXL2	cervical cancer	24817949	invasion and metastasis	suppresses	KD enhances invasion	HeLa, Siha
FOXL2	gastric cancer	29060929	proliferative signalling	promotes	downregulation via miR-937 results in inhibition of growth	BGC-823, AGX-7901, HGC-27
FOXL2		26134413	proliferative signalling	promotes	mice homozygous for gene deletion display reduced postnatal growth	
FUBP1		18400844	interaction with pathogen		required for efficient replication of hepatitis C virus 	
FUBP1		22926519	function summary		DNA-binding protein that regulates c-Myc gene transcription through binding to the far upstream element (FUSE) in the promoter region 1.5 kb upstream of the TSS, regulates mRNA translation or stability of genes, such as GAP43, p27(Kip) and nucleophosmin 	
FUBP1		22926519	role in cancer	oncogene	oncogene	
FUBP1		22926519	invasion and metastasis	promotes	enhances cell migration 	
FUBP1		22926519	proliferative signalling	promotes	enhances cell proliferation	
FUBP1		22926519	escaping programmed cell death	promotes	inhibits apoptosis	
FUS	myoepithelial tumours 	25706482	fusion partner		KLF17	
FUS		26148230	role in cancer	fusion	fusion	
FUS	glioblastoma	26081814	invasion and metastasis	suppresses	acts as a tumour suppressor gene by upregulating miR-197 in human glioblastoma, which suppresses migration and invasion of the cells	
FUS	glioblastoma	26081814	suppression of growth	promotes	acts as a tumour suppressor gene by upregulating miR-197 in human glioblastoma, which suppresses the proliferation	
FUS		26246474	function summary		tumour suppressor that controls immune response and tumour growth via maintenance of mitochondrial homeostasis 	
FUS	liposarcoma	26865464	fusion partner		DDIT3	
FUS		26246474	role in cancer	TSG	TSG	
FUS	AML	26148230	fusion partner		ERG	
FUS	AML	26148230	impact of mutation on function		oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway	
GAS7		26506240	invasion and metastasis	suppresses	low GAS7C activity increases cancer cell motility by promoting N-WASP/FAK/F-actin cytoskeleton dynamics, as well as enhances beta-catenin stability via hnRNP U/beta-TrCP complex formation 	
GAS7	 therapy-related AML 	10706619	fusion partner		KMT2A	
GAS7		10706619	role in cancer	fusion	fusion	
GAS7		8643452	function summary		alpha-receptor for PDGF, expressed preferentially in serum-deprived cells 	
GAS7		21452305	differentiation and development		mediates the differentiation of human bone marrow-derived mesenchymal stem cells into functional osteoblasts	
GAS7		12957285	impact of mutation on function		in fusion protein it provides the coiled-coil oligomerisation domains to activate KMT2A 	
GATA1	cholangiocarcinoma	31456644	role in cancer	oncogene	oncogene	
GATA1	colorectal cancer	31069596	role in cancer	oncogene	oncogene	
GATA1	Down Syndrome AMKL	21779441	role in cancer	TSG	TSG	
GATA1	pancreatic cancer	31093285	role in cancer	oncogene	oncogene	
GATA1	primary myelofibrosis	28240607	role in cancer	TSG	TSG	
GATA1	AML	7579412	clinical impact		patients expressing GATA1 have a reduced rate of complete remission and a lower probability of survival	
GATA1	breast cancer	26848522	clinical impact		higher expression correlates with shorter disease-free and overall survival	
GATA1	CCRCC	25230694	clinical impact		decreased expression is associated with lymph node and distant metastasis, and an increased risk of recurrence	
GATA1	colorectal cancer	31069596	clinical impact		patients displaying increased GATA1 expression have shorter disease-free and overall survival	
GATA1	pancreatic cancer	31093285	clinical impact		gemcitabine-treated patients with a high level of GATA1 expression have shorter recurrence-free and overall survival, KD increases sensitivity to gemcitabine	CFPAC-1, PANC-1
GATA1	Down Syndrome AMKL	15895080	mouse model		expresses N-terminal truncated GATA1s as a model of transient myeloproliferative disorder and AMKL in Down Syndrome patients	
GATA1	AML	30755706	types of alteration in cancer		promoter CpG methylation and decreased expression	
GATA1	breast cancer	20101202	types of alteration in cancer		protein expressed (undetectable in normal breast tissue)	
GATA1	CCRCC	25230694	types of alteration in cancer		frequently decreased expression	
GATA1	cholangiocarcinoma	31456644	types of alteration in cancer		typically increased expression	
GATA1	colorectal cancer	31069596	types of alteration in cancer		frequently increased expression	
GATA1	Down Syndrome AMKL	15659348	types of alteration in cancer		insertions, deletions, nonsense, missense and splice mutations in exon 2	
GATA1	pancreatic cancer	31093285	types of alteration in cancer		protein expression upregulated	
GATA1	primary myelofibrosis	28240607	types of alteration in cancer		ribosomal deficiency-effected reduced expression in megakaryocytes	
GATA1		24638828	global regulation of gene expression		regulates expression of erythroid-specific genes and genes involved in haematopoetic cell differentiation	
GATA1	erythroid	19513100	differentiation and development		GATA1-hypophosphorylated pRb-E2F-2 complex inhibits erythroid precursor proliferation and induces terminal differentiation	UT-7, G1E, GAK14
GATA1	primary myelofibrosis	28240607	differentiation and development		restoration of expression in CD34+cells induces differentiation of megakaryocytes	
GATA1		24638828	differentiation and development		regulates expression of genes involved in haematopoetic cell differentiation	
GATA1	erythroid	20495378	cell division control		stimulates transcription of cell cycle regulator p21	HeLa, MEL
GATA1	fibroblast	19513100	cell division control		GATA1-hypophosphorylated pRb-E2F-2 complex arrests mouse embryo fibroblasts in G1 phase of cell cycle	NIH-3T3, UT-7, G1E, GAK14
GATA1	acute basophilic leukaemia	21474671	fusion partner		MYB	
GATA1	Down Syndrome AMKL	15659348	impact of mutation on function		truncating exon 2 mutations are associated with transient myeloproliferative disorder, a precursor lesion to AMKL in Down Syndrome patients	
GATA1		15659348	function summary		transcription factor that regulates erythroid cell-specific genes and genes involved in haematopoetic cell differentiation	
GATA1	breast cancer	26848522	angiogenesis	promotes	interacts with SET7 to increase VEGF expression, secretion and angiogenesis	MCF7, ZR75-1, DA-MB-231, HUVEC
GATA1	cholangiocarcinoma	31456644	escaping programmed cell death	promotes	overexpression decreases stem cell apoptosis	QBC-939, RBE
GATA1	breast cancer	26848522	proliferative signalling	promotes	KD inhibits growth of xenografts	MCF7, MDA-MB-231
GATA1	cholangiocarcinoma	31456644	proliferative signalling	promotes	overexpression increases stem cell proliferation	QBC-939, RBE
GATA1	colorectal cancer	31069596	proliferative signalling	promotes	KD decreases cell proliferation	HCT-8, HCT-116
GATA1	ovarian cancer	31897811	proliferative signalling	promotes	overexpression promotes cell proliferation via JAG1-activated Notch signalling	SKOV3
GATA1	pancreatic cancer	31093285	proliferative signalling	promotes	overexpression increases cell proliferation	CFPAC-1, PANC-1
GATA1	colorectal cancer	31069596	proliferative signalling	promotes	silencing suppresses tumour xenograft growth	HCT-8
GATA1	breast cancer	25726523	invasion and metastasis	promotes	expression promotes migration and invasion and in xenografts promotes metastasis	MCF7
GATA1	colorectal cancer	31069596	invasion and metastasis	promotes	KD decreases cell migration and invasion	HCT-8, HCT-116
GATA1	osteosarcoma	31930127	invasion and metastasis	promotes	in hypoxic conditions, increases in cell migration and invasion effected by HIF1A upregulation of HMGN5 achieved through GATA1	U-2 OS, Saos-2
GATA1	ovarian cancer	31897811	invasion and metastasis	promotes	overexpression promotes migration and invasion via JAG1-activated Notch signalling	SKOV3
GATA1	acute basophilic leukaemia	21474671	role in cancer	fusion	fusion	
GNA11		12759536	function summary		involved in signalling of gonadotropin-releasing hormone receptor, which negatively regulates cell growth	
GNA11	uveal melanoma	21083380	types of alteration in cancer		GOF recurrent mutations	
GNA11	uveal melanoma	27727438	types of alteration in cancer		highly recurrent Q209L	
GNA11	melanocytes	24141786	proliferative signalling	promotes	GOF mutations activate PKC and MAPK signalling, stimulating cell proliferation	
GNA11	uveal melanoma	21083380	types of alteration in cancer		frequently mutated	
GNA11		23802516	function summary		RAS family G-protein taking part in signal transduction to regulate intracellular calcium levels	
GNA11		21083380	role in cancer	oncogene	oncogene	
GNAQ		15322542	proliferative signalling	promotes	GOF mutation in codon 209 stimulates proliferation of melanocytes in mice 	
GNAQ		18719078	impact of mutation on function		most recurrently mutated codon 209 maps to the catalytic domain of GNAQ, which is involved in GTPase activity, mutation of this codon inactivates the catalytic domain, preventing hydrolysis of GTP and locking GNAQ in its active, GTP-bound state 	
GNAQ		21083380	role in cancer	oncogene	oncogene	
GNAQ		23802516	function summary		RAS family G-protein taking part in signal transduction to regulate intracellular calcium levels	
GNAQ	uveal melanoma	21083380	types of alteration in cancer		frequently mutated	
GNAQ	melanocytes	24141786	proliferative signalling	promotes	GOF mutations activate PKC and MAPK signalling, stimulating cell proliferation	
GNAQ	uveal melanoma	27727438	types of alteration in cancer		highly recurrent Q209L	
GNAQ	uveal melanoma	21083380	types of alteration in cancer		GOF recurrent mutations	
GNAS	pituitary adenoma	2549426	proliferative signalling	promotes	activation of adenylyl cyclase bypasses the cells' normal requirement for trophic hormone	
GNAS	mouse models	20531296	proliferative signalling	promotes	GNAS R201C expression was associated with elevated expression of Wnt and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) pathway target genes, increased phosphorylation of ERK1/2 MAPK and increased immunostaining for the proliferation marker Ki67 	
GNAS		25851935	function summary		G protein mediating the actions of many hormones, neurotransmitters, and paracrine/autocrine factors via generation of the second messenger cAMP	
GNAS	pituitary adenoma	27727438	types of alteration in cancer		highly recurrent R201C	
GNAS	pancreatic neoplasia	27727438	types of alteration in cancer		highly recurrent R201C	
GNAS		20531296	impact of mutation on function		R201C mutation results in the constitutive activation of GNAS and adenylate cyclase and leads to the autonomous synthesis of cyclic adenosine monophosphate (cAMP)	
GNAS	RCC	28051330	proliferative signalling	promotes	promotes cell proliferation	
GNAS	pituitary adenoma	2549426	role in cancer	oncogene	oncogene	
GNAS	Shh-driven medulloblastoma	25150496	suppression of growth	promotes	suppresses Shh signalling-dependent cell proliferation by regulating both the cAMP-dependent pathway and ciliary trafficking of Hedgehog pathway components	
GNAS	Shh-driven medulloblastoma	25150496	role in cancer	TSG	TSG	
GPC3	ovarian cancer	25967456	invasion and metastasis	promotes	downregulation of glypican-3 expression increases migration, invasion, and tumourigenicity	
GPC3		24496449	function summary		activator of Wnt pathway 	
GPC3		12816733	role in cancer	TSG	TSG	
GPC3		28476031	role in cancer	oncogene	oncogene	
GPC3		11286501	types of alteration in cancer		inactivating mutations are associated with Simpson-Golabi-Behmel overgrowth syndrome, which symptoms include increased risk of embryonal cancers 	
GPC3	hepatocellular carcinoma	25572615	invasion and metastasis	promotes	promotes epithelial-mesenchymal transition through ERK signaling pathway 	
GPC3	renal cell carcinoma	25168166	suppression of growth	promotes	overexpression arrests cells in G1 phase and reduces cell proliferation	786-O and ACHN
GRIN2A		20716669	function summary		subunit of the N-methyl-d-aspartate receptor which, upon ligand binding, facilitates influx of calcium into cells, leading to the activation of signalling cascades	
GRIN2A	bladder cancer	24469795	proliferative signalling	promotes	KD decreases proliferation and tumour growth	HT-1376
GRIN2A	melanoma	24739903	suppression of growth	promotes	KD increases proliferation	31T
GRIN2A	melanoma	24739903	invasion and metastasis	suppresses	KD increases anchorage-independent growth in soft agar, and cell migration	31T
GRIN2A	bladder cancer	24469795	role in cancer	Oncogene	Oncogene	
GRIN2A	melanoma	24739903	impact of mutation on function		W372X, Q891X, and W1271X decrease glutamate receptor complex formation and increase anchorage-independent growth and migration	31T
GRIN2A		27727438	types of alteration in cancer		recurrent E962K, D114N, S1341fs*56	
GRIN2A	melanoma	21499247	types of alteration in cancer		frequently mutated	
GRIN2A	lung adenocarcinoma	22080568	types of alteration in cancer		frequently overexpressed In ALK-positive tumours	
GRIN2A	colorectal cancer	17922030	types of alteration in cancer		frequent promoter hypermethylation	
GRIN2A	bladder cancer	24469795	types of alteration in cancer		frequent amplification in high-grade superficial and muscle invasive samples	
GRIN2A	melanoma	24739903	role in cancer	TSG	TSG	
H3F3A		24229707	global regulation of gene expression		post-translational modifications of H3.3 have impact on transcriptional activity of multiple genes	
H3F3A		23539183	impact of mutation on function		K28M GOF mutant inhibits the enzymatic activity of the Polycomb repressive complex 2 through interaction with the EZH2 subunit 	
H3F3A	GBM	23414300	impact of mutation on function		EZH2 mediated trimethylation of H3K27 is inhibited by K28M mutations 	
H3F3A	GBM	27727438	types of alteration in cancer		highly recurrent K28M, G35R	
H3F3A	bone giant cell tumour	27727438	types of alteration in cancer		recurrent G35W	
H3F3A		24229707	function summary		a variant of H3 histone deposited into transcriptionally active regions to replace displaced nucleosomes throughout the cell cycle	
H3F3A		23539183	role in cancer	oncogene	oncogene	
H3F3B		24229707	global regulation of gene expression		post-translational modifications of H3.3 have impact on transcriptional activity of multiple genes	
H3F3B	chondroblastoma	27727438	types of alteration in cancer		recurrent K37M	
H3F3B		21263457	function summary		one of two genes encoding histone 3.3, displays constitutive expression and enables histone deposition/exchange through a DNA synthesis-independent pathway	
H3F3B		23570311	mouse model		KO mice exhibit a semilethal phenotype with defective cell division, chromosome segregation, and infertility	
H3F3B		27864305	role in cancer	Oncogene	Oncogene	
H3F3B	chondroblastoma	27229140	impact of mutation on function		K37M mutation leads to reduced H3K36 methylation resulting in increased ability to form colonies, resistance to apoptosis, and defects in differentiation	
H3F3B	ovarian cancer	30485824	types of alteration in cancer		amplified	
HEY1	mesenchymal chondrosarcoma	22034177	fusion partner		NCOA2	
HEY1		19802006	impact of mutation on function		L94M gene polymorphism converts HEY1 from an androgen receptor corepressor to an androgen receptor co-activator, and also abolishes HEY1-mediated activation of p53 	
HEY1		18363832	proliferative signalling	promotes	ectopic expression of HEY1 induces cell proliferation in neural stem cells, while depletion of HEY1 by RNA interference reduces proliferation of glioblastoma cells in tissue culture 	
HEY1		25985737	cell replicative immortality	promotes	involved in the maintenance of liver cancer stem cells self-reneval, silencing reduced xenograft tumour growth and tumour-initiating capacity 	
HEY1		18363832	role in cancer	oncogene	oncogene	
HEY1	mesenchymal chondrosarcoma	22034177	impact of mutation on function		HEY1-NCOA2 fusion replaces the C-terminal portion of HEY1 by the NCOA2 AD1/CID and AD2 domains, while retaining the HEY1 bHLH DNA-binding/dimerisation domain 	
HEY1		11095750	function summary		E-box binding transcriptional repressor, downstream target for transcriptional activation by Notch signaling	
HEY1		22034177	role in cancer	fusion	fusion	
HIF1A		25587028	impact of mutation on function		K213Q mutant has increased ability to impede mitochondrial respiration	
HIF1A	lung cancer	23033341	fusion partner		SNAPC	
HIF1A	glioblastoma	18772890	types of alteration in cancer		recurrent K213Q, D238N	
HIF1A	renal cell carcinoma	12019178	types of alteration in cancer		frequently upregulated	
HIF1A	prostate cancer	11454426	types of alteration in cancer		frequently amplified	
HIF1A		23999440	role in cancer	oncogene	oncogene	
HIF1A		24984035	senescence	suppresses	suppresses senescence through negative regulation of p53 and CDKN1A	
HIF1A		25589622	escaping immune response to cancer	promotes	promotes resistance to lysis in tumour cells by tumour-specific cytotoxic T lymphocytes	
HIF1A		11943784	change of cellular energetics	promotes	upregulation induces the Warburg effect in cancer cells	
HIF1A	lung cancer	17335808	invasion and metastasis	promotes	overexpression enhances cell invasion	
HIF1A	melanoma	25587028	escaping programmed cell death	promotes	ectopic expression of K213Q mutant supresses menadione-dependent ferroxitosis	
HIF1A	ovarian cancer	15832512	escaping programmed cell death	promotes	downregulation of HIF1A promotes the induction of cell death 	
HIF1A		15656883	angiogenesis	promotes	stimulates angiogenesis	
HIF1A		23999440	function summary		transcription factor, master regulator of the adaptive response to hypoxia	
HIF1A		15071503	cell division control		induces cell cycle arrest by functionally counteracting Myc	
HIP1		9616134	role in cancer	fusion	fusion	
HIP1		12781365	function summary		HIP1 overexpression promotes tumour formation and is associated with a general alteration in receptor trafficking 	
HIP1		12163454	escaping programmed cell death	promotes	overexpressed in prostate and colon cancer and its antiapoptotic activity is critical for cellular survival 	
HIP1	lung adenocarcinoma	24518094	fusion partner		ALK	
HIP1		10428802	impact of mutation on function		HIP1-PDGFRB fusion protein requires its HIP1 component to drive IL-3-independent growth of hematopoietic cells 	
HIP1		15059611	function summary		endocytic protein that partially co-localizes, co-sediments and co-purifies with clathrin-coated vesicles 	
HIP1	CML	9616134	fusion partner		PDGFRB	
HIP1		9616134	impact of mutation on function		HIP1-PDGFRB fusion protein is constitutively tyrosine phosphorylated 	
HIP1		12781365	role in cancer	oncogene	oncogene	
HNF1A	pancreatic cancer	25793983	suppression of growth	promotes	KD results in a 2-fold higher rate of cell proliferation, 20% increased S phase and G2 phase cells	
HNF1A	pancreatic cancer	25793983	escaping programmed cell death	suppresses	KD results in a 30-40% reduced apoptosis in pancreatic cancer cell lines 	
HNF1A	hepatocellular carcinoma	21975049	invasion and metastasis	suppresses	inhibition triggers epithelial-mesenchymal transition	
HNF1A		10966642	function summary		transcription factor, important regulator of genes in liver, kidney, stomach and pancreatic islet cells	
HNF1A	pancreatic cancer	25233928	role in cancer	TSG	TSG	
HNRNPA2B1	prostate cancer	20693979	fusion partner		ETV1	
HNRNPA2B1	NSCLC	26774881	tumour promoting inflammation	promotes	activates cyclooxygenase-2 and promotes tumour growth in human lung cancers 	
HNRNPA2B1		25586062	escaping programmed cell death	promotes	KD induced apoptosis and reactive oxygen species (ROS) generation in glioma U251 and SHG44 cells 	
HNRNPA2B1		24356509	function summary		controls the sorting of miRNAs into exosomes through binding to specific motifs 	
HNRNPA2B1		24675500	escaping programmed cell death	promotes	by regulating DNA-PK activity, can affect p53-mediated cell cycle progression and apoptosis, resulting in greater cell survival and subsequent proliferation 	
HNRNPA2B1		28351333	role in cancer	oncogene	oncogene	
HNRNPA2B1		21175803	differentiation and development		hnRNP-A2/B1 affected tumour cell differentiation through interaction with oncogenes and tumour-suppressor genes, and it was overexpressed in human gastric cancer 	
HNRNPA2B1	breast cancer	28351333	proliferative signalling	promotes	KD reduced cell proliferation and prolonged the S phase of the cell cycle in vitro and suppressed subcutaneous tumourigenicity in vivo 	MCF-7 and MDA-MB-231
HNRNPA2B1	breast cancer	28351333	escaping programmed cell death	promotes	KD induced apoptosis	MCF-7 and MDA-MB-231
HNRNPA2B1	pancreatic cancer	28077929	invasion and metastasis	promotes	promotes EMT through the ERK/snail signalling 	MIA Paca-2, PANC-1 and Patu-8988
HNRNPA2B1		20693979	role in cancer	fusion	fusion	
HNRNPA2B1		21642356	escaping programmed cell death	promotes	downregulation results in the increased formation of the pro-apoptotic Bcl-x(s) and promotes apoptosis of BxPc3 cells 	
HOXA11	gastric cancer	25590359	escaping programmed cell death	suppresses	restoration of HOXA11 expression induced apoptosis and G2/M phase arrest	
HOXA11	gastric cancer	25590359	invasion and metastasis	suppresses	epigenetic silencing of HOXA11 promotes migration and invasion through activation of Wnt signaling, restoration of HOXA11 expression reduced invasion and cell migration	
HOXA11	ALL	15674412	fusion partner		TRC	
HOXA11		24996520	role in cancer	oncogene	oncogene	
HOXA11		25590359	role in cancer	TSG	TSG	
HOXA11		15674412	role in cancer	fusion	fusion	
HOXA11		22916278	differentiation and development		regulates chondrocyte differentiation	
HOXA11		12050232	differentiation and development		essential regulator of embryonic uterine development and the cyclic development of the adult uterine endometrium	
HOXA11		24996520	function summary		master regulatory transcription factor participating in embryogenesis and development	
HOXA11	uterosacral ligaments	19372592	proliferative signalling	promotes	promotes fibroblast proliferation and represses expression of p53	
HOXA11	gastric cancer	25590359	suppression of growth	promotes	epigenetic silencing of HOXA11 promotes proliferation through activation of Wnt signaling, restoration of HOXA11 expression reduced cell proliferation	
HRAS		26544625	escaping programmed cell death	promotes	suppresses apoptosis through downregulation of TDG	
HRAS		26985062	role in cancer	oncogene	oncogene	
HRAS		17384584	function summary	1	a small GTPase that cycles between inactive GDP-bound and active GTP-bound conformations, regulates cellular responses to many extracellular stimuli, including soluble growth factors, the protein is farnesylated at a terminal CAAX motif and additionally modified by palmitic acid residues just upstream of the CAAX motif to anchor the protein in the membrane	
HRAS		17384584	proliferative signalling	promotes	activating mutations cause hypersensitivity to external growth-stimulating factors	
HRAS		27727438	types of alteration in cancer		recurrent missense mutations at Q61, G12 and G13	
HRAS		25026275	escaping programmed cell death	promotes	H-Ras upregulation is associated with a surface deficiency of TRAIL death receptor	
HRAS		23548900	angiogenesis	promotes	KD of H-Ras blocked VEGF-induced PI3K-dependent Akt (Ser-473) and eNOS (Ser-1177) phosphorylation and nitric oxide-dependent cell migration of endothelial cells	
HRAS		23028055	escaping immune response to cancer	suppresses	G12V mutant can be transferred from melanoma cells to tumour infiltrating T-cells, where it stimulates production of IFN-gamma and cytotoxic activity of TILs	
HRAS		22573884	proliferative signalling	promotes	H-Ras G12V induces the internalisation of PDGFR beta by macropinocytosis, enhancing its signalling activity and increasing anchorage-independent proliferation	
HRAS	mouse keratinocytes	11309506	senescence	promotes	oncogenic H-Ras induces a senescence-like permanent growth arrest	
HRAS		21841825	genome instability and mutations	promotes	H-Ras G12V promotes hydrogen peroxide (H2O2) generation via NADPH oxidase NOX4, resulting in increased DNA DSBs 	
HRAS	renal cell carcinoma	21808062	escaping programmed cell death	promotes	H-Ras-ERK-induced and HO-1-mediated pathway promotes the survival of cancer cells by inhibiting cellular apoptosis	
HRAS	breast cancer	21524920	invasion and metastasis	promotes	H-Ras-specific upregulation of granulocyte colony-stimulating factor promotes invasion via matrix metalloproteinase-2	
HRAS		20392691	escaping programmed cell death	promotes	expression of the apoptosis repressor ARC is upregulated by H-Ras in a MEK/ERK-dependent manner, Ras also stabilises ARC protein by suppressing its polyubiquitination and subsequent proteasomal degradation	
HRAS		9184223	escaping programmed cell death	promotes	G12V is associated with suppression of anoikis	
HRAS		9705357	tumour promoting inflammation	promotes	activation of Hcox2 by GOF Ras mutant results in increased prostaglandin E2 production	
HRAS		2654132	invasion and metastasis	promotes	stimulates the expression of urokinase plasminogen activator	
HRAS		7553632	angiogenesis	promotes	stimulates expression of VEGFA	
HRAS		2547513	impact of mutation on function		activating mutations at G12, G13 or Q61 cause Ras to accumulate in the active GTP bound state by impairing intrinsic GTPase activity and conferring resistance to GTPase activating proteins	
IDH1		19935646	impact of mutation on function		missense mutation R132H causes a shift in the active site resulting in decreased binding affinity of the enzyme for isocitrate and increased affinity for NADPH promoting NADPH-dependent reduction of alpha-ketoglutarate to 2-hydroxyglutarate	
IDH1		22343889	global regulation of gene expression		 the activity of R132H mutant alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas	
IDH1		29805076	function summary		cytosolic Krebs cycle enzyme, catalysing the formation of alpha-ketoglutarate from isocitrate	
IDH1		28711227	role in cancer	oncogene	oncogene	
IDH2	AML	28588020	global regulation of gene expression		elevated levels of 2-hydroxyglutarate result in DNA and histone hypermethylation, which leads to blocked cellular differentiation	
IDH2		28588020	impact of mutation on function		mutations within the conserved enzymatic active sites of IDH2, R140 and R172 IDH2, produce neomorphic activity synthesizing 2-hydroxyglutarate	
IDH2		29805076	function summary		mitochondrial Krebs cycle enzyme, catalysing the formation of alpha-ketoglutarate from isocitrate	
IDH2		28711227	role in cancer	oncogene	oncogene	
IGH		24638926	role in cancer	fusion	fusion	
IGH	B-CLL	15273723	impact of mutation on function		in fusion with CHST11 causes a disturbance of the cellular distribution of CHST11 leading to deregulation of a chondroitin-sulfate-dependent pathway specific to the hematopoietic lineage 	
IGH		24638926	function summary		the IGH translocations were found to drive expression levels of the partner genes to significantly higher levels (spikes) than copy-number variations in multiple myeloma 	
IGH	B-CLL	15273723	fusion partner		CHST11	
IL6ST		26188635	role in cancer	oncogene	oncogene	
IL6ST		24213527	proliferative signalling	promotes	mutated gp130 induces downstream signalling from both ER and endosomes, and both signals contribute to ligand-independent cell proliferation	
IL6ST		2261637	function summary		a membrane glycoprotein, which associates with IL-6 receptor to transduce the IL6-dependent growth signal	
IL6ST		26188635	impact of mutation on function		clustered inframe deletions mutations from Y186 to N193 are predicted to disrupt key residues involved in the IL6ST-IL-6 binding interface and results in a ligand independent constitutive activation	
IL6ST	hepatocellular adenoma	26188635	types of alteration in cancer		somatic GOF mutations, leading to constitutive JAK1/STAT3 pathway activation	
IL6ST		19020503	tumour promoting inflammation	promotes	GOF mutants activate the inflammatory phenotype in benign liver tumours via STAT3 activation	
JAK1		12039028	function summary		non-receptor tyrosine kinase, phosphorylates STATs, leading to their activation, involved in signalling via members of the IL-2 receptor family, the IL-4 receptor family, the gp130 receptor family and class II cytokine receptors	
JAK1	murine interleukin-3 dependent pro-B cell	20868368	impact of mutation on function		cells expressing V658L, with a deletion of amino acids 629-630 in the pseudokinase domain, as well as L910P, F938S, P960S, K1026E and Y1035C mutants have higher STAT1 phosphorylation and are more sensitive to interferon-gamma-mediated growth inhibition	BaF3
JAK1		27727438	types of alteration in cancer		recurrent missense mutations in pseudokinase domain	
JAK1	NSCLC	21216930	proliferative signalling	promotes	inhibition of JAK1 with small molecules or RNA interference results in the loss of STAT3 tyrosine phosphorylation and the inhibition of cell growth	
JAK1		26188635	role in cancer	oncogene	oncogene	
JAK1		12576323	proliferative signalling	promotes	deficiency is associated with a loss in the ability of interferon-gamma to induce growth arrest of v-abl-transformed pre-B cells or tumour growth in SCID mice	
JAK1		24154688	escaping immune response to cancer	suppresses	JAK1 deficient cancer cells are defective in IFN-gamma-induced LMP2 and TAP1 expression, loss of which inhibits presentation of tumour antigens	
JAK1		26188635	impact of mutation on function		expression of S703I or A723D in Hep3B cells induces an inflammatory response and phosphorylation of STAT3 at Y705, the two JAK1 mutant proteins are phosphorylated at Y1022/1023, two regulatory tyrosines known to activate JAK1 when phosphorylated	
JAK1		24154688	role in cancer	TSG	TSG	
JAK1		12576323	escaping programmed cell death	suppresses	deficiency is associated with a loss in the ability of interferon-gamma to induce apoptosis in v-abl-transformed pre-B cells	
JAK2		16632470	cell division control		V617F GOF mutant promotes G1/S phase transition	
JAK2	B-cell ALL	18618714	fusion partner		SSBP2	
JAK2	Hodgkin lymphoma	21325169	fusion partner		SECC31A	
JAK2	B-cell ALL	19020546	fusion partner		PAX5	
JAK2	AML	18503828	fusion partner		BCR	
JAK2	T-cell ALL	9360930	fusion partner		ETV6	
JAK2	CML	16091753	fusion partner		PCM1	
JAK2		27727438	types of alteration in cancer		recurrent V617F, V615L, V617I, N542_E543del	
JAK2		26697989	role in cancer	oncogene	oncogene	
JAK2		12039028	function summary		non-receptor tyrosine kinase, phosphorylates STATs, leading to their activation, involved in signalling by members of the single chain receptors, the IL-3 receptor family, the gp130 receptor family and the class II receptor cytokine family, essential for Epo signalling	
JAK2		19783980	global regulation of gene expression		phosphorylates histone H3Y41 and excludes HP1alpha from chromatin	
JAK2	oesophageal SCC	25405520	tumour promoting inflammation	promotes	inhibition of JAK2 by AG490 blocks inflammation	TE1
JAK2	oesophageal SCC	25405520	proliferative signalling	promotes	inhibition of JAK2 by AG490 suppresses cell proliferation	TE1
JAK2		25619393	escaping programmed cell death	promotes	inhibition of JAK2 by bigelovin induces apoptosis in 10 different human cancer cell lines	
JAK2	breast cancer	26191195	escaping programmed cell death	promotes	suppression of JAK2 expression by miR-204 induces apoptosis	
JAK2		24069558	proliferative signalling	promotes	V617F mutation confers cytokine hypersensitivity, constitutive activation of the JAK-STAT pathway, and cytokine-independent growth	
JAK2	liver cancer	27788478	proliferative signalling	promotes	KO inhibits cell proliferation	
JAK2	liver cancer	27788478	change of cellular energetics	promotes	KO induces autophagy	
JAK2		21841788	impact of mutation on function		V617F affects the activity of autoinhibitory JH2 pseudokinase domain resulting in increased activity of JAK2	
JAK2	neutrophils	11390502	escaping programmed cell death	promotes	contributes to granulocyte-macrophage colony-stimulating factor-delayed apoptosis	
JAK2		27473563	proliferative signalling	promotes	V617F GOF mutant stimulates proliferation of erythropoietin-dependent erythroid progenitors	
JAK2		27473563	differentiation and development		V617F GOF mutant delays differentiation of erythropoietin-dependent erythroid progenitors	
JAK2	liver cancer	27788478	escaping programmed cell death	promotes	KO induces apoptosis through activation of caspase 3	
JAK3	extranodal nasal-type natural killer cell lymphoma	23689514	proliferative signalling	promotes	JAK3 deregulation by activating mutations confers invasive growth advantage	
JAK3		12039028	function summary		non-receptor tyrosine kinase, phosphorylates STATs, leading to their activation, involved in signalling by all receptors that employ the common gamma receptor chain, expression is largely restricted to hematopoietic cells	
JAK3		16455959	differentiation and development		critical component of signalling pathways that regulate T cell differentiation	
JAK3	murine interleukin-3 dependent pro-B cell	16843266	proliferative signalling	promotes	A572V GOF somatic mutation transform cells to factor-independent growth	BaF3
JAK3		7481768	differentiation and development		essential for lymphoid development and signalling	
JAK3	extranodal nasal-type natural killer cell lymphoma	23689514	impact of mutation on function		A573V or V722I mutation in the pseudokinase domain cause constitutive activation	
JAK3		23689514	role in cancer	oncogene	oncogene	
JAK3		27727438	types of alteration in cancer		recurrent somatic mutations M511I, A572V, A573V, M511fs, R657Q, V722I	
KDM6A	breast cancer	26303947	invasion and metastasis	suppresses	 inhibits EMT-induced CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1 	
KDM6A		26944678	function summary		histone 3 Lys27 (H3K27) demethylase, pro-oncogenic cofactor essential for leukaemia maintenance in TAL1-positive (but not TAL1-negative) T-ALL 	
KDM6A	TAL1-positive T-ALL 	26944678	role in cancer	oncogene	oncogene	
KDM6A		24561908	role in cancer	TSG	TSG	
KDM6A	breast cancer	24491801	invasion and metastasis	promotes	KD resulted in significant decrease of invasiveness of cancer cells in vitro and in a mouse xenograft model	
KDM6A		22493065	global regulation of gene expression		modulates H3K27 acetylation	
KDM6A		26944678	global regulation of gene expression		performs demethylation of H3K27	
KDM6A	breast cancer	24491801	proliferative signalling	promotes	KD resulted in significant decrease in the proliferation of cancer cells in vitro and in a mouse xenograft model	
KDM6A		24561908	function summary		essential during normal development, required for correct reprogramming, embryonic development and tissue-specific differentiation	
KDR		23454747	role in cancer	oncogene	oncogene	
KDR		26631613	invasion and metastasis	promotes	primary cultures derived from melanomas harbouring the Q472H KDR variant are more invasive than the KDR wild type	
KDR		26631613	proliferative signalling	promotes	primary cultures derived from melanomas harbouring the Q472H KDR variant are more proliferative than KDR wild type	
KDR		26631613	angiogenesis	promotes	melanomas harbouring the Q472H KDR variant have higher tumour microvessel density 	
KDR	glioma	23536763	cell replicative immortality	promotes	KD of KDR reduces the capacity of self-renewal	
KDR	glioma	23536763	invasion and metastasis	promotes	KD of KDR reduces the capacity of initiating xenograft tumours	
KDR	glioma	23536763	angiogenesis	promotes	KD of KDR reduces the capacity of promoting vascularization and the establishment of vasculogenic mimicry	
KDR		27727438	types of alteration in cancer	promotes	recurrent somatic Q472H, V297I, R1032Q	
KDR		19570985	tumour promoting inflammation	promotes	contributes to vascular inflammation	
KDR		23172303	function summary		transmembrane receptor with five Ig domains in the extracellular region	
KDR		23172303	angiogenesis	promotes	induces proliferation of epithelial cells	
KDR		7596436	mouse model		knockout mice exhibit a lethal phenotype at E8.5-9.0 due to a lack of vasculogenesis	
KEAP1		23434765	escaping programmed cell death	suppresses	suppresses the expression of survival genes through inhibition of Nrf2	
KEAP1		22743616	function summary		adaptor for CUL3 ubiquitin ligase in complex targeting Nrf2, IKKB, Bcl2, master regulator of cytoprotective gene expression through Nrf2	
KEAP1	prostate cancer	20124447	types of alteration in cancer		hypermethylation of the promoter and aberrant splicing	DU-145
KEAP1		22743616	role in cancer	TSG	TSG	
KEAP1		14585973	impact of mutation on function		KEAP1 cysteines are alkylated during oxidative stress which negatively affects Keap1 ability to interact with Nrf2, additional cysteine (R470C) may decrease protein's activity	
KEAP1		16507366	impact of mutation on function		LOF mutations reduce the affinity to Nrf2	
KEAP1		27727438	types of alteration in cancer		recurrent R470C	
KIT	mast cells	18579792	escaping programmed cell death	promotes	D816V GOF mutant increases cell survival via Stat5/PI3-kinase signalling cascade	
KIT		11079457	differentiation and development		necessary for successful differentiation of spermatozoa	
KIT	melanocytes	16410786	invasion and metastasis	promotes	active cKit RTK primarily transmits pro-migration signals, which may antagonize pro-proliferation and pro-differentiation signals	
KIT		27727438	types of alteration in cancer		recurrent D816V, L576P, V559D, inframe indels within the transmembrane domain	
KIT		26973244	role in cancer	oncogene	oncogene	
KIT		23073628	function summary		a type III receptor tyrosine kinase, receptor of the Stem Cell Factor (SCF) 	
KIT		9651683	proliferative signalling	promotes	gain-of-function mutations increase mitogenic and PI 3-kinase activation potential	
KIT		9651683	escaping programmed cell death	promotes	inhibits apoptosis by promoting phosphorylation of Bad, a pro-apoptotic protein, leading to its inactivation	
KIT		19265199	impact of mutation on function		D816V mutation results in constitutive activation of kinase activity and increased intracellular localisation of KIT	
KIT	SCF-dependent mouse hematopoietic cells	19265199	escaping programmed cell death	promotes	D816V GOF mutant enables cell survival in the absence of the Stem Cell Factor	Ba/F3
KIT	SCF-dependent mouse hematopoietic cells	19265199	proliferative signalling	promotes	D816V GOF mutant stimulates cell proliferation in the absence of the Stem Cell Factor	Ba/F3
KIT	SCF-dependent mouse hematopoietic cells	19265199	invasion and metastasis	promotes	D816V GOF mutant induces colony formation in soft agar	Ba/F3
KIT	mast cells	18579792	proliferative signalling	promotes	D816V GOF mutant stimulates cell proliferation via Stat5/PI3-kinase signalling cascade	
KLF4	meningioma	27727438	types of alteration in cancer		recurrent K409Q	
KLF4	breast cancer	21242971	invasion and metastasis	promotes	KD suppresses cell migration and invasion	MCF-7 and MDA-MB-231
KLF4	ESC	20071344	cell replicative immortality	promotes	functions upstream of Nanog in ES cell self-renewal and in preventing ES cell differentiation	
KLF4	breast cancer	25834779	escaping programmed cell death	suppresses	overexpression promotes apoptosis 	SK-BR-3
KLF4	colorectal cancer	26224477	proliferative signalling	promotes	downregulation of KLF4 by miR-375 suppresses proliferation	
KLF4	bladder cancer	24573354	invasion and metastasis	suppresses	silencing KLF4 promotes cell migration and invasion	
KLF4	breast cancer	25834779	suppression of growth	promotes	overexpression inhibits proliferation	SK-BR-3
KLF4	T-cell ALL	25644173	role in cancer	TSG	TSG	
KLF4	breast cancer	25834779	role in cancer	TSG	TSG	SK-BR-3
KLF4	pancreatic cancer	26977883	role in cancer	oncogene	oncogene	
KLF4	Burkitt lymphoma	24067139	clinical impact		positive correlation between KLF4 expression and unfavourable overall survival	
KLF4	urothelial cancer	24018236	types of alteration in cancer		promoter hypermethylation	
KLF4		25418733	differentiation and development		inducing low expression of KLF4 results in IPSC generation	
KLF4		26908828	differentiation and development		controls differentiation of blood cells	
KLF4		27184424	differentiation and development		controls epithelial stratification	
KLF4	RKO colon cancer	11390382	cell division control		inducible expression of KLF4 causes a block in the G1/S phase	
KLF4		21290164	impact of mutation on function		the most recurrently mutated residue, K409, lies within the first zinc finger domain responsible for DNA contact	
KLF4	pancreatic intraepithelial neoplasia	26977883	invasion and metastasis	promotes	induces acinar-to-ductal transition, ectopic expression of KLF4 in acinar cells reduces acinar lineage- and induces ductal lineage-related marker expression	
KLF4	breast cancer	21242971	cell replicative immortality	promotes	required for maintenance of breast cancer stem cells	
KLF4		16372018	function summary		transcriptional regulator, stimulates the expression of the cell-cycle regulator p21, involved in cell-cycle-arrest and differentiation, transcriptionally suppresses p53 expression	
KMT2C		25794446	function summary		histone H3 lysine 4 methylase, part of COMPASS-like complexes, coactivator enzymes recruited to enhancers via a number of nuclear receptor and other transcription factors to regulate enhancer activities	
KMT2C	mouse embryonic fibroblasts	19433796	genome instability and mutations	suppresses	acts as co-activator of p53 target gene expression in response to DNA damage	
KMT2C	mice	19047629	differentiation and development		plays crucial role in adipogenesis	
KMT2C	bladder cancer	30665945	clinical impact		cells with low activity of KMT2C are sensitive to PARP1/2 inhibitor olaparib	
KMT2C	bladder cancer	30665945	genome instability and mutations	suppresses	cells with low KMT2C activity are deficient in homologous recombination-mediated double-strand break DNA repair	
KMT2C		24794707	differentiation and development		KD impairs differentiation of haematopoietic stem and progenitor cells	
KMT2C	breast cancer	29755131	global regulation of gene expression		KD causes H3K4me1 and H3K27ac loss selectively at ER-alpha enhancers	
KMT2C	medulloblastoma	21163964	types of alteration in cancer		frequent inactivating mutations	
KMT2C		27727438	types of alteration in cancer		recurrent missense mutations including P309S, C988F, Y987H, R284Q, D348N	
KMT2C		19433796	mouse model		KO promotes tumour formation in urothelial cells	
KMT2C		24794707	mouse model		KD promotes leukemogenesis in conjunction with Nf1 KD and p53 KO	
KMT2C	breast cancer	29755131	clinical impact		ER-positive patients with truncations or deletions have shorter progression-free survival	
KMT2C	AML	26438511	clinical impact		inactivating mutations are associated with worse overall and relapse-free survival	
KMT2C	pancreatic ductal adenocarcinoma	27280393	clinical impact		low expression is associated with better overall survival	
KMT2C	AML	24794707	role in cancer	TSG	TSG	
KMT2C	gastric epithelial cells	30108106	invasion and metastasis	suppresses	KD promotes EMT, migration and invasion	HFE-145
KMT2C	AML	26438511	suppression of growth	promotes	KD increases cell growth in vitro and tumour growth in xenografts	MV4-11
KMT2C	breast cancer	29755131	proliferative signalling	promotes or suppresses	promotes hormone-dependent tumour cell proliferation while suppressing hormone-independent tumour growth	
KMT2C	gastric epithelial cells	30108106	cell replicative immortality	suppresses	KD increases spheroid formation and increases expression of cancer stem cell markers and self-renewal proteins	
KMT2D		28669924	function summary		histone-lysine N-methyltransferase targeting H3 lysine 4	
KMT2D		24368734	mouse model		KO mice show early embryonic lethality around E9.5	
KMT2D	pancreatic cancer	30337373	change of cellular energetics	promotes	KD increases aerobic glycolysis and alters the lipidomic profiles of tumour cells through regulation of SLC2A3 glucose transporter	
KMT2D	NSCLC	29627316	clinical impact		mutations are associated with poor prognosis	
KMT2D	granulosa cell tumors of the ovary	29950560	clinical impact		inactivation by truncating mutations is associated with recurrence	
KMT2D		30753827	global regulation of gene expression		patterns of H3K4me1 generated by KMT2D determine the patterns of CpG islands hypermethylation in breast and prostate cancer	
KMT2D	colorectal cancer	24240169	invasion and metastasis	promotes	KO of a single allele reduces migratory potential and proliferation of transformed cells	HCT116 and DLD-1
KMT2D	medulloblastoma	24240169	invasion and metastasis	promotes	KO of a single allele reduces migratory potential and proliferation of transformed cells	D425MED and D283MED
KMT2D	B-cell lymphoma	26366710	global regulation of gene expression		sustains a gene expression program that represses tumour development	
KMT2D	B-cell lymphoma	26366712	differentiation and development		lymphoma-associated KMT2D mutations impair KMT2D enzymatic activity, leading to diminished global H3K4 methylation in germinal-center B cells and disturbing their development	
KMT2D	SCLC	28007623	types of alteration in cancer		frequent inactivating mutations	
KMT2D	bladder cancer	27387124	cell replicative immortality	promotes	the G5189A mutant increases the self-renewal capabilities of cells	
KMT2D	undifferentiated epidermal keratinocytes 	29440247	differentiation and development		KD results in reduced proliferation, premature spurious activation of terminal differentiation genes, and disorganized epidermal stratification	
KMT2D	undifferentiated epidermal keratinocytes 	29440247	global regulation of gene expression		KD results in a broad loss of enhancer histone modifications H3 Lys 4 (H3K4) monomethylation (H3K4me1) and H3K27 acetylation (H3K27ac) as well as reduced expression of p63 target genes	
KMT2D	Oesophageal SCC	29532228	clinical impact		patients with low MLL2 expression have a better overall survival	
KMT2D	Oesophageal SCC	29532228	invasion and metastasis	promotes	KO restricts cell migration ability and inhibits EMT	Eca109
KMT2D	Oesophageal SCC	29532228	proliferative signalling	promotes	KO inhibits cell proliferation	Eca109
KMT2D		24240169	role in cancer	Oncogene, TSG	Oncogene, TSG	
KMT2D		24368734	differentiation and development		required for enhancer activation during cell differentiation, essential for adipogenesis and myogenesis	
KNL1		18045986	function summary		protein responsible for kinetochore assembly during mitosis	
KNL1		18045986	genome instability and mutations	suppresses	essential for cell viability and proper chromosome segregation in vertebrates	
KNL1		26348410	escaping programmed cell death	promotes	silencing induces apoptosis in a p53-independent manner	
KNL1		24425691	fusion partner		KMT2A	
KNL1		12087463	types of alteration in cancer		highly expressed in testis, but also in multiple cancers	
KNL1		17981135	cell division control		required for chromosome alignment and mitotic checkpoint function	
KNL1		22331849	cell division control		contributes to spindle checkpoint silencing at the kinetochore	
KNL1		24425691	role in cancer	fusion	fusion	
KRAS		27727438	types of alteration in cancer		recurrent missense mutations G12D, G12V, G12C, G12A, G12S, G12R, G13D, G13C, Q61H	
KRAS		20188103	invasion and metastasis	promotes	oncogenic K-Ras and its effector Raf1 convert death receptors CD95 ligand and TRAIL into invasion-inducing receptors by suppressing the ROCK/LIM kinase pathway	
KRAS		12085227	tumour promoting inflammation	promotes	oncogenic K-Ras induces transactivation of NF-kappaB through the NIK-IKKbeta-IkappaBalpha pathway	
KRAS		26544625	escaping programmed cell death	promotes	suppresses apoptosis through downregulation of TDG	
KRAS	colon cancer	26744320	cell replicative immortality	promotes	oncogenic KRAS activates an embryonic stem cell-like program	
KRAS	colorectal cancer	26418750	change of cellular energetics	promotes	GOF mutants induce autophagy, contributing to cell survival during starvation, via up-regulation of the MEK/ERK pathway	
KRAS	breast epithelial cells	26028026	change of cellular energetics	promotes	expression of the oncogenic KRAS mutant is sufficient to induce de novo lipogenesis	
KRAS	mouse	15644420	differentiation and development		essential for normal foetal liver erythropoiesis	
KRAS		16483930	escaping programmed cell death	suppresses	phosphorylation by protein kinase C promotes its association with BCL2L1 on the outer membrane of mitochondria and induces apoptosis	
KRAS		2547513	impact of mutation on function		activating mutations at G12, G13 or Q61 cause Ras to accumulate in the active GTP bound state by impairing intrinsic GTPase activity and conferring resistance to GTPase activating proteins	
KRAS		17384584	function summary	1	a small GTPase that cycles between inactive GDP-bound and active GTP-bound conformations, regulates cellular responses to many extracellular stimuli, including soluble growth factors, through PI3K, MEK/ERK and other pathways, the protein is farnesylated at a terminal CAAX motif and may be additionally modified by one or two palmitic acids just upstream of the CAAX motif to anchor the protein in the membrane; two isoforms occur in a cell as a result of alternative splicing at the C-terminus	
KRAS		17384584	proliferative signalling	promotes	activating mutations cause hypersensitivity to external growth-stimulating factors	
KRAS	colorectal cancer	26132860	invasion and metastasis	promotes	regulates the composition of microRNAs secreted in exosomes, growth suppressing miRNAs are exported from a mutant cell, which enhances tumour growth and may affect the growth of the surrounding cells	
KRAS		23506169	angiogenesis	promotes	cells expressing G13D mutant present higher levels of VEGF-A	
KRAS		15994921	change of cellular energetics	promotes	cells expressing G12C mutant present a highly glycolytic phenotype	
KRAS		27550813	invasion and metastasis	promotes	repression of endogenous mir-200 expression by oncogenic KRAS promotes EMT	
KRAS		27550813	escaping programmed cell death	promotes	repression of endogenous mir-200 expression by oncogenic KRAS increases cell resistance to apoptosis	
KRAS		23324341	escaping programmed cell death	promotes	mutant K-Ras contributes to the maintenance of the aberrantly high levels of survivin in tumours by regulating its stability	
KRAS		20848283	escaping programmed cell death	promotes	cancer cell lines with mutated G12D K-ras are resistant to the proapoptotic actions of TRAIL	
KRAS		26985062	role in cancer	oncogene	oncogene	
LATS1	Basal cell carcinoma	26950094	types of alteration in cancer		recurrent R995C	
LATS1	breast cancer	11850843	escaping programmed cell death	suppresses	ectopic expression promotes apoptosis	MCF7
LATS1	glioma	22909338	suppression of growth	suppresses	overexpression negatively impacts colony formation 	U251
LATS1	breast cancer	15746036	types of alteration in cancer		frequent promoter hypermethylation in tumour tissue associated with lower expression	
LATS1	Basal cell carcinoma	26950094	impact of mutation on function		in silico modelling localises residue 995 to the core of the kinase domain, R995C is predicted to severely disrupt protein stability and activity	
LATS1		11641775	suppression of growth	promotes	overexpression suppresses proliferation	Hela, C33A, A549, HCT116, MCF7, and UB7
LATS1	glioma	22909338	types of alteration in cancer		expression is significantly decreased in tumour compared to adjecent normal tissue in 13 of 17 samples	
LATS1	mouse embryonic fibroblasts	26530630	genome instability and mutations	suppresses	KO inhibits Cdc25B degradation and leads to centrosome overduplication, formation of multipolar spindles, cytokinesis failure and an increased proportion of cells with micronuclei and enlarged nuclei	
LATS1		9988269	mouse model		lats1-deficient mice develop ovarian stromal cell tumours, soft tissue sarcomas and are highly senstive to carcinogenic agents; Lats1-heterozygotes do not develop spontaneous tumours	
LATS1		11641775	cell division control		ectopic expression causes G2/M arrest	Hela, C33A, and U87MG
LATS1	mouse embryonic fibroblasts	25218637	genome instability and mutations	suppresses	promotes the formation of stabilising RAD51 nucleofilaments at stalled replication forks, in response to genotoxic stress	
LATS1		29438698	mouse model		mice with schwann-cell ablation of Lats1 and one copy of Lats2 develop high-grade nerve-associated tumours with 100% penetrance and have reduced lifespan	
LATS1	astrocytoma	17049657	types of alteration in cancer		frequent promoter hypermethylation in tumour tissue associated with lower expression	
LATS1		20935475	function summary		serine threonine kinase that phophorylates YAP/TAZ oncogenic transcriptional coactivators leading to their cytoplasmic retention and proteasomal degradation	
LATS1	human breast epithelial cells	28068668	differentiation and development		KD increases the number of bipotent and luminal progenitor cells	
LATS1	rat fibroblasts	15122335	genome instability and mutations	suppresses	expression of kinase-deficient Lats interferes with mitotic progression and abrogates the G1 tetraploidy checkpoint, resulting in polyploidy	
LATS1	breast cancer	11850843	suppression of growth	promotes	ectopic expression suppresses colony growth in vitro and in xenograft assay	MCF7
LATS1	breast cancer	11850843	cell division control		ectopic expression decreases Cyclin A/Cyclin B protein levels, decreases CDC2 kinase activity and inhibits G2/M transition	MCF7
LATS1	Basal cell carcinoma	25119020	role in cancer	TSG	TSG	
LATS1	glioma	22909338	clinical impact		lower expression is associated with advanced tumour grade and worse survival	
LATS2	transformed mouse embryonic fibroblasts	12853976	suppression of growth	promotes	ectopic expression suppresses cell proliferation in vitro and tumour growth in xenografts	NIH3T3
LATS2	osteosarcoma	17015431	genome instability and mutations	suppresses	spindle damage leads to LATS2 nuclear translocation, invoking a positive feedback loop of p53 activation driving LATS2 upregulation and activating the G1/S tetraploidy checkpoint	U2OS
LATS2	colon cancer	24360964	clinical impact		low expression associated with poor prognosis	
LATS2	malignant mesothelioma	21245096	types of alteration in cancer		deletions or inactivating mutations detected in multiple cell lines and primary tumours	
LATS2	malignant mesothelioma	28003305	types of alteration in cancer		large exon deletions or inactivating mutations in multiple patient samples	
LATS2	mouse embryonic fibroblasts	15343267	cell division control		cytokinesis is impaired in null cells, midbody cleavage is incomplete with incorrectly segregated chromatin spanning the midbody between daughter cells	
LATS2	immortalised human lung embryonic fibroblasts	19855428	escaping programmed cell death	suppresses	KD reduces oncogenic-HRAS-induced apoptosis	
LATS2	immortalised human lung embryonic fibroblasts	19855428	invasion and metastasis	suppresses	KD increases oncogenic-HRAS-induced cell migration	WI-38
LATS2	acute lymphoblastic leukaemia	16208412	clinical impact		low expression associated with poor outcome	
LATS2	malignant mesothelioma	21245096	role in cancer	TSG	TSG	
LATS2	osteosarcoma	17015431	genome instability and mutations	suppresses	ectopic expression of kinase-dead enzyme or KD of endogenous gene promotes accumulation of polyploid cells following nocodazole treatment	U2OS
LATS2	colon cancer	24360964	types of alteration in cancer		decreased expression in colorectal cancer tissue versus adjacent normal tissue with lower expression in metastatic versus primary colorectal tumours	
LATS2	mouse embryonic fibroblasts	15343267	genome instability and mutations	suppresses	null cells display centrosome amplification and increased levels of aneuploidy and chromosomal abnormalities, ectopic expression of Lats2 in WT cells supresses hydroxyurea-induced centrosome duplication 	
LATS2	astrocytoma	17049657	types of alteration in cancer		frequent promoter hypermethylation in tumour tissue associated with lower expression	
LATS2	lung cancer	15265683	escaping programmed cell death	suppresses	ectopic expression promotes apotosis	A549 and H1299
LATS2	immortalised human lung embryonic fibroblasts	19855428	senescence		KD abrogates HRAS-induced senescence	WI-38
LATS2	breast epithelial cells	21952048	invasion and metastasis	promotes	enhances EMT in a Snail1 dependent manner	MCF10A
LATS2	transformed mouse embryonic fibroblasts	12853976	cell division control		ectopic expression inhibits G1/S transition and downregulates cyclin E/CDK2 kinase activity	NIH3T3
LATS2		20935475	function summary		serine threonine kinase that functions to suppress cellular proliferation at high cell density	
LATS2	breast cancer	15746036	types of alteration in cancer		frequent promoter hypermethylation in tumour tissue associated with lower expression	
LATS2	breast cancer	21952048	invasion and metastasis	promotes	KD inhibits cell migration and invasion in metastatic cell lines, expression is increased in metastatic versus normal cells	MDA_MB_231 and BT549
LATS2	malignant mesothelioma	21245096	suppression of growth	promotes	ectopic expression of wild-type LATS2 inhibits proliferation, exon 6-deleted mutant LATS2 fails to inhibit proliferation	Y-MESO-27 and  Y-MESO-30
LATS2	mouse embryonic fibroblasts	15343267	suppression of growth	promotes	null cells lose contact inhibition of growth	
LATS2		26544935	function summary		phosphorylates transcriptional coactivators YAP1, YAP2 and TAZ, promoting their degradation	
LCK		8049439	role in cancer	fusion	fusion	
LCK		9488037	proliferative signalling	promotes	participates in the anchorage independent growth of a TGFa initiated tumour cells 	
LCK	endothelial cells	27402674	escaping programmed cell death	suppresses	knockdown of p56/Lck blocks HKa-induced apoptosis and activation of p53, Bax, and Bak	
LCK	endothelial cells	27402674	angiogenesis	suppresses	knockdown of p56/Lck promotes endothelial proliferation 	
LCK		25477210	differentiation and development		essential for T-cells development 	
LCK		9880255	function summary		activates STAT5A and STAT5B 	
LCK	T-ALL	8049439	fusion partner		TRB	
LCK		25595912	role in cancer	oncogene	oncogene	
LCK	SCLC	9788619	proliferative signalling	promotes	inhibition of LCK antagonized SCF-mediated proliferation	H526
LCK	PAX5 translocated BCP-ALL 	25595912	function summary		LCK over-expression drives STAT5 oncogenic signaling	
LCK	SCLC	9788619	escaping programmed cell death	promotes	inhibition of LCK antagonizes SCF-mediated inhibition of apoptosis	H526
LEF1		25394300	types of alteration in cancer		frequently overexpressed in colorectal carcinoma	
LEF1	breast cancer	18794125	function summary		transcriptional inhibitor of estrogen receptor activity	MCF-7
LEF1	renal cell carcinoma	24897388	cell division control		EF1 promotes proliferation depending on suppressing G2/M cell-cycle arrest	
LEF1	mouse	18316418	differentiation and development		constitutive expression of Lef-1 results in a severe perturbation of haematopoiesis	
LEF1	prostate cancer	19351848	function summary		positively regulates AR expression	
LEF1		19653274	function summary		member of the high-mobility group transcription factors, participates in Wnt pathway	
LEF1	renal cell carcinoma	24897388	proliferative signalling	promotes	cells expressing high levels of LEF1 have significantly increased proliferative ability	
LEF1	pancreatic cancer	19653274	invasion and metastasis	promotes	isoform without exon 6 is involved in reducing cellular aggregation and increasing cell migration	
LEF1	sebaceous tumours	16565724	role in cancer	TSG	TSG	
LEF1	T-ALL	20124220	role in cancer	TSG	TSG	
LEF1	renal cell carcinoma	24897388	role in cancer	oncogene	oncogene	
LEF1		11782404	mouse model		isoform lacking beta-catenin binding site expressed in mouse results in skin tumour formation	
LEF1		20124220	types of alteration in cancer		overexpression and inactivating mutations are found in cancer cells, as it regulates gonadotropin hormone response, the outcome of GOF or LOF is tissue dependent 	
LEF1	endometrial cancer	22792274	types of alteration in cancer		overexpressed	
LIFR		21394649	role in cancer	fusion	fusion	
LIFR		9242667	function summary		receptor of the leukemia inhibitory factor cytokine	
LIFR	salivary gland adenoma	21394649	fusion partner		PLAG1	
LIFR	hepatocellular carcinoma	26249360	invasion and metastasis	suppresses	suppresses metastasis by negatively regulating phosphoinositide 3-kinase/AKT pathway	
LIFR	melanoma	26329521	invasion and metastasis	promotes	high expression stimulates cell migration	
LIFR	breast cancer	23001183	invasion and metastasis	suppresses	suppressor of metastasis	
LIFR	hepatocellular carcinoma	19733004	types of alteration in cancer		23 of 48 (47.9%) tumour tissues showed promoter hypermethylation of LIFR gene, and the expression level was clearly reduced	
LIFR		27642788	invasion and metastasis		induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow	
LIFR	pancreatic cancer	27375070	invasion and metastasis	suppresses	suppressor of metastasis	
LMNA		18538321	function summary		nuclear protein, plays a role in supporting the nuclear architecture and anchoring chromatin and the nuclear pore complexes to the nuclear membrane	
LMNA		17360326	impact of mutation on function		deletion of 50-aa at the C-terminus causes an abnormal association of LADelta50/progerin with membranes during mitosis, which delays the onset and progression of cytokinesis and is accompained by the defects in the retinoblastoma protein-mediated transition into S-phase and causes premature aging	
LMNA		26029982	impact of mutation on function		 deletion in the sequence required for processing by the protease ZMPSTE24, leads to accumulation of farnesylated lamin A in the nuclear envelope, causes cell division arrest in interphase as polyploid cells with features of cellular senescence including increased expression of inflammatory gene products and a significant reduction of tumourigenicity 	
LMNA		24445538	role in cancer	fusion	fusion	
LMNA		26549451	genome instability and mutations	suppresses	promotes SIRT6-dependent DNA-PKcs recruitment to chromatin 	
LMNA	congenital infantile fibrosarcoma 	26563356	fusion partner		NTRK1	
LMNA	colorectal cancer 	26563355	fusion partner		NTRK1	
LMNA		24445538	types of alteration in cancer		fusion with NTRK1 is caused by a 743 kb deletion of chromosome 1q, joining the first two exons of LMNA with NTRK1 starting at exon 11 	
LMNA	Spitz tumour	24445538	fusion partner		NTRK1	
LRP1B		21057533	role in cancer	TSG	TSG	
LRP1B		1423604	differentiation and development		homozygotic mice KOs are lethal with lack of embryo implantation	
LRP1B		18626063	function summary		endocytic receptor able to recognise 30+ distinct ligands, binds a large number of cytoplasmic adaptor proteins via determinants located on its cytoplasmic domain in a phosphorylation-specific manner and modulates the activity of other transmembrane receptors such as integrins and receptor tyrosine kinases	
LRP1B		15166012	invasion and metastasis	suppresses	reduces membrane localisation of urokinase and PDGF receptors attenuating cell migration	
LRP1B		21057533	invasion and metastasis	suppresses	inactivation results in changes to the tumour environment that confer cancer cells an increased invasive capacity, restoration of LRP1B inhibited cell invasion and leads to a reduction of matrix metalloproteinase 2 in the extracellular medium	
LRP1B		21057533	suppression of growth	promotes	inactivation (by chromosomal, epigenetic and microRNA (miR)-mediated mechanisms) results in increased growth, restoration of LRP1B impaired tumour growth in vitro and in vivo	
LZTR1		16356934	function summary		BTB-kelch Golgi matrix-associated protein localised exclusively on the cytoplasmic surface of the Golgi network, upon induction of apoptosis LZTR-1 is phosphorylated on tyrosine residues and subsequently degraded	
LZTR1	schwannomatosis	24362817	role in cancer	TSG	TSG	
LZTR1	schwannomatosis	25335493	types of alteration in cancer		frequently inactivated	
MACC1	colon cancer	19098908	clinical impact		high expression is associated with poor prognosis	
MACC1		19098908	role in cancer	oncogene	oncogene	
MACC1	colorectal cancer	28649004	escaping programmed cell death	promotes	KD enhances Fas agonist induced reduction in cell viability	HCT116, Hkh-2, Hke-3, LS174T and HT29
MACC1	gastric cancer	23457029	clinical impact		higher expression is associated with a worse prognosis	
MACC1	colon cancer	19098908	invasion and metastasis	promotes	ectopic expression increaeses cell migration, invasion and colony formation	SW480
MACC1	colon cancer	19098908	invasion and metastasis	promotes	MACC1-expressing mouse xenografts develop larger tumours and more frequent metastasis	SW480
MACC1	hepatocellular	25660117	clinical impact		high expression is associated with worse survival	
MACC1		19098908	function summary		transcriptional activator of MET and regulator of HGF-MET signalling	
MACC1	colon cancer	19098908	types of alteration in cancer		significantly overexpressed	
MACC1	gastric cancer	23457029	invasion and metastasis	promotes	ectopic expression increases migration and invasion and upregulates EMT markers, KD decreases migration and invasion	BGC-823 and MKN-28
MACC1	gastric cancer	27280289	angiogenesis	promotes	co-culture of human umbilical vein endothelial cells (HUVECs) with conditioned media from ovexpressing cells increases density of vascular tube-like structures, density is decreased in HUVECs cultured with media from MACC1 KD cells.	BGC-823 and MKN-28
MACC1	gastric cancer	25895023	angiogenesis	promotes	overexpression increases vasculogenic mimicry in xenografts	
MAP3K1	breast, prostate, and stomach cancer, and DLBCL	29795445	types of alteration in cancer		frequent LOF somatic mutations	
MAP3K1		16568086	mouse model		KO mice have decreased levels of urokinase-type plasminogen activator, which results in reduced activity of extracellular proteinases and delays lung metastasis of mammary tumours	
MAP3K1	pancreatic cancer	19513748	clinical impact		 expression is positively correlated with lymphatic metastases	
MAP3K1	breast cancer	26759750	types of alteration in cancer		frequently overexpressed	
MAP3K1	Langerhans cell histiocytosis	25899310	types of alteration in cancer		truncating mutations	
MAP3K1		25613373	function summary		serine and threonine kinase that phosphorylates Map2 kinases within their activation domains	
MAP3K1	breast and colorectal cancer	29795445	clinical impact		LOF mutations confer sensitivity to MEK inhibition by disabling JNK-JUN-mediated feedback loop upon MEK inhibition	
MAP3K1	pancreatic cancer	12185592	escaping programmed cell death	promotes	dominant negative mutant fails to inhibit JNK activation and reduces cell survival	PANC-1, MIAPaCa-2, BxPC-3
MAP3K1	breast cancer	26759750	proliferative signalling	promotes	KD inhibits proliferation	MCF-7, MDA-MB-231
MAP3K1	NSCLC	29344125	invasion and metastasis	promotes	silencing transcription with miR1455p results in inhibition of JNK signaling and EMT	A549, H520
MAP3K1	murine breast cancer	26759750	invasion and metastasis	promotes	KD inhibits invasion, and high expression is associated with invasive disease 	4T1
MAP3K1	pancreatic cancer	19513748	invasion and metastasis	promotes	KD inhibits invasion and migration	BxPC-3
MAP3K1		24386504	role in cancer	oncogene, TSG	oncogene, TSG	
MAP3K1	breast and cervical cancer	24386504	escaping programmed cell death	promotes or suppresses	full length MAP3K1 promotes anti-apoptotic signalling through ERK and NF-kB activation, whilst caspase 3 mediated cleavage of MAP3K1 generates a C-terminal kinase domain that promotes apoptosis	
MAP3K13		26918941	proliferative signalling	promotes	promotes tumour growth in high Myc-expressing cell lines	MB231, HepG2
MAP3K13	HNSCC	28760853	proliferative signalling	promotes	KD reduces cell density, viability and colony forming ability in vitro and tumour growth in vivo	CAL33
MAP3K13		9353328	function summary		mitogen activated protein kinase kinase kinase that activates JNK signalling	
MAP3K13	HNSCC	28760853	role in cancer	Oncogene	Oncogene	
MAP3K13	breast cancer	22722201	role in cancer	TSG	TSG	
MAP3K13	breast cancer	22722201	types of alteration in cancer		truncating and missense mutations	
MAP3K13		26918941	function summary		stabilizes Myc by promoting its N-terminal phosphorylation and enhancing its transcriptional activity	
MAP3K13	upper aerodigestive tract	27727438	types of alteration in cancer		frequently amplified and overexpressed	
MAP3K13	HNSCC	28760853	types of alteration in cancer		frequent amplification	
MAP3K13	breast cancer	26918941	clinical impact		high expression is associated with worse overall survival in ER-negative disease	
MAPK1	glioblastoma	26510428	types of alteration in cancer		target of miR-129-1	
MAPK1	prostate cancer	26346167	types of alteration in cancer		target of miR-378, this regulation is disturbed due to miR-378 downregulation	
MAPK1	HNSCC	27004400	role in cancer	oncogene	oncogene	
MAPK1		26190261	change of cellular energetics	promotes	activation during metabolic stress contributes to changes in the TCA cycle and amino acid metabolism, and cell death, which is suppressed by glutamate and alpha-ketoglutarate supplementation	
MAPK1		19282669	function summary		component of the MAPK pathway downstream of RAS, RAF and MEK, key regulator of cell proliferation	
MAPK1		16273204	impact of mutation on function		recurrent E322K, located in the cytoplasmic retention motif, causes constitutive activation leading to enhanced EGFR phosphorylation and activation of downstream signalling	
MAPK1		19282669	escaping programmed cell death	suppresses	promotes cell death by suppressing survival signalling pathways upon retention in the cytoplasm	
MAPK1		26190261	escaping programmed cell death	suppresses	activated by phosphorylation promotes low-glucose-induced cell death	
MAPK1	prostate cancer	26346167	escaping programmed cell death	promotes	promotes cell survival due to downregulation of miR-378	
MAPK1	prostate cancer	26346167	invasion and metastasis	promotes	promotes cell migration and invasiveness through downregulation of miR-378	
MAPK1	T lymphocytes	11032809	escaping programmed cell death	promotes	activation prevents Fas-induced apoptosis	
MED12		24746821	impact of mutation on function		exon 2 mutations in MED12 uncouple Cyclin C-CDK8/19 from core Mediator and implicate aberrant CDK8/19 activity 	
MED12		16565090	function summary		promotes beta-catenin transactivation in response to Wnt signalling 	
MED12	colorectal cancer	28183795	invasion and metastasis	suppresses	modulates TGF-beta-induced epithelial-mesenchymal transition signalling	
MED12		28183795	role in cancer	TSG	TSG	
MED12	leiomyoma	27727438	types of alteration in cancer		highly recurrent G44D, G44S, G44V, a range of somatic mutations in exon 2	
MED12	breast phyllodes tumour	27727438	types of alteration in cancer		highly recurrent G44D, G44S, G44V, a range of somatic mutations in exon 2	
MED12	leiomyoma	27967206	proliferative signalling	promotes	plays a key role in the regulation of cell proliferation through the modulation of Wnt/-catenin, and cell cycle-associated protein expression	
MED12		23836153	function summary		a subunit of the Mediator Complex regulating its activity in promoting gene transcription	
MED12	leiomyoma	26193636	genome instability and mutations	promotes	expression of G44D GOF variant is associated with development of chromosomal rearrangements	
MEN1	mouse embryonic fibroblasts	14688275	escaping programmed cell death	suppresses	overexpression induces apoptosis, enhances CASP8 mRNA and protein levels and increases CASP8 enzymatic activity in response to TNF-alpha	
MEN1	breast cancer	28273452	proliferative signalling	promotes	KD suppresses proliferation	MCF-7
MEN1	pancreatic neuroendocrine tumours	21252315	types of alteration in cancer		very frequent inactivating somatic mutations	
MEN1	prostate cancer	25822367	clinical impact		expression is increased in metastatic versus localised disease, and high expression is asociated with disease progression and poor prognosis	
MEN1		23850066	function summary		nuclear scaffold protein with a diverse range of interacting partners that can regulate gene transcription through chromatin remodelling	
MEN1	Multiple endocrine neoplasia type 1	9215689	types of alteration in cancer		germline inactivating mutations	
MEN1	breast cancer	28273452	role in cancer	oncogene	oncogene	
MEN1		27727438	types of alteration in cancer		recurrent R516fs*43, I85fs*33, p.R516fs*15	
MEN1	mouse pancreatic islets	16195383	suppression of growth	promotes	menin-dependent histone H3K4 methylation maintains expression of CDK inhibitors p27 and p18, controlling cell proliferation	
MEN1	Multiple endocrine neoplasia type 1	26767918	types of alteration in cancer		frequent frameshift and nonsense mutations	
MEN1	prostate cancer	25822367	role in cancer	oncogene	oncogene	
MEN1	prostate cancer	25822367	proliferative signalling	promotes	KD decreases cell proliferation in vitro,  KD or blockade of menin:MLL interaction reduces tumour growth in mouse xenografts in vivo	LNCaP and VCaP
MEN1	breast cancer	28273452	global regulation of gene expression		while promoting expression of antiproliferative genes in normal mammary tissue, menin co-regulates proliferative gene expression program in ER-positive cancer cells	
MEN1	transformed mouse embryonic fibroblasts	10557080	suppression of growth	promotes	overexpression slows cell proliferation rate	NIH3T3
MEN1		11158604	mouse model		heterozygous KO mice develop tumours in endocrine tissues tumours show loss of wild-type Men1 allele	
MEN1	transformed mouse embryonic fibroblasts	10557080	role in cancer	TSG	TSG	NIH3T3
MEN1	breast cancer	28273452	global regulation of gene expression		KD reduces H3K4me3 at the ESR1 locus and ER-alpha protein levels whilst inhibition of the menin:MLL interaction decreases ESR1 mRNA levels and ER-alpha protein levels	MCF-7
MEN1	transformed mouse embryonic fibroblasts	16740708	suppression of growth	promotes	KO leads to enhanced cell proliferation, accelerates S phase entry, increases CDK2 activity and decreases levels of p18Ink4c and p27Kip1	
MEN1		16195383	global regulation of gene expression		histone H3K4 tri-methylation is reduced in pancreatic islets from heterozygous KO mice	
MEN1		23579270	global regulation of gene expression		interacts with SUVH39, mediating H3K9 methylation	
MEN1	mouse embryonic fibroblasts	17766243	impact of mutation on function		menin mutants L22R and A242V fail to bind to CASP8 5'UTR sites, fail to induce CASP8 expression at the mRNA and protein level and fail to potentiate TNF-alpha induced apoptosis	
MEN1	prostate cancer	25822367	global regulation of gene expression		KD decreases dihydrotestosterone-induced expression of androgen receptor target genes	LNCaP
MEN1	parathyroid tumours	9241276	types of alteration in cancer		somatic mutation followed by LOH has been detected in multiple patients with sporadic disease	
MET	HNSCC	29286169	invasion and metastasis	promotes	increased expression promotes migration and invasion of xenografts	SCC9
MET	breast cancer, glioblastoma	28973887	invasion and metastasis	promotes	formation of MET/integrin beta 1 complexes increases cell migration, extravasation and metastasis in xenografts	MDA-MB-231, HCC1143, HCC3153, U87 GBM
MET	prostate cancer	28440432	invasion and metastasis	promotes	KD decreases migration and invasion	PC3, DU145
MET	HNSCC	28440510	invasion and metastasis	promotes	KD or suppression with inhibitor SU11274 decreases migration via filopodia and lamellipodia	HSC4, SAS, Ca9-22
MET	colorectal cancer 	27793046	invasion and metastasis	promotes	KD suppresses migration and invasion	HCT116, DLD-1, LoVo
MET	renal cancer	25645920	escaping immune response to cancer	promotes	induces expression of PD-L1 via Ras/Raf pathway	786-0
MET	gastric cancer	27185371	senescence	suppresses	KD or inhibition sensitises cells to DNA damage induced senescence in vitro and in vivo and occurs through downregulation of FOXM1 	GTL-16, MKN-45, SNU-5
MET		28603720	role in cancer	oncogene	oncogene	
MET		31097696	role in cancer	fusion	fusion	
MET	colorectal cancer	29576428	clinical impact		overexpression is associated with poor prognosis	
MET		29551767	clinical impact		mutations, overexpression, amplification and fusions can result in oncogene addiction and may identify a subset of patients that respond well to RTK inhibitors 	
MET	NSCLC	29848294	clinical impact		X-ray irradiation activates MET and SRC, leading to MET mediated radiation resistance, dependent on aggregation of lipid rafts	A549, H1993
MET	NSCLC	28592790	clinical impact		upregulation of MET expression (via miR -19a downregulation) confers gefitinib resistance	HCC827, H1975, A549, Pc9, Pc9 GR
MET	gastric cancer	29790169	clinical impact		amplification and high expression are indicators of poor prognosis	
MET	HNSCC	29103754	clinical impact		higher levels associated with worse survival and metastatic disease	
MET	CML	28418880	clinical impact		KD resensitises BCR-ABL1 cells with acquired imatinib and TKI resistance through inhibition of ERK1/2 and JNK activation	K562
MET	NSCLC	28396313	clinical impact		acquired Y1248H and D1246N mutations mediate resistance to MET inhibitors	
MET	breast cancer	25065564	clinical impact		gene amplification and mutation is associated with high grade tumours and metastatic disease 	
MET		25985180	mouse model		deletion in haematopoietic cells reduces Met-mediated chemotraction of anti-tumoral (Met dependent nitric oxide release) neutrophils to tumour sites and increases metastases in syngeneic mouse models 	LLC, B16F10, A549, Panc02, T241
MET		29303510	mouse model		overexpression synergises with deletion of PTEN to develop hepatocellular carcinoma, dependent on mTORC2 pathway activation	
MET	NSCLC	28590585	types of alteration in cancer		gene amplification is more frequent in metastatic lymph nodes than in primary cancerous tissue	
MET	renal carcinoma	28603720	types of alteration in cancer		germline missense mutations within the kinase domain of MET result in predisposition to hereditary papillary renal carcinoma, somatic mutations in the same domain are found in sporadic disease as well as nonrandom duplication of mutant allele in most tumours	
MET	multiple solid tumours 	28603720	types of alteration in cancer		missense mutations affecting kinase domain, juxtamembrane domain and SEMA domain	
MET	low-grade glioma, hepatocellular carcinoma, lung adenocarcinoma, thyroid carcinoma 	25204415	types of alteration in cancer		translocations to a range of partners	
MET	lung cancer	28373408	types of alteration in cancer		frequent overexpression, GOF mutations, gene amplifications leading to sustained MET signaling	
MET	colorectal adenocarcinoma	29641976	types of alteration in cancer		overexpression is common, gene amplification uncommon and exon 14 mutation rare	
MET	cancers of unknown primary (CUP)	29037604	types of alteration in cancer		frequent mutations affecting kinase and SEMA domains	
MET	prostate cancer	28440432	types of alteration in cancer		frequently overexpressed	
MET	pulmonary sarcomatoid carcinoma	26215952	types of alteration in cancer		Exon 14 splice site mutations common	
MET		30371878	types of alteration in cancer		recurrent L982_D1028del, T1010I, Y1253D	
MET	skeletal muscle	25471370	differentiation and development		truncated isoform lacking exon 13 and intracellular kinase domain blocks MET signaling and induces differentiation	
MET	vascular smooth muscle cells	21920521	differentiation and development		Met signaling induces osteogenic differentiation via activation of Notch3	
MET		30108016	cell division control		KD induces cell cycle arrest	Bel-7402
MET	malignant glioma	29571074	fusion partner		PTPRZ1	
MET	osteogenic sarcoma	28528776	fusion partner		TPR	
MET	NSCLC	30015159	fusion partner		KIF5B	
MET	paediatric glioblastoma	27748748	fusion partner		TFG, CLIP2	
MET	salivary secretory carcinoma	29683815	fusion partner		ETV6	
MET	Spitz tumour	26013381	fusion partner		ZKSCAN1, PPFIBP1, LRRFIP1, TRIM4, DCTN1, EPS15	
MET		10498872	impact of mutation on function		kinase domain mutations constitutively activate MET, but dimerisation of receptor by ligand binding is necessary for cellular transformation	
MET			function summary		receptor tyrosine kinase expressed on the surfaces of various cells, activated upon binding hepatocyte growth factor (HGF)	
MET		24440758	function summary		mutations in kinase domain trigger constitutive receptor endosomal trafficking and promote MET dependent migration, anchorage independent growth and tumorigenesis	
MET		20584748	genome instability and mutations	promotes	constitutive MET activation or prolonged HGF exposure results in supernumerary centrosomes, chromosome segregation defects and CIN, dependent on PI3K/AKT and TP53 status	
MET	human brain endothelial cells	27893712	angiogenesis	promotes	KD or inhibition inhibits vascular transformation, normalises blood vessels and suppresses tumour growth in xenografts	
MET	alveolar rhabdomyosarcoma	26384300	angiogenesis	promotes	KD inhibits tumour vascularisation through downregulation of VEGF and MMP9	RH30
MET	renal cancer	25645920	escaping programmed cell death	promotes	receptor activation by HGF activates RAS and inhibits apoptosis	786-O
MET	liver cancer	24122846	escaping programmed cell death	promotes	inhibits apoptosis on caspase 3 cleavage by release of a peptide that blocks caspase 3 activity	HepG2
MET		24136235	escaping programmed cell death	suppresses	promotes apoptosis on caspase 3 cleavage, releasing a p40 intracellular kinase domain that localises to mitochondria and induces mitochondrial permeabilization	MCF-10A, HEK293
MET	HNSCC	29286169	proliferative signalling	promotes	increased expression stimulates proliferation and colony formation	SCC9
MET	ovarian cancer	28698064	proliferative signalling	promotes	KD results in decreased proliferation	HO-8910PM
MET	hepatocellular carcinoma	30108016	proliferative signalling	promotes	KD inhibits cell growth	Bel-7402
MLLT10	AML and ALL	7564531	fusion partner		KMT2A	
MLLT10	T-ALL	25377562	fusion partner		XPO1	
MLLT10	T-ALL	24584351	fusion partner		DDX3X	
MLLT10		25464900	function summary		chromatin regulatory factor	
MLLT10	AML	25464900	global regulation of gene expression		regulates progressive H3K79 methylation at HOX loci and HOX gene expression, inactivation reverses leukaemia-associated epigenetic profiles, precludes abnormal HOXA gene expression, and impairs the transforming ability of KMT2A-MLLT3, KMT2A-AFDN, and NUP98-NSD1 fusions - other HOX-activating oncogenes 	
MLLT10		7564531	role in cancer	fusion	fusion	
MLLT10		25464900	role in cancer	oncogene	oncogene	
MLLT10		23284727	cell replicative immortality	promotes	plays a key role in the maintenance of multipotent hematopoietic cells 	
MTOR		25762619	function summary		regulates cell adhesion	
MTOR		26391637	function summary		serine/threonine kinase belonging to the phosphoinositide3-kinase (PI3K) related kinase family, activated by nutrients, growth factors, and cellular energy levels, plays a key role in mediating cell growth and homeostasis	
MTOR	breast cancer	26427711	angiogenesis	promotes	upregulates VEGF expression	
MTOR	NSCLC	25893736	escaping programmed cell death	promotes	inactivation induces apoptosis	
MTOR	breast cancer	26753650	proliferative signalling	promotes	stimulates proliferation	
MTOR		24631838	impact of mutation on function		GOF mutations diminish binding of mTOR to its endogenous inhibitor Deptor, S2215Y results in preferentially enhanced activation of RPS6KB1/EIF4EBP1	
MTOR		26391637	change of cellular energetics	promotes	activates glycolysis, upregulates protein, lipid and nucleotide biosynthesis, inhibits autophagy, stimulates HIF1A	
MTOR		26391637	role in cancer	oncogene	oncogene	
MTOR	lung cancer	21383697	types of alteration in cancer		loss of miRNA control of MTOR leads to increased tumour growth	
MTOR		27727438	types of alteration in cancer		recurrent activating missense mutations S2215Y/F, L2427Q/R, L2431P, E1799K	
MTOR		25460505	cell division control		inactivation of mTOR results in lack of DNA damage-induced Chk1 activation and prevents etoposide-induced S and G2/M cell cycle arrest	
MTOR	prostate cancer	25043657	invasion and metastasis	promotes	promotes EMT	
MYC	breast cancer	22581054	invasion and metastasis	suppresses	acts as a suppressor of cell motility, invasiveness and metastasis by direct transcriptional silencing of alpha v and beta 3 integrin subunits	
MYC		28233639	escaping immune response to cancer	promotes	suppresses immune surveillance	
MYC		20043278	proliferative signalling	promotes	stimulates epidermal stem cell proliferation	
MYC		16760657	cell division control		promotes transit from G1 to S and G2 to S phase in cell cycle	
MYC		16094360	impact of mutation on function		P57S and T58A mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim, and effectively inhibit Bcl2	
MYC		11416148	escaping programmed cell death	suppresses	potentiates apoptosis by stimulating Bax activity at the mitochondria	
MYC		1555236	escaping programmed cell death	suppresses	cells with higher levels of c-myc protein are more prone to cell death upon serum deprivation	
MYC	immature T cells	1378649	escaping programmed cell death	suppresses	c-myc expression is a necessary component of activation-induced apoptosis	
MYC		11438650	escaping programmed cell death	suppresses	necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle	
MYC		15983382	genome instability and mutations	promotes	induces chromosomal rearrangements through telomere and chromosome remodelling in the interphase nucleus	
MYC		10022123	genome instability and mutations	promotes	combination of p53 inactivation and c-myc overexpression in diploid cells markedly accelerates the spontaneous development of tetraploidy	
MYC		10409725	genome instability and mutations	promotes	overexpression uncouples DNA replication from mitosis inducing polyploidy in immortalised fibroblasts	
MYC		12368264	angiogenesis	promotes	essential for vasculogenesis and angiogenesis during development and tumour progression	
MYC		15545632	cell replicative immortality	suppresses	controls the balance between hematopoietic stem cell self-renewal and differentiation	
MYC		9353256	differentiation and development		promotes differentiation of human epidermal stem cells	
MYC		9190899	proliferative signalling	promotes	stimulates cell proliferation by repressing the growth arrest gene GADD45A	
MYC		16724113	global regulation of gene expression		Myc widely influences chromatin, in part, through upregulation of the histone acetyltransferase GCN5	
MYC		17597761	cell division control		interacts with the pre-replicative complex, localises to early sites of DNA synthesis and plays a role in the initiation of DNA replication	
MYC		27727438	types of alteration in cancer		recurrent P59L	
MYC		19029958	function summary		transcription factor, human homologue of a retroviral oncogene	
MYC		19029958	types of alteration in cancer		frequently amplified or overexpressed in cancers	
MYC		19029958	role in cancer	oncogene, fusion	oncogene, fusion	
MYC	lymphomas	24994904	change of cellular energetics	promotes	overexpression alters cellular lipid profile	
MYC		19029958	fusion partner		IGH	
MYC		28443280	change of cellular energetics	promotes	regulates glycolysis, glutaminolysis, lipid metabolism and glutathione biosynthesis	
MYC	colon cancer	19183865	proliferative signalling	promotes	KD of c-myc expression inhibits cell proliferation	
MYD88		27048211	mouse model		B-cell-specific expression ofMyd88 L252P(equivalent to human MYD88 L265P) leads to the development of DLBCL in mice	
MYD88	hepatocellular carcinoma	23549880	clinical impact		high MYD88 expression is associated with late tumour stage, high recurrence rate and low recurrence-free survival and overall survival	
MYD88	ABC-DLBCL	26792260	clinical impact	promotes	L265P is associated with extranodal tumour desemination	
MYD88	ABC-DLBCL	21179087	role in cancer	oncogene	oncogene	
MYD88		24166959	interaction with pathogen		in a mouse model of Helicobacter pylori-induced gastric cancer, MyD88 deficient mice experience accelerated progression to severe gastric dysplasia	
MYD88	ovarian cancer	22533866	clinical impact		expression of MYD88 is associated with poor disease-free survial and overall survival	
MYD88	hepatocellular carcinoma	23549880	invasion and metastasis	promotes	ectopic Myd88 expression increases, while KD reduces invasive and metastatic capacity	HCC-LM3
MYD88	hepatocellular carcinoma	23549880	proliferative signalling	promotes	ectopic expression promotes cell proliferation in normal and tumour cells	HCC-LM3
MYD88	ABC-DLBCL	26792260	clinical impact		L265P is associated with poor outcome	
MYD88	DLBCL	21179087	proliferative signalling	promotes	ectopic expression of L265P, M232T, S243N, T294P mutants induces constituitive NF-kB signalling	BJAB
MYD88	colorectal cancer	20145615	clinical impact		high expression is correlated with poor prognosis	
MYD88	ABC-DLBCL	21179087	impact of mutation on function		L265P in MYD88 Toll/interluekin-1 receptor (TIR) homology domain leads to receptor activation-independent Myddosome formation and constituitive activation of NFKB and JAK-STAT3 signalling	
MYD88	ABC-DLBCL	21179087	types of alteration in cancer		recurrent L265P	
MYD88	hepatocellular carcinoma mouse xenografts	23549880	escaping programmed cell death	promotes	Myd88-deficiency results in increased apoptosis	
MYD88	mice	18178624	tumour promoting inflammation	promotes	Myd88 deficient mice are more resistant to skin papilloma formation in a model of inflammation induced cancer	
MYD88	CLL	21642962	types of alteration in cancer		recurrent L265P	
MYD88	mouse activated B-cells	24534189	proliferative signalling	promotes	ectopic MYD88-L265P expression promotes transient spontaneous proliferation, rapidly limited by induction of a TNFAIP3 negative feedback loop	
MYD88	Waldenstroems macroglobulinemia	22931316	types of alteration in cancer		recurrent L265P	
MYD88		25580251	function summary		cytosolic adapter protein for signalling through Toll like and interleukin 1 receptors	
NAB2	solitary fibrous tumours 	23761323	fusion partner		STAT6	
NAB2		12427750	function summary		a corepressor of EGR-1	
NAB2		11567222	role in cancer	TSG	TSG	
NAB2		11567222	types of alteration in cancer		NAB2 protein expression is lost in a majority of primary prostate carcinoma specimens 	
NAB2		23761323	role in cancer	fusion	fusion	
NAB2		12427750	angiogenesis	suppresses	 inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells 	
NCOR2		14977406	function summary		corepressor of genes induced by retinoic acid and thyroid hormones	
NCOR2		22695118	function summary		corepressor of AR	
NCOR2		24971610	function summary		coactivator and corepressor for estrogen receptor-alpha	
NCOR2		21075309	genome instability and mutations	suppresses	silencing increases H4K5ac (epi-bookmarking) and causes DNA damage due to decrease of HDAC3 activity	
NCOR2		15930272	escaping programmed cell death	suppresses	reexpression in immortalised fibroblasts with silenced NCOR2 induced apoptosis	
NCOR2		23690919	escaping programmed cell death	promotes	delays DNA damage-induced caspase activation by repressing proapoptotic genes and modulating the dynamics of checkpoint kinase 2 activation	
NCOR2	prostate cancer	22695118	impact of mutation on function		loss of NCOR2 promotes AR-mediated transcription	
NCOR2		15930272	suppression of growth	promotes	immortalised fibroblasts, after silencing, presented loss of contact inhibition, foci formation, and a 5- fold increase in colony formation	
NCOR2	B-cell NHL	15930272	role in cancer	TSG	TSG	
NCOR2	prostate cancer	22695118	role in cancer	TSG	TSG	
NCOR2	B-cell NHL 	15930272	types of alteration in cancer		expression is altered as a consequence of genomic deletion	
NCOR2		12840002	global regulation of gene expression		recruits HDAC3 to chromatin and promotes histone deacetylation	
NCOR2	ER+ breast cancer	24971610	cell division control		reduction of NCOR2 levels results in loss of estradiol-induced progression through the G1/S transition	
NCOR2	ER+ breast cancer	24971610	escaping programmed cell death	promotes	depletion is associated with increased apoptosis	
NDRG1	prostate cancer	19649210	fusion partner		ERG	
NDRG1		27338835	invasion and metastasis	suppresses	KD promotes epithelial-mesenchymal transition of colorectal cancer via NF-kB signaling 	
NDRG1		26359353	proliferative signalling	promotes	promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3 beta and Nur77 to prevent beta-catenin degradation 	
NDRG1	prostate cancer	26202882	invasion and metastasis	suppresses	downregulation of NDRG1 caused by the methylation of CpG islands of NDRG1 promoter promotes invasion	
NDRG1		25218595	function summary		modulator to regulate tumor cell differentiation, proliferation, invasion, and metastasis	
NDRG1	prostate cancer	28371345	invasion and metastasis	suppresses	NDRG1-deficient cells exhibit a collective invasion phenotype and are highly invasive 	
NDRG1		19649210	role in cancer	fusion	fusion	
NDRG1		22678098	role in cancer	TSG	TSG	
NDRG1	colorectal cancer	26418878	cell replicative immortality	suppresses	inhibits stemness of cancer cells via down-regulation of nuclear beta-catenin and CD44	
NDRG1	prostate cancer	26202882	suppression of growth	promotes	downregulation of NDRG1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation	
NF1		25877329	role in cancer	TSG	TSG	
NF1	mouse model of melanoma	23171796	suppression of growth	promotes	Nf1 LOF mutations promote melanocyte hyperproliferation	
NF1		17096025	escaping programmed cell death	suppresses	increases cell's sensitivity to apoptosis	
NF1	pheochromocytoma	18218617	differentiation and development		regulates the neuronal differentiation	PC-12
NF1	neuroblastoma	20655465	differentiation and development		loss of NF1 inhibits transcriptional response to retinoic acid which inhibits cell differentiation	SH-SY5Y
NF1	mouse	21478499	differentiation and development		required for skeletal muscle development	
NF1		22945628	escaping programmed cell death	suppresses	loss of NF1 activates HSF1 to promote heat shock response and cell survival	
NF1	endothelial cells	23145129	angiogenesis	suppresses	KD promotes autonomous proliferation and altered vascular morphogenesis	
NF1	keratinocytes 	23528211	angiogenesis	suppresses	KD results in elevated expression of VEGF, HIF-1alpha and phosphorylated mTOR at the protein level	HaCaT
NF1	paediatric spindle cell tumour	28498454	fusion partner		SETD2	
NF1		20033038	role in cancer	fusion	fusion	
NF1	gastric cancer	27827403	suppression of growth	promotes	KD increases cell proliferation	MGC803
NF1	gastric cancer	27827403	invasion and metastasis	suppresses	KD increases cell migration and invasion	MGC803
NF1	neural stem cells	26272820	suppression of growth	promotes	negatively controls proliferation through PI3K/AKT pathway	
NF1		27622733	function summary		Ras-GTPase-activating protein, a negative regulator of the Ras pathway, regulates melanin synthesis and keratinocyte differentiation	
NF1	mouse models	23171796	senescence		LOF mutations suppress Braf-induced senescence	
NF1	breast cancer	20033038	fusion partner		ACCN1	
NF2	pancreatic cancer	26483206	invasion and metastasis	suppresses	inhibits metastasis by suppressing Wnt/beta-catenin signalling	
NF2	pancreatic cancer	26483206	suppression of growth	promotes	inhibits cell proliferation by suppressing Wnt/beta-catenin signalling	
NF2	lung adenocarcinoma	26549232	invasion and metastasis	suppresses	downregulation by miR-146a results in enhanced cell migration and tissue invasion	A549
NF2	lung adenocarcinoma	26549232	suppression of growth	promotes	downregulation by miR-146a enhances cell proliferation	A549
NF2	hepatocellular carcinoma	26443326	invasion and metastasis	promotes or suppresses	splicing variant of Nf-2 that lacks exons 2, 3 and 4 interferes with the capacity of wild-type Nf-2 to bind beta-catenin and ERM, is expressed in the cytoplasm rather than at the cell surface, and promotes tumour metastasis	
NF2	glioblastoma	26923924	invasion and metastasis	suppresses	KD increases the invasiveness	T98G
NF2		28729415	change of cellular energetics	promotes	Nf2-deficient cells display elevated expression levels of key enzymes involved in lipogenesis	
NF2		27285107	function summary		inhibits Wnt/beta-catenin signalling	
NF2		20154721	mouse model		NF2 knockout mouse embryonic fibroblasts lose contact inhibition of cell proliferation 	
NF2		17548515	function summary		coordinates the processes of adherens junction stabilisation and negative regulation of epidermal growth factor receptor (EGFR) signalling by restraining the EGFR into a membrane compartment upon cell-cell contact 	
NF2		24726726	function summary		A FERM (4.1 protein/Ezrin/Radixin/Moesin) domain protein 	
NF2		17548515	role in cancer	TSG	TSG	
NFE2L2		11309284	function summary		Cap'n'Collar basic leucine zipper transcription factor, coordinates upregulation of oxidative stress response genes	
NFE2L2		21734707	escaping programmed cell death	promotes	allows tumour cell to survive the high levels of ROS that K-Ras, B-Raf, and Myc oncogenes produce	
NFE2L2		27727438	types of alteration in cancer		recurrent and clustered somatic mutations in a region responsible for interactions with KEAP1	
NFE2L2		27568559	role in cancer	oncogene	oncogene	
NFE2L2		27568559	impact of mutation on function		recurrent loss of exon 2 leads to impaired interaction with KEAP1, a negative regulator of NFE2L2, leading to hyperactivation of Nrf2 pathway	
NFE2L2		22789539	change of cellular energetics	promotes	redirects glucose and glutamine into anabolic pathways, augments purine nucleotide synthesis	
NONO	renal cell carcinoma	9393982	fusion partner		TFE3	
NONO		26148231	change of cellular energetics	promotes	regulates lipid metabolism and breast cancer growth through SREBP-1A 	
NONO		25893301	cell division control		necessary for the induction of the intra-S-phase checkpoint in response to UV radiation 	
NONO		9171077	function summary		DNA-binding protein that enhances the association of other DNA-binding proteins to their targets	
NONO	melanoma	21642354	invasion and metastasis	promotes	KD leads to reduced migratory potential of the cells	
NONO		9393982	role in cancer	fusion	fusion	
NONO	melanoma	21642354	proliferative signalling	promotes	KD leads to reduced proliferation rates	
NOTCH1	glioma	22249262	escaping programmed cell death	promotes	KD increases apoptosis and decreases expression of anti-apoptotic MCL1 and BCL-XL	U251MG
NOTCH1		11895769	cell replicative immortality	promotes	promotes haematopoietic stem cell renewal	
NOTCH1	T-ALL	26390244	change of cellular energetics	promotes	inhibition of Notch1 in a mouse model of Notch1-induced T-ALL decreases glycolysis and glutaminolysis	
NOTCH1	CRC	26152787	clinical impact		increased copy number is associated with worse survival	
NOTCH1	T-ALL	17114293	proliferative signalling	promotes	directly regulates expression of c-MYC, promoting leukaemic cell growth	
NOTCH1		27525720	senescence		NOTCH1 contributes to  induction of senescence that expands to other surrounding cells through a juxtacrine NOTCH-JAG1 pathway	
NOTCH1	T-lymphocyte	14583609	escaping programmed cell death	promotes	ectopic expression of activated NOTCH1 decreases apoptosis, increases anti-apoptotic protein expression and protects against treatment with apoptotic stimuli	2B4 and Jurkat
NOTCH1	mouse bone marrow progenitors	18677410	impact of mutation on function		expression of L1601P mutant drives ectopic CD4+/CD8+ T-cell development and inhibits myeloid and B-cell development but does not induce T-ALL, L1601P coupled with PEST domain deletion enhances ectopic CD4+/CD8+ T-cell development and increases leukemogenesis	
NOTCH1	SCLC	26168399	role in cancer	TSG	TSG	
NOTCH1		11895769	differentiation and development		NOTCH1 inhibits differentiation in RAG1-null mice	
NOTCH1	T-ALL	15472075	types of alteration in cancer		frequent missense mutations and small in-frame insertions and deletions affecting HD domain and frequent truncating mutations affecting PEST domain	
NOTCH1		10367900	differentiation and development		promotes T-cell fate specification in early haematopoietic progenitors	
NOTCH1		27959635	function summary		transmembrane receptor, functions as a ligand-activated transcription factor	
NOTCH1	T-ALL	18411416	types of alteration in cancer		tandem duplications causing in-frame insertions in the extracellular juxtamembrane domain	
NOTCH1	T-ALL	15472075	impact of mutation on function		missense HD domain mutations or PEST domain truncation increase NOTCH activity	U2OS
NOTCH1	CRC	20665495	proliferative signalling	promotes	KD reduces proliferation in vitro and tumorigenic growth in mouse xenografts	SW480, HT_29
NOTCH1	T-ALL	15472075	role in cancer	oncogene	oncogene	
NOTCH1	T-ALL	22237151	global regulation of gene expression		activation of NOTCH1 induces loss of the repressive histone mark H3K27me3 by antagonising the activity of PRC2	
NOTCH1	neuroblastoma	18559519	angiogenesis	promotes	inhibition of Notch1 signalling disrupts angiogenesis in mouse xenografts	NGP
NOTCH1	T-ALL	1831692	fusion partner		TRB	
NOTCH1	CLL	20813007	clinical impact		NOTCH1 mutations are associated with worse prognosis	
NOTCH1		17681135	differentiation and development		crucial for the differentiation of corneal epithelial cells during wound repair	
NOTCH1		27727438	types of alteration in cancer		recurrent P2514fs*4, L1600P, L1678P, L1574P, R1598P, T311P, L1585P, T194P	
NOTCH1	CRC	26152787	types of alteration in cancer		a subset of patients characterised by NOTCH1 copy number gain	
NOTCH1	oesophageal keratinocytes	24931169	senescence		ectopic expression of activated NOTCH1 induces senescence in immortalised cells	
NOTCH2	bladder cancer	26769750	proliferative signalling	promotes	ectopic expression of intracellular domain induces increased proliferation	RT4V6 and  RT112
NOTCH2	non small cell lung carcinoma	24509876	suppression of growth	promotes	KD increases colony formation in H358 cells, KO increases proliferation in mouse model of Kras-G12D driven tumouriogenesis	
NOTCH2		16574107	function summary		single-pass transmembrane receptor, part of conserved signalling cascade initiated by cell-cell contact where ligand-receptor interaction results in cleavage of NOTCH intracellular domain which translocates to the nucleus where it acts as a transcriptional co-activator, serves as a gate-keeper in cell fate decisions	
NOTCH2	lung adenocarcinoma	22190591	invasion and metastasis	promotes	ectopic expression of NOTCH2 intracellular domain promotes EMT and NOTCH2 expression is increased in invasive cells	NCI-H441
NOTCH2	 laryngeal SCC	27572051	invasion and metastasis	promotes	KD reduces invasive capacity of cells	HEp2
NOTCH2	non small cell lung carcinoma	24509876	mouse model		tumours from Kras-G12D/Notch2 KO mice are poorly differentiated	
NOTCH2	chronic lymphocytic leukaemia	18796623	escaping programmed cell death	promotes	KD of NOTCH2 increases spontaneous apoptosis	
NOTCH2		27727438	types of alteration in cancer		recurrent A21T, C19W, N46S, R2400X	
NOTCH2	splenic marginal zone lymphoma	22891273	types of alteration in cancer		truncating mutations cluster in exon 34 hotspot, affecting TAD/PEST domains	
NOTCH2	bladder cancer	26769750	clinical impact		high mRNA expression associated with poor prognosis	
NOTCH2	splenic marginal zone lymphoma	25779943	clinical impact		NOTCH2 mutations are associated with worse outcome	
NOTCH2	bladder cancer	26769750	invasion and metastasis	promotes	ectopic expression of intracellular domain promotes invasion and EMT, KD decreases colony formation and invasion	RT4V6, RT112, UM-UC3, and UM-UC13
NOTCH2	bladder cancer	25574842	impact of mutation on function		Y407C substitution reduces Notch activity in vitro and alters disulphide bridges close to ligand interaction domain	T24
NOTCH2	medulloblastoma	15520184	proliferative signalling	promotes	ectopic expression of activated intracellular domain increases, while KD decreases proliferation	DAOY
NOTCH2	mice	22018469	differentiation and development		required for the differentation of pre-dendritic cells into distinct functional subsets of dendritic cells in the spleen and intestine	
NOTCH2	mice	21285514	differentiation and development		notch2 inhibits myeloid differentiation and enhances repopulating progenitor cell generation in the bone marrow following injury	
NOTCH2	DLBCL	19445024	role in cancer	oncogene	oncogene	
NOTCH2	aggressive cutaneous squamous cell carcinoma	25303977	clinical impact		patients with NOTCH2 mutations have a more aggressive phenotype	
NOTCH2	colorectal cancer	21378202	clinical impact		higher expression is associated with improved overall survival	
NOTCH2	mice	12753744	differentiation and development		required for the differentiation of transitional B-cells into marginal zone B-cells	
NOTCH2	mice	29386140	differentiation and development		maintains the quiescent state of CNS neural stem cells	
NOTCH2	DLBCL	29641966	clinical impact		co-occurrence of NOTCH2 mutation with BCL6 fusion defines one of four genetic subtypes	
NOTCH2	mantle cell lymphoma	24145436	clinical impact		NOTCH2 truncating mutations are associated with poor overall survival	
NOTCH2	bladder cancer	26769750	role in cancer	oncogene	oncogene	
NOTCH2	bladder cancer	26769750	types of alteration in cancer		frequently amplified	
NOTCH2	glioma	26669487	mouse model		expression of the Notch2 intracellular domain delays tumour formation	
NOTCH2	pancreatic ductal adenocarcinoma	20624967	mouse model		KO increases survival time and results in a phenotypic switch towards anaplastic pancreatic cancer in a mouse model of Kras-G12D driven carcinogenesis	
NOTCH2	uveal melanoma	22228632	invasion and metastasis	promotes	KD reduces, while ectopic expression of constitutively active intracellular domain increases invasion	OCM1 and Mel290
NOTCH2	DLBCL	19445024	impact of mutation on function		mutations affecting the PEST domain increase NOTCH2 activity in vitro	
NOTCH2	small cell lung carcinoma	26168399	mouse model		activation of Notch2 reduces tumour formation and increases survival	
NOTCH2	uveal melanoma	22228632	proliferative signalling	promotes	KD reduces, while ectopic expression of constitutively active intracellular domain increases cell growth	
NOTCH2	 laryngeal SCC	27572051	proliferative signalling	promotes	KD decreases cell proliferation	HEp2
NOTCH2	squamous cell carcinoma	28154375	role in cancer	TSG	TSG	
NOTCH2	 laryngeal SCC	27572051	escaping programmed cell death	promotes	KD induces apoptosis	HEp2
NPM1		27553022	function summary		a histone chaperone with functions in DNA repair pathways, regulation of apoptosis and ribosome biogenesis	
NPM1	AML	16455950	impact of mutation on function		most common forms of NPM1 mutation in exon 12 result in frameshift, loss of a nucleolar localization signal  and gain of a novel nuclear export signal (NES), leading to aberrant cytoplasmic accumulation of the NPM1 mutant protein	
NPM1	cervical cancer	18332108	function summary		associates directly with rRNA gene chromatin as a histone chaperone and positively regulates transcription of rRNA	HeLa
NPM1	AML	28111462	function summary		one of the most commonly mutated genes in AML, more often associated with a normal karyotype	
NPM1		24576674	function summary		specifically recognizes and binds to DNA G-quadruplexes through its C-terminal region	
NPM1	bone osteosarcoma, cervical cancer, breast cancer	20713529	genome instability and mutations	suppresses	recruited to DNA DSB after phosphorylation at Thr199 and required for resolution of RAD51 mediated repair of DSB	HeLa, U2OS, MCF7
NPM1	salivary gland adenoid cystic carcinoma	27501253	escaping programmed cell death	promotes	KD induces apoptosis	SACC
NPM1	cervical cancer and AML	20606168	escaping programmed cell death	promotes	c-terminal W288fs mutations result in cytoplasmic accumulation of NPM1 that binds caspases 6 and 8 and inhibits caspase induced apoptosis	HeLa, HL-60
NPM1	breast, cervical, and gastric cancer	19734942	escaping programmed cell death	promotes	after oligomerisation, negatively regulates TP53 levels through direct interaction with p14ARF and suppresses apoptosis 	MCF7, HeLa, SGC7901
NPM1		17951246	escaping programmed cell death	promotes	suppresses apoptosis through interaction with isoform p48 of PA2G4	
NPM1	salivary gland adenoid cystic carcinoma	27501253	proliferative signalling	promotes	KD inhibits proliferation	ACCM
NPM1	mouse fibroblast	19033198	proliferative signalling	promotes	regulates transcriptional activity of Myc overexpression of NPM1 enhances MYC induced proliferation	MEFs
NPM1		17951246	proliferative signalling	promotes	interacts with PA2G4 (EBP1) isoforms and promotes cell proliferation through PA2G4 isoform p42	PC12, HEK293, HeLa
NPM1	AML	26884713	invasion and metastasis	promotes	W288fs mutant promotes adhesion, migration and invasion through MMP upregulation via increased Ras/ERK MAPK signaling	THP-1
NPM1	acute myeloid leukaemia	28740552	change of cellular energetics	promotes	W288fs mutant enhances autophagy and increases cell survival through delocalization of NPM1/PML complex to the cytoplasm 	OCI-AML3
NPM1	bone osteosarcoma	12080348	suppression of growth	promotes	promotes growth arrest on overexpression by direct interaction and stabilising of TP53	 U2OS
NPM1	osteogenic sarcoma	15144954	suppression of growth	promotes	promotes growth arrest by interaction with MDM2, thus stabilising TP53	SaOS-2
NPM1	colorectal cancer	23536448	senescence	suppresses	KD promotes senescence	MIP101, RKO, HCT116
NPM1	mouse fibroblasts	19033198	role in cancer	oncogene	oncogene	MEFs
NPM1	lymphoid malignancies	18212245	role in cancer	TSG	TSG	
NPM1		21278791	role in cancer	oncogene, TSG, fusion	oncogene, TSG, fusion	
NPM1	ALCL	8122112	role in cancer		fusion	
NPM1	AML	28370403	clinical impact		NPM1 mutations in de novo AML lacking recurrent cytogenetic abnormalities define a prognostic subgroup in revised 2016 WHO classification	
NPM1	hepatocellular carcinoma	28259962	clinical impact		KD in cell lines with established multi drug resistance results in decreased expression of MDR1 and reversal of MDR	HepG2, SMMC7721
NPM1	solid tumours	30126359	clinical impact		higher protein level expression is associated with poor overall survival	
NPM1	breast cancer	21689627	clinical impact		decreased level of expression associated with poor prognosis	
NPM1	salivary gland adenoid cystic carcinoma	27501253	types of alteration in cancer		frequently overexpressed and higher levels associated with perineural invasion and lymph node metastasis	ACCM
NPM1	colorectal cancer	23536448	types of alteration in cancer		frequently overexpressed	
NPM1	AML	28111462	types of alteration in cancer		patients with frameshift mutation in NPM1 have increased co-occurrence of internal tandem duplication of FLT3	
NPM1	acute myeloid leukaemia	27669739	differentiation and development	suppresses	W288fs mutant inhibits myeloid differentiation by upregulating miR-10b, which then targets  the 3'UTR of KLF4 and decreases KLF4 levels	OCI-AML3
NPM1	mouse fibroblast	11051553	cell division control		binds to unduplicated centrosomes, dissociates from centrosomes when phosphorylated by CDK2/CCNE1, thus initiating centrosome duplication 	swiss 3T3
NPM1	colorectal cancer	23536448	cell division control	promotes	KD results in block of cell cycle progression mediated by TP53	MIP101, RKO, HCT116
NPM1	ALCL	8122112	fusion partner		ALK	
NPM1	APL	8562957	fusion partner		RARA	
NPM1	MDS and AML	8570204	fusion partner		MLF1	
NPM1		23271972	interaction with pathogen		escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells	
NPM1	APL	24183235	impact of mutation on function		NPM1-RARA fusion protein produced from t(5;17) translocation inhibits myeloid differentiation, dependent on interaction with RXR 	U937
NPM1	mouse fibroblast	19033198	function summary	promotes	binds to and regulates transcriptional activity of Myc, overexpression of NPM1 enhances MYC induced oncogene-mediated transformation	
NRAS		20392691	escaping programmed cell death	promotes	expression of the apoptosis repressor ARC is upregulated by N-Ras in a MEK/ERK-dependent manner, Ras also stabilises the ARC protein by suppressing its polyubiquitination and subsequent proteasomal degradation	
NRAS		26985062	role in cancer	oncogene	oncogene	
NRAS		17384584	function summary	1	a small GTPase that cycles between inactive GDP-bound and active GTP-bound conformations, regulates cellular responses to many extracellular stimuli, including soluble growth factors; NRAS is farnesylated at a terminal CAAX motif and additionally modified by palmitic acid residues just upstream of the CAAX motif to anchor the protein in the membrane	
NRAS		2547513	impact of mutation on function		activating mutations at G12, G13 or Q61 cause Ras to accumulate in the active GTP bound state by impairing intrinsic GTPase activity and conferring resistance to GTPase activating proteins	
NRAS		27727438	types of alteration in cancer		recurrent missense mutations at Q61, G12 and G13	
NRAS	melanoma	15688405	escaping programmed cell death	promotes	KD of oncogenic NRAS induces apoptosis	224 and BL
NRAS	follicular thyroid carcinoma	24820091	invasion and metastasis	promotes	NRAS Q61R mutation is associated with distant metastasis	
NRAS	murine model of AML	25316678	cell replicative immortality	promotes	G12V mutant facilitates self-renewal	
NRAS		24586049	function summary		has 5 naturally occurring isoforms with distinct binding affinities to known downstream targets and abilities to regulate the RAS signalling pathway	
NRAS	melanoma	18814281	proliferative signalling	promotes	downregulation of cyclin E2 and cyclin D1 and also upregulation of the negative cell-cycle regulator HBP1 in NRAS(Q61R) knockdown cells contribute to the inhibition of cell proliferation	224 and BL
NRAS	melanoma	18814281	invasion and metastasis	promotes	suppression of oncogenic NRAS results in reduced migration and invasion, which is accompanied by downregulation of EPHA2 (a receptor tyrosine kinase), PLAUR (urokinase receptor) and cytoskeleton proteins such as leupaxin, paxillin and vinculin	224 and BL
NRAS		25252692	impact of mutation on function		Q61R shows enhanced nucleotide binding, decreased intrinsic GTPase activity, and increased stability when compared with Nras G12D and Nras Q61R but not G12D is able to efficiently promote melanoma in vivo	
NT5C2		15963349	function summary		cytosolic nucleotidase that promotes clearance of excess purine nucleotides from cells	
NT5C2	glioblastoma	26079827	proliferative signalling	promotes	overexpression increases proliferation	ADF
NT5C2	ALL	29990496	role in cancer	Oncogene	Oncogene	
NT5C2	T-ALL	23377281	clinical impact		K359Q, R367Q and D407A increase resistance to 6-mercaptopurine and 6-thyogunanine therapy	CCRF-CEM
NT5C2		29342136	mouse model		R367Q promotes resistance to 6-MP treatment	
NT5C2	astrocytoma	18445485	escaping programmed cell death	promotes	decrease of enzyme activity causes apoptosis of the cultured cells without altering intracellular nucleotide and nucleoside concentration or energy charge	ADF
NT5C2	ALL	23377281	types of alteration in cancer		frequently mutated at relapse	
NT5C2	ALL	23377281	impact of mutation on function		K359Q, R367Q and D407A increase 5-IMP nucleotidase activity and resistance to 6-mercaptopurine and 6-thyogunanine therapy	
NT5C2	ALL	29990496	impact of mutation on function		K359Q, L375F lead to conformational change that causes constituitive enzyme activity, R39Q, R238W, R367Q, D407A, S408R, S445F and R478S disrupt a built-in switch-off mechanism, Q523X decreases the threshold for allosteric activation	
NT5C2	childhood ALL	23377183	clinical impact		R238W and R367Q result in increased enzymatic activity and resistance to treatment with nucleoside analog therapies as well as are associated with earlier relapse	
NT5C2	ALL	27727438	types of alteration in cancer		recurrent R367Q, R238W	
PAFAH1B2		25945974	change of cellular energetics	promotes	pharmacological blockade of PAFAH1B2 causes unique changes in lipid metabolism, including heightened levels of tumour-suppressing lipids 	
PAFAH1B2	MYC-negative Burkitt lymphoma	25795716	types of alteration in cancer		upregulated	
PAFAH1B2		8083218	function summary		 hydrolyzes the platelet-activating factor (PAF) in vitro 	
PAFAH1B2	neuroblastoma	21860421	fusion partner		FOXR1	
PAFAH1B2		21860421	role in cancer	fusion	fusion	
PAX3	melanoma	24903325	invasion and metastasis	promotes	the absence of phosphorylation at Ser205 promotes the invasive capacity of both primary and metastatic cells	
PAX3	brainstem progenitors	25330836	escaping programmed cell death	promotes	inhibits apoptosis	
PAX3	brainstem progenitors	25330836	proliferative signalling	promotes	in the absence of p53, Pax3 promotes proliferation	
PAX3	sinonasal sarcoma	24859338	fusion partner		MAML3	
PAX3		24859338	impact of mutation on function		the fusion with MAML3 results in a phenotype characterized by aberrant expression of genes involved in neuroectodermal and myogenic differentiation, closely simulating the developmental roles of PAX3 	
PAX3		24188742	invasion and metastasis	promotes	KD decreases the attachment of neuroblastoma SH-EP1 cells to ECM proteins and inhibits cell migration and invasion 	
PAX3		18303411	role in cancer	fusion	fusion	
PAX3		25330836	role in cancer	oncogene	oncogene	
PAX3		16951170	function summary		transcription factor involved in regulation of migration of cells from the dorsal dermomyotome or neural crest during myogenesis, melanogenesis, and neurogenesis	
PAX3	melanoma	24903325	proliferative signalling	promotes	phosphorylation at Ser201 enhances the proliferative capacity of the metastatic cell line 	
PAX3	melanoma	24903325	suppression of growth	promotes	Pax3 phosphorylated at Ser209 inhibits the proliferative capacity of both primary and metastatic tumour cells	
PAX3		15956257	escaping programmed cell death	promotes	KD induces apoptosis 	
PAX3	rhabdomyosarcoma	19953635	fusion partner		NCOA2	
PAX3	alveolar rhabdomyosarcoma	18303411	fusion partner		FOXO1	
PAX3	alveolar rhabdomyosarcoma	19953635	fusion partner		NCOA1	
PAX5	ALL	17179230	fusion partner		ELN	
PAX5	multiple myeloma	20882442	escaping programmed cell death	suppresses	overexpression of PAX5 induces apoptosis	
PAX5		21319196	role in cancer	TSG	TSG	
PAX5		17179230	role in cancer	fusion	fusion	
PAX5	hepatocellular carcinoma	21319196	escaping programmed cell death	suppresses	restoring PAX5 expression in silenced cell lines suppressed cell proliferation, induced apoptosis in vitro, and inhibited tumour growth in nude mice	
PAX5	hepatocellular carcinoma	21319196	types of alteration in cancer		frequently methylated	
PAX5	ALL	17897302	fusion partner		PML	
PAX5		22127921	function summary		transcription factor,  a master regulator of B cell development	
PAX5		17851532	role in cancer	TSG	haploinsufficient TSG	
PAX5	B-cell malignancies	17851532	differentiation and development		conditional deletion of Pax5 in mice allowed mature B cells from peripheral lymphoid organs to dedifferentiate in vivo back to early uncommitted progenitors in the bone marrow	
PAX5	B-NHL	15942942	fusion partner		IGH	
PAX5	B-cell lymphoma 	17717600	invasion and metastasis	promotes	promotes lymphomagenesis through stimulation of B cell receptor signaling, KD negatively affected cell expansion	
PAX5	breast cancer	18497074	proliferative signalling	promotes	changes mediated by Pax5 are responsible for autocrine hGH-induced cell proliferation	MCF-7
PAX5	B-cell	18617575	escaping programmed cell death		suppression of B isoform of Pax5 leads to an increase of CD19 and Pax5A isoform expression, and increases apoptotic activity	REH
PAX5		17717600	role in cancer	oncogene	oncogene	
PAX7		16397527	function summary		transcription factor	
PAX7	sarcoma	26234681	invasion and metastasis	promotes	Pax7 can promote metastasis in vivo through MyoD-dependent regulation of pro-metastatic miR-182 	
PAX7		11030621	differentiation and development		required for the specification of myogenic satellite cells 	
PAX7		15277541	differentiation and development		during muscle regeneration quiescent satellite cells are synchronously activated to coexpress the transcription factors Pax7 and MyoD, most then proliferate, down-regulate Pax7, and differentiate, other proliferating cells maintain Pax7 but lose MyoD and withdraw from immediate differentiation 	
PAX7	embryonal rhabdomyosarcoma	24554430	proliferative signalling	promotes	enhances cell proliferation by reducing MyoD levels in a proteasome-dependent manner	
PAX7	alveolar rhabdomyosarcoma	7530783	fusion partner		FOXO1	
PAX7		7530783	role in cancer	fusion	fusion	
PAX8	thyroid papillary carcinoma 	16728576	fusion partner		PPARG	
PAX8		15077183	impact of mutation on function		fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARG inhibition 	
PAX8	ovarian cancer	24766781	proliferative signalling	promotes	KD reduces proliferation	
PAX8	ovarian cancer	24766781	invasion and metastasis	promotes	KD reduces migration and invasion ability, essential for anchorage-independent growth of SKOV-3 cells, expression induces EMT	
PAX8		16397527	function summary		transcription factor	
PAX8		16728576	role in cancer	fusion	fusion	
PAX8	glioblastoma	24602166	escaping programmed cell death	promotes	stimulates expression of antiapoptotic BCL2 and promotes survival 	
PBRM1		21654818	function summary		chromatin-targeting subunit of the polybromo BRG1-associated factor SWI/SNF chromatin remodeling complex (PBAF)	
PBRM1	mouse embryonic stem cells	24613357	genome instability and mutations	suppresses	KD promotes aberrant centromeric cohesion, chromosome instability and aneuploidy	
PBRM1	renal cancer	27100670	global regulation of gene expression		re-expression in cells with inactive PBRM1 triggers upregulation of genes involved in cellular adhesion, carbohydrate metabolism, apoptotic process and response to hypoxia, and downregulation of genes involved in different stages of cell division	
PBRM1		30585695	impact of mutation on function		tumor-derived point mutations in BD2 alone lower PBRM1's affinity to H3K14ac and disrupt promoter binding and gene expression	
PBRM1	renal cancer	29229903	escaping programmed cell death	suppresses	KD induces H3K9me3-marked chromatin reorganisation, which rescues loss-of-VHL-dependent replication stress and confers a survival and proliferative advantage	
PBRM1	colon cancer	28940253	tumour promoting inflammation	suppresses	KD increases the expression of two receptor genes (RIG-I and MDA5) and upregulates interferon (IFN)-related and inflammation-related gene signatures	HCT116
PBRM1	mice	18508041	differentiation and development		KO impairs the normal EMT of the epicardial cells for coronary development	
PBRM1	clear cell renal cell carcinoma	29986887	impact of mutation on function		binding pocket missense mutations in bromodomain BD4, observed in ccRCC, disrupt PBRM1-chromatin interactions and accelerate cell proliferation	
PBRM1		24613357	impact of mutation on function		T232P and M538I promote aberrant centromeric cohesion	
PBRM1	malignant mesothelioma	27834213	types of alteration in cancer		frequent biallelic inactivation	
PBRM1	intrahepatic cholangiocarcinomas	24185509	types of alteration in cancer		frequent truncating mutations	
PBRM1	clear cell renal cell carcinoma	21248752	invasion and metastasis	suppresses	KD increases cell migration	
PBRM1	clear cell renal cell carcinoma	27100670	change of cellular energetics	promotes	ectopic expression reduces cellular glucose uptake and alters the cellular cholesterol ester profile	Caki2
PBRM1	breast cancer	18339845	suppression of growth	promotes	ectopic expression upregulates p21 and inhibits proliferation	HCC1143
PBRM1	clear cell renal cell carcinoma	21248752	suppression of growth	promotes	KD increases proliferation	
PBRM1	malignant mesothelioma	27834213	suppression of growth	promotes	KD increases proliferation	PPM-Mill
PBRM1	bladder cancer	25978027	suppression of growth	promotes	overexpression suppresses proliferation	UMUC-3, EJ, 5637
PBRM1	mouse melanoma	29301958	escaping immune response to cancer	promotes	confers resistance to T-cell mediated killing as part of the PBAF complex	B16F10
PBRM1	human fibroblasts	20660729	senescence		KD delays senescence	BJ
PBRM1	clear cell renal cell carcinoma	21248752	role in cancer	TSG	TSG	
PBRM1	clear cell renal cell carcinoma	29426696	clinical impact		loss of expression is associated with worse prognosis	
PBRM1	clear cell renal cell carcinoma	29301960	clinical impact		loss-of-function mutations are associated with better response to anti-PD-1 immune checkpoint therapy	
PBRM1	clear cell renal cell carcinoma	28329682	mouse model		double Pbrm1 and Vhl deficient animals develop multifocal tumours with hyperactive mTORC signalling	
PBRM1	renal cancer	27727438	types of alteration in cancer		recurrent E846X	
PBRM1	clear cell renal cell carcinoma	21248752	types of alteration in cancer		frequent truncating mutations	
PBRM1	pancreatic cancer	22233809	types of alteration in cancer		frequently deleted or mutated	
PBX1	soft tissue myoepithelial tumours	20815032	fusion partner		EWSR1	
PBX1	ALL	23859904	fusion partner		TCF3	
PBX1	lung adenocarcinoma	23688269	fusion partner		TCF3	
PBX1		23859904	role in cancer	fusion	fusion	
PBX1		22125492	role in cancer	oncogene	oncogene	
PBX1		16328158	angiogenesis	promotes	required for Hox D3-mediated angiogenesis	
PBX1		19522013	differentiation and development		upregulates NANOG to maintain the pluripotent and undifferentiated state of hESCs	
PBX1		22125492	function summary		promotes chromatin openness at specific genomic locations through its capacity to read specific epigenetic signatures, accordingly, PBX1 guides ER_ recruitment to a specific subset of sites, breast cancer cells depleted of PBX1 do not proliferate following estrogen stimulation	
PBX1	breast cancer	28263391	change of cellular energetics	promotes	suppressing PBX1 resulted in decrease of expression of lipid metabolism genes	MDA-MB-453
PBX1	ovarian cancer	18974129	escaping programmed cell death	promotes	Notch3-regulated gene that mediates the survival signal of Notch3 in ovarian cancer	
PDCD1LG2		21752471	suppression of growth	promotes	down-modulates cytokine production and T-cell proliferation 	
PDCD1LG2		21752471	function summary		immune inhibitory molecule expressed on activated CD4 and CD8 T cell subsets	
PDCD1LG2		24497532	impact of mutation on function		fusion with active promoter or regulatory elements increases expression of PDCD1LG2 	
PDCD1LG2	primary mediastinal large B-cell lymphoma 	24497532	fusion partner		CIITA, IGH	
PDCD1LG2		24497532	role in cancer	oncogene, fusion	fusion, oncogene	
PDGFRA	papillary thyroid cancer	27682510	differentiation and development	suppresses	inhibits differentiation by disrupting nuclear localisation and expression of TTF1	
PDGFRA	myeloproliferative neoplasms	28028030	fusion partner		FLP1L1	
PDGFRA	myeloproliferative neoplasms	26319757	fusion partner		FOXP1	
PDGFRA	chronic eosinophilic leukaemia	24975316	fusion partner		ETV6	
PDGFRA	chronic eosinophilic leukaemia	17555450	fusion partner		STRN	
PDGFRA		12522257	impact of mutation on function		D842V, D842_H845del, S566_E571delinsR result in constitutive, ligand-independent activation	
PDGFRA		24703957	function summary		type III family transmembarne receptor tyrosine kinases (RTK), binds to all PDGF isoforms except PDGF-DD, signaling activates MAPK and RAS pathways	
PDGFRA	melanoma	19649203	angiogenesis	suppresses	overexpression inhibits angiogenesis in xenografts	
PDGFRA	endothelial cells	23671131	angiogenesis	promotes	promotes angiogenesis 	
PDGFRA	melanoma	19649203	escaping programmed cell death	suppresses	overexpression induces apoptosis	SK-MEL-110
PDGFRA	lung squamous cell carcinoma	28087642	proliferative signalling	promotes	KD suppresses tumour growth in vitro and in vivo	
PDGFRA	breast cancer, GIST, melanoma, glioma	30389923	invasion and metastasis	promotes	activating mutations including Y288C, P345S, V561D and D842V increase cell migration 	
PDGFRA	thyroid cancer	27845909	invasion and metastasis	promotes	receptor activation drives invadopodia formation, promotes cell migration, and upregulates EMT markers Snail and Snug	B-CPAP
PDGFRA	papillary thyroid cancer	22744707	invasion and metastasis	promotes	expression is assiociated with lympatic metastases in patients, signaling promotes migration and invasion 	TPC-1, 8305C
PDGFRA	prostate cancer	20442296	invasion and metastasis	promotes	overexpression promotes bone metastasis of xenografts	
PDGFRA	melanoma	27764787	suppression of growth	promotes	transient overexpression inhibits growth in vitro and in vivo	SK-MEL-28, A375, Preyer
PDGFRA		25427437	role in cancer	oncogene	oncogene	
PDGFRA		29486293	clinical impact		germline activating mutations give rise to gastrointestinal stromal tumours (GIST)	
PDGFRA	breast cancer	29380207	clinical impact		high expression linked to lymph node involvement and recurrence	
PDGFRA	adipocytes	29158445	differentiation and development	promotes	 PDGFRA signaling in progenitor cells promotes beige adipocyte commitment  	
PDGFRA		30371878	types of alteration in cancer		recurrent D842V, V561D, N659K, D842_H845del, I843_D846del	
PDGFRA	inflammatory fibroid polyps	22394371	types of alteration in cancer		activating mutations in exons 12,14 and 18 identified	
PDGFRA	haematological malignancies	28010895	types of alteration in cancer		in fusion with multiple partners	
PDGFRA	colorectal cancer	18288404	clinical impact		expression correlates with lymph node metastasis	
PDGFRA	breast cancer, GIST, melanoma, glioma	30389923	types of alteration in cancer		range of activating mutations, amplification, gene fusions identified	
PER1	gingival cancer 	21459569	escaping programmed cell death	promotes	KD of PER1 enhanced apoptosis	CA9-22
PER1	pancreatic and hepatic cancer	19675098	escaping programmed cell death	promotes	has antiapoptotic activity	
PER1	prostate cancer	19752089	escaping programmed cell death	suppresses	overexpression of Per1 resulted in significant growth inhibition and apoptosis	
PER1		19752089	function summary		inhibits transactivation of the androgen receptor (AR) both in 293T cells overexpressing the AR and in the prostate cancer cell line LNCaP 	
PER1	colon cancer	16678109	escaping programmed cell death	suppresses	overexpression of Per1 sensitized cells to DNA damage-induced apoptosis; in contrast, inhibition of Per1 blunted apoptosis 	HCT116
PER1	oral SCC	27143919	suppression of growth	promotes	after PER1 downregulation, the cell proliferation index was significantly higher	SCC15
PER1		12661008	role in cancer	fusion	fusion	
PER1	NSCLC	17332281	types of alteration in cancer		frequently hypermethylated and silenced via H3 acetylation	
PER1	NSCLC	17332281	suppression of growth	promotes	forced expression of Per1 leads to significant growth reduction and loss of clonogenic survival 	
PER1	AML	12661008	fusion partner		ETV6	
PER1		12661008	impact of mutation on function		fusion with ETV6 creates a fusion transcript with antisense strand of PER1, resulting in its inactivation	
PER1		27143919	role in cancer	TSG	TSG	
PER1	oral SCC	27143919	escaping programmed cell death	suppresses	after PER1 downregulation, the apoptotic index was significantly lower	SCC15
PHOX2B	neuroblastoma	26840262	invasion and metastasis	suppresses	suppresses metastasis in neuroblastoma 	
PHOX2B		20957039	function summary		upregulates ALK transcription by directly binding its promoter 	
PHOX2B		19573018	differentiation and development		controls the differentiation of noradrenergic neurons during embryogenesis 	
PHOX2B		12100889	function summary		neuronal-type-specific transcription factor	
PHOX2B		17637745	impact of mutation on function		overexpression of wild-type PHOX2B in neuroblastoma cell lines suppresses cell proliferation and synergizes with all-trans retinoic acid to promote differentiation, mutant protein retains the ability to suppress cellular proliferation, but is not able to promote differentiation or activate expression of a known PHOX2B target gene in vitro 	
PHOX2B		17637745	suppression of growth	promotes	overexpression suppresses cell proliferation	
PHOX2B	neuroblastoma	18292934	role in cancer	TSG	TSG	
PICALM		10436022	function summary		clathrin adaptor protein containing multiple domains functioning in clathrin-coated vesicle formation 	
PICALM		26075887	change of cellular energetics	promotes	loss of PICALM increases cellular cholesterol pool size 	
PICALM	NSCLC	27614248	fusion partner		ALK	
PICALM		25241929	change of cellular energetics	promotes	PICALM-dependent SNARE endocytosis is required for autophagy 	
PICALM		12461747	role in cancer	fusion	fusion	
PICALM	ALL and AML 	8643484	fusion partner		MLLT10	
PICALM		25552701	differentiation and development		Picalm/PIP2 interaction is necessary for erythroid differentiation 	
PICALM		24397609	impact of mutation on function		in PICALM-MLLT10 fusion protein PICALM provides a NES signal, mutations in the NES eliminated the capacity of PICALM-MLLT10 to immortalize murine bone-marrow cells in vitro and to promote development of acute myeloid leukaemia in mouse models and a fusion of MLLT10 with the minimal NES can immortalize bone-marrow cells and induce leukaemia in mice 	
PICALM	AML	12461747	fusion partner		KMT2A	
PIK3CA	breast cancer	26266985	differentiation and development		oncogenic Pik3ca(H1047R) activates a multipotent genetic program in normally lineage-restricted populations at the early stage of tumour initiation	
PIK3CA		23643389	impact of mutation on function		E545K helical domain mutant proteins gain new interaction with IRS1, which stabilises PIK3CA independently of its canonical partner - p85, and lacks the p85's ability to inhibit the lipid kinase activity of PIK3CA	
PIK3CA	glioblastoma	24718026	proliferative signalling	promotes	inhibition of PIK3CA activity impaired the anchorage-dependent growth of glioblastoma cells and induced tumour regression in vivo	
PIK3CA	glioblastoma	24718026	invasion and metastasis	promotes	inhibition of PIK3CA activity decreased the migratory capacity of cancer cells	
PIK3CA	glioblastoma	24967401	escaping programmed cell death	promotes	KD suppresses cell viability and induces apoptosis	T98G
PIK3CA	colon carcinoma	17363507	escaping programmed cell death	promotes	cells harbouring PIK3CA GOF mutations display resistance to growth factor deprivation induced apoptosis	
PIK3CA		23500680	angiogenesis	promotes	activated by VEFR, required for vessel development and remodelling	
PIK3CA	lung cancer	17992665	types of alteration in cancer		frequently amplified	
PIK3CA		23500680	differentiation and development		crucial for the differentiation of the nascent vascular plexus into arteries and veins	
PIK3CA		16341083	role in cancer	oncogene	oncogene	
PIK3CA		16341083	function summary		catalytic subunit of a kinase which phosphorylates phosphatidylinositol and its phosphorylated derivatives at the 3' position of the inositol ring, generating secondary messengers that control cellular activities and properties including proliferation, survival, motility and morphology	
PIK3CA		15647370	impact of mutation on function		E542K, E545K, and H1047R mutations induce an oncogenic transformation with high efficiency; transforming ability is correlated with elevated catalytic activity in in vitro kinase assays	
PIK3CA		27727438	types of alteration in cancer		recurrent missense somatic mutations: H1047R, H1047L, E545K, E545A, E542K, Q546K, R88Q	
PIK3CA	mouse mammary gland	22666336	proliferative signalling	promotes	physiological levels of Pik3ca H1047R GOF mutant results in ductal hyperplasia and formation of ER alpha-positive tumours	
PIK3CA	NSCLC	24486107	invasion and metastasis	promotes	PIK3CA downregulation by miR-1 mimics leads to a significant reduction of cell migration and invasion	A549
PIK3CA	NSCLC	24486107	proliferative signalling	promotes	PIK3CA downregulation by miR-1 mimics led to a significant reduction of cell proliferation	A549
PIK3CA	osteosarcoma	26036761	proliferative signalling	promotes	overexpression of miR-375, targeting PIK3CA, markedly suppressed cell proliferation	
PIK3CA		17540175	function summary		effector of ras	
PIK3CB		21383062	escaping programmed cell death	promotes	when localised in the nucleus, suppresses apoptosis	
PIK3CB		18285463	cell division control		regulates S-phase entry	
PIK3CB		20368419	genome instability and mutations	suppresses	controls double-strand break DNA repair in kinase-independent way by regulation of the Nbs1 sensor protein binding to damaged DNA	
PIK3CB		19416922	cell division control		modulation of PI3Kbeta activity alters the DNA replication rate by controlling proliferating cell nuclear antigen (PCNA) binding to chromatin and to DNA polymerase delta	
PIK3CB		25982275	impact of mutation on function		D1067V promoted PI3K pathway signalling, enhanced cell growth in vitro, and was sufficient for tumour formation in vivo	
PIK3CB	endothelium	25139353	function summary		plays a critical role in microvascular repair following injury	
PIK3R1	breast cancer	28630349	impact of mutation on function		partial loss of p85alpha increases the amount of p110alpha-p85 heterodimers bound to active receptors, augmenting PI3K signalling and oncogenic transformation	
PIK3R1	RCC	25757764	role in cancer	TSG	TSG	
PIK3R1	RCC	25757764	suppression of growth	promotes	depletion results in increased proliferation	
PIK3R1	RCC	25757764	cell replicative immortality	suppresses	negatively regulates stem-like phenotype of cancer cells through the AKT/GSK3beta/CTNNB1 signalling pathway	
PIK3R1	RCC	25757764	invasion and metastasis	suppresses	negatively regulates the epithelial-mesenchymal transition cancer cells through the AKT/GSK3beta/CTNNB1 signalling pathway	
PIK3R1		26222500	function summary		homodimeric but not monomeric p85alpha suppresses the PI3K pathway by protecting PTEN from E3 ligase WWP2-mediated proteasomal degradation	
PIK3R1	breast cancer	26676464	invasion and metastasis	suppresses	PIK3R1 suppresses growth, invasiveness and metastatic properties of cancer cells	
PIK3R1		20713702	impact of mutation on function		mutations in the iSH2 and nSH2 domains induce oncogenic cellular transformation, stimulate cellular proliferation, and enhance PI3K signalling, these mutations weaken an inhibitory interaction between p85alpha and p110alpha while preserving the stabilizing interaction between p85alpha iSH2 and the adapter-binding domain of p110alpha	
PIK3R1		20379207	function summary		p85alpha, stabilizes the p110 alpha, the catalytic subunit of PI3K and inhibits its lipid kinase activity	
PIM1		25551195	role in cancer	oncogene	oncogene	
PIM1	DLBCL	10637510	fusion partner		BCL6	
PIM1	hepatocellular carcinoma	25834102	change of cellular energetics	promotes	regulates glycolysis and promotes tumour progression	
PIM1	prostate cancer	26934497	invasion and metastasis	promotes	promotes cell migration and adhesion 	
PIM1		26598507	angiogenesis	promotes	promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase 	
PIM1	astrocytoma	27088547	escaping programmed cell death	promotes	repression of PIM1 by miR-124-3p promoted apoptosis 	
PIM1		10637510	role in cancer	fusion	fusion	
PIM1	astrocytoma	27088547	invasion and metastasis	promotes	repression of PIM1 by miR-124-3p suppressed invasion	
PIM1	astrocytoma	27088547	proliferative signalling	promotes	repression of PIM1 by miR-124-3p suppressed proliferation	
PIM1	oesophageal cancer	27983525	escaping programmed cell death	promotes	silencing promotes apoptosis	Eca-109
PIM1	oesophageal cancer	27983525	proliferative signalling	promotes	silencing inhibits proliferation	Eca-109
PIM1		25238262	function summary		serine/threonine kinase involved in cell survival and proliferation 	
PIM1	astrocytoma	27088547	change of cellular energetics	promotes	repression of PIM1 by miR-124-3p suppressed aerobic glycolysis	
PLCG1	breast cancer	19074886	invasion and metastasis	promotes	KD reduces migration and invasion	MDA-MB-231
PLCG1	gastric cancer	26811493	invasion and metastasis	promotes	KD reduces migration in vitro and metastasis in a xenograft model	BGC-823
PLCG1	angiosarcoma	25252913	role in cancer	Oncogene	Oncogene	
PLCG1		27727438	types of alteration in cancer		recurrent S345F, R48W, E1163K	
PLCG1	angiosarcoma	24633157	types of alteration in cancer		recurrent R707Q	
PLCG1	squamous cell carcinoma	20510673	cell division control		KD reduces EGF-induced mitogenesis	SCC4, SCC12B2
PLCG1	T-cell cutaneous lymphoma	24497536	impact of mutation on function		S345F increases nuclear factor of activated T cells (NFAT) actvity	
PLCG1		25252913	impact of mutation on function		R707Q activates PLC gamma 1 signalling	HEK293
PLCG1		11048639	function summary		phospholipase, enzyme involved in intracellular signalling, mainly activated downstream of receptor tyrosine kinases, catalyses the production of diacylglycerol and 1,4,5-trisphosphate	
PLCG1	mice	11744703	angiogenesis	promotes	KO impairs erythropoiesis and vasculogenesis	
PLCG1	porcine aortic endothelial cells	12598525	angiogenesis	promotes	pharmacological inhibition reduces the ability of a VEGFR2 chimera to stimulate tubulogenesis	
PLCG1	gastric cancer	21986528	escaping programmed cell death	promotes	KD promotes cisplatin-induced apoptosis in RhoGDI2-overexpressing cells	SNU-484
PLCG1	gastric cancer	26811493	proliferative signalling	promotes	KD suppresses colony growth in vitro and tumour growth in xenograft models	BGC-823
PLCG1	normal human keratinocytes	22749651	proliferative signalling	promotes	KD blocks EGF-induced cell proliferation	
PLCG1	prostate cancer	18367108	invasion and metastasis	promotes	KD reduces invasion	PC-3
PMS2	granulosa cell tumour	28347324	genome instability and mutations	suppresses	mutation results in DNA mismatch repair system failure	
PMS2	prostate cancer	26036629	suppression of growth	promotes	expression of PMS2 in PMS2 deficient cells causes decreased cell proliferation and in vivo growth	DU145
PMS2	prostate cancer	26036629	invasion and metastasis	suppresses	expression of PMS2 in PMS2 deficient cells causes decreased  migration and invasion	DU145
PMS2	prostate cancer	11358834	types of alteration in cancer		expression frequently lost	
PMS2		26036629	role in cancer	TSG	TSG	
PMS2		26746812	function summary		DNA Mismatch repair protein 	
PMS2	prostate cancer	26036629	escaping programmed cell death	suppresses	expression of PMS2 in PMS2 deficient cells causes increased apoptosis 	DU145
POT1		27135879	function summary		part of the shelterin complex, interacts with TPP1 and the single stranded telomeric DNA overhang, functions to repress the DNA damage response at chromosome ends and to regulate telomerase activity	
POT1	mouse embryonic fibroblasts	16839876	genome instability and mutations	suppresses	required for telomere integrity and genomic stability	
POT1	familial melanoma	24686846	impact of mutation on function		carriers of S270N have longer telomeres and greater numbers of fragile telomeres	
POT1	familial melanoma	24686849	impact of mutation on function		Y89C, Q94E and R273L disrupt POT1-ssDNA binding and lead to elongated telomeres	
POT1	cardiac angiosarcoma	26403419	impact of mutation on function		R117C reduced telomere binding, increases telomere length and increased telomere fragility	
POT1	cutaneous T-cell lymphoma	27239034	impact of mutation on function		F62V and K90E induce telomere fragility, replication fork stalling and telomere elongation	
POT1	chronic lymphocytic leukemia	23502782	impact of mutation on function		Y36N and Y223C localise to telomeres but are unable to bind telomeric ssDNA, cells expressing mutant POT1 have increased numbers of chromosomal beaks and fusions	
POT1	chronic lymphocytic leukemia	23502782	types of alteration in cancer		frequently mutated	
POT1	familial melanoma	24686849	types of alteration in cancer		germline mutations	
POT1	cardiac angiosarcoma	26403419	types of alteration in cancer		germline R117C mutation	
POT1		27727438	types of alteration in cancer		recurrent V183G	
POT1	chronic lymphocytic leukemia	23502782	clinical impact		mutations are more frequent in IGHV-unmutated versus IGHV-mutated disease	
POT1	mouse embryonic fibroblasts	17053789	senescence		overexpression of mutant Pot1b promotes p53-dependent senescence	
POT1	mouse embryonic fibroblasts	16839876	senescence		Pot1a KO leads to p53-dependent replicative senescence	
POT1	mouse embryonic fibroblasts	17053789	genome instability and mutations	suppresses	KD leads to cytogenetic abnormalities, Pot1b KD in Pot1a deficient cells enhances this effect	
POU2AF1		14552839	differentiation and development		regulates B-cell development and function 	
POU2AF1		26927796	function summary		transcription cofactor, regulator of host defense genes in the human airway epithelium 	
POU2AF1	multiple myeloma	17621271	proliferative signalling	promotes	promotes growth by directly regulating expression of a B-cell maturation factor, TNFRSF17 	
POU2AF1	B-ALL	8618432	fusion partner		BCL6	Karpas 231
POU2AF1		17621271	role in cancer	oncogene	oncogene	
POU2AF1		8618432	role in cancer	fusion	fusion	
POU5F1		27788386	function summary		transcription factor, major regulator of cell pluripotency	
POU5F1		27369080	impact of mutation on function		K156N, with reduced binding to Sox2, significantly down-regulates the stemness genes that are cooperatively controlled by the Oct4/Sox2 complex and specifically up-regulates the mesendodermal genes and the SNAIL family genes that promote EMT 	
POU5F1		27369080	cell replicative immortality	promotes	in complex with Sox2 upregulates the stemness genes crucial for maintaining the pluripotency of stem cells	
POU5F1	colon cancer	26398480	proliferative signalling	promotes	B1 splice variant B1 promotes cell growth	
POU5F1	colon cancer	26398480	invasion and metastasis	promotes	B1 splice variant B1 promotes migration and invasion	
POU5F1		20815032	role in cancer	fusion	fusion	
POU5F1		26398480	role in cancer	oncogene	oncogene	
POU5F1	myoepithelial tumour	20815032	fusion partner		EWSR1	
PPARG	thyroid papillary carcinoma 	16728576	fusion partner		PAX8	
PPARG	cardiac myxoma	27109478	suppression of growth	promotes	suppresses the proliferation through downregulation of MEF2D in a miR-122-dependent manner 	
PPARG	angiolipomyoma	28275008	proliferative signalling	promotes	stimulates proliferation	
PPARG		27579030	function summary		nuclear receptor with transcription factor capabilities, modulates the expression and repression of genes involved in metabolic homeostasis, regulating energy expenditure and storage, vital for development of organs such as heart and the placenta 	
PPARG		21917928	change of cellular energetics	promotes	mediates a Ski oncogene-induced shift from glycolysis to oxidative energy metabolism 	
PPARG		16728576	role in cancer	fusion	fusion	
PPARG		15231248	role in cancer	TSG	TSG	
PPM1D		24880341	function summary		regulator of TP53 and CHK2 by dephosphorylation	
PPM1D		16897432	cell division control		silences p16 expression	
PPM1D		27727438	types of alteration in cancer		recurrent C478*	
PPM1D		12021785	types of alteration in cancer		amplified in human breast tumour cell lines and in approximately 11% of primary breast tumours	
PPM1D	glioma	24880341	role in cancer	oncogene	oncogene	
PPM1D	glioma	24880341	proliferative signalling	promotes	truncating alterations in exon 6 enhance the ability of PPM1D to suppress the activation of the DNA damage response checkpoint protein CHK2 thus promoting proliferation	
PPM1D		23907125	function summary		dephosphorylates ATM and H2AX 	
PPM1D		24880341	impact of mutation on function		mutants with truncated C-terminus manifest higher activity resulting in a decrease of TP53 and CHK2 phosphorylation	
PPM1D		15327777	genome instability and mutations	promotes	negatively regulates base excision repair	
PPM1D	breast cancer	12021784	escaping programmed cell death	promotes	overexpression leads to attenuation of apoptosis induced by serum starvation and transformation of primary cells in cooperation with RAS	
PPP6C		23729733	role in cancer	TSG	TSG	
PPP6C		17568194	cell division control		restricts G1 to S phase progression 	
PPP6C		21451261	function summary		required for homology-directed DNA repair, dephosphorylates gamma-H2AX 	
PPP6C		21187329	impact of mutation on function		loss of PP6 function by depletion of catalytic or regulatory subunits interferes with spindle formation and chromosome alignment because of increased Aurora A activity 	
PPP6C		24336958	impact of mutation on function		R264C and truncating mutations at the 3'end result in inability to dephosphorylate Aurora A kinase 	
PPP6C		26462736	genome instability and mutations	suppresses	depletion of PP6c resulted in defects in chromosome condensation and segregation in anaphase, due to dysregulation of condensin I function 	
PRDM16	prostate cancer	27511603	escaping programmed cell death	promotes	associated with evasion of apoptosis	
PRDM16		19285866	differentiation and development		controls a bidirectional cell fate switch between skeletal myoblasts and brown adipocytes 	
PRDM16		26688472	function summary		transcriptional coactivator and corepressor	
PRDM16		18496560	role in cancer	oncogene	oncogene	
PRDM16		16015645	role in cancer	fusion	fusion	
PRDM16		18496560	mouse model		upregulation of Prdm16 in mice is sufficient to initiate a leukemogenic cascade 	
PRDM16	AML	24673627	fusion partner		SKI	
PRDM16	AML	16015645	fusion partner		RUNX1	
PRDM16		12816872	differentiation and development		overexpression of shorter of the two PRMD16 transcripts blocked granulocytic differentiation induced by granulocyte colony-stimulating factor (G-CSF) in interleukin-3 (IL-3)-dependent murine myeloid L-G3 cells 	
PREX2		25829446	invasion and metastasis	promotes	cancer mutants are resistant to PTEN-mediated inhibition of invasion	
PREX2	melanoma	26884185	role in cancer	oncogene	oncogene	
PREX2	xenograft mice	22622578	types of alteration in cancer		overexpression of the mutated protein results in accelerated tumourigenesis in NRAS(G12D) expressing cells	
PREX2		25829446	impact of mutation on function		 PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumour cell invasion and PREX2 V432M, G844D, and P948S are resistant to PTEN-mediated inhibition of GEF activity and PI3K signalling but retain the ability to inhibit the lipid phosphatase activity of PTEN	
PREX2	melanoma	26884185	impact of mutation on function		truncating mutations increase GEF activity and abrupt binding to PTEN, which activates the PI3K pathway	
PREX2		19729658	function summary		activates PI3K pathway by inhibition of PTEN	
PREX2		15304343	function summary		guanine nucleotide exchange factor (GEF) for Rac1, activates Rac1	
PRKACA		26687711	function summary		Part of protein kinase A holoenzyme	
PRKACA		26978032	escaping programmed cell death	promotes	activation of PKA increases the resistance of cancer cell to glucose starvation and anoikis	
PRKACA		25477193	impact of mutation on function		mutations cause high basal catalytic activity and lack of regulation by cAMP through interference of the complex formation between the regulatory and the catalytic subunits of PKA	
PRKACA		24578576	impact of mutation on function		in fusion with DNAJB1, the DNAJB1 promoter is more active, PK domain from PRKACA is constantly active	
PRKACA	hepatocellular carcinoma	24578576	fusion partner		DNAJB1	
PRKACA		27727438	types of alteration in cancer		recurrent L206R	
PRKACA		25477193	role in cancer	oncogene	oncogene	
PRKACA	cortisol-producing adrenal tumours	24747643	proliferative signalling	promotes	PKA activity induces cortisol production and cell proliferation	
PRKAR1A	adrenocortical carcinoma	25268545	escaping programmed cell death	suppresses	depletion of PRKAR1A promotes the expression of Bcl-xL and resistance to apoptosis	H295R
PRKAR1A	thyroid papillary carcinoma 	10946873	fusion partner		RET	
PRKAR1A		21151042	escaping programmed cell death	suppresses	positively regulates apoptosis by stabilising proapoptotic protein Bim 	
PRKAR1A	adrenocortical carcinoma	25268545	proliferative signalling	promotes	depletion of PRKAR1A is associated with a high percentage of cells in S and G2 phase	H295R
PRKAR1A	cholangiocarcinoma	20824711	proliferative signalling	promotes	silencing PRKAR1A expression induced growth inhibition with an associated decrease in mitogen-activated protein kinases, PI3K/Akt, JAK/STAT and Wnt/beta-catenin pathway signaling 	
PRKAR1A		10946873	role in cancer	fusion	fusion	
PRKAR1A		18413734	invasion and metastasis	suppresses	inactivation stimulates EMT 	
PRKAR1A		12203783	function summary		the most abundant regulatory subunit of protein kinase A and a principal cyclic AMP-signaling modulator	
PRKAR1A		20824711	role in cancer	oncogene	oncogene	
PRKAR1A		25336503	role in cancer	TSG	TSG	
PRKAR1A	cholangiocarcinoma	20824711	escaping programmed cell death	promotes	silencing PRKAR1A expression induced apoptosis	
PSIP1		17363574	function summary		an Hsp70-2-regulated guardian of lysosomal stability	
PSIP1		17363574	escaping programmed cell death	promotes	KD of PSIP1 in cancer cells induces destabilisation of lysosomal membranes followed by caspase-independent and Bcl-2-resistant cell death, ectopic PSIP1 stabilizes lysosomes and protects cancer cells against cytotoxicity induced by anticancer agents that trigger the lysosomal cell death pathway 	
PSIP1		16980622	differentiation and development		plays a role in embryonic development 	
PSIP1	AML	11737860	fusion partner		NUP98	
PSIP1		22276150	role in cancer	oncogene	oncogene	
PSIP1	prostate, colon, thyroid, liver and uterine tumours	22276150	types of alteration in cancer		frequently overexpressed	
PSIP1		19934313	invasion and metastasis	promotes	stimulates  lymphangiogenesis by inducing expression of VEGFC in ovarian cancer 	
PSIP1		11737860	role in cancer	fusion	fusion	
PSIP1		22773103	genome instability and mutations	suppresses	depletion of PSIP1 impairs the recruitment of C-terminal binding protein interacting protein (CtIP) to DNA DSBs and the subsequent CtIP-dependent DNA-end resection 	
PTEN		26869029	suppression of growth	promotes	attenuates epidermal growth factor receptor (EGFR) signalling by promoting late endosome maturation	
PTEN		9865719	escaping programmed cell death	suppresses	promotes apoptosis via downregulation of antiapoptotic AKT1	
PTEN	glioma	10554022	invasion and metastasis	suppresses	PTEN markedly reduce the invasive potential of cancer cells in a phosphatase-independent manner	
PTEN		12620407	function summary		regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms	
PTEN		12133897	escaping programmed cell death	suppresses	inducible expression promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells	
PTEN		10339565	suppression of growth	promotes	PTEN -/- mouse ES cells exhibit an increased growth rate and proliferate even in the absence of serum	
PTEN	human xenograft model of prostate cancer	20197621	senescence	suppresses	pharmacological inhibition of PTEN drives senescence and inhibits tumourigenesis in vivo	
PTEN		14718524	suppression of growth	promotes	negatively regulates PDGF receptor activation	
PTEN		16633340	differentiation and development		has essential roles in restricting the activation of HSCs, in lineage fate determination, and in the prevention of leukaemogenesis	
PTEN		19117948	cell replicative immortality	suppresses	PTEN loss can cause the development of cancer stem cells and ultimately tumourigenesis	
PTEN		15970699	genome instability and mutations	suppresses	PTEN loss inhibits CHK1, which results in DNA DSBs in cells	
PTEN		17218262	genome instability and mutations	suppresses	C-terminal PTEN mutants disrupt the association of PTEN with centromeres and cause centromeric instability while PTEN null cells exhibit spontaneous DNA DSBs due to downregulation of RAD51 expression	
PTEN		22970944	change of cellular energetics	promotes	PTEN haploinsufficiency is a monogenic cause of profound constitutive insulin sensitisation associated with increased risk of obesity and cancer	
PTEN		23245767	change of cellular energetics	promotes	promotes oxidative phosphorylation and decreases glycolysis, thus preventing the metabolic reprogramming characteristic of cancer cells	
PTEN		17240336	invasion and metastasis	suppresses	modulates cell migration of mesoderm cells in the chick embryo through at least two distinct mechanisms: controlling EMT, which involves its protein phosphatase activity; and controlling the directional motility of mesoderm cells, through its lipid phosphatase activity	
PTEN		10564676	types of alteration in cancer		germline and somatic mutations in the PTEN/MMAC1 gene occur mostly in the protein coding region and involve the phosphatase domain and poly(A)(6) stretches	
PTEN		10772829	cell division control		exogenous wild-type PTEN arrests some, but not all human breast cancer cell lines in G1, in a manner dependent of its protein phosphatase activity	
PTEN		10772829	function summary		can dephosphorylate protein substrates on serine/threonine and tyrosine residues	
PTEN		26645196	escaping immune response to cancer	suppresses	PTEN loss in tumour cells increases the expression of immunosuppressive cytokines, resulting in decreased T-cell infiltration in tumours, and inhibits autophagy, decreases T cell-mediated cell death and results in inferior outcomes of PD-1 inhibitor therapy	
PTEN		9593664	function summary	1	lipid phosphatase, modulator of the PI3K/AKT pathway, catalyses dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate, a key molecule involved in cell growth signalling, specifically at the 3 position on the inositol ring	
PTEN		26504226	impact of mutation on function		A126G GOF mutation, shifts the function of PTEN from a phosphoinositide (PI) 3-phosphatase to a phosphoinositide (PI) 5-phosphatase, resulting in hyperactivation of the PI3K/Akt cell proliferation pathway and increased cell migration	
PTEN		11237521	role in cancer	TSG	TSG	
PTEN		27727438	types of alteration in cancer		recurrent R130G, R130Q, R130*, R233*, T319fs, T267fs, R173C	
PTEN		26504226	role in cancer	oncogene	oncogene	
PTK6	prostate cancer	20953141	cell division control		loss of nuclear localisation and retention in cytoplasm causes increased activation of AKT and lack of nuclear PSF activation leading to cell cycle arrest	PC-3
PTK6	mouse small intestine epithelial cells	16782882	differentiation and development		promotes differentiation of enterocytes	
PTK6	mouse	9405638	differentiation and development		promotes differentiation of keratinocytes	
PTK6	breast cancer	25999240	role in cancer	oncogene	oncogene	
PTK6	prostate cancer	20953141	role in cancer	TSG	TSG	
PTK6	mouse small intestine epithelial cells	16782882	suppression of growth	promotes	negatively regulates growth	
PTK6		22231447	function summary		sustains activated EGFR signalling through inhibiting EGFR degradation and transactivating EGFR	
PTK6		15572663	invasion and metastasis	promotes	activates rac1 and promotes cell migration and invasion by phosphorylating paxillin	
PTK6	prostate cancer	20953141	proliferative signalling	promotes	promotes cell proliferation upon cytoplasmatic retention, which disrupts ability to regulate nuclear substrates	
PTK6	breast cancer	12902983	proliferative signalling	promotes	promotes cell proliferation	
PTK6	mammary epithelial cells	8940083	proliferative signalling	promotes	overexpression potentiates mitogenic effects of EGF	
PTK6	rat fibroblasts	16082217	escaping programmed cell death	suppresses	positively regulates the apoptotic response to DNA-damage and stress	Rat1a
PTK6		26825173	function summary		non-receptor tyrosine-protein kinase induced by HIF1A and HIF2A	
PTK6	breast cancer	20687930	invasion and metastasis	promotes	stimulates hepatocyte growth factor-induced cell migration in kinase activity-independent way	
PTPN11	melanoma	27930879	escaping immune response to cancer	promotes	increased secretion of PTPN11 via exosomes inhibits T cell proliferation in response to IL2	
PTPN11	CD4+ T lymphocytes	24088816	escaping immune response to cancer	promotes	in a mouse model of melanoma metastasis, CD4+ cell-specific gene deletion is associated with increased tumour-associated CD4 cell-derived inflammatory gene expression, an increased tumour immunosuppressive MDSC content, and increased pulmonary metastasis	
PTPN11	NK cells	19915046	escaping immune response to cancer	promotes	expression of wild type or gain of function mutants (E76K) exhibit decreased cytolytic activity via a KIR independent mechanism	KHYG-1, NKL
PTPN11	murine liver cancer 	29505847	senescence		hepatocyte-specific KD induces hepatocyte senescence in mice with oncogene-driven hepatocellular carcinoma	
PTPN11	murine PyMT-induced mammary gland tumour 	25736378	senescence		KD induces senescence in mammospheres	
PTPN11	hepatocellular carcinoma	25865556	role in cancer	oncogene	oncogene	
PTPN11	juvenile myelomonocytic leukaemia	15710330	role in cancer	oncogene	oncogene	
PTPN11	ovarian cancer	28814887	role in cancer	oncogene	oncogene	
PTPN11	thyroid cancer	26622699	role in cancer	oncogene	oncogene	
PTPN11	colorectal cancer	27582544	role in cancer	TSG	TSG	
PTPN11	colorectal cancer	27582544	role in cancer	oncogene	oncogene	
PTPN11	hepatocellular carcinoma	21575863	role in cancer	TSG	TSG	
PTPN11	breast cancer	32944401	clinical impact		elevated expression is associated with reduced survival	
PTPN11	hepatocellular carcinoma	25865556	clinical impact		high expression is associated with reduced survival	
PTPN11	laryngeal cancer	24297342	clinical impact		high expression is associated with reduced survival	
PTPN11	thyroid cancer	26622699	clinical impact		elevated expression correlates with lymph node metastasis at presentation	
PTPN11		29323748	mouse model		p.E76K conditional knock-in promotes colitis-associated colorectal cancer development	
PTPN11	hepatocellular carcinoma	25865556	types of alteration in cancer		frequently increased expression (typically poorly differentiated tumours)	
PTPN11	juvenile myelomonocytic leukaemia	30371878	types of alteration in cancer		missense mutation in 42% of tumours, the most common being p.E76K	
PTPN11	laryngeal cancer	24297342	types of alteration in cancer		frequently increased expression	
PTPN11	cutaneous melanoma	30371878	types of alteration in cancer		missense mutations in 9% of tumours	
PTPN11	ovarian cancer	28814887	types of alteration in cancer		frequently increased expression	
PTPN11	thyroid cancer	26622699	types of alteration in cancer		frequently increased expression	
PTPN11	neuronal	12425940	global regulation of gene expression		acts as a negative regulator of LIF signalling-mediated neuronal gene expression	IMR32
PTPN11	acute myeloid leukaemia	30764849	differentiation and development		downregulation enhances cell differentiation via SRC and CTNNB1	HEL
PTPN11	primary chondrocytes	29659837	differentiation and development		differentiation of primary chondrocytes from mice heterozygous for D61G mutation is impaired via ERK activation	ATDC5
PTPN11	umbilical cord blood	21670473	differentiation and development		KD inhibits myeloid and erythroid differentiation of CD34 positive cells	
PTPN11		32751109	differentiation and development		involved in the regulation of several processes central to embryo development	
PTPN11	breast cancer	32944401	cell division control		KD delays cell G1 to S phase transition via PI3K/AKT/GSK3_ pathway-mediated degradation of cyclin D	
PTPN11	glioblastoma	31807022	cell division control		overexpression increases cell transition from G1 to S, a larger effect is observed for a E76K mutation-containing gene	A172, U87
PTPN11	murine haematopoetic progenitors 	18640765	cell division control		D61Y and E76K gain of function mutations promote cell progression to S and G2, in association with cyclin D upregulation and downregulation of p27 and p21	
PTPN11	gastric carcinoma	11743164	interaction with pathogen		activation by sh2 domain binding of tyrosine phosphorylated Helicobacter pylori protein CagA is required for CagA-induced gastric carcinoma-associated morphological changes	AGS, COS-7
PTPN11	glioblastoma	31807022	impact of mutation on function		E76K mutation enhances cell proliferation, migration and invasion effects effected by overexpression	A172, U87
PTPN11		30375388	impact of mutation on function		most commonly reported cancer mutation E76K changes basal autoinhibited conformation to open substrate accessible state	
PTPN11		30644389	function summary		WT and E76K mutant PTPN11 dephosphorylates SRC phosphorylated KRAS WT and G12V mutant, thereby enhancing RAF binding to RAS	HEK293
PTPN11		12826400	function summary		Src homology-2 domain-containing protein tyrosine phosphatase involved in growth factor and cytokine-dependent intracellular signal transduction regulating multiple processes	
PTPN11		26755576	genome instability and mutations	promotes	gain of function mutations (E76K, D61G) induce chromosome instability via SRC mediated hyperactivation of PLK1	MEFs, HeLa
PTPN11		22890240	genome instability and mutations	suppresses	KD increases chromosome instability by decreasing PLK1 activity	HeLa, MEFs
PTPN11	endothelial cells	23065156	angiogenesis	suppresses	inhibits angiogenesis upon activation by PROS1 (protein S)	HUVECs
PTPN11	glioma	26004555	angiogenesis	promotes	silencing reduces extent of vasculogenic mimicry by irradiated cells	SHG44, U251, U87
PTPN11	umbilical vein endothelial cells	17962719	angiogenesis	promotes	KD reduces capillary-like structure formation	
PTPN11		19008228	angiogenesis	promotes	enhanced angiogenesis in mice heterozygous for D61G mutation	
PTPN11	murine embryonic fibroblasts 	12594211	escaping programmed cell death	suppresses	KD reduces the extent of DNA damage-induced apoptosis effected through c-Abl activation	
PTPN11	glioma	26004555	escaping programmed cell death	promotes	silencing increases extent of radiation-induced apoptosis	SHG44, U251, U87
PTPN11	helper T lymphocytes	17330819	escaping programmed cell death	suppresses	ectopic expression of truncated cDNAs that retain an adapter-like function causes increased apoptosis via caspase activation	
PTPN11	lung cancer	29207183	escaping programmed cell death	promotes	overexpression inhibits cisplatin induced apoptosis by activating RAS/PI3K/AKT1 pathway	H446
PTPN11	lung cancer, pancreatic cancer, colorectal cancer	30104724	escaping programmed cell death	promotes	inhibition leads to caspase 3/7 activation in KRAS mutant cells	NCI-H358, RMC-4550, NCI-H1838, MIA PaCa-2, A-375, NCI-H1755
PTPN11	neuroblastoma	28947394	escaping programmed cell death	suppresses	expression enhances ER stress response and induces apoptosis	SH-SY5Y
PTPN11	ovarian cancer	28814887	escaping programmed cell death	promotes	overexpression associated with decreased paclitaxel-induced apoptosis	A2780
PTPN11	thyroid cancer	26622699	escaping programmed cell death	promotes	suppression causes apoptosis	SW579
PTPN11	umbilical vein endothelial cells	17962719	escaping programmed cell death	promotes	KD induces apoptosis	
PTPN11	breast cancer	32944401	proliferative signalling	promotes	KD reduces cell proliferation	
PTPN11	glioblastoma	31807022	proliferative signalling	promotes	overexpression increases cell proliferation via MAPK and CREB, a higher increase is effected when expressing E76K mutation-containing gene	A172, U87
PTPN11	melanoma	30355677	proliferative signalling	promotes	KD suppresses anchorage-independent growth of wild-type BRAF and NRAS cells	MeWO, WM3211
PTPN11	non-small cell lung cancer	29808006	proliferative signalling	promotes	KD in KRAS mutant xenografts and PDXs impairs tumour growth	H2122
PTPN11	ovarian cancer	28814887	proliferative signalling	promotes	overexpression leads to increased cell proliferation	A2780
PTPN11	pancreatic cancer	27213290	proliferative signalling	promotes	degradation via LINC00673 mediated ubiquitination suppresses cell growth via decrease in SRC signaling	BXPC-3, CFPAC-1
PTPN11	skeletal muscle	17015617	proliferative signalling	promotes	mice homozygous for a skeletal muscle-specific inactivating exon 11 deletion have smaller skeletal muscle myofibres	
PTPN11	breast cancer	30467378	invasion and metastasis	promotes	KD in ERBB2 amplified cell lines blocks tumour growth and metastasis by blocking ERBB2 overexpression	BT474, SUM225, Skbr-3, JIMT-1, MCF-10A
PTPN11	colorectal cancer	29323748	invasion and metastasis	promotes	WT and E76K mutant promote migration in vitro and metastasis in vivo	HT29, HCT116
PTPN11	glioblastoma	31807022	invasion and metastasis	promotes	overexpression increases cell migration and invasion via MAPK and CREB, the effect is more pronounced when expressing E76K mutation-containing gene	A172, U87
PTPN11	glioma	26004555	invasion and metastasis	promotes	silencing reduces invasive capability of irradiated cells	SHG44, U251, U87
PTPN11	hepatocellular carcinoma	25865556	invasion and metastasis	promotes	KD decreases cell migration and invasion, and is associated with reduced liver and lung metastasis in a mouse xenograft model	SMMC-7221
PTPN11	ovarian cancer	28814887	invasion and metastasis	promotes	overexpression increases cell migration and invasion, and is associated with liver metastasis in a mouse xenograft model	A2780
PTPN11	peritoneal macrophages	30610104	tumour promoting inflammation	promotes	KD suppresses production of inflammatory cytokines by activated macrophages in an IL-10-STAT3 signalling-dependent manner	
PTPN11	rheumatoid arthritis fibroblast-like synoviocytes	23335101	tumour promoting inflammation	promotes	KD reduces TNFalpha-induced phosphorylation of MAPKs involved in pro-inflammatory signalling	
PTPN11		23530062	tumour promoting inflammation	suppresses	mice homozygous for an intestinal epithelial cell-specific exon 4 deletion develop intestinal inflammation	
PTPN11		15520383	change of cellular energetics		mice expressing a brain-specific exon 4 deletion mutant display altered activation of Jak2/STAT3 and ERK leptin signalling pathways	
PTPN11		10514516	change of cellular energetics		mice expressing protein tyrosine phosphatase domain-lacking form display decreased activation of insulin signalling pathway members	
PTPN11	cardiomyocytes	18757826	suppression of growth	promotes	silencing increases cell size via FAK/Src signalling complex and mTOR pathway activation	
PTPN11	neuroblastoma	28947394	suppression of growth	promotes	overexpression inhibits cell growth	SH-SY5Y
PTPN11	oesophageal squamous cell cancer	28085101	suppression of growth	promotes	inhibits proliferation in vitro and in xenografts via dephosphorylation of STAT3	Eca109
PTPN11	macrophage	29795405	escaping immune response to cancer	promotes	KO in macrophages attenuates melanoma growth in a mouse model by increasing numbers of CD8 positive T cells via increased intratumoral production of CXCL9	B16
PTPN13	melanoma	12724420	escaping programmed cell death	promotes	attenuates Fas export to the cell surface, inhibiting Fas ligand-mediated apoptosis	OM431, 1205Lu
PTPN13		18265946	function summary		non-receptor type protein tyrosine phosphatase	
PTPN13		16572203	types of alteration in cancer		inactivated by promoter hypermethylation in lymphoma, breast, liver, and gastric cancer cell lines	
PTPN13		12354757	escaping programmed cell death	suppresses	has a key role in the apoptotic process in human breast cancer cells independent of Fas but associated with an early inhibition of the insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway	
PTPN13	breast cancer	19004008	clinical impact		high expression level is an independent prognostic indicator of favourable outcome 	
PTPN13	pancreatic adenocarcinoma	11683408	escaping programmed cell death	promotes	can protect pancreatic carcinoma cells from Fas/CD95-mediated apoptosis, by preventing translocation of CD95 from intracellular stores to the cell surface	Panc89
PTPN13	pancreatic adenocarcinoma	11683408	types of alteration in cancer		frequently overexpressed	
PTPN13	astrocytoma	16187021	types of alteration in cancer		frequently overexpressed	
PTPN13		17982484	impact of mutation on function		inactivation of PTPN13 affects apoptotic signalling and boosts invasiveness of cancer cells 	
PTPN13		17982484	role in cancer	TSG	TSG	
PTPN13		17982484	invasion and metastasis	suppresses	negatively regulates Her2/ErbB2 malignant signalling, mutant cells with decreased phosphatase activity are characterized by decreased invasiveness	
PTPN13	breast cancer	17638892	escaping programmed cell death	suppresses	necessary for induction of apoptosis by antiestrogens	
PTPN13	astrocytoma	16187021	escaping programmed cell death	promotes	blocks apoptosis through dephosphorylation of FAS	
PTPN13		25193362	function summary		regulates cellular signalling and beta-catenin function during megakaryocytic differentiation	
PTPN13		20501847	function summary		negatively regulates src kinase	
PTPN13		17982484	function summary		negatively regulates Her2/ErbB2 malignant signalling	
PTPRB	brown adipocytes	30845793	differentiation and development		overexpression inhibits differentiation of brown preadipocytes by dephosphorylating VEGFR2	
PTPRB	osteosarcoma	31829261	types of alteration in cancer		typically decreased expression	
PTPRB	non-small cell lung cancer	27314562	types of alteration in cancer		typically decreased expression	
PTPRB	hepatocellular carcinoma	30237408	types of alteration in cancer		typically decreased expression	
PTPRB	murine mammary epithelial 	28870991	differentiation and development		KD in mammary fat pad transplants leads to smaller and more densely branched epithelial outgrowths	
PTPRB	colorectal cancer	31040266	types of alteration in cancer		frequently increased expression	
PTPRB	angiosarcoma	24633157	types of alteration in cancer		mutations, predominantly truncating, present in a high proportion of tumours that are secondary to ionizing radiation	
PTPRB	pancreatic ductal adenocarcinoma	32663515	clinical impact		decreased protein level in serum is associated with reduced overall survival	
PTPRB	osteosarcoma	31829261	clinical impact		low expression is associated with lung metastasis	
PTPRB	non-small cell lung cancer	27314562	clinical impact		low expression is associated with lymph node metastasis and reduced survival	
PTPRB	osteosarcoma	31829261	role in cancer	TSG	TSG	
PTPRB	non-small cell lung cancer	27314562	role in cancer	TSG	TSG	
PTPRB	hepatocellular carcinoma	30237408	role in cancer	TSG	TSG	
PTPRB	colorectal cancer	31040266	role in cancer	oncogene	oncogene	
PTPRB	non-small-cell lung cancer	27314562	suppression of growth	promotes	overexpression reduces proliferation and tumour growth in xenografts	A549, H1299
PTPRB	hepatocellular carcinoma	30237408	suppression of growth	promotes	downregulation results in increased growth	HEPG2, SMMC-7721, Huh7, Hep3B, MHCC-97H, LO2
PTPRB	cutaneous melanoma	30371878	types of alteration in cancer		primarily missense (55% of tumours) and nonsense (5% of tumours) mutations	
PTPRB	non-small cell lung cancer	27314562	suppression of growth	promotes	KD increases cell proliferation in vitro and the volume of xenografts	A549
PTPRB	murine endothelial	19451274	suppression of growth	promotes	negatively regulates Tie-2 angiopoietin receptor, which controls endothelial cell proliferation	bEnd.5, HUVEC
PTPRB	kidney	30886059	tumour promoting inflammation	promotes	KD in diabetic, hypertensive mice leads to decreased kidney fibrosis and glomerulosclerosis via Tie-2 activation and reduced pro-inflammatory gene expression	
PTPRB	osteosarcoma	31829261	invasion and metastasis	suppresses	suppression by miR-624-5p promotes cell migration and invasion via Hippo pathway attenuation	MG63, U2OS
PTPRB	non-small-cell lung cancer	27314562	invasion and metastasis	suppresses	KD increases Src phosphorylation and cell invasion	A549, H1299
PTPRB		19451274	function summary		a receptor-type tyrosine phosphatase involved in the regulation of processes including cell differentiation and angiogenesis	
PTPRB	cutaneous melanoma	32117706	angiogenesis	promotes	silencing reduces the formation of vasculogenic mimicry structures in an in vitro angiogenesis assay	MUM 2B
PTPRB	murine embryo 	17360632	angiogenesis	promotes	mice homozygous for exon 2 and 3 deletion do not develop branched vascular network from primitive scaffold	
PTPRB	endothelial	24633157	angiogenesis	suppresses	KD increases angiogenesis in a VEGF-dependent manner	HUVECs
PTPRB	murine endothelial 	19451274	angiogenesis	promotes	down-regulation by antibody-mediated endocytosis leads to the development of larger vascular endothelial cords with fewer branches	
PTPRB	microvascular endothelial	19136612	angiogenesis	promotes	suppression decreases endothelial cell tubular morphogenesis	
PTPRB	colorectal cancer	31040266	invasion and metastasis	promotes	overexpression increases migration and invasion in vitro and increases metastasis from xenografts via an EMT-like process	LOVO, HCT116, HT29
PTPRB	fibroblast	20301196	invasion and metastasis	promotes	overexpression promotes integrin and Ras-dependent cell spreading and lamellipodia formation via Src kinase activation	CHO-Ras
PTPRB	hepatocellular carcinoma	30237408	invasion and metastasis	suppresses	downregulated by miR-665 resulting in increased invasion and metastasis via modulation of the Hippo pathway	HEPG2, SMMC-7721, Huh7, Hep3B, MHCC-97H, LO2
PTPRT		24395800	function summary		Tyrosine phosphatase, dephosphorylates STAT3	
PTPRT	hepatoma	24434140	suppression of growth	promotes	hepatitis B virus X protein mutant HBxDelta127 enhances proliferation of cells through up-regulating miR-215, which targets PTPRT	
PTPRT		21179176	role in cancer	TSG	TSG	
PTPRT	colorectal cancer	15155950	types of alteration in cancer		mutants with loss of phosphatase function	
PTPRT	HNSCC	25982282	types of alteration in cancer		frequent promoter hypermethylation	
PTPRT		21179176	impact of mutation on function		inactivation results in abnormal activation of STAT3	
QKI		16641098	function summary		RNA-binding protein, crucial for myelinisation and differentiation of oligodendrocytes	
QKI		24722255	function summary		regulates the alternative splicing of NUMB via binding to two RNA elements in its pre-mRNA	
QKI		11297509	escaping programmed cell death	promotes or suppresses	QKI-7 isoform induces apoptosis in rat oligodendrocytes, formation of heterodimers with other QKI isoforms, which have distinct C-terminal end induces translocation to the nucleus and suppresses apoptosis	
QKI		24722255	suppression of growth	promotes	selectively competes with SF1 for binding to the branchpoint sequence, which in effect suppresses cell proliferation and prevents the activation of the Notch signalling pathway 	
QKI	oral cancer	25457822	suppression of growth	promotes	suppresses cyclin D1 expression and proliferation of cells via MAPK signalling pathway	
QKI	GBM	22751500	role in cancer	TSG	TSG	
QKI	angiocentric glioma	26829751	impact of mutation on function		in fusion with MYB, MYB is activated by truncation and the influence of the QKI enhancer, as a result of the fusion, QKI loses its TSG function	
QKI	GBM	22751500	types of alteration in cancer		QKI expression is activated by p53, QKI binds to and stabilises miR-20a, which negatively regulates the expression of TGFBR2	
QKI	colorectal cancer	22810696	types of alteration in cancer		recurrent K134fs mutations	
QKI	lung cancer	24722255	types of alteration in cancer		reduced expression	
QKI	oral cancer	24918581	types of alteration in cancer		reduced expression	
QKI		26829751	role in cancer	fusion	fusion	
QKI	angiocentric glioma	26829751	fusion partner		MYB	
QKI		24918581	role in cancer	TSG	TSG	
RABEP1		11588050	impact of mutation on function		the RABEP1 part of the fusion protein includes 3 of 4 coiled-coil homodimerisation domains 	
RABEP1	CML	11588050	fusion partner		PDGFRB in CML	
RABEP1		22975325	invasion and metastasis		disruption of Rabaptin-5 Ser407 phosphorylation reduces persistent cell migration in 2D and alpha-v beta-3-dependent invasion, but invasive migration, that is dependent on alpha-5 beta-1 integrin is promoted by disrupting Rabaptin phosphorylation 	
RABEP1		26680696	suppression of growth	promotes	increased expression accelerates EGFR endocytosis suppressing tumour progression 	
RABEP1		26430212	function summary		regulates endosome maturation 	
RABEP1		11588050	role in cancer	fusion	fusion	
RAC1	thyroid carcinoma	28234980	proliferative signalling	promotes	overexpression of Rac1b, a constitutely active splice variant, stimulates proliferation	
RAC1		28277539	genome instability and mutations	suppresses	regulates the DNA damage response and protects from UV-light-induced keratinocyte apoptosis and skin carcinogenesis in mice 	
RAC1	gastric adenocarcinoma	28461325	invasion and metastasis	promotes	promotes the EMT  and the acquisition of a cancer stem-like cell state, its inhibition blocks EMT and CSC phenotypes	
RAC1		25640224	invasion and metastasis	promotes	 Rac1 nuclear accumulation alters the balance between cytosolic Rac1 and Rho, increasing RhoA signaling in the cytoplasm and promoting a highly invasive phenotype 	
RAC1		26176707	escaping immune response to cancer	promotes	P29S GOF mutation results in upregulation of PD-L1 	
RAC1	thyroid carcinoma	28234980	escaping programmed cell death	promotes	overexpression of Rac1b, a constitutely active splice variant, stimulates NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells 	
RAC1	CLL	24501217	proliferative signalling	promotes	positively regulates proliferation	
RAC1		12134084	angiogenesis	promotes	regulates endothelial morphogenesis and capillary assembly 	
RAC1		26549372	invasion and metastasis	promotes	mediates HMGB1-nduced hyperpermability in pulmonary endothelial cells via MAPK signalling 	
RAC1		12194856	function summary		essential in formation of cell-cell adhesions 	
RAC1		15516977	role in cancer	oncogene	oncogene	
RAC1		24072884	function summary		Rho GTPase, a modulator of the cytoskeleton, critical for a number of cellular activities, including phagocytosis, mesenchymal-like migration, axonal growth, adhesion and differentiation of multiple cell types as well as ROS-mediated cell killing 	
RAD21		25408876	function summary		a subunit of cohesin complex	
RAD21		24148822	role in cancer	oncogene	oncogene	
RAD21		26438359	role in cancer	TSG	TSG	
RAD21	breast cancer	24148822	invasion and metastasis	promotes	KD significantly  decreases the ability of cells to form colonies in anchorage-independent conditions, in soft agar, induces cell cycle arrest and apoptosis	HCC1937 and MCF7
RAD21		20404533	genome instability and mutations	suppresses	required for centrosome integrity in human cells independently of its role in chromosome cohesion 	
RAD21		11700297	cell division control		holds sister chromatids together until anaphase 	
RAD21		12417729	escaping programmed cell death	suppresses	cleaved by caspases during initiation of apoptosis, the C-terminal product of the cleavage further stimulates apoptosis 	
RAD21	breast cancer	26529363	senescence		suppression of RAD21 induces senescence through RB1 pathway activation via c-Myc downregulation 	MDA-MB-231
RAF1		11427728	escaping programmed cell death	promotes	promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 	
RAF1		21424530	role in cancer	fusion	fusion	
RAF1		9819434	proliferative signalling	promotes	interacts with Rb and inhibits its antiproliferative function 	
RAF1		18483265	proliferative signalling	promotes	disruption of Rb/Raf1 interaction inhibits cell proliferation and growth of human tumour xenografts in nude mice 	
RAF1		18483265	angiogenesis	promotes	disruption of Rb/Raf1 interaction inhibits angiogenesis	
RAF1	prostate cancer	20526349	fusion partner		ESRP1	
RAF1	breast cancer	20033038	fusion partner		DAZL	
RAF1	pilocytic astrocytoma 	27810072	fusion partner		NFIA	
RAF1		27810072	impact of mutation on function		NFIA:RAF1 fusion results in constitutive Raf1 kinase activity, leading to activation of downstream MEK1/2 cascade and increased proliferation of cancer cells 	
RAF1	endometriosis	22225925	invasion and metastasis	promotes	stimulates migration of primary endometrial stromal cells	
RAF1	breast cancer	22447278	invasion and metastasis	promotes	stimulates EMT	
RAF1	pilocytic astrocytoma 	21424530	fusion partner		SRGAP3	
RAF1	pancreatic cancer	25266736	fusion partner		HACL1	
RAF1		21577205	role in cancer	oncogene	oncogene	
RAF1		28666118	function summary		a small GTPase that cycle between inactive GDP-bound and active GTP-bound conformations, regulates cellular responses to many extracellular stimuli	
RAF1		16916643	cell division control		Raf hyperactivation reduces kinetochore localisation and kinase activity of Aurora B, a regulator of the spindle checkpoint 	
RANBP2	inflammatory myofibroblastic tumour 	18701132	fusion partner		ALK	
RANBP2		24113188	genome instability and mutations	suppresses	depletion of RanBP2 results in impaired chromosomal alignment and induces G2/M phase arrest, metaphase catastrophe and mitotic cell death 	
RANBP2		18394551	role in cancer	TSG	TSG	
RANBP2		23630457	function summary		potentiates the translation of a subset of mRNAs encoding secretory proteins 	
RANBP2	BRAF-like colorectal cancer	27058664	genome instability and mutations	suppresses	loss of RANBP2 induces mitotic abnormalities and cell death 	
RANBP2		18701132	role in cancer	fusion	fusion	
RANBP2		21995724	function summary		functions as a cargo- and receptor-specific assembly platform, increasing the efficiency of nuclear import of proteins 	
RAP1GDS1	NSLC	17951244	invasion and metastasis	promotes	upregulates cell migration	
RAP1GDS1	NSLC	17951244	proliferative signalling	promotes	upregulates cell proliferation, migration	
RAP1GDS1	breast cancer	21429211	invasion and metastasis		stimulates migration	MCF-7
RAP1GDS1	breast cancer	24197117	proliferative signalling	promotes	KD of SmgGDS-558 splice variant, but not SmgGDS-607 decreased NF-kB activity, proliferation, in vivo tumour growth, and RhoA activity	
RAP1GDS1		23640485	function summary		upregulation of RAP1GDS1 results in degradation of Rac1 oncogene 	
RAP1GDS1	T-ALL	10929031	fusion partner		NUP98	
RAP1GDS1		10929031	role in cancer	fusion	fusion	
RAP1GDS1		17951244	role in cancer	oncogene	oncogene	
RB1		26845683	senescence	promotes	induces cellular senescence	
RB1	bladder cancer	27922689	invasion and metastasis	suppresses	Rb KD enhanced tumour cell migration	
RB1	bladder cancer	27922689	suppression of growth	promotes	Rb KD enhanced tumour cell proliferation	
RB1		28101510	global regulation of gene expression		controls nucleosome and chromatin structures via physical interactions with histone modifiers and chromatin factors	
RB1		26711265	impact of mutation on function		N-terminal domain of retinoblastoma directly inhibits DNA replication, initiation and elongation via inactivation of CMG helicase, mutations resulting in loss of this region impair the ability of Rb to inhibit DNA replication and block G1-to-S cell cycle transit	
RB1		27401552	role in cancer	TSG	TSG	
RB1		27401552	function summary		chromatin-associated protein that limits the transcription of cell cycle genes, primarily via regulation of the E2F transcription factor	
RB1		7736585	cell division control		controls transition from a serum-dependent to a serum-independent state and further into the S-phase, during the G1 phase of the cell cycle, inactivation compromises the ability of the cell to exit the cell cycle	
RB1		27727438	types of alteration in cancer		inactivating somatic mutations	
RB1		5279523	function summary		the first tumour suppressor gene identified	
RB1		23359405	suppression of growth	promotes	participates in a regulatory network that governs the cellular response to antimitogenic signals	
RB1		20551164	genome instability and mutations	suppresses	loss of Rb proteins causes genomic instability in the absence of mitogenic signalling	
RB1		20551165	genome instability and mutations	suppresses	loss of Rb causes centromere dysfunction and chromosomal instability	
RB1		12853964	senescence		loss of Rb in senescent cells leads to reversal of the cellular senescence programme	
RB1		12563312	escaping programmed cell death	promotes	inhibits apoptosis	
RB1		15716273	escaping programmed cell death	promotes	phosphorylated Rb protects cells from apoptosis	
RB1		26160835	escaping programmed cell death	promotes or suppresses	may promote or suppress apoptosis	
RB1		8957005	differentiation and development		insufficient pRb results in failure of myogenesis in vivo	
RB1		26009982	change of cellular energetics	promotes	activates both glycolysis and mitochondrial oxidative phosphorylation in cells that have undergone oncogene-induced senescence 	
RB1		24824777	escaping immune response to cancer	suppresses	potentiates the innate immune response	
RBM10		24530524	function summary		regulates alternative splicing of FAS and BCL genes	
RBM10		27727438	types of alteration in cancer		recurrent E698*, E119D	
RBM10	lung cancer	26853560	role in cancer	TSG	TSG	
RBM10	lung cancer	24332178	suppression of growth	promotes	RBM10 mutations disrupt NUMB splicing regulation to promote cell growth	
RBM10	breast cancer	18820371	escaping programmed cell death		expression positively correlates with the expression of caspase 3	
RBM10	breast cancer	16552754	escaping programmed cell death		expression positively correlates with the expression of Bax	
RBM10		26853560	function summary		alternative splicing regulator	
RBM10		26853560	impact of mutation on function		inactivating mutations affect the mechanism of repression of Notch signalling and cell proliferation through the regulation of NUMB alternative splicing 	
RBM15		15849773	role in cancer	fusion	fusion	
RBM15		19542301	differentiation and development		 required for normal HSC-niche interactions, for the ability of HSCs to contribute normally to adult hematopoiesis, and for normal megakaryocyte development	
RBM15		17376872	differentiation and development		 deletion of RBM15 in adult mice causes a loss of peripheral B cells due to a block in pro/pre-B differentiation	
RBM15		18667423	impact of mutation on function		 interaction of RBM15 with histone deacetylase 3 is abolished in RBM15-MKL1 fusion protein, and cellular localisation of MKL1 is changed from predominantly cytoplasmatic to exclusively nuclear	
RBM15		26575292	function summary		binds to pre-messenger RNA intronic regions of genes important for megakaryopoiesis such as GATA1, RUNX1, TAL1 and c-MPL where it recruits the splicing factor SF3B1 for alternative splicing	
RBM15	acute megakaryoblastic leukaemia	11431691	fusion partner		MKL1	
RBM15	AML	15849773	fusion partner		MKL1	
RECQL4		18693251	genome instability and mutations	suppresses	required for the efficient removal of UV lesions by NER	
RECQL4		19567405	genome instability and mutations	suppresses	regulates both directly and indirectly base excision repair capacity	
RECQL4		22296597	genome instability and mutations	suppresses	preserves mitochondrial DNA integrity	
RECQL4	breast cancer	23894508	types of alteration in cancer		amplification and high expression is associated with increased in vitro clonogenic survival and in vivo tumorigenicity	
RECQL4	prostate cancer	21045146	invasion and metastasis	promotes	KD reduces their cell invasiveness in vitro and tumorigenicity in vivo	
RECQL4	prostate cancer	21045146	escaping programmed cell death	promotes	KD leads to increased poly(ADP-ribose) polymerase (PARP) synthesis and induction of PARP-dependent apoptosis	
RECQL4		24942867	genome instability and mutations	suppresses	participates in the NHEJ pathway of DSB repair via a functional interaction with the Ku70/Ku80 complex	
RECQL4	breast cancer	26690729	role in cancer	oncogene	oncogene	
RECQL4	breast cancer	23894508	types of alteration in cancer		amplified or overexpressed	MDA-MB453
RECQL4	breast cancer	23894508	escaping programmed cell death	promotes	physically interacts with a major survival factor-survivin and its protein level affects survivin expression, KD significantly inhibits the in vitro clonogenic survival and in vivo tumourigenicity 	MDA-MB453
RECQL4		20065033	cell division control		depletion reduces origin firing efficiency, and suppresses cell proliferation 	
RECQL4		20096650	function summary		plays primary role in DNA replication initiation 	
RECQL4		19177149	function summary		DNA helicase, promotes ATP-dependent DNA unwinding 	
RECQL4		22940096	role in cancer	TSG	TSG	
RET	medullary thyroid carcinoma	28931560	types of alteration in cancer		range of activating germline and somatic mutations identified	
RET	familial medullary thyroid carcinoma, Multiple endocrine neoplasia, type 2A and type 2B	25440022	types of alteration in cancer		germline mutations affecting codons 804, 634 and 918 are the most common	
RET		30371878	types of alteration in cancer		recurrent M918T, C634R/W/Y, E632_L633del, D898_E901del	
RET	haematopoietic stem cells	25079320	differentiation and development		drives haematopoietic stem cell survival, expansion and in vivo transplantation efficiency via p38MAPK and CREB mediated Bcl2 and Bcl2l1 upregulation	
RET	neuroblastoma 	18286198	differentiation and development		required for induction of differentiation in a ligand independent mechanism involving crosstalk with NTRK2 (TrkB)	
RET	secretory carcinoma of the salivary gland	30130630	fusion partner		ETV6	
RET	lung adenocarcinoma	29549897	fusion partner		KIF5B	
RET	papillary thyroid carcinoma	2406025	fusion partner		CCDC6	
RET		30941048	role in cancer	fusion	fusion	
RET	papillary thyroid carcinoma	10337992	fusion partner		ERC1	
RET		12203787	impact of mutation on function		oligomerization of ERC1-RET chimeric proteins through the coiled-coil domain of ERC1 dimerizes the RET kinase domains leading to constitutive autophosphorylation of RET	
RET	papillary thyroid carcinoma	17464312	fusion partner		NCOA4	
RET	colorectal cancer	22751117	types of alteration in cancer		frequent aberrant methylation of RET correlates with decreased RET expression	
RET	lung adenocarcinoma	23533264	fusion partner		TRIM33	
RET		30941048	types of alteration in cancer		multiple fusion partners in lung and thyroid cancers	
RET		24561444	differentiation and development		required for the development of neural and genitourinary tissues	
RET		29175871	impact of mutation on function		mutations affecting the intracellular domain of RET signal independently of ligand as monomeric oncoproteins,  showing altered catalytic activity and altered substrate specificity towards substrates that are usually preferred by cytoplasmic tyrosine kinases such as SRC and FAK, particularly,  M918T catalytic domain mutant enhances autophosphorylation kinetics, M918T subverts cis-inhibition by promoting intermolecular substrate phosphorylation	
RET	lung carcinoma	25064355	mouse model		KIF5B-RET fusion is sufficient for development of lung adenocarcinomas 	
RET	medullary thyroid carcinoma	26868437	role in cancer	oncogene	oncogene	
RET	colorectal cancer	22751117	role in cancer	TSG	TSG	
RET	multiple endocrine neoplasia 2 (MEN2)	28931560	escaping immune response to cancer	promotes	activating mutations promote escape from immune mediated anti-cancer response	
RET	thyroid carcinoma	28931560	tumour promoting inflammation	promotes	RET induced modulation of cancer associated fibroblasts drives pro-inflammatory response that sustains tumour growth and metastatic ability	
RET	pancreatic ductal adenocarcinoma	28092668	invasion and metastasis	promotes	KD inhibits perineural invasion	
RET	prostate cancer	28490466	invasion and metastasis	promotes	KD inhibits migration and invasion	LNCaP, 22Rv1
RET	HNSCC	27090738	proliferative signalling	promotes	KD reduces growth	HN6
RET	prostate cancer	28490466	proliferative signalling	promotes	KD inhibits growth in vitro and in vivo	
RET	colon cancer	22751117	escaping programmed cell death	suppresses	receptor re-expression induces apoptosis in the absence of ligand 	SW48, RKO
RET	medullary thyroid carcinoma	25795775	escaping programmed cell death	promotes	mediates suppression of apoptotic target genes through ubiquitination and degradation of ATF4	TT, MZCRC1
RET	HNSCC	27090738	escaping programmed cell death	promotes	KD increases apoptosis in xenografts	
RET		10921886	escaping programmed cell death	suppresses	receptor expression induces apoptosis by release of a pro-apoptotic fragment on caspase cleavage	
RET		24561444	function summary		transmembrane receptor tyrosine kinase activated by the glial cell line-derived neurotrophic factors (GDNFs), which include GDNF, neurturin (NTRN), artemin (ARTN) and persephin (PSPN)	
RET		24561444	function summary		3 isoforms have been identified with unique C terminals and distinct signaling potentials	
RHOA		19693013	function summary		plays a role in the initial events of cell protrusion 	
RHOA		27138333	invasion and metastasis	promotes	plays a role in cancer cell invasion 	
RHOA		25413277	role in cancer	TSG	TSG	
RHOA		8524848	role in cancer	oncogene	oncogene	
RHOA	colorectal cancer 	25413277	invasion and metastasis	suppresses	inactivation of RHOA enhances Wnt signalling resulting in increased invasion and de-differentiation	
RHOA	colorectal cancer 	25413277	suppression of growth	promotes	inactivation of RHOA enhances Wnt signalling and promotes proliferation	
RHOA	intestinal epithelium 	26752649	tumour promoting inflammation	suppresses	suppressed Rho-A activation promotes inflamation	
RHOA		26649141	escaping programmed cell death	promotes or suppresses	both inactive and constitutively active mutants cause reduced proliferation and survival compared to WT after radiation with increased number of cells arrested at various cell cycle stages correlated with increased cellular senescence and apoptosis 	
RHOA		26649141	genome instability and mutations	suppresses	DNA damage repair is delayed in HeLa cell line with reduced RhoA activity	
RHOA		26649141	invasion and metastasis	promotes	cells expressing the dominant negative RhoA mutant display decreased migration rates	
RHOH		15494435	suppression of growth	promotes	KD stimulates proliferation, overexpression is associated with impaired activation of Rac GTPases and reduced proliferation	
RHOH		11809807	differentiation and development		involved in  in functional differentiation of T cells 	
RHOH		11809807	function summary		potent inhibitor of the activation of NFkappaB and p38 by other Rho GTPases, GTPase deficient, remaining in a GTP-bound activated state without cycling	
RHOH	B-cell lymphoma	7784061	fusion partner		BCL6	VAL
RHOH		15494435	invasion and metastasis	suppresses	KD stimulates stromal cell-derived factor-1 alpha (SDF-1 alpha)-induced migration in vitro, overexpression is associated with defective actin polymerisation and chemotaxis 	
RHOH		15494435	escaping programmed cell death	suppresses	KD stimulates cell survival and overexpression is associated with increased apoptosis	
RHOH		15494435	role in cancer	TSG	TSG	
RNF213		23151810	fusion partner		SLC26A11	
RNF213		27323329	function summary		downstream mediator of the effects of PTPN1 on hypoxia sensitivity, KD of RNF213 rescues PTPN1-KD HER2+  breast cancer cells from hypoxia-induced cell death, and restores the growth of PTPN1-KD tumours 	
RNF213	ALCL	12112524	fusion partner		ALK	
RNF213		12112524	role in cancer	fusion	fusion	
RNF213		23151810	impact of mutation on function		the fusion event decreased expression of SLC26A11 under the control of the promoter of RNF213 	
RNF213		26278786	angiogenesis	promotes	KD leads to decrease of endogenous expression of cell cycle-promoting genes and decreased angiogenic potential in cultured endothelial cells 	
RNF213		21799892	function summary		protein containing a RING E3-ligase and an AAA+ ATPase domain, involved in vascular development and associated with susceptibility to moyamoya disease 	
RNF43		22895187	function summary		a stem-cell E3 ligase that induces endocytosis of Wnt receptors 	
RNF43		22895187	impact of mutation on function		the RNF43 RING mutants showed no inhibition of Wnt signalling but instead acted in a dominant-negative manner and enhanced Wnt signalling activity 	
RNF43	gastric cancer	28446252	cell replicative immortality	suppresses	attenuates the stemness of cancer stem-like cells 	
RNF43		25825523	impact of mutation on function		missense mutations of RNF43 in the extracellular domain (I48T, L82S and R127P) facilitated Wnt3a-induced activation of Wnt/beta-catenin signaling due to their mislocalisation, stabilisation, and/or dominant negative effect 	
RNF43		26184844	role in cancer	TSG	TSG	
RNF43	gastric cancer	26184844	escaping programmed cell death	suppresses	promotes apoptosis	
RNF43	gastric cancer	26184844	suppression of growth	promotes	inhibits cell proliferation	
RNF43		26350900	function summary		inhibits Wnt signalling downstream of beta-catenin by sequestering TCF4 to the nuclear membrane 	
ROS1	lung adenocarcinoma	22215748	fusion partner		SLC34A2	
ROS1	Spitz tumour	24445538	fusion partner		ZCCHC8, CLIP1, KIAA1598, PPFIBP1, PWWP2A	
ROS1	lung adenocarcinoma	18083107	fusion partner		CD74	
ROS1	ovarian serous tumour	22163003	fusion partner		GOPC	
ROS1	lung adenocarcinoma	22327623	fusion partner		SDC4, TPM3, EZR, LRIG3	
ROS1		23719267	role in cancer	oncogene	oncogene	
ROS1		24971615	differentiation and development		regulates epithelial differentiation in the epididymis necessary for sperm maturation	
ROS1		8657124	proliferative signalling	promotes	stimulates cell proliferation	
ROS1	NSCLC	22659450	impact of mutation on function		fusion oncogene CD74-ROS1 activates invasiveness pathway through E-syt1 phosphorylation	
ROS1	intrahepatic cholangiocarcinoma	24968753	impact of mutation on function		downregulation of ROS1-GOPC fusion protein inhibits cell proliferation, colony formation, cell cycle progression, migration and invasion, while inducing apoptosis	HUCCT1
ROS1		18083107	role in cancer	fusion	fusion	
ROS1		23719267	function summary		receptor tyrosine kinase (RTK) that is most closely related to the ALK and LTK human RTKs	
RUNX1T1	gastric cancer	27522676	suppression of growth	promotes	ectopic expression inhibits proliferation	MKN28 and MKN45
RUNX1T1	colorectal cancer	27798886	suppression of growth	promotes	forced expression of RUNX1T1 inhibits cellular proliferation	
RUNX1T1		25881961	differentiation and development		positively regulates adipogenesis	
RUNX1T1		9724795	role in cancer	oncogene	oncogene	
RUNX1T1		12559562	role in cancer	fusion	fusion	
RUNX1T1		19289505	global regulation of gene expression		acts as a transcriptional co-repressor binding to and inactivating the E proteins family transcription factors which activate transcription from E-box	
RUNX1T1		24586690	function summary		transcriptional repressor, controls proliferation and the neurotoxic effect of microglia by epigenetically regulating Cdk4 and LAT2 via its interaction with HDACs 	
RUNX1T1		28640846	angiogenesis	promotes	positively regulates angiogenesis	
RUNX1T1		27798886	role in cancer	TSG	TSG	
RUNX1T1		9724795	impact of mutation on function		RUNX1-RUNX1T1 fusion transcript binds to RUNX1-regulated promoters with N-terminal Runx1-derived domain, and suppresses their transcription via RUNX1T1 repressor activity	
SDHA		24781757	function summary		mitochondrial succinate-coenzyme Q reductase subunit alpha, responsible for transferring electrons from succinate to ubiquinone (coenzyme Q)	
SDHA		20484225	angiogenesis	suppresses	pseudo-hypoxia induced by inactivation of SDHA leads to a subsequent increase in angiogenesis	
SDHA		20484225	change of cellular energetics	promotes	SDHA LOF mutations cause a loss of SDH enzymatic activity in tumour tissue and in the yeast model leading to pseudo-hypoxia	
SDHA		24886695	role in cancer	TSG	TSG	
SDHA		23797725	types of alteration in cancer		germline LOF mutations associated with paraganglioma	
SETDB1		16682412	function summary		a histone H3 lysine 9 methyltransferase participating in the control of chromatin epigenetic state and gene transcription	
SETDB1	mice	27301860	differentiation and development		essential for the maintenance of hematopoietic stem and progenitor cells (HSPCs)	
SETDB1	lung cancer	23770855	types of alteration in cancer		recurrently amplified in cell lines and primary tumours	
SETDB1		29897144	function summary		surveillant of retroelement expression	
SETDB1	breast cancer	29233829	invasion and metastasis	suppresses	suppression of SETDB1 facilitates EMT and promotes carcinoma cell dissemination	
SETDB1	colorectal cancer	29158805	clinical impact		up-regulation of SETDB1 is negatively correlated with the survival rate	
SETDB1	NSCLC	25404354	proliferative signalling	promotes	forced expression of SETDB1 enhances clonogenic growth in vitro and increases tumour size in a murine xenograft model	
SETDB1	nasopharyngeal carcinoma	29901162	invasion and metastasis	promotes	enhanced expression promotes cell migration and invasion	
SETDB1	malignant pleural mesothelioma	26824986	types of alteration in cancer		frequent inactivating mutations	
SETDB1	lung cancer	25477335	invasion and metastasis	suppresses	a metastasis suppressor that is strongly downregulated in highly metastatic cells	
SETDB1	prostate cancer	24556744	proliferative signalling	promotes	KD inhibits cell growth, and induces G0/G1 cell cycle arrest	22RV1
SETDB1	breast cancer	29926931	role in cancer	oncogene	oncogene	
SETDB1	nasopharyngeal carcinoma	29901162	proliferative signalling	promotes	enhanced expression promotes cell proliferation	
SETDB1	mice	27070551	differentiation and development		maternal copy of the gene controls meiotic progression and is essential for early embryogenesis	
SETDB1	breast cancer	29926931	proliferative signalling	promotes	enhances c-MYC and cyclin D1 expression by promoting their internal ribosome entry site (IRES)-mediated translation and provides a growth advantage to breast cancer cells	
SETDB1	HCC	29739365	proliferative signalling	promotes	enhanced expression promotes cell proliferation	
SETDB1	AML	28887438	escaping immune response to cancer	promotes	expression is elevated in primary patient samples, and loss of SETDB1 triggers rapid desilencing of transposable elements (Tes), which induces a type I IFN antiviral response and apoptosis through a cytosolic dsRNA-sensing pathway	
SETDB1	colorectal cancer	29158805	escaping programmed cell death	promotes	over-expression of SETDB1 inhibits apoptosis induced by 5-Fluorouracil	
SETDB1	prostate cancer	24556744	invasion and metastasis	promotes	KD decreases cell migratory and invasive capacity	22RV1
SETDB1	breast cancer	29233829	cell replicative immortality	suppresses	decreasing SETDB1 expression enhances the epithelial stem cell population	
SETDB1	HCC	29739365	invasion and metastasis	promotes	enhanced expression promotes cell migration and invasion	
SETDB1	colorectal cancer	29158805	proliferative signalling	promotes	over-expression of SETDB1 promotes cell proliferation in vitro and in vivo, while KD suppresses growth	
SETDB1	lung cancer	23770855	role in cancer	oncogene	oncogene	
SF3B1	MDS and leukaemias	28545085	differentiation and development		K700E mutant inhibits erythroid differentiation via aberrant alternative splicing of TAL1	
SF3B1		27524419	impact of mutation on function		cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures, altering the cellular splicing program	
SF3B1	CD34+ cells	30194306	global regulation of gene expression		mutation is associated with reduced expression of intron containing isoforms and 3' splice site alterations, leading to pronounced reduction of canonical transcripts, including tumour suppressor genes NF1, PML, DICER1	
SF3B1		27524419	role in cancer	oncogene	oncogene	
SF3B1	myelodysplastic syndromes	27391606	types of alteration in cancer		most commonly mutated gene in MDS, especially associated with presence of ring sideroblasts	
SF3B1		28177281	types of alteration in cancer		copy loss common in cancer cell lines, but never homozygous loss, copy loss and mutation are mutually exclusive	
SF3B1		27089234	types of alteration in cancer		R625C/H mutations enriched in non-uveal melanoma, K700E common in myelodysplastic syndrome and chronic lymphocytic leukemia	
SF3B1	CLL	25371178	escaping programmed cell death	promotes	SF3B1 mutants exhibit defective apoptotic response to DNA damaging agents	
SF3B1		27639445	function summary		core component of spliceosome required for 3' splice site recognition during mRNA processing	
SF3B1		30371878	types of alteration in cancer		recurrent K700E, and missense mutations at R625, K666, and G742	
SFPQ		19625619	function summary		contains a DNA-binding domain (DBD) that binds to the regulatory region of a proto-oncogene and represses transcription, and 2 RNA-binding domains (RBDs) that bind multiple RNAs, releasing PSF from a repressed proto-oncogene and activating transcription	
SFPQ	melanotic kidney carcinoma	24288667	fusion partner		TFE3	
SFPQ	colon cancer	24288667	escaping programmed cell death	promotes	KD enhances apoptosis via downregulation of LC3B	DLD-1 and HT-29
SFPQ		22156371	function summary		activator for the meiosis-specific recombinase DMC1 via its DNA aggregation activity, which increases the local concentrations of ssDNA and dsDNA for homologous pairing by DMC1 	
SFPQ		27019013	function summary		acts in nuclei, cytoplasm and axons to regulate functionally related mRNAs essential for axon survival 	
SFPQ		19809274	role in cancer	fusion	fusion	
SFPQ		19625619	role in cancer	TSG	TSG	
SIX1		24488862	function summary		transcription factor, a master regulator of the development of a number of tissues and organs	
SIX1		25670083	impact of mutation on function		Q177R alters DNA binding specificity	
SIX1	mammary epithelial cells	18381426	genome instability and mutations	promotes	overexpression increases incidence of DNA breaks and chromosomal abnormalities	MCF12A
SIX1	colon cancer	28199476	angiogenesis	promotes	ectopic expression promotes tumour angiogenesis in a mouse model	MC38
SIX1	mice	19726883	cell replicative immortality	promotes	overexpression increases mammosphere-forming capabilities of mammary epithelial cells	
SIX1	ovarian cancer	17409410	escaping programmed cell death	promotes	inhibits TRAIL-mediated apoptosis	SKOV3
SIX1	breast cancer	24184484	escaping programmed cell death	promotes	ectopic expression induces resistance to paclitaxel-mediated apoptosis	MCF7
SIX1	pancreatic cancer	23527134	proliferative signalling	promotes	overexpression promotes proliferation and upregulates expression of cyclin D1	PANC-1
SIX1	breast cancer	15123840	proliferative signalling	promotes	overexpression promotes proliferation, increases tumor burden and increases expression of cyclin A1	MCF7
SIX1	hepatocellular carcinoma	20013809	proliferative signalling	promotes	KD slows growth rate and decreases colony formation	MHCC97L
SIX1	mice	19726883	invasion and metastasis	promotes	SIX1-driven mammary tumours undergo EMT	
SIX1	breast cancer	19726885	invasion and metastasis	promotes	ectopic expression promotes metastasis in mouse xenografts	MCF7
SIX1	hepatocellular carcinoma	20013809	invasion and metastasis	promotes	KD suppresses pulmonary metastasis	MHCC97L
SIX1	breast cancer	29455928	change of cellular energetics	promotes	increases expression of glycolytic genes, promoting the Warburg effect	ZR75-1
SIX1	fibroblasts	26500063	senescence		KD promotes senescence	IMR90
SIX1	breast cancer	18381426	role in cancer	Oncogene	Oncogene	
SIX1	breast cancer	19726883	clinical impact		high SIX1 expression correlates with poor outcome	
SIX1		19726885	clinical impact		increased expression is associated with aggressive disease in a variety of cancers	
SIX1		27727438	types of alteration in cancer		recurrent Q177R in Wilm's tumour	
SIX1	breast cancer	9770533	genome instability and mutations	promotes	overexpression abrogates the DNA damage-induced G2 cell cycle checkpoint	MCF7
SLC34A2		26598821	function summary		major intestinal NaPi transporter	
SLC34A2	lung adenocarcinoma	22215748	fusion partner		ROS1	
SLC34A2		26156586	role in cancer	TSG	TSG	
SLC34A2		22215748	role in cancer	fusion	fusion	
SLC34A2		26156586	invasion and metastasis	suppresses	has inhibitory effect on migration and invasion of several NSCLC cell lines confirmed by xenograft assays 	
SLC34A2		26156586	suppression of growth	promotes	has inhibitory effect on cell growth of several NSCLC cell lines confirmed by xenograft assays 	
SLC34A2	hepatocellular carcinoma	28281971	invasion and metastasis	promotes	KD inhibits migration and EMT by suppressing activation of the PI3K/AKT signaling pathway in hepatocellular carcinoma cells 	
SLC34A2	hepatocellular carcinoma	28281971	proliferative signalling	promotes	KD inhibits proliferation by suppressing activation of the PI3K/AKT signaling pathway in hepatocellular carcinoma cells 	
SLC34A2	breast cancer	28381172	cell replicative immortality	promotes	regulates SOX2 to maintain the stem cell-like features in CD147+  cancer stem-like cells through PI3K/AKT pathway 	
SLC45A3		22719019	types of alteration in cancer		SLC45A3-ELK4 RNA is generated in the absence of chromosomal rearrangement by cis-splicing of adjacent genes/read-through 	
SLC45A3	prostate cancer	22719019	fusion partner		ELK4	
SLC45A3		22719019	function summary		prostate specific, androgen responsive gene	
SLC45A3	prostate cancer	17671502	fusion partner		ETV1	
SLC45A3	prostate cancer	28716526	impact of mutation on function		when the fusion RNA is silenced, cell proliferation is inhibited in both androgen-dependent and castration-resistant cells; this growth arrest can be rescued by exogenous expression of either the fusion and a mutant designed to prevent translation of the ELK4 protein, indicating that SLC45A3-ELK4 regulates cancer cell proliferation by its transcript, not translated protein	
SLC45A3	prostate cancer	20118910	fusion partner		ERG	
SLC45A3		22719019	role in cancer	fusion	fusion	
SMAD2		12034739	function summary		 intracellular signal transducer and transcriptional modulator activated by TGF-beta	
SMAD2		23649632	cell replicative immortality	promotes	essential for the maintenance of the primed pluripotent stem cell state	
SMAD2	podocytes	24086574	escaping programmed cell death	suppresses	Smad2-dependent downregulation of miR-30 is required for TGF-beta-induced apoptosis	
SMAD2	esophageal squamous-cell carcinoma	26674378	invasion and metastasis	suppresses	silencing by miR-425 promotes increased cellular metastasis	
SMAD2	esophageal squamous-cell carcinoma	26674378	suppression of growth	promotes	silencing by miR-425 promotes cell proliferation and colony formation	
SMAD2		27727438	types of alteration in cancer		recurrent S464*	
SMAD2	esophageal squamous-cell carcinoma	26674378	types of alteration in cancer		target of miR-425	
SMAD2		9689088	differentiation and development		required for mesoderm induction	
SMAD2		10535967	differentiation and development		required during embryonic development	
SMAD2	colorectal cancer	23139211	impact of mutation on function		mutations in the MH1 domain alter the protein stability, DNA binding, prevent nuclear translocation, and enhance interactions with the MH2 domain; selected mutations reduce the ability of SMAD2 to form a complex with SMAD4, homozygous deletion is lethal while Apc/Smad2 cis-compound heterozygotes developed accelerated malignant progression of tumours	
SMAD2	colorectal cancer	23139211	role in cancer	TSG	TSG	
SMAD3		17327236	function summary		positively regulates PDPK1 kinase activity	
SMAD3		19218245	function summary		intracellular signal transducer and transcriptional modulator activated by TGF-beta	
SMAD3	breast cancer	25205100	function summary		balance between C-tail and linker phosphorylation directs tumourigenesis towards growth or metastasis	
SMAD3	mouse kidney	15253712	escaping programmed cell death	suppresses	Smad3 deficiency attenuates apoptosis	
SMAD3	breast cancer	25205100	escaping programmed cell death	promotes	mutation of Smad3 linker phosphorylation sites enhances apoptosis	
SMAD3	breast cancer	25205100	proliferative signalling	promotes	mutation of Smad3 linker phosphorylation sites suppresses cell proliferation	
SMAD3	renal tubular epithelial cells	23022526	invasion and metastasis	promotes	mutations in Smad3 linker phosphorylation sites positively regulate TGF-beta driven EMT	
SMAD3	breast cancer	25205100	invasion and metastasis	promotes	mutation of Smad3 linker phosphorylation sites enhances TGF-beta driven EMT and invasiveness	
SMAD3		10082515	suppression of growth	promotes	takes part in TGF-beta-mediated growth inhibition	
SMAD3		21035443	differentiation and development		regulator of chondrogenesis and osteogenesis, inhibits early healing of bone fractures	
SMAD3	murine colorectal cancer	9753318	role in cancer	TSG	TSG	
SMAD4	colorectal cancer	27528036	angiogenesis	promotes	increases angiogenesis via PSG9 overexpression, which increases SMAD4 nuclear retention with SMAD2/3 complexes and upregulation of angiogenic factors, including VEGFA 	HT-29, HCT116
SMAD4	gastric cancer	27685626	angiogenesis	suppresses	negatively regulates angiogenesis via repression of HPSE transcription	AGS
SMAD4	vulvar squamous cell carcinoma	29512734	invasion and metastasis	suppresses	downregulation mediated by miR-3147 promotes migration and invasion 	A-431
SMAD4	renal cell carcinoma	28901475	invasion and metastasis	promotes	drives expression of EMT genes and promotes migration and invasion 	786O, Caki1
SMAD4	colorectal cancer	28638476	invasion and metastasis	suppresses	KD results in increased cell migration	HCT116, HT-29
SMAD4	ovarian cancer 	28145479	invasion and metastasis	suppresses	downregulation by overexpressed miR-205 promotes metastasis of xenografts 	HO-8910
SMAD4	lung cancer	27492974	invasion and metastasis	suppresses	downregulation results in promotion of lung metastasis in xenografts	
SMAD4	colorectal cancer	27286257	invasion and metastasis	suppresses	loss of expression (via miR-20a-5p in human metastatic disease) promotes metastasis in xenografts 	HT-29, HCT116
SMAD4	colorectal cancer	27492974	tumour promoting inflammation	promotes	downregulation increases CCL15 expression and recruitment of tumour associated neutrophils, which contributes to invasion and liver metastasis	
SMAD4	colorectal cancer	28938919	suppression of growth	promotes	downregulation by overexpressed MiR-19b-3p, results in increased cell growth	SW480, RKO
SMAD4	NSCLC	28199217	suppression of growth	promotes	KD promotes proliferation 	A549
SMAD4	lung adenocarcinoma	25893305	genome instability and mutations	suppresses	reduced Smad4 expression is associated with increased DNA damage and DNA damage-induced apoptosis	A549
SMAD4		29483830	function summary		a core mediator of canonical TGF-beta and BMP signaling pathways	
SMAD4		23139211	impact of mutation on function		mutations in the hotspot region (D351-P356, R361) disrupt formation of both homo- and hetero-oligomeric complexes, while MH2 domain missense mutations affect binding the C-terminal phosphorylated Ser-Ser-X-Ser motifs of SMAD2 and SMAD3	
SMAD4		30371878	types of alteration in cancer		recurrent missense mutations at R361	
SMAD4	HNSCC, esophageal squamous cell carcinoma, skin SCC	22321641	types of alteration in cancer		LOH occurs frequently and is associated with more aggressive tumour behaviour	
SMAD4	pancreatic, colorectal, small intestinal, head and neck, gastric cancers	29483830	types of alteration in cancer		frequent genetic alteration including LOH, frameshift, nonsense and non synonymous changes	
SMAD4	NSCLC	28199217	types of alteration in cancer		expression is reduced by overexpressed miR-205	
SMAD4	colorectal cancer	28638476	types of alteration in cancer		expression negatively regulated by overexpressed miR-4260 in metastatic tumours	
SMAD4	pancreatic cancer	29483830	types of alteration in cancer		frequently deleted or mutated	
SMAD4		19841536	mouse model		Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation	
SMAD4		17114584	mouse model		conditional KO on KRAS G12D background results in rapid development of pancreatic tumours, KRAS G12D driven pancreatic tumorigenesis is suppressed by normal SMAD4 expression	
SMAD4	NSCLC	25893305	clinical impact		Smad4-deficient cells demonstrate increased sensitivity to DNA topoisomerase inhibitors and drugs that block NHEJ	
SMAD4	colorectal cancer	26647806	clinical impact		sensitizes to 5-fluorouracil by inhibiting PI3K/Akt/CDC2/survivin cascade and inducing cell cycle arrest, loss of SMAD4 induces chemoresistance to 5-FU in vitro and in xenografts	
SMAD4	HNSCC	28522603	clinical impact		SMAD4 loss induces cetuximab resistance in vitro and is associated with aggressive, HPV-negative phenotype	
SMAD4	colorectal cancer	29551247	clinical impact		somatic mutations are independently associated with poorer outcomes in patients undergoing resection of liver metastasis	
SMAD4	pancreatic ductal adenocarcinoma	29329157	clinical impact		after tumour resection and adjuvant chemo-radiotherapy, SMAD4 loss correlates with higher risk of local recurrence and distal failure, but not with survival	
SMAD4	prostate cancer	21289624	role in cancer		TSG	
SMAD4	cholangiocellular carcinoma	16767220	role in cancer		TSG	
SMAD4	colorectal cancer	23139211	role in cancer	TSG	TSG	
SMAD4	juvenile polyposis	10811127	role in cancer	TSG	TSG	
SMAD4	rat thyroid cells	23591524	suppression of growth	promotes	C324Y LOF mutation promotes TSH independent growth 	FRTL-5
SMAD4	ovarian cancer 	28145479	suppression of growth	promotes	downregulation by overexpressed miR-205 promotes growth of xenografts 	HO-8910
SMAD4	gastric cancer	27685626	suppression of growth	promotes	KD increases cell growth and viability	AGS
SPOP	prostate cancer	30124983	genome instability and mutations	suppresses	KD leads to spontaneous replication stress and impaired recovery from replication fork stalling	PC3
SPOP	CCRCC	27572476	invasion and metastasis	promotes	drives EMT and cell invasion via activation of beta-catenin/TCF4 complex	
SPOP	gastric cancer	25204354	suppression of growth	promotes	suppresses tumourigenesis by regulating Hedgehog/Gli2 signalling pathway, overexpression prevents tumour cells from proliferation, repression promotes proliferation	
SPOP	gastric cancer	25204354	invasion and metastasis	suppresses	overexpression prevents tumour cells from migration and colony formation, repression promotes cell migration	
SPOP		26344095	role in cancer	TSG	TSG	
SPOP	prostate cancer	26344095	function summary		functions as a tumour suppressor by negative regulation of the stability of the ERG oncoprotein	
SPOP		24451148	genome instability and mutations	suppresses	depletion results in an impaired DDR and hypersensitivity to ionizing radiation 	
SPOP		22610119	impact of mutation on function		overexpression of the F133V mutant  or KD of SPOP increases the invasive properties of prostate cancer cells, mutations in MATH domain impair binding of the substrate and its targeting for ubiquitin-mediated degradation 	
SPOP	gastric cancer	25204354	escaping programmed cell death	suppresses	repression attenuates apoptosis 	
STAG2		19822671	function summary		component of cohesin complex, required for cohesion at centromeres	
STAG2		25867412	genome instability and mutations	suppresses	loss of STAG2 causes aneuploidy in normal human bladder cells	
STAG2	glioma	21852505	genome instability and mutations	suppresses	loss of STAG2 leads to abnormal sister chromatid cohesion	H4, 42MGBA
STAG2	glioma	21852505	role in cancer	TSG	TSG	
STAG2	bladder cancer	24121789	clinical impact		loss of STAG2 associated with better prognosis in non-muscle invasive disease	
STAG2		27500726	clinical impact		KD decreases BRAFi sensitivity in BRAF-mutant melanoma cells	
STAG2		27727438	types of alteration in cancer		recurrent nonsense mutations including R216X, R259X, R1012X, R1033X, R216X	
STAG2	bladder cancer	24121789	types of alteration in cancer		frequent truncating mutations, more common in non-invasive diasese	
STAG2		25074805	cell division control		promotes the correction of kinetochoremicrotubule attachment errors to ensure faithful chromosome segregation during mitosis	
STAG2	bladder cancer	24121789	impact of mutation on function		truncating mutations result in undetectable expression	
STAG2	fibroblasts	28819029	cell replicative immortality	suppresses	KD results in increased recombination at telomeres, delayed telomere shortening and postponed senescence onset	BJ
STAG2	mice	26438359	differentiation and development		KD alters haematopoiesis with skew towards myeloid lineages	
STAG2	Ewing sarcoma	25223734	types of alteration in cancer		frequently mutated	
STAG2	Ewing sarcoma	25223734	clinical impact		mutation associated with poor outcome	
STAG2		29867216	function summary		STAG2 containing cohesin complexes promote cell-type-specific contacts between enhancers and promoters independently of CTCF	
SUZ12		17406994	function summary		member of the EED/EZH2 histone methyltransferase complexes necessary for trimethylation of histone H3 on lysine 27 in differentiated but not undifferentiated mouse embryonic stem cells 	
SUZ12	endometrial stromal sarcoma	12850374	fusion partner		JAZF1	
SUZ12	gastric cancer	25672609	proliferative signalling	promotes	promotes cell proliferation	
SUZ12	gastric cancer	25672609	invasion and metastasis	promotes	promotes metastasis	
SUZ12	gastric cancer	26176059	invasion and metastasis	promotes	KD suppresses invasion	
SUZ12		25240281	role in cancer	TSG	TSG	
SUZ12	NSCLC	24633887	proliferative signalling	promotes	promotes cell proliferation	
SUZ12	NSCLC	24633887	invasion and metastasis	promotes	promotes metastasis	
SUZ12		12850374	role in cancer	fusion	fusion	
SUZ12		24633887	role in cancer	oncogene	oncogene	
SUZ12	hereditary neurofibromatosis 1 	25305755	types of alteration in cancer		LOF somatic mutations play a role in development of malignant peripheral nerve sheath tumours from benign neurofibromas	
TBL1XR1	breast and ovarian cancer 	27822424	proliferative signalling	promotes	promotes cell proliferation	
TBL1XR1	breast and ovarian cancer 	27822424	invasion and metastasis	promotes	promotes cell migration and invasion	
TBL1XR1		26708416	role in cancer	fusion	fusion	
TBL1XR1		24243687	role in cancer	TSG	TSG	
TBL1XR1		27822424	role in cancer	oncogene	oncogene	
TBL1XR1	DLBCL	22496164	fusion partner		TP63	
TBL1XR1	splenic hemangioma	26708416	fusion partner		HMGA1	
TBL1XR1		26708416	impact of mutation on function		in fusion with HMGA1, the entire coding region of HMGA1 comes under the control of the TBL1XR1 promoter, causing dysregulation of HMGA1 	
TBL1XR1	oesophageal SCC	24667177	invasion and metastasis	promotes	promotes lymphangiogenesis and lymphatic metastasis via upregulation of VEGF-C	
TBL1XR1	cervical cancer	24874481	invasion and metastasis	promotes	promotes EMT	
TBL1XR1	prostate cancer	24243687	suppression of growth	promotes	ectopic expression leads to androgen-dependent growth suppression by selective activation of androgen-regulated genes associated with differentiation and growth suppression 	
TBL1XR1		16893456	function summary		regulates the expression of nuclear hormone receptor co-repressors 	
TCF7L2		28165569	role in cancer	oncogene	oncogene	
TCF7L2		21892161	role in cancer	fusion	fusion	
TCF7L2	cervical cancer	28165569	invasion and metastasis	promotes	silencing of TCF7L2 by miR-212 suppressed invasion in vitro 	
TCF7L2	cervical cancer	28165569	proliferative signalling	promotes	silencing of TCF7L2 by miR-212 suppressed cell proliferation in vitro 	
TCF7L2	colon cancer	23029137	escaping programmed cell death	promotes	KD inhibits induces apoptosis	SW480 and HCT116
TCF7L2	colon cancer	23029137	proliferative signalling	promotes	KD inhibits proliferation	SW480 and HCT116
TCF7L2		25015099	function summary		master regulator of insulin production and processing 	
TCF7L2	colorectal cancer	21892161	fusion partner		VTI1A	
TCL1A		10983986	role in cancer	oncogene	oncogene	
TCL1A	T-cell prolymphocytic leukaemia 	11241786	fusion partner		TRA	
TCL1A		11241786	types of alteration in cancer		 activated by chromosomal rearrangement or by hypomethylation 	
TCL1A		19668332	escaping programmed cell death	promotes	by interfering with the inhibition of NF-kB by IkB, TCL1A may increase the concentration of free NF-kB molecules sufficiently to trigger expression of anti-apoptotic genes 	
TCL1A		10983986	escaping programmed cell death	promotes	increases cell survival 	
TCL1A		10983986	proliferative signalling	promotes	enhances cell proliferation	
TCL1A		10983986	function summary		facilitates the oligomerisation and activation of Akt, increases Akt kinase activity and as a consequence enhances substrate phosphorylation, stabilises the mitochondrial transmembrane potential	
TCL1A		11241786	role in cancer	fusion	fusion	
TCL1A	CLL	22308499	global regulation of gene expression		Tcl1 overexpression drastically inhibits Dnmt3A function, samples with high Tcl1 expression showed a decrease in DNA methylation 	
TERT		27727438	types of alteration in cancer		somatic mutations affecting promoter region	
TERT		23932019	function summary		reverse transcriptase, protein component of telomerase	
TERT		11017190	senescence		telomere elongation by telomerase prevents replicative senescence	
TERT		12204535	genome instability and mutations	suppresses	telomere dysfunction provokes regional amplification and deletion in cancer genomes	
TERT		23932019	role in cancer	TSG, oncogene	TSG, oncogene	
TERT		15928077	genome instability and mutations	suppresses	fibroblasts lacking hTERT exhibit increased radiosensitivity, diminished capacity for DNA repair, and fragmented chromosomes	
TERT		18208333	proliferative signalling	promotes	promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program	
TERT		21071633	escaping programmed cell death	promotes	inhibits ROS-mediated apoptosis in cancer cells	
TERT		11769092	escaping programmed cell death	promotes	confers resistance to caspase-mediated apoptosis	
TERT		19559675	angiogenesis	promotes	activates transcription of VEGF	
TERT		11287649	proliferative signalling	promotes	overexpression in cells lacking telomerase and p16 activity induces resistance to growth inhibition by TGF beta	
TERT	glioma	10168478	cell replicative immortality	promotes	overexpression of TERT712, a telomerase activity-deficient form of TERT, promotes cell self-renewal in vitro	U87MG
TERT	gastric cancer	23045275	invasion and metastasis	promotes	promotes EMT, TGFB1 and beta-catenin-mediated EMT is abolished by KD of hTERT	
TET1		19372391	function summary		2-oxoglutarate (2OG)- and Fe(II)-dependent enzyme that catalyzes conversion of 5mC to 5-hydroxymethylcytosine (hmC)	
TET1		19372391	global regulation of gene expression		plays a role in epigenetic regulation through modification of 5mC to hmC	
TET1		23818607	role in cancer	oncogene	oncogene	
TET1		25362856	role in cancer	TSG	TSG	
TET1		19144982	role in cancer	fusion	fusion	
TET1		25517638	invasion and metastasis	promotes	serves as a transcription co-activator of HIF1A and EPAS1 to regulate hypoxia-responsive gene expression and EMT, KD of TET1 mitigates hypoxia-induced EMT 	
TET1	colon cancer	25362856	suppression of growth	promotes	inhibits tumour growth by de-repressing inhibitors of the WNT pathway 	
TET1	renal cell carcinoma	26165803	invasion and metastasis	suppresses	inhibitis invasion 	
TET1	renal cell carcinoma	26165803	suppression of growth	promotes	inhibits cell proliferation	
TET1	renal cell carcinoma	26165803	escaping programmed cell death	suppresses	involved in tumour inhibition in renal carcinoma by promoting cell apoptosis	
TET1	ALL	19144982	fusion partner		KMT2A	
TET2	parathyroid tumour	28642344	suppression of growth	promotes	methylation of TET2 promoter leads to loss of its expression associated with increased proliferation 	sHPT-1
TET2	murine myeloid malignancies	21803851	role in cancer	TSG	TSG 	
TET2	melanoma	27852070	invasion and metastasis	suppresses	KD leads to induction of an EMT-like process with associated increase in migration and metastasis	A375
TET2	parathyroid tumour	28642344	invasion and metastasis	suppresses	TET2 promoter methylation leads to loss of expression associated with increased invasion	sHPT-1
TET2	hepatocellular carcinoma	29331390	invasion and metastasis	promotes	upregulation of expression promotes invasion	Huh7, MHCC97-L and MHCC97-H
TET2	osteosarcoma	29515232	invasion and metastasis	promotes	TET2 mediated demethylation of IL-6 promotes lung metastasis in xenografts by upregulating ICAM1	SaOS2
TET2	hepatocellular carcinoma	29331390	proliferative signalling	promotes	upregulation of expression promotes proliferation	Huh7, MHCC97-L and MHCC97-H
TET2	murine Pro-B lymphocytes	27289557	genome instability and mutations	promotes	exogenous TET2 expression induces chromosomal and centrosomal instability arising from increased 5-hmC levels	Ba/F3
TET2	myeloid malignancies, haematopoietic stem and progenitor cells	28440315	genome instability and mutations	suppresses	TET2 loss associated with higher mutation numbers	
TET2		27848178	function summary		enzyme catalysing transfer of an oxygen atom to the methyl group of 5-methylcytocine (5-mC), converting it to 5-hydroxymethylcytocine (5-hmC)	
TET2	gastric cancer	27027260	suppression of growth	promotes	KD promotes proliferation and colony formation	AGS, MKN-28
TET2	prostate cancer	26404510	suppression of growth	promotes	AR signalling mediated TET2 loss results in increased cell growth	VCaP, LNCaP
TET2	AML	25601757	suppression of growth	promotes	exogenous TET2 expression results in decreased cell growth and clonogenicity	HL60
TET2		27848178	impact of mutation on function		somatic mutations cause impairment of enzymatic activity, resulting in the failure of 5-mC to 5-hmC conversion, and eventually failure of demethylation	
TET2		30606231	differentiation and development	promotes	promotes lineage commitment of bone marrow stem cells (BMSCs) to osteogenic and adipogenic cells	
TET2	AML	25886910	global regulation of gene expression		inactivation by somatic mutations results in lekaemogenic enhancer hypermethylation phenotype	
TET2	MDS	24220272	types of alteration in cancer		gene with the highest frequency of somatic mutations	
TET2		28440315	mouse model		KO mice are characterised by hypermutagenicity in haematopoietic stem/progenitor cells	
TET2	MDS	19666869	clinical impact		TET2 mutations are an independent favorable prognostic factor	
TET2	haematological malignancies	22240200	role in cancer	TSG	TSG	
TET2	osteosarcoma	29515232	change of cellular energetics	promotes	TET2 mediated demethylation of IL-6 facilitates glycolytic metabolism in tumour cells by activating the MEK/ERK1/2/HIF-1 pathway	SaOS2
TFE3		24448649	function summary		nutrient-responsive transcription factor that promotes autophagy, lysosomal biogenesis, and clearance of cellular debris	
TFE3		24448649	change of cellular energetics	promotes	promotes autophagy	
TFE3		22360977	function summary		regulator of mast cell-mediated allergic response 	
TFE3	alveolar soft part sarcoma	11244503	fusion partner		ASPSCR1	
TFE3	renal cell carcinoma	8986805	fusion partner		PRCC	
TFE3	perivascular epithelioid cell tumour 	19606011	fusion partner		SFPQ	
TFE3	renal cell carcinoma	12917640	fusion partner		CLTC	
TFE3	renal cell carcinoma	9393982	fusion partner		NONO	
TFE3		16327801	change of cellular energetics	promotes	overexpression of TFE3 in hepatocytes in culture and in vivo strongly activated expression of IRS-2 and Akt and enhanced phosphorylation of insulin-signaling kinases such as Akt, glycogen synthase kinase 3beta and p70S6 kinase 	
TFE3		16832349	role in cancer	fusion	fusion	
TFE3		23288701	role in cancer	oncogene	oncogene	
TGFBR2		11057902	function summary		receptor of TGF beta, activator of SMAD, PI3K signalling	
TGFBR2	diffuse gastric cancer	25315765	invasion and metastasis	suppresses	suppressor of metastasis	
TGFBR2		7665626	suppression of growth	promotes	participates in TGF beta-dependent growth inhibition	
TGFBR2		11057902	role in cancer	TSG	TSG	
TGFBR2		22314103	impact of mutation on function		inactivation results in loss of SMAD4 expression	
TGFBR2	oesophageal cancer	22314103	types of alteration in cancer		promoter is frequently hypermethylated	
TGFBR2	oral cancer	24846200	types of alteration in cancer		five aberrantly spliced isoforms with a deficient kinase domain have been detected	
TGFBR2		27727438	types of alteration in cancer		recurrent R528H (kinase domain), K128fs	
TGFBR2	mouse	25687406	mouse model		suppressing TGF beta signalling by TGFBR2 deletion in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer	
TMPRSS2		11245484	function summary		secreted serine protease that is highly expressed in the prostate and in prostate cancer in an androgen-dependent way 	
TMPRSS2	prostate adenocarcinoma	16254181	fusion partner		ERG, ETV1	
TMPRSS2	prostate adenocarcinoma	18794152	fusion partner		ETV4	
TMPRSS2		16254181	role in cancer	fusion	fusion	
TMPRSS2		25734995	function summary		induces proteolytic activity, activates trigeminal neurons, and produces marked mechanical hyperalgesia when administered into the hind paw of wild-type mice. Its expression is directly correlated with cancer pain severity in cancer patients 	
TMPRSS2	prostate cancer	17032499	impact of mutation on function		androgen-regulated promoter of TMPRSS2 fused to ERG results in overexpression of the later	
TMPRSS2	prostate adenocarcinoma	18172298	fusion partner		ETV5	
TNFAIP3		19258598	function summary		negative regulator of NFkB 	
TNFAIP3		26936212	tumour promoting inflammation	suppresses	downregulation increases the susceptibility of keratinocytes to external pro-inflammatory stimuli 	
TNFAIP3		25856582	role in cancer	TSG	TSG	
TNFAIP3		26642243	function summary		germline loss-of-function mutations in TNFAIP3 lead to A20 haploinsufficiency causing an early-onset autoinflammatory disease 	
TNFAIP3		26561336	escaping immune response to cancer	suppresses	inhibition of expression in tumour microenvironment exerts anti-tumour effect through inducing myeloid-derived suppressor cells apoptosis 	
TP53		15619621	cell replicative immortality	suppresses	induces differentiation of mouse embryonic stem cells by suppressing Nanog expression	
TP53		19766563	cell replicative immortality	suppresses	stem cells with targeted mutation of the tumour suppressor p53 possess the same self-renewal properties as cancer SCs, and their number increases progressively in the p53 null premalignant mammary gland	
TP53		26845683	senescence	promotes	induces cellular senescence	
TP53		20504879	differentiation and development		involved in neural, osteogenic, myogenic, hematopoietic and adipogenic differentiation	
TP53		17311302	types of alteration in cancer		loss of transactivation capacity is a key factor for the selection of missense mutations, the majority of the most common mutants show a capacity to exert dominant-negative effect over wild-type p53	
TP53	osteosarcoma	26672768	impact of mutation on function		fusions and intragenic rearrangements in osteosarcoma result in the loss of p53 function	
TP53		26672768	role in cancer	fusion	fusion	
TP53	osteosarcoma	26672768	fusion partner		PPRAD, VAV1, EMR1, DDX39B, SAT2,	
TP53	Spitz nevus	24445538	fusion partner		NTRK1	
TP53		16814724	change of cellular energetics	promotes	loss of p53 results in decreased oxygen consumption and aerobic respiration and promotes a switch to glycolysis	
TP53		21852209	genome instability and mutations	suppresses	obstructs aneuploidy by either instigating irreversible cell cycle arrest or apoptosis	
TP53		23787049	escaping immune response to cancer	suppresses	through a non-cell-autonomous mechanism p53 stimulates the innate immune system to maintain tissue homeostasis and suppress tumourigenesis	
TP53		21779518	tumour promoting inflammation	suppresses	constitutive pro-inflammatory activation of NF-kB reduces the tumour suppressor activity of p53, while enforced p53 activation reduces NF-kB activity, inflammation, and immune response	
TP53		18614011	suppression of growth	promotes	inhibitor of tumour growth	
TP53	neuroblastoma	8622657	types of alteration in cancer		preventing nuclear accumulation of wt p53 through sequestration in cytoplasm impairs G1 checkpoint after DNA damage	
TP53		26780878	function summary		maintains the integrity of mitochondrial DNA	
TP53	thyroid epithelial cells	10580091	escaping programmed cell death	suppresses	loss of endogenous p53 activity in cells transfected with a dominant-negative mutated p53 inhibits anoikis	
TP53		1614522	function summary		guardian of the genome	
TP53		8266084	function summary		Molecule of the Year 1993	
TP53		15688066	function summary		traffic cop at the crossroads of DNA repair and recombination	
TP53		2175676	interaction with pathogen		type 16 and 18 HPV E6 oncoprotein binds p53 and promotes its degradation via ubiquitin-dependent protease system	
TP53		9305847	escaping programmed cell death	suppresses	induces apoptosis through the transcriptional induction of redox-related genes followed by the formation of reactive oxygen species and oxidative degradation of mitochondrial components, culminating in cell death	
TP53		7600570	genome instability and mutations	suppresses	directly binds and forms stable complexes with DNA containing insertion/deletion mismatches, providing a signal for DNA damage	
TP53		15688066	role in cancer	TSG	TSG	
TP53		12242345	genome instability and mutations	suppresses	induces transcription of NER genes	
TP53		10359074	genome instability and mutations	suppresses	activator of base excision repair pathway	
TP53		9150391	genome instability and mutations	suppresses	suppresses spontaneous homologous recombination	
TP53		14743204	genome instability and mutations	suppresses	protects from stalled replication fork-associated DNA double-strand breaks	
TP53	mouse embryonic fibroblasts	8596939	genome instability and mutations	suppresses	cells which lack p53 display multiple copies of functionally competent centrosomes generated during a single cell cycle	
TP53		20044243	change of cellular energetics	promotes	regulator of autophagy, nuclear p53 transactivates transcription of proautophagic genes, cytoplasmic p53 can operate at mitochondria to promote cell death and repress autophagy	
TP53		20182618	role in cancer	oncogene	oncogene	
TP53		6095117	cell replicative immortality	promotes	transfection of mutant p53 expression constructs into cells of finite lifespan in vitro results in cellular immortality	
TP53		17417627	impact of mutation on function		R248W and R273H mutants interact with the nuclease Mre11 and suppress the binding of the Mre11-Rad50-NBS1 (MRN) complex to DNA double-stranded breaks, leading to impaired ATM activation	
TP53		17363498	impact of mutation on function		R273H mutant impairs apoptotic response by downregulating caspase-3	
TP53		17363498	escaping programmed cell death	promotes	R273H GOF mutation impairs apoptotic response by downregulating caspase-3	
TP53		19448627	invasion and metastasis	suppresses	wild-type p53 suppresses cancer invasion by inducing Slug degradation, GOF mutant p53 inactivates Slug degradation and leads to Slug accumulation and increased cancer cell invasiveness	
TP53	breast cancer	22265415	change of cellular energetics	promotes	GOF mutants R280K and R273H gain the ability to activate the mevalonate pathway leading to the activation of sterol biosynthesis genes and promoting tumour growth	
TP53		24343302	change of cellular energetics	promotes	R175H, R248Q and R273H mutants strongly stimulate the Warburg effect through promoting GLUT1 translocation to the plasma membrane, which is mediated by activated RhoA and its downstream effector ROCK	
TP53		11099028	function summary		transcription factor that coordinates cellular response to stress caused by a variety of signals including DNA damage, aberrant growth signalling, hypoxia, and a wide range of chemotherapeutic drugs, ultraviolet light, and protein-kinase inhibitors	
TP53		11099028	cell division control		activation leads to cell cycle arrest	
TP53		10742136	angiogenesis	suppresses	inhibits angiogenesis through the upregulation of maspin expression	
TP63		20064378	invasion and metastasis	suppresses	loss of p63 promotes invasion and random migration of cells	
TP63		15280445	function summary		sequence specific DNA binding transcriptional activator or repressor, TAp63 isoform can activate p53 target genes and induce apoptosis, deltaNp63 acts in dominant negative way to counteract activator function	
TP63	DLBCL	22496164	fusion partner		TBL1XR1	
TP63		15280445	cell division control		essential for limb formation and epidermal morphogenesis	
TP63		24488880	differentiation and development		regulates epithelial morphogenesis and adult epithelial stem cell maintenance and differentiation	
TP63		27727438	types of alteration in cancer		recurrent R379C, S365L, E609K, R594*, 	
TP63		23420876	types of alteration in cancer		repressor of p53 in melanoma where it is expressed in contrast to primary melanocytes	
TP63	SCC	10805802	types of alteration in cancer		amplified with overexpression of the variant lacking the terminal transactivation domain	
TP63		24488880	role in cancer	TSG	TSG	
TP63	SCC	10805802	role in cancer	oncogene	oncogene	
TP63		22787154	invasion and metastasis	suppresses	deltaNp63a provides inhibitory signals for cell motility	
TP63		20962848	invasion and metastasis	suppresses	controls antimetastatic RNAi regulation by activating DICER promoter	
TP63		21637289	proliferative signalling	promotes	deltaNp63a up-regulates keratinocyte proliferation by repressing expression and nuclear translocation of PTEN	
TP63		15280445	escaping programmed cell death	suppresses	TAp63 isoform induces apoptosis	
TP63		15280445	impact of mutation on function		truncating mutations may result in a product identical to one of the natural isoforms lacking C-terminal fragment	
TRAF7		27808423	function summary		E3 ubiquitin ligase, promotes ubiquitination of a number of protein targets, including NEMO, p65, c-FLIP and p53 as well as sumoylation of c-Myb	
TRAF7	adenomatoid tumours of male and female genital tract	29148537	role in cancer	oncogene	oncogene	
TRAF7	breast cancer	23128672	escaping programmed cell death	suppresses	downregulation results in cytosolic accumulation of p53	
TRAF7		15001576	escaping programmed cell death	suppresses	overexpression induces caspase-mediated cell death	
TRAF7		21518757	escaping programmed cell death	suppresses	ectopic expression promotes cell death	HEK293
TRAF7	meningioma	23348505	types of alteration in cancer		frequently mutated with majority of mutations mapping to WD40 repeats, occuring mutually exclusive to NF2 mutations and co-occurring with KLF4 K409Q	
TRAF7	breast cancer	23128672	clinical impact		low TRAF7 expression is associated with poorer prognosis	
TRAF7	pleural mesothelioma	26928227	types of alteration in cancer		mutations occur 80% mutually exclusive to NF2 mutations, 80% occur in WD40 domain	
TRAF7	intraneural perineurioma	28019650	types of alteration in cancer		frequent mutations affecting WD40 repeats	
TRAF7	adenomatoid tumours of male and female genital tract	29148537	types of alteration in cancer		frequent mutations affecting WD40 domain, S561R and H521R are recurrent	
TRAF7		29148537	impact of mutation on function		H521R, S561R and Y538S increase activation of NFkB signalling	
TRAF7		23128672	role in cancer	TSG	TSG	
TRAF7	meningioma	27548314	types of alteration in cancer		TRAF7 mutations co-occur with mutations that activate PI3K signalling in subset of patients in meninigoma	
UBR5	ovarian cancer	18349819	clinical impact		high expression associated with worse prognosis	
UBR5	colorectal cancer	29296225	clinical impact		high mRNA levels, gene amplification, or high nuclear UBR5 protein levels are assiciated with poor prognoses	
UBR5	triple negative breast cancer xenografts	28330927	escaping programmed cell death	promotes	loss of UBR5 results in increased apoptosis, necrosis, and growth arrest	
UBR5	triple negative breast cancer xenografts	28330927	angiogenesis	promotes	loss of UBR5 impairs angiogenesis within the tumor	
UBR5	triple negative breast cancer xenografts	28330927	invasion and metastasis	promotes	absence of UBR5 in the tumor triggers aberrant EMT, resulting in severely reduced tumor metastasis to secondary organs	
UBR5	triple negative breast cancer	28330927	types of alteration in cancer		overexpression and strong gene amplifications of UBR5 associated with the disease	
UBR5		26464214	function summary		ubquitin E3 ligase, interacting with proteins involved in a diverse range of cellular processes, 	
UBR5	cervical cancer	18073532	genome instability and mutations	suppresses	KD compromises the maintenance of cell-cycle checkpoints, leading to polyploidy and cell death via mitotic catastrophe	HeLa
UBR5	breast cancer	17074762	genome instability and mutations	suppresses	KD reduces CHK2 kinase activity and inhibits DNA damage response	MCF7
UBR5	mouse embryonic fibroblasts	25092319	genome instability and mutations	suppresses	ubiquitinates ATMIN, promoting its dissociation from ATM and facilitating checkpoint activation in response to ionising radiation	
UBR5	triple negative breast cancer	28330927	angiogenesis	promotes	KO impairs tumour angiogenesis in a syngeneic mouse model	
UBR5		24189493	angiogenesis	promotes	KD impairs vascular tube formation through a repressive effect on the angiogenic factor ACVRL1	HUVECs
UBR5	ovarian cancer	27721409	escaping programmed cell death	promotes	inhibits cisplatin-induced apoptosis by both ubiquitylation and downregulation of expression of the proapoptotic protein MOAP1	A2780
UBR5	ovarian cancer	24379240	escaping programmed cell death	promotes	KD induces apoptosis	A2780ip2, OVCAR5 and ES-2
UBR5		27727438	types of alteration in cancer		recurrent E2121fs*28 in catalytic HECT domain	
UBR5	mantle cell lymphoma	23407552	types of alteration in cancer		frequent mutations clustering within HECT domain	
UBR5	ovarian cancer	12902990	types of alteration in cancer		allelic imbalance and ovexpression	
UBR5	breast cancer	12902990	types of alteration in cancer		frequent amplification and overexpression	
UBR5		15282321	differentiation and development		KO causes embryonic lethality due to failed yolk sac vascular development and defective chorioallantoic fusion	
UBR5	gastric cancer xenograft model	27590582	proliferative signalling	promotes	KD reduces proliferation in vitro and tumour weight	AGS
UBR5	triple negative breast cancer	28330927	role in cancer	Oncogene	Oncogene	
USP8		24378640	change of cellular energetics	promotes	increases stability of HIF1A	
USP8	Cushing's disease	25675982	impact of mutation on function		mutations clustered around the 14-3-3 protein binding site result in enhanced catalytic capacity of USP8 and increased EGFR stability, sustained EGF signalling and adrenocorticotropic hormone overproduction	
USP8	Cushing's disease	26162929	role in cancer	oncogene	oncogene	
USP8		25733871	genome instability and mutations	suppresses	increases the stability of the DDR protein BRIT1 through deubiquitination, loss of USP8 impairs BRIT1 deubiquitination, BRIT1 binding with gamma-H2AX, the formation of BRIT1 DNA damage foci, and chromatin relaxation	
USP8		24378640	function summary		hydrolase that removes conjugated ubiquitin from proteins, counteracts VHL-mediated ubiquitination of HIF1A	
USP8		17121848	function summary		promotes EGFR degradation through its deubiquitination	
VHL		25533676	role in cancer	TSG	TSG	
VHL	renal cell carcinoma	27460078	escaping programmed cell death	suppresses	in cells lacking functional VHL Akt is activated resulting in resistance to mitochondria-activating apoptosis inducers	
VHL	oral squamous cell carcinoma	24998140	invasion and metastasis	suppresses	loss of VHL expression contributes to epithelial-mesenchymal transition	
VHL	renal cell carcinoma	8855223	angiogenesis	suppresses	inhibits expression of VEGFA and PDGFB under normoxic conditions	
VHL	renal cell carcinoma	8855223	change of cellular energetics	promotes	inhibits expression of SLC2A1 and SLC2A3 glucose transporters	
VHL		18297059	senescence		VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400	
VHL		25533676	function summary		plays a key part in cellular oxygen sensing by targeting HIF1A for ubiquitination and proteasomal degradation	
VHL	renal cell carcinoma	12944410	suppression of growth	promotes	in VHL (-/-) cells activation of TGFA and EGFR by HIF1A leads to increased proliferation	
VHL		16678111	escaping programmed cell death	suppresses	directly associates with and stabilises p53 by suppressing Mdm2-mediated ubiquitination and nuclear export of p53, upon genotoxic stress, invokes an interaction between p53 and p300 and the acetylation of p53, which ultimately leads to an increase in p53 transcriptional activity and p53-mediated cell cycle arrest and apoptosis	
VHL	renal cell carcinoma	17936701	escaping programmed cell death	suppresses	pVHL-defective cells exhibit increased NF-kappaB activity via Card9 leading to resistance to cytokine-induced apoptosis	
VHL	pheochromocytoma	16098468	escaping programmed cell death	suppresses	inactivating mutations lead to increased expression of JunB, which negatively affects neuronal apoptosis after NGF withdrawal	
VHL		10353251	change of cellular energetics	promotes	targets HIF1A for oxygen-dependent proteolysis	
WAS	mouse transgenic and breast cancer	23911287	invasion and metastasis	promotes	WAS supports the migration of Tumour-Associated Macrophages and the production of EGF, which promote breast tumour metastasis; leukocyte-restricted WASP expression is required for metastasis of breast tumour cells to the lungs	MDA-MB-231
WAS		25941446	function summary		effector protein for Rho GTPases, controls actin polymerisation and is critical in the formation of the actin-based membrane protrusions	
WAS		25941446	role in cancer	oncogene	oncogene	
WIF1	neuroblastoma	24561119	function summary	TSG	functions as a tumour suppressor through modulating Wnt/beta-catenin signalling	
WIF1		18828159	role in cancer	fusion	fusion	
WIF1	salivary gland carcinoma ex-pleomorphic adenoma 	24853424	senescence		induces cellular senescence	
WIF1		24853424	role in cancer	TSG	TSG	
WIF1	salivary gland adenoma	18828159	fusion partner		HMGA2	
WIF1	salivary gland carcinoma ex-pleomorphic adenoma 	24853424	cell replicative immortality	suppresses	suppresses cancer cell stemness	
XPA		19197159	function summary		part of the NER machinery, required for the efficient repair of UV damage to DNA	
XPO1	CLL	23034282	role in cancer	oncogene	oncogene	
XPO1		25476752	proliferative signalling	promotes	stimulates proliferation by nuclear export of p21, p27, FOXO	
XPO1		25476752	function summary		mediator of nuclear export, controls sub-cellular localisation of NES-containing oncogenes and tumour suppressor proteins, mitotic apparatus and chromosome segregation and maintenance of nuclear and chromosomal structures	
XPO1		25476752	escaping programmed cell death	promotes	suppresses apoptosis by nuclear export of p53, FOXO, IkB, Survivin, FAS	
ZBTB16		25808865	role in cancer	TSG	TSG	
ZBTB16	APL	9070655	fusion partner		RARA	
ZBTB16	prostate cancer	25808865	types of alteration in cancer		recurrently deleted	
ZBTB16		26676652	function summary		transcription factor involved in major biological processes during development	
ZBTB16		9070655	role in cancer	fusion	fusion	
ZBTB16		26676652	cell replicative immortality	promotes or suppresses	regulates the balance of self-renewal and differentiation in stem cells 	
ZFHX3		20720010	impact of mutation on function		inactivation results in disturbed estrogen regulation	
ZFHX3		25501155	types of alteration in cancer		in top 10 genes that regulatory network changes during transition from benign to malignant breast cancer	
ZFHX3	endometrial cancer	26330387	role in cancer	TSG	TSG	
ZFHX3		20720010	function summary		positive and negative transcriptional regulator, competitive inhibitor of ER in breast cancer	
ZFHX3	prostate cancer	15750593	suppression of growth	promotes	silencing ZFHX3 increases proliferation, reexpression decreases colony-forming efficiency	PC-3
ZRSR2		21041408	function summary		splice factor involved in recognition of 3-intron splice sites.	
ZRSR2	MDS	23645565	role in cancer	TSG	TSG	
ZRSR2	MDS	22343920	clinical impact		patients with mutations often present with isolated neutropenias and mutations occur more frequently in patients with refractory anaemia with excess blasts	
ZRSR2	MDS	22343920	types of alteration in cancer		frequent inactivating mutations	
ZRSR2	MDS	25586593	global regulation of gene expression		KD leads to splicing defects, primarily affecting U12 introns	TF-1
ZRSR2		25586593	differentiation and development		KD alters myeloid and erythroid differentiation	
ZRSR2	MDS	25586593	impact of mutation on function		mutant cases display aberrant splicing of U12 introns	
